0001193125-21-315476.txt : 20211101 0001193125-21-315476.hdr.sgml : 20211101 20211101163028 ACCESSION NUMBER: 0001193125-21-315476 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211101 DATE AS OF CHANGE: 20211101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 211367628 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 10-Q 1 d232147d10q.htm FORM 10-Q Form 10-Q
Table of Contents
false0.023750.03511Q30000860730--12-31 0000860730 2021-01-01 2021-09-30 0000860730 2020-01-01 2020-09-30 0000860730 2020-07-01 2020-09-30 0000860730 2021-07-01 2021-09-30 0000860730 2020-12-31 0000860730 2021-09-30 0000860730 2020-01-01 2020-03-31 0000860730 2020-10-01 2020-12-31 0000860730 2021-01-01 2021-03-31 0000860730 2021-04-01 2021-06-30 0000860730 2020-04-01 2020-06-30 0000860730 2021-01-01 2021-06-30 0000860730 2021-10-25 0000860730 2019-12-31 0000860730 2021-03-31 0000860730 2021-06-30 0000860730 2020-09-30 0000860730 2020-06-30 0000860730 2020-03-31 0000860730 us-gaap:CorporateAndOtherMember 2021-07-01 2021-09-30 0000860730 hca:AmericanGroupMember 2021-07-01 2021-09-30 0000860730 hca:NationalGroupMember 2021-07-01 2021-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000860730 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000860730 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000860730 hca:MedicareMember 2021-07-01 2021-09-30 0000860730 hca:ManagedMedicareMember 2021-07-01 2021-09-30 0000860730 hca:MedicaidMember 2021-07-01 2021-09-30 0000860730 hca:ManagedMedicaidMember 2021-07-01 2021-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2021-07-01 2021-09-30 0000860730 hca:InternationalMember 2021-07-01 2021-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2021-07-01 2021-09-30 0000860730 us-gaap:CorporateAndOtherMember 2020-07-01 2020-09-30 0000860730 hca:AmericanGroupMember 2020-07-01 2020-09-30 0000860730 hca:NationalGroupMember 2020-07-01 2020-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000860730 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000860730 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000860730 hca:MedicareMember 2020-07-01 2020-09-30 0000860730 hca:ManagedMedicareMember 2020-07-01 2020-09-30 0000860730 hca:MedicaidMember 2020-07-01 2020-09-30 0000860730 hca:ManagedMedicaidMember 2020-07-01 2020-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2020-07-01 2020-09-30 0000860730 hca:InternationalMember 2020-07-01 2020-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0000860730 us-gaap:CorporateAndOtherMember 2021-01-01 2021-09-30 0000860730 hca:AmericanGroupMember 2021-01-01 2021-09-30 0000860730 hca:NationalGroupMember 2021-01-01 2021-09-30 0000860730 hca:HospitalMember 2021-01-01 2021-09-30 0000860730 hca:OtherNonhospitalHealthCareEntitiesMember 2021-01-01 2021-09-30 0000860730 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember hca:SouthernGeorgiaMember 2021-01-01 2021-09-30 0000860730 hca:SouthernGeorgiaMember hca:HospitalMember 2021-01-01 2021-09-30 0000860730 hca:HospitalMember country:TN 2021-01-01 2021-09-30 0000860730 us-gaap:InterestRateSwapMember 2021-01-01 2021-09-30 0000860730 hca:RealEstateAndOtherInvestmentsMember 2021-01-01 2021-09-30 0000860730 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember stpr:GA 2021-01-01 2021-09-30 0000860730 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000860730 us-gaap:FixedIncomeInterestRateMember hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyTwoMember 2021-01-01 2021-09-30 0000860730 us-gaap:FixedIncomeInterestRateMember hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMember 2021-01-01 2021-09-30 0000860730 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2021-01-01 2021-09-30 0000860730 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember hca:NorthernGeorgiaMember 2021-01-01 2021-09-30 0000860730 hca:MedicareMember 2021-01-01 2021-09-30 0000860730 hca:ManagedMedicareMember 2021-01-01 2021-09-30 0000860730 hca:MedicaidMember 2021-01-01 2021-09-30 0000860730 hca:ManagedMedicaidMember 2021-01-01 2021-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2021-01-01 2021-09-30 0000860730 hca:InternationalMember 2021-01-01 2021-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-09-30 0000860730 srt:MinimumMember 2021-01-01 2021-09-30 0000860730 hca:OutOfNetworkServicesMember 2021-01-01 2021-09-30 0000860730 hca:HomeHealthAndHospiceMember 2021-01-01 2021-09-30 0000860730 us-gaap:CorporateAndOtherMember 2020-01-01 2020-09-30 0000860730 hca:AmericanGroupMember 2020-01-01 2020-09-30 0000860730 hca:NationalGroupMember 2020-01-01 2020-09-30 0000860730 hca:HospitalAndOtherNonhospitalHealthCareEntitiesMember 2020-01-01 2020-09-30 0000860730 hca:RealEstateAndOtherInvestmentsMember 2020-01-01 2020-09-30 0000860730 hca:MedicareMember 2020-01-01 2020-09-30 0000860730 hca:ManagedMedicareMember 2020-01-01 2020-09-30 0000860730 hca:MedicaidMember 2020-01-01 2020-09-30 0000860730 hca:ManagedMedicaidMember 2020-01-01 2020-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2020-01-01 2020-09-30 0000860730 hca:InternationalMember 2020-01-01 2020-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0000860730 hca:OutOfNetworkServicesMember 2020-01-01 2020-09-30 0000860730 hca:ReorganizationGroupUnitsMember us-gaap:CorporateAndOtherMember 2021-09-30 0000860730 hca:ReorganizationGroupUnitsMember hca:AmericanGroupMember 2021-09-30 0000860730 hca:ReorganizationGroupUnitsMember hca:NationalGroupMember 2021-09-30 0000860730 us-gaap:FixedIncomeInterestRateMember hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMember 2021-09-30 0000860730 us-gaap:FixedIncomeInterestRateMember hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyTwoMember 2021-09-30 0000860730 hca:MoneyMarketFundsAndOtherMember 2021-09-30 0000860730 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:DebtSecuritiesMember 2021-09-30 0000860730 us-gaap:DebtSecuritiesMember 2021-09-30 0000860730 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 hca:MoneyMarketFundsAndOtherMember 2021-09-30 0000860730 hca:MoneyMarketFundsAndOtherMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0000860730 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000860730 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 hca:SeniorSecuredRevolvingCreditFacilityMember 2021-09-30 0000860730 hca:SeniorSecuredAssetBasedRevolvingCreditFacilityMember 2021-09-30 0000860730 hca:SeniorSecuredTermLoanFacilitiesMember 2021-09-30 0000860730 hca:SeniorSecuredNotesMember 2021-09-30 0000860730 hca:OtherSeniorSecuredDebtMember 2021-09-30 0000860730 hca:SeniorUnsecuredNotesMember 2021-09-30 0000860730 srt:BoardOfDirectorsChairmanMember 2021-09-30 0000860730 hca:HomeHealthAndHospiceMember 2021-09-30 0000860730 us-gaap:InterestRateSwapMember 2021-09-30 0000860730 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 hca:OtherNonhospitalHealthCareEntitiesMember 2021-09-30 0000860730 hca:OtherAccruedExpensesMember us-gaap:InterestRateSwapMember 2021-09-30 0000860730 hca:OtherAccruedExpensesMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:DebtSecuritiesMember 2020-12-31 0000860730 hca:MoneyMarketFundsAndOtherMember 2020-12-31 0000860730 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000860730 us-gaap:DebtSecuritiesMember 2020-12-31 0000860730 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000860730 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000860730 hca:MoneyMarketFundsAndOtherMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000860730 hca:MoneyMarketFundsAndOtherMember 2020-12-31 0000860730 hca:SeniorSecuredRevolvingCreditFacilityMember 2020-12-31 0000860730 hca:SeniorSecuredAssetBasedRevolvingCreditFacilityMember 2020-12-31 0000860730 hca:SeniorSecuredNotesMember 2020-12-31 0000860730 hca:SeniorSecuredTermLoanFacilitiesMember 2020-12-31 0000860730 hca:OtherSeniorSecuredDebtMember 2020-12-31 0000860730 hca:SeniorUnsecuredNotesMember 2020-12-31 0000860730 us-gaap:InterestRateSwapMember 2020-12-31 0000860730 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000860730 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000860730 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000860730 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000860730 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0000860730 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000860730 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000860730 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000860730 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000860730 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000860730 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000860730 us-gaap:SeniorNotesMember hca:SeniorSecuredNotesDue2051Member 2021-06-30 0000860730 us-gaap:SeniorNotesMember hca:SeniorSecuredNotesDue2031Member 2021-06-30 0000860730 us-gaap:SeniorNotesMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanBThirteenFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanBTwelveFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanASixFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanBFourteenFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanASevenFacilityMember 2021-06-30 0000860730 hca:AssetBasedRevolvingCreditFacilityMember 2021-06-30 0000860730 srt:BoardOfDirectorsChairmanMember 2019-01-31 0000860730 srt:BoardOfDirectorsChairmanMember 2020-01-31 0000860730 srt:BoardOfDirectorsChairmanMember 2021-02-28 0000860730 us-gaap:CommonStockMember 2021-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000860730 us-gaap:RetainedEarningsMember 2021-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-09-30 0000860730 us-gaap:CommonStockMember 2020-09-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000860730 us-gaap:RetainedEarningsMember 2020-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-09-30 0000860730 us-gaap:CommonStockMember 2019-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000860730 us-gaap:RetainedEarningsMember 2019-12-31 0000860730 us-gaap:NoncontrollingInterestMember 2019-12-31 0000860730 us-gaap:CommonStockMember 2020-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000860730 us-gaap:RetainedEarningsMember 2020-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-03-31 0000860730 us-gaap:CommonStockMember 2020-06-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000860730 us-gaap:RetainedEarningsMember 2020-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-06-30 0000860730 us-gaap:CommonStockMember 2020-12-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000860730 us-gaap:RetainedEarningsMember 2020-12-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-12-31 0000860730 us-gaap:CommonStockMember 2021-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000860730 us-gaap:RetainedEarningsMember 2021-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2021-03-31 0000860730 us-gaap:CommonStockMember 2021-06-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000860730 us-gaap:RetainedEarningsMember 2021-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-06-30 iso4217:USD utr:Year xbrli:shares xbrli:pure hca:Hospital iso4217:USD xbrli:shares hca:Surgery_Center hca:Endoscopy_Center hca:State
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Form 10-Q
 
 
(Mark One)
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
Or
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                 to                 
Commission file number
1-11239
 
 
HCA Healthcare, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
27-3865930
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
   
One Park Plaza
Nashville, Tennessee
 
37203
(Address of principal executive offices)
 
(Zip Code)
(615344-9551
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Voting common stock, $.01 par value    HCA    New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in
Rule 12b-2
of the Exchange Act.
 
Large accelerated filer
 
  
Accelerated filer
 
       
Non-accelerated
filer
 
  
Smaller reporting company
 
       
Emerging growth company
 
        
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2
of the Exchange Act).    Yes ☐    No  
Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.
 
Class of Common Stock
  
Outstanding at October 25, 2021
Voting common stock, $.01 par value    311,022,800 shares
 
 
 

HCA HEALTHCARE, INC.
Form 10-Q
September 30, 2021
 
 
  
 
  
Page of
Form 10-Q
 
Part I.
  
Financial Information
  
Item 1.
  
Financial Statements (Unaudited):
  
  
  
 
2
 
  
  
 
3
 
  
  
 
4
 
  
  
 
5
 
  
  
 
6
 
  
  
 
7
 
Item 2.
  
  
 
18
 
Item 3.
  
  
 
37
 
Item 4.
  
  
 
37
 
Part II.
  
  
Item 1.
  
  
 
37
 
Item 1A.
  
  
 
37
 
Item 2.
  
  
 
37
 
Item 6.
  
  
 
39
 
  
 
40
 
 
1

HCA HEALTHCARE, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
FOR THE QUARTERS AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020
Unaudited
(Dollars in millions, except per share amounts)
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Revenues
  
$
15,276
 
  $ 13,311    
$
43,688
 
  $ 37,240  
         
Salaries and benefits
  
 
7,094
 
    6,097    
 
19,780
 
    17,545  
Supplies
  
 
2,463
 
    2,128    
 
7,067
 
    5,999  
Other operating expenses
  
 
2,530
 
    2,251    
 
7,424
 
    6,825  
Government stimulus income reversal
  
 
 
    822    
 
 
     
Equity in earnings of affiliates
  
 
(35
    (40  
 
(78
    (48
Depreciation and amortization
  
 
716
 
    694    
 
2,125
 
    2,059  
Interest expense
  
 
398
 
    385    
 
1,168
 
    1,201  
Losses (gains) on sales of facilities
  
 
(1,047
    (14  
 
(1,057
    6  
Losses on retirement of debt
  
 
 
       
 
12
 
    295  
    
 
 
   
 
 
   
 
 
   
 
 
 
    
 
12,119
 
    12,323    
 
36,441
 
    33,882  
    
 
 
   
 
 
   
 
 
   
 
 
 
Income before income taxes
  
 
3,157
 
    988    
 
7,247
 
    3,358  
Provision for income taxes
  
 
685
 
    209    
 
1,531
 
    665  
    
 
 
   
 
 
   
 
 
   
 
 
 
Net income
  
 
2,472
 
    779    
 
5,716
 
    2,693  
Net income attributable to noncontrolling interests
  
 
203
 
    111    
 
574
 
    365  
    
 
 
   
 
 
   
 
 
   
 
 
 
Net income attributable to HCA Healthcare, Inc.
  
$
2,269
 
  $ 668    
$
5,142
 
  $ 2,328  
    
 
 
   
 
 
   
 
 
   
 
 
 
Per share data:
                                
Basic earnings
  
$
7.13
 
  $ 1.97    
$
15.67
 
  $ 6.89  
Diluted earnings
  
$
7.00
 
  $ 1.95    
$
15.43
 
  $ 6.79  
Shares used in earnings per share calculations (in millions):
                                
Basic
  
 
318.072
 
    338.168    
 
328.048
 
    338.057  
Diluted
  
 
324.029
 
    343.346    
 
333.248
 
    343.014  
The accompanying notes are an integral part of the condensed consolidated financial statements.
 
2

HCA HEALTHCARE, INC.
CONDENSED CONSOLIDATED COMPREHENSIVE INCOME STATEMENTS
FOR THE QUARTERS AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020
Unaudited
(Dollars in millions)
 
    
Quarter
    
Nine Months
 
    
2021
   
2020
    
2021
   
2020
 
Net income
  
$
2,472
 
  $ 779     
$
5,716
 
  $ 2,693  
Other comprehensive income (loss) before taxes:
                                 
Foreign currency translation
  
 
(31
    42     
 
(20
    (39
         
Unrealized gains (losses) on
available-for-sale
securities
  
 
(3
    1     
 
(12
    13  
         
Defined benefit plans
  
 
 
        
 
 
     
Pension costs included in salaries and benefits
  
 
7
 
    4     
 
21
 
    12  
    
 
 
   
 
 
    
 
 
   
 
 
 
    
 
7
 
    4     
 
21
 
    12  
         
Change in fair value of derivative financial instruments
  
 
(1
        
 
(1
    (66
Interest costs included in interest expense
  
 
10
 
    9     
 
28
 
    15  
    
 
 
   
 
 
    
 
 
   
 
 
 
    
 
9
 
    9     
 
27
 
    (51
    
 
 
   
 
 
    
 
 
   
 
 
 
Other comprehensive income (loss) before taxes
  
 
(18
    56     
 
16
 
    (65
Income taxes (benefits) related to other comprehensive income items
  
 
(1
    9     
 
6
 
    (10
    
 
 
   
 
 
    
 
 
   
 
 
 
Other comprehensive income (loss)
  
 
(17
    47     
 
10
 
    (55
    
 
 
   
 
 
    
 
 
   
 
 
 
Comprehensive income
  
 
2,455
 
    826     
 
5,726
 
    2,638  
Comprehensive income attributable to noncontrolling interests
  
 
203
 
    111     
 
574
 
    365  
    
 
 
   
 
 
    
 
 
   
 
 
 
Comprehensive income attributable to HCA Healthcare, Inc.
  
$
2,252
 
  $ 715     
$
5,152
 
  $ 2,273  
    
 
 
   
 
 
    
 
 
   
 
 
 
The accompanying notes are an integral part of the condensed consolidated financial statements.
 
3

HCA HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
Unaudited
(Dollars in millions)
 
    
September 30,
2021
   
December 31,
2020
 
ASSETS
                
Current assets:
                
Cash and cash equivalents
  
$
1,027
 
  $ 1,793  
Accounts receivable
  
 
8,433
 
    7,051  
Inventories
  
 
2,019
 
    2,025  
Other
  
 
1,769
 
    1,464  
    
 
 
   
 
 
 
    
 
13,248
 
    12,333  
     
Property and equipment, at cost
  
 
50,695
 
    49,317  
Accumulated depreciation
  
 
(27,148
    (26,118
    
 
 
   
 
 
 
    
 
23,547
 
    23,199  
     
Investments of insurance subsidiaries
  
 
418
 
    388  
Investments in and advances to affiliates
  
 
412
 
    422  
Goodwill and other intangible assets
  
 
9,153
 
    8,578  
Right-of-use
operating lease assets
  
 
2,099
 
    2,024  
Other
  
 
685
 
    546  
    
 
 
   
 
 
 
    
$
49,562
 
  $ 47,490  
    
 
 
   
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
3,759
 
  $ 3,535  
Accrued salaries
  
 
2,134
 
    1,720  
Other accrued expenses
  
 
3,481
 
    3,240  
Long-term debt due within one year
  
 
250
 
    209  
    
 
 
   
 
 
 
    
 
9,624
 
    8,704  
     
Long-term debt, less debt issuance costs and discounts of $253 and $236
  
 
32,049
 
    30,795  
Professional liability risks
  
 
1,522
 
    1,486  
Right-of-use
operating lease obligations
  
 
1,742
 
    1,673  
Income taxes and other liabilities
  
 
2,800
 
    1,940  
     
Stockholders’ equity:
                
Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 313,502,400 shares — 2021 and 339,425,600 shares — 2020
  
 
3
 
    3  
Capital in excess of par value
  
 
 
    294  
Accumulated other comprehensive loss
  
 
(492
    (502
Retained (deficit) earnings
    
(206
)
 
    777  
    
 
 
   
 
 
 
Stockholders’ (deficit) equity attributable to HCA Healthcare, Inc.
  
 
(695
    572  
Noncontrolling interests
  
 
2,520
 
    2,320  
    
 
 
   
 
 
 
    
 
1,825
 
    2,892  
    
 
 
   
 
 
 
    
$
49,562
 
  $ 47,490  
    
 
 
   
 
 
 
The accompanying notes are an integral part of the condensed consolidated financial statements.
 
4

HCA HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
FOR THE QUARTERS AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020
Unaudited
(Dollars in millions)
 
    
Equity (Deficit) Attributable to HCA Healthcare, Inc.
   
Equity
Attributable to
Noncontrolling
Interests
   
Total
 
    
Common Stock
    
Capital in
Excess of
Par
Value
   
Accumulated
Other
Comprehensive
Loss
   
Retained
Earnings
(Deficit)
 
    
Shares
(in millions)
   
Par
Value
 
Balances, December 31, 2019
     338.446     $  3      $     $ (460   $ (2,351   $ 2,243     $ (565
Comprehensive income
                              (111     581       117       587  
Repurchase of common stock
     (3.287                              (441             (441
Share-based benefit plans
     2.449                2               (35             (33
Cash dividends declared ($0.43 per share)
                                      (148             (148
Distributions
                                              (154     (154
Other
                      (2                     53       51  
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, March 31, 2020
     337.608       3              (571     (2,394     2,259       (703
Comprehensive income
                              9       1,079       137       1,225  
Share-based benefit plans
     0.352                93                               93  
Distributions
                                              (45     (45
Other
                      (5                     3       (2
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, June 30, 2020
     337.960       3        88       (562     (1,315     2,354       568  
Comprehensive income
                              47       668       111       826  
Share-based benefit plans
     0.410                97                               97  
Distributions
                                              (194     (194
Other
                                              2       2  
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, September 30, 2020
     338.370       3        185       (515     (647     2,273       1,299  
Comprehensive income
                              13       1,426       268       1,707  
Share-based benefit plans
     1.056                108                               108  
Cash dividends declared ($0.43 per share)
                                      (2             (2
Distributions
                                              (233     (233
Other
                      1                       12       13  
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, December 31, 2020
     339.426       3        294       (502     777       2,320       2,892  
Comprehensive income
                              11       1,423       157       1,591  
Repurchase of common stock
     (8.477              (225             (1,302             (1,527
Share-based benefit plans
     2.765                (75                             (75
Cash dividends declared ($0.48 per share)
                                      (163             (163
Distributions
                                              (234     (234
Other
                      6                       (8     (2
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, March 31, 2021
     333.714       3              (491     735       2,235       2,482  
Comprehensive income
                              16       1,450       214       1,680  
Repurchase of common stock
     (11.261              (142             (2,145             (2,287
Share-based benefit plans
     0.372                140                               140  
Cash dividends declared ($0.48 per share)
                                      (161             (161
Distributions
                                              (123     (123
Other
                      2                       57       59  
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, June 30, 2021
     322.825       3              (475     (121     2,383       1,790  
Comprehensive income
                           
 
(17
 
 
2,269
 
 
 
203
 
 
 
2,455
 
Repurchase of common stock
  
 
(9.605
          
 
(130
         
 
(2,199
         
 
(2,329
Share-based benefit plans
  
 
0.282
 
          
 
127
 
                         
 
127
 
Cash dividends declared ($0.48 per share)
                                   
 
(155
         
 
(155
Distributions
                                           
 
(144
 
 
(144
Other
                   
 
3
 
                 
 
78
 
 
 
81
 
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances, September 30, 2021
  
 
313.502
 
 
$
3
 
  
$
 
 
$
(492
 
$
(206
 
$
2,520
 
 
$
1,825
 
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of the condensed consolidated financial statements.
 
5

HCA HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020
Unaudited
(Dollars in millions)
 
    
2021
   
2020
 
Cash flows from operating activities:
                
Net income
  
$
5,716
 
  $ 2,693  
Adjustments to reconcile net income to net cash provided by operating activities:
                
Increase (decrease) in cash from operating assets and liabilities:
                
Accounts receivable
  
 
(1,312
    930  
Inventories and other assets
  
 
(333
    (36
Accounts payable and accrued expenses
  
 
731
 
    542  
Contract liabilities-deferred revenues
  
 
 
    6,123  
Depreciation and amortization
  
 
2,125
 
    2,059  
Income taxes
  
 
185
 
    (114
Losses (gains) on sales of facilities
  
 
(1,057
    6  
Losses on retirement of debt
  
 
12
 
    295  
Amortization of debt issuance costs and discounts
  
 
21
 
    22  
Share-based compensation
  
 
341
 
    229  
Other
  
 
87
 
    66  
    
 
 
   
 
 
 
Net cash provided by operating activities
  
 
6,516
 
    12,815  
    
 
 
   
 
 
 
Cash flows from investing activities:
                
Purchase of property and equipment
  
 
(2,385
    (2,087
Acquisition of hospitals and health care entities
  
 
(488
    (380
Sales of hospitals and health care entities
  
 
1,980
 
    68  
Change in investments
  
 
(38
    (40
Other
  
 
2
 
    (44
    
 
 
   
 
 
 
Net cash used in investing activities
  
 
(929
    (2,483
    
 
 
   
 
 
 
Cash flows from financing activities:
                
Issuances of long-term debt
  
 
4,337
 
    2,700  
Net change in revolving credit facilities
  
 
500
 
    (2,480
Repayment of long-term debt
  
 
(3,787
    (3,403
Distributions to noncontrolling interests
  
 
(501
    (393
Payment of debt issuance costs
  
 
(38
    (35
Payment of dividends
  
 
(476
    (153
Repurchase of common stock
  
 
(6,143
    (441
Other
  
 
(241
    (156
    
 
 
   
 
 
 
Net cash used in financing activities
  
 
(6,349
    (4,361
    
 
 
   
 
 
 
Effect of exchange rate changes on cash and cash equivalents
  
 
(4
    (4
    
 
 
   
 
 
 
Change in cash and cash equivalents
  
 
(766
    5,967  
Cash and cash equivalents at beginning of period
  
 
1,793
 
    621  
    
 
 
   
 
 
 
Cash and cash equivalents at end of period
  
$
1,027
 
  $ 6,588  
    
 
 
   
 
 
 
Interest payments
  
$
1,127
 
  $ 1,230  
Income tax payments, net
  
$
1,346
 
  $ 779  
The accompanying notes are an integral part of the condensed consolidated financial statements.
 
6

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
Reporting Entity
HCA Healthcare, Inc. is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At September 30, 2021, these affiliates owned and operated 183 hospitals, 123 freestanding surgery centers, 21 freestanding endoscopy centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA.
Basis of Presentation
The accompanying unaudited condensed consolidated financial
 
statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to
Form 10-Q
and Article 10 of
Regulation S-X.
Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.
The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $87 million and $117 million for the quarters ended September 30, 2021 and 2020, respectively, and $301 million and $289 million for the nine months ended September 30, 2021 and 2020, respectively. Operating results for the quarter and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on
Form 10-K
for the year ended December 31, 2020.
COVID-19
Pandemic
On March 11, 2020, the World Health Organization designated
COVID-19
as a global pandemic. Patient volumes and the related revenues for most of our services were significantly impacted during the latter portion of the first quarter and the first half of the second quarter of 2020 and have continued to be impacted as various policies were implemented by federal, state and local governments in response to the
COVID-19
pandemic. During the second quarter of 2021, our patient volumes experienced a strong rebound as the effects of the pandemic moderated and certain pandemic-related restrictions and policies were eased. During the third quarter of 2021, our patient volumes remained strong, with the exception of inpatient surgeries, and included a resurgence of
COVID-19
admissions. Inpatient surgery volumes were constrained during the quarter as capacity was used to treat the surge of COVID-19 patients. We believe the extent of the
COVID-19
pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate how long or to what extent the pandemic will impact our operations.
Revenues
Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods
 
7

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenues (continued)
 
that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted
fee-for-service
rates. Our revenues for the nine months ended September 30, 2021 and 2020 included $33 million and $55 million, respectively, related to the settlement of Medicare outlier calculations for prior periods. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for
non-elective
care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
 
    
Quarter
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
2,645
 
  
 
17.3
  $ 2,603        19.6
Managed Medicare
  
 
2,124
 
  
 
13.9
 
    1,760        13.2  
Medicaid
  
 
692
 
  
 
4.5
 
    445        3.3  
Managed Medicaid
  
 
813
 
  
 
5.3
 
    707        5.3  
Managed care and insurers
  
 
7,998
 
  
 
52.4
 
    6,752        50.7  
International (managed care and insurers)
  
 
324
 
  
 
2.1
 
    307        2.3  
Other
  
 
680
 
  
 
4.5
 
    737        5.6  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
15,276
 
  
 
100.0
  $ 13,311        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
 
8

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenues (continued)
 
    
Nine Months
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
7,816
 
  
 
17.9
  $ 7,618        20.5
Managed Medicare
  
 
6,281
 
  
 
14.4
 
    5,074        13.6  
Medicaid
  
 
1,722
 
  
 
3.9
 
    1,423        3.8  
Managed Medicaid
  
 
2,369
 
  
 
5.4
 
    1,904        5.1  
Managed care and insurers
  
 
22,300
 
  
 
51.0
 
    19,028        51.0  
International (managed care and insurers)
  
 
995
 
  
 
2.3
 
    838        2.3  
Other
  
 
2,205
 
  
 
5.1
 
    1,355        3.7  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
43,688
 
  
 
100.0
  $ 37,240        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
To quantify the total impact of the trends related to
 
uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions):
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)
  
$
12,803
 
  $ 11,170    
$
36,396
 
  $ 32,428  
Cost-to-charges
ratio (patient care costs as percentage of gross patient charges)
  
 
11.8
    12.0  
 
11.4
    12.1
Total uncompensated care
  
$
7,782
 
  $ 7,023    
$
22,299
 
  $ 21,625  
Multiply by the
cost-to-charges
ratio
  
 
11.8
    12.0  
 
11.4
    12.1
    
 
 
   
 
 
   
 
 
   
 
 
 
Estimated cost of total uncompensated care
  
$
916
 
  $ 843    
$
2,542
 
  $ 2,617  
    
 
 
   
 
 
   
 
 
   
 
 
 
The total uncompensated care amounts include
 
charity care of $3.509 billion and $3.160 billion, respectively, and the related estimated costs of charity care were $413 million and $376 million, respectively, for the quarters ended September 30, 2021 and 2020. The total uncompensated care amounts include charity care of $10.135 billion and $9.972 billion, respectively, and the related estimated costs of charity care were $1.155 billion and $1.207 billion, respectively, for the nine months ended September 30, 2021 and 2020.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.
NOTE 2 — ACQUISITIONS AND DISPOSITIONS
During the nine months ended September 30, 2021, we paid $67 million to acquire two hospital facilities, one in southern Georgia and one in Tennessee, and $91 million to acquire other nonhospital health care
entities (noncontrolling interests of $111 million were recorded).
 We also paid $330 million and assumed certain liabilities to acquire an 80% interest (noncontrolling interests of $101 million were recorded) in a venture providing post-acute care services (home health and hospice). Purchase price amounts have been allocated to the related assets acquired and liabilities assumed based upon their respective fair values. The purchase price paid in excess of the fair value of identifiable net assets of these acquired entities aggregated $601 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2020, we paid $380 million to acquire a hospital in New Hampshire
and other nonhospital health care entities. The consolidated financial statements include the accounts and operations of the acquired entities subsequent to the respective acquisition
 
9

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 2 — ACQUISITIONS AND DISPOSITIONS (continued)
 
dates. The pro forma effects of these acquired entities on our results of operations for periods prior to the respective acquisition dates were not significant.
During the nine months ended September 30, 2021, we received proceeds of $860 million and recognized a pretax gain of $655 million related to the sale of four hospital facilities in Georgia (two facilities in northern Georgia and two facilities in southern Georgia). We received proceeds of $647 million on September 30, 2021 related to the sale of a hospital facility in northern Georgia, which sale was effective October 1, 2021. We also received proceeds of $473 million and recognized a pretax gain of $402 
million related to sales of other health care entity investments and minor real estate assets. During the nine months ended September 30, 2020, we received proceeds of
 
$
68
 million and recognized a net pretax loss of $
6
 million related to the
sale
of a hospital facility in Mississippi and sales of real estate and other investments.
NOTE 3 — INCOME TAXES
Our provisions for income taxes for the quarters ended September 30, 2021 and 2020 were $685 million and $209 million, respectively, and the effective tax rates were 23.2% and 23.8%, respectively. Our provisions for income taxes for the nine months ended September 30, 2021 and 2020 were $1.531 billion and $665 million, respectively, and the effective tax rates were 22.9% and 22.2%, respectively. Our provisions for income taxes included tax benefits related to settlements of employee equity awards of $96 million and $59 million for the nine months ended September 30, 2021 and 2020, respectively.
Our liability for unrecognized tax benefits was $626 million, including accrued interest of $95 million, as of September 30, 2021 ($508 million and $73 million, respectively, as of December 31, 2020). Unrecognized tax benefits of $192 million ($157 million as of December 31, 2020) would affect the effective rate, if recognized.
The Internal Revenue Service was conducting an examination of the Company’s 2016, 2017 and 2018 federal income tax returns at September 30, 2021. We are also subject to examination by state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change.
NOTE 4 — EARNINGS PER SHARE
We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards, computed using the treasury stock method.
 
10

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 4 — EARNINGS PER SHARE (continued)
 
The following table sets forth the computation of basic and diluted earnings per share for the quarters and nine months ended September 30, 2021 and 2020 (dollars and shares in millions, except per share amounts):
 
    
Quarter
    
Nine Months
 
    
2021
    
2020
    
2021
    
2020
 
Net income attributable to HCA Healthcare, Inc.
  
$
2,269
 
   $ 668     
$
5,142
 
   $ 2,328  
         
Weighted average common shares outstanding
  
 
318.072
 
     338.168     
 
328.048
 
     338.057  
Effect of dilutive incremental shares
  
 
5.957
 
     5.178     
 
5.200
 
     4.957  
    
 
 
    
 
 
    
 
 
    
 
 
 
Shares used for diluted earnings per share
  
 
324.029
 
     343.346     
 
333.248
 
     343.014  
    
 
 
    
 
 
    
 
 
    
 
 
 
Earnings per share:
                                   
Basic earnings
  
$
7.13
 
   $ 1.97     
$
15.67
 
   $ 6.89  
Diluted earnings
  
$
7.00
 
   $ 1.95     
$
15.43
 
   $ 6.79  
NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES
A summary of our insurance subsidiaries’ investments at September 30, 2021 and December 31, 2020 follows (dollars in millions):
 
    
September 30, 2021
 
    
Amortized
Cost
    
Unrealized
Amounts
    
Fair
Value
 
    
Gains
    
Losses
 
Debt securities
  
$
391
 
  
$
21
 
  
$
(1
  
$
411
 
Money market funds and other
  
 
119
 
  
 
 
  
 
 
  
 
119
 
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
510
 
  
$
21
 
  
$
(1
  
 
530
 
    
 
 
    
 
 
    
 
 
          
Amounts classified as current assets
                             
 
(112
                               
 
 
 
Investment carrying value
                             
$
418
 
                               
 
 
 
 
    
December 31, 2020
 
    
Amortized
Cost
    
Unrealized
Amounts
    
Fair
Value
 
    
Gains
    
Losses
 
Debt securities
   $ 384      $ 32      $      $ 416  
Money market funds and other
     88                      88  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ 472      $ 32      $        504  
    
 
 
    
 
 
    
 
 
          
Amounts classified as current assets
                                (116
                               
 
 
 
Investment carrying value
                              $ 388  
                               
 
 
 
At September 30, 2021 and December 31, 2020, the investments in debt securities of our insurance subsidiaries were classified as
“available-for-sale.”
Changes in unrealized gains and losses that are not credit-related are recorded as adjustments to other comprehensive income (loss).
 
11

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES (continued)
 
Scheduled maturities of investments in debt securities at September 30, 2021 were as follows (dollars in millions):
 
    
Amortized
Cost
    
Fair
Value
 
Due in one year or less
   $      $  
Due after one year through five years
     134        141  
Due after five years through ten years
     177        187  
Due after ten years
     80        83  
    
 
 
    
 
 
 
     $ 391      $ 411  
    
 
 
    
 
 
 
The average expected maturity of the investments in debt securities at September 30, 2021 was 5.5 years, compared to the average scheduled maturity of 9.3 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date.
NOTE 6 — FINANCIAL INSTRUMENTS
Interest Rate Swap Agreements
We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between us and our counterparties based on common notional principal amounts and maturity dates.
Pay-fixed
interest rate swaps effectively convert variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions.
The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at September 30, 2021 (dollars in millions):
 
    
Notional
Amount
    
Maturity Date
    
Fair
Value
 
Pay-fixed
interest rate swaps
   $ 2,000        December 2021      $ (7
Pay-fixed
interest rate swaps
     500        December 2022        (12
During the next 12 months, we estimate $17 million will be reclassified from other comprehensive income (“OCI”) and will be included in interest expense.
Derivatives — Results of Operations
The following table presents the effect of our interest rate swaps on our results of operations for the nine months ended September 30, 2021 (dollars in millions):
 
Derivatives in Cash Flow Hedging Relationships
  
Amount of Loss
Recognized in OCI on
Derivatives, Net of Tax
    
Location of Loss
Reclassified from
Accumulated OCI
into Operations
    
Amount of Loss
Reclassified from
Accumulated OCI
into Operations
 
Interest rate swaps
   $ 1        Interest expense      $ 28  
 
12

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 6 — FINANCIAL INSTRUMENTS (continued)
 
Credit-risk-related Contingent Features
We have agreements with each of our derivative counterparties that contain a provision where we could be declared in default on our derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to our default on the indebtedness. As of September 30, 2021, we have not been required to post any collateral related to these agreements. If we had breached these provisions at September 30, 2021, we would have been required to settle our obligations under the agreements at their aggregate, estimated termination value of $19 million.
NOTE 7 — ASSETS AND LIABILITIES MEASURED
 
AT FAIR
 
VALUE
Accounting Standards Codification 820,
Fair Value Measurements and Disclosures
(“ASC 820”), emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).
Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment.
Investment Securities
The investments of our insurance subsidiaries are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.
Derivative Financial Instruments
We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments.
 
13

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 7 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)
 
The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):
 
    
September 30, 2021
 
          
Fair Value Measurements Using
 
    
Fair Value
   
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Assets:
                                
Investments of insurance subsidiaries:
                                
Debt securities
  
$
411
 
 
$
 
 
$
411
 
 
$
 
Money market funds and other
  
 
119
 
 
 
119
 
 
 
 
 
 
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Investments of insurance subsidiaries
  
 
530
 
 
 
119
 
 
 
411
 
 
 
 
Less amounts classified as current assets
  
 
(112
 
 
(105
 
 
(7
 
 
 
    
 
 
   
 
 
   
 
 
   
 
 
 
    
$
418
 
 
$
14
 
 
$
404
 
 
$
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                
Interest rate swaps (Other accrued expenses)
  
$
17
 
 
$
 
 
$
17
 
 
$
 
Interest rate swaps (Income taxes and other liabilities)
  
 
2
 
 
 
 
 
 
2
 
 
 
 
 
    
December 31, 2020
 
          
Fair Value Measurements Using
 
    
Fair Value
   
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Assets:
                                
Investments of insurance subsidiaries:
                                
Debt securities
   $ 416     $     $ 416     $  
Money market funds and other
     88       88              
    
 
 
   
 
 
   
 
 
   
 
 
 
Investments of insurance subsidiaries
     504       88       416        
Less amounts classified as current assets
     (116     (87     (29      
    
 
 
   
 
 
   
 
 
   
 
 
 
     $ 388     $ 1     $ 387     $  
    
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                
Interest rate swaps (Income taxes and other liabilities)
   $ 46     $     $ 46     $  
The estimated fair value of our long-term debt was $36.567 billion and $35.814 billion at September 30, 2021 and December 31, 2020, respectively, compared to carrying amounts, excluding debt issuance costs and discounts, aggregating $32.552 billion and $31.240 billion, respectively. The estimates of fair value are generally based upon the quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities.
 
14

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 
NOTE 8 — LONG-TERM DEBT
A summary of long-term debt at September 30, 2021 and December 31, 2020, including related interest rates at September 30, 2021, follows (dollars in millions):
 
    
September 30,
2021
   
December 31,
2020
 
Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)
  
$
500
 
  $  
Senior secured revolving credit facility
  
 
 
     
Senior secured term loan facilities (effective interest rate of 3.1%)
  
 
1,980
 
    3,671  
Senior secured notes (effective interest rate of 4.8%)
  
 
16,200
 
    13,850  
Other senior secured debt (effective interest rate of 4.2%)
  
 
920
 
    767  
    
 
 
   
 
 
 
Senior secured debt
  
 
19,600
 
    18,288  
Senior unsecured notes (effective interest rate of 5.5%)
  
 
12,952
 
    12,952  
Debt issuance costs and discounts
  
 
(253
    (236
    
 
 
   
 
 
 
Total debt (average life of 9.5 years, rates averaging 4.9%)
  
 
32,299
 
    31,004  
Less amounts due within one year
  
 
250
 
    209  
    
 
 
   
 
 
 
    
$
32,049
 
  $ 30,795  
    
 
 
   
 
 
 
During June 2021, we issued $2.350 billion aggregate principal amount of senior secured notes comprised of $850 million aggregate principal amount of 2 3/8% notes due 2031 and $1.500 billion aggregate principal amount of 3 1/2% notes due 2051 (the “June 2021 Notes”). We also amended and restated our senior secured revolving credit facility and our senior secured asset-based revolving credit facility, including increasing availability under the asset-based revolving credit facility to $4.500 billion, extending the maturity date on both facilities to June 30, 2026 and entering into a new $1.500 billion term
loan A-7
facility and a new $500 million term
loan B-14
facility (the “Credit Agreement Transactions”). We used the net proceeds from the June 2021 Notes and the Credit Agreement Transactions to retire the $1.071 billion term
loan A-6
facility, the $1.455 billion term
loan B-12
facility and the $1.131 billion term
loan B-13
facility. The pretax loss on retirement of debt was $12 million.
NOTE 9 — CONTINGENCIES
We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity.
Health care companies are routinely subject to investigations by various governmental agencies. Under the federal False Claims Act (“FCA”), private parties have the right to bring
qui tam
, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity.
 
15

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 9 — CONTINGENCIES (continued)
 
Texas operates a state Medicaid program pursuant to a waiver from the Centers for Medicare & Medicaid Services under Section 1115 of the Social Security Act (“Program”). The Program includes uncompensated-care pools; payments from these pools are intended to defray the uncompensated costs of services provided by our and other hospitals to Medicaid eligible or uninsured individuals. Separately, we and other hospitals provide charity care services in several communities in the state. In 2018, the Civil Division of the U.S. Department of Justice and the U.S. Attorney’s Office for the Southern District of Texas requested information about whether the Program, as operated in Harris County, complied with the laws and regulations applicable to provider related donations, and the Company cooperated with that request. On May 21, 2019, a
qui tam
lawsuit asserting violations of the FCA and the Texas Medicaid Fraud Prevention Act related to the Program, as operated in Harris County, was unsealed by the U.S. District Court for the Southern District of Texas. Both the federal and state governments declined to intervene in the
qui tam
lawsuit. The Company believes that our participation is and has been consistent with the requirements of the Program and is vigorously defending against the lawsuit being pursued by the relator. We cannot predict what effect, if any, the
qui tam
lawsuit could have on the Company.
NOTE 10 — SHARE REPURCHASE TRANSACTIONS AND OTHER COMPREHENSIVE LOSS
During January 2020 and 2019, our Board of Directors authorized share repurchase programs for up to $4 billion ($2 billion for each authorization) of our outstanding common stock. During February 2021, our Board of Directors authorized an additional $6 billion for repurchases of our outstanding common stock. During the nine months ended September 30, 2021, we repurchased 29.343 million shares of our common stock at an average price of $209.35 per share through market purchases pursuant to the January 2019 authorization (which was completed during the first quarter of 2021), the January 2020 authorization (which was completed during the second quarter of 2021) and the February 2021 authorization. At September 30, 2021, we had $2.658 billion of repurchase authorization available under the February 2021 authorization.
The components of accumulated other comprehensive loss are as follows (dollars in millions):
 
   
Unrealized
Gains on
Available-
for-Sale

Securities
   
Foreign
Currency
Translation
Adjustments
   
Defined
Benefit
Plans
   
Change
in Fair
Value of
Derivative
Instruments
   
Total
 
Balances at December 31, 2020
  $ 25     $ (271   $ (220   $ (36   $ (502
Unrealized losses on
available-for-sale
securities, net of $3 income tax benefit
    (9                             (9
Foreign currency translation adjustments, net of $2 income tax benefit
            (18                     (18
Change in fair value of derivative instruments
                            (1     (1
Expense reclassified into operations from other comprehensive income, net of $5 and $6 income tax benefits, respectively
                    16       22       38  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances at September 30, 2021
  $ 16     $ (289   $ (204   $ (15   $ (492
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION
We operate in
one
line of business, which is operating hospitals and related health care entities. We operate in two geographically organized groups: the National and American Groups. The National Group includes 96 hospitals located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, North Carolina, South Carolina, Utah and Virginia, and the American Group includes 80 hospitals located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Missouri, Tennessee and
 
16

HCA HEALTHCARE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION (continued)
 
Texas. We also operate seven hospitals in England, and these facilities are included in the Corporate and other group.
Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, losses and gains on sales of facilities, losses on retirement of debt, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
 
    
Quarter
    
Nine Months
 
    
2021
    
2020
    
2021
    
2020
 
Revenues:
                                   
National Group
  
$
7,787
 
   $ 6,633     
$
22,143
 
   $ 18,653  
American Group
  
 
6,767
 
     6,073     
 
19,562
 
     16,920  
Corporate and other
  
 
722
 
     605     
 
1,983
 
     1,667  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
15,276
 
   $ 13,311     
$
43,688
 
   $ 37,240  
    
 
 
    
 
 
    
 
 
    
 
 
 
Equity in earnings of affiliates:
                                   
National Group
  
$
(14
   $ (23   
$
(30
   $ (26
American Group
  
 
(14
     (15   
 
(38
     (26
Corporate and other
  
 
(7
     (2   
 
(10
     4  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
(35
   $ (40   
$
(78
   $ (48
    
 
 
    
 
 
    
 
 
    
 
 
 
Adjusted segment EBITDA:
                                   
National Group
  
$
1,780
 
   $ 1,128     
$
5,330
 
   $ 3,828  
American Group
  
 
1,604
 
     1,130     
 
4,698
 
     3,653  
Corporate and other
  
 
(160
     (205   
 
(533
     (562
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
3,224
 
   $ 2,053     
$
9,495
 
   $ 6,919  
    
 
 
    
 
 
    
 
 
    
 
 
 
Depreciation and amortization:
                                   
National Group
  
$
343
 
   $ 312     
$
1,005
 
   $ 930  
American Group
  
 
295
 
     286     
 
884
 
     868  
Corporate and other
  
 
78
 
     96     
 
236
 
     261  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
716
 
   $ 694     
$
2,125
 
   $ 2,059  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted segment EBITDA
  
$
3,224
 
   $ 2,053     
$
9,495
 
   $ 6,919  
Depreciation and amortization
  
 
716
 
     694     
 
2,125
 
     2,059  
Interest expense
  
 
398
 
     385     
 
1,168
 
     1,201  
Losses (gains) on sales of facilities
  
 
(1,047
     (14   
 
(1,057
     6  
Losses on retirement of debt
  
 
 
         
 
12
 
     295  
    
 
 
    
 
 
    
 
 
    
 
 
 
Income before income taxes
  
$
3,157
 
   $ 988     
$
7,247
 
   $ 3,358  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
17

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
This quarterly report on
Form 10-Q
includes certain disclosures which contain “forward-looking statements” within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include statements regarding expected share-based compensation expense, expected capital expenditures and expected net claim payments and all other statements that do not relate solely to historical or current facts, and can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) developments related to
COVID-19,
including, without limitation, the length and severity of the pandemic and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume of
COVID-19
patients cared for across our health systems; measures we are taking to respond to the
COVID-19
pandemic; the impact and terms of government and administrative regulation and stimulus (including the Families First Coronavirus Response Act, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, the Paycheck Protection Program and Health Care Enhancement Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021 and other enacted and potential future legislation) and whether such programs continue or new similar programs are enacted in the future; changes in revenues due to declining patient volumes, changes in payer mix and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions, including the impact of any current or future vaccine mandates; supply shortages and disruptions; and the timing, availability and adoption of effective medical treatments and vaccines, (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the
COVID-19
pandemic, which could impact us from a financial perspective, (3) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), including the effects of changes or court challenges to the Affordable Care Act or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, including proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), and also including any such laws or governmental regulations which are adopted in response to the
COVID-19
pandemic, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and those required under the
Pay-As-You-Go
Act of 2010 (“PAYGO Act”) as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) the highly competitive nature of the health care business, (9) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (10) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (11) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (12) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical
 
18

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF (Continued)
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Forward-Looking Statements (continued)
 
and technical support personnel, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry) resulting from the
COVID-19
pandemic, (16) the emergence of and effects related to other pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of potential cybersecurity incidents or security breaches, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (25) changes in the U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on
Form 10-K
for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ from those expressed in any forward-looking statements made by or on behalf of HCA. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this report, which forward-looking statements reflect management’s views only as of the date of this report. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise.
COVID-19
Pandemic
On March 11, 2020, the World Health Organization designated
COVID-19
as a global pandemic. Patient volumes and the related revenues for most of our services were significantly impacted during the latter portion of the first quarter and the first half of the second quarter of 2020 and have continued to be impacted as various policies were implemented by federal, state and local governments in response to the
COVID-19
pandemic. During the second quarter of 2021, our patient volumes experienced a strong rebound as the effects of the pandemic moderated and certain pandemic-related restrictions and policies were eased. During the third quarter of 2021, our patient volumes remained strong, with the exception of inpatient surgeries, and included a resurgence of
COVID-19
admissions. Inpatient surgery volumes were constrained during the quarter as capacity was used to treat the surge of COVID-19 patients. We believe the extent of the
COVID-19
pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate how long or to what extent the pandemic will impact our operations.
Third Quarter 2021 Operations Summary
Revenues increased to $15.276 billion in the third quarter of 2021 from $13.311 billion in the third quarter of 2020. Net income attributable to HCA Healthcare, Inc. totaled $2.269 billion, or $7.00 per diluted share, for the quarter ended September 30, 2021, compared to $668 million, or $1.95 per diluted share, for the quarter ended September 30, 2020. Third quarter results for 2021 and 2020 include gains on sales of facilities of $1.047 billion, or $2.43 per diluted share, and $14 million, or $0.03 per diluted share, respectively. Third quarter results for 2020 include the reversal of $822 million, or $1.72 per diluted share, of government stimulus income recorded in the second quarter of 2020 related to general distribution Provider Relief Funds (“PRFs”) established by the CARES Act. During October 2020, we announced we would return, or repay early, our share of the PRFs of approximately $1.6 billion and approximately $4.4 billion in Medicare accelerated payments (repaid during
 
19

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Third Quarter 2021 Operations Summary (continued)
 
the fourth quarter of 2020). All “per diluted share” disclosures are based upon amounts net of the applicable income taxes. Shares used for diluted earnings per share were 324.029 million shares for the quarter ended September 30, 2021 and 343.346 million shares for the quarter ended September 30, 2020. During the first nine months of 2021, we repurchased 29.343 million shares of our common stock.
Revenues increased 14.8% on a consolidated basis and 15.0% on a same facility basis for the quarter ended September 30, 2021, compared to the quarter ended September 30, 2020. The increase in consolidated revenues can be primarily attributed to the combined impact of a 5.9% increase in revenue per equivalent admission and a 8.4% increase in equivalent admissions. The same facility revenues increase primarily resulted from the combined impact of a 5.2% increase in same facility revenue per equivalent admission and a 9.3% increase in same facility equivalent admissions.
During the quarter ended September 30, 2021, consolidated admissions increased 5.9% and same facility admissions increased 6.8% compared to the quarter ended September 30, 2020. Surgeries increased 2.6% on a consolidated basis and 2.3% on a same facility basis during the quarter ended September 30, 2021, compared to the quarter ended September 30, 2020. Emergency department visits increased 28.9% on a consolidated basis and 31.2% on a same facility basis during the quarter ended September 30, 2021, compared to the quarter ended September 30, 2020. Consolidated and same facility uninsured admissions increased 0.7% and 1.2%, respectively, for the quarter ended September 30, 2021, compared to the quarter ended September 30, 2020.
Cash flows from operating activities declined $440 million, from $2.717 billion for the third quarter of 2020 to $2.277 billion for the third quarter of 2021. The decline in cash provided by operating activities was primarily related to the net impact of negative changes in working capital items of $797 million, primarily related to an increase in accounts receivable, offset by a $269 million increase in net income, excluding the government stimulus income reversal and gains on sales of facilities.
Results of Operations
Revenue/Volume Trends
Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted
fee-for-service
rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
 
20

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF (Continued)
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Revenue/Volume Trends (continued)
 
Revenues increased 14.8% from $13.311 billion in the third quarter of 2020 to $15.276 billion in the third quarter of 2021. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record
self-pay
revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for
non-elective
care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
 
    
Quarter
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
2,645
 
  
 
17.3
  $ 2,603        19.6
Managed Medicare
  
 
2,124
 
  
 
13.9
 
    1,760        13.2  
Medicaid
  
 
692
 
  
 
4.5
 
    445        3.3  
Managed Medicaid
  
 
813
 
  
 
5.3
 
    707        5.3  
Managed care and insurers
  
 
7,998
 
  
 
52.4
 
    6,752        50.7  
International (managed care and insurers)
  
 
324
 
  
 
2.1
 
    307        2.3  
Other
  
 
680
 
  
 
4.5
 
    737        5.6  
  
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
15,276
 
  
 
100.0
  $ 13,311        100.0
  
 
 
    
 
 
   
 
 
    
 
 
 
    
Nine Months
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
7,816
 
  
 
17.9
  $ 7,618        20.5
Managed Medicare
  
 
6,281
 
  
 
14.4
 
    5,074        13.6  
Medicaid
  
 
1,722
 
  
 
3.9
 
    1,423        3.8  
Managed Medicaid
  
 
2,369
 
  
 
5.4
 
    1,904        5.1  
Managed care and insurers
  
 
22,300
 
  
 
51.0
 
    19,028        51.0  
International (managed care and insurers)
  
 
995
 
  
 
2.3
 
    838        2.3  
Other
  
 
2,205
 
  
 
5.1
 
    1,355        3.7  
  
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
43,688
 
  
 
100.0
  $ 37,240        100.0
  
 
 
    
 
 
   
 
 
    
 
 
 
 
21

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Revenue/Volume Trends (continued)
 
Consolidated and same facility revenue per equivalent admission increased 5.9% and 5.2%, respectively, in the third quarter of 2021, compared to the third quarter of 2020. Consolidated and same facility equivalent admissions increased 8.4% and 9.3%, respectively, in the third quarter of 2021, compared to the third quarter of 2020. Consolidated and same facility outpatient surgeries increased 7.2% and 6.4%, respectively, in the third quarter of 2021, compared to the third quarter of 2020. Consolidated and same facility inpatient surgeries declined 5.3% and 4.9%, respectively, in the third quarter of 2021, compared to the third quarter of 2020. Consolidated and same facility emergency department visits increased 28.9% and 31.2%, respectively, in the third quarter of 2021, compared to the third quarter of 2020.
To quantify the total impact of the trends related to uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions):
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)
  
$
12,803
 
  $ 11,170    
$
36,396
 
  $ 32,428  
Cost-to-charges
ratio (patient care costs as percentage of gross patient charges)
  
 
11.8
    12.0  
 
11.4
    12.1
Total uncompensated care
  
$
7,782
 
  $ 7,023    
$
22,299
 
  $ 21,625  
Multiply by the
cost-to-charges
ratio
  
 
11.8
    12.0  
 
11.4
    12.1
  
 
 
   
 
 
   
 
 
   
 
 
 
Estimated cost of total uncompensated care
  
$
916
 
  $ 843    
$
2,542
 
  $ 2,617  
  
 
 
   
 
 
   
 
 
   
 
 
 
Same facility uninsured admissions increased by 463 admissions, or 1.2%, in the third quarter of 2021 compared to the third quarter of 2020. Same facility uninsured admissions increased 6.6% in the second quarter of 2021 compared to the second quarter of 2020. Same facility uninsured admissions declined 15.7% in the first quarter of 2021 compared to the first quarter of 2020. Same facility uninsured admissions in 2020, compared to 2019, declined 9.1% in the fourth quarter, declined 14.2% in the third quarter, declined 10.0% in the second quarter, and increased 7.1% in the first quarter. The declines in the first quarter of 2021, compared to the first quarter of 2020, and the last three quarters of 2020, compared to the last three quarters of 2019, were primarily due to the reimbursement received, as provided for under the Families First Coronavirus Response Act and subsequent legislation, for uninsured patients diagnosed with
COVID-19
and the resulting classification of those patients as an insured admission, as well as general declines in patient volumes resulting from the pandemic’s impact on our operations.
 
22

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Revenue/Volume Trends (continued)
 
The approximate percentages of our admissions related to Medicare, managed Medicare, Medicaid, managed Medicaid, managed care and insurers and the uninsured for the quarters and nine months ended September 30, 2021 and 2020 are set forth in the following table.
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Medicare
  
 
21
    25  
 
23
    26
Managed Medicare
  
 
21
 
    19    
 
21
 
    19  
Medicaid
  
 
4
 
    5    
 
5
 
    6  
Managed Medicaid
  
 
14
 
    13    
 
13
 
    12  
Managed care and insurers
  
 
32
 
    30    
 
31
 
    29  
Uninsured
  
 
8
 
    8    
 
7
 
    8  
  
 
 
   
 
 
   
 
 
   
 
 
 
  
 
100
    100  
 
100
    100
  
 
 
   
 
 
   
 
 
   
 
 
 
The approximate percentages of our inpatient revenues related to Medicare, managed Medicare, Medicaid, managed Medicaid, managed care and insurers for the quarters and nine months ended September 30, 2021 and 2020 are set forth in the following table.
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Medicare
  
 
22
    25  
 
24
    27
Managed Medicare
  
 
16
 
    15    
 
16
 
    15  
Medicaid
  
 
7
 
    5    
 
6
 
    5  
Managed Medicaid
  
 
5
 
    6    
 
6
 
    6  
Managed care and insurers
  
 
50
 
    49    
 
48
 
    47  
  
 
 
   
 
 
   
 
 
   
 
 
 
  
 
100
    100  
 
100
    100
  
 
 
   
 
 
   
 
 
   
 
 
 
At September 30, 2021, we had 91 hospitals in the states of Texas and Florida. During the quarter ended September 30, 2021, 57% of our admissions and 50% of our revenues were generated by these hospitals. Uninsured admissions in Texas and Florida represented 71% of our uninsured admissions during the quarter ended September 30, 2021.
We receive a significant portion of our revenues from government health programs, principally Medicare and Medicaid, which are highly regulated and subject to frequent and substantial changes. In December 2017, the Centers for Medicare & Medicaid Services (“CMS”) announced that it will phase out federal matching funds for Designated State Health Programs under waivers granted under Section 1115 of the Social Security Act. Texas currently operates its Healthcare Transformation and Quality Improvement Program pursuant to a Medicaid waiver. In December 2017, CMS approved an extension of this waiver through September 30, 2022, but indicated that it will phase out some of the federal funding. Our Texas Medicaid revenues included Medicaid supplemental payments of $151 million and $154 million during the third quarters of 2021 and 2020, respectively, and $437 million and $455 million during the first nine months of 2021 and 2020, respectively.
In addition, we receive supplemental payments in several other states. We are aware these supplemental payment programs are currently being reviewed by certain state agencies and some states have made requests to CMS to replace their existing supplemental payment programs. It is possible these reviews and requests will
 
23

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Revenue/Volume Trends (continued)
 
result in the restructuring of such supplemental payment programs and could result in the payment programs being reduced or eliminated. Because deliberations about these programs are ongoing, we are unable to estimate the financial impact the program structure modifications, if any, may have on our results of operations.
Key Performance Indicators
We present certain metrics and statistical information that management uses when assessing our results of operations. We believe this information is useful to investors as it provides insight to how management evaluates operational performance and trends between reporting periods. Information on how these metrics and statistical information are defined is provided in the following tables summarizing operating results and operating data.
Operating Results Summary
The following is a comparative summary of results of operations for the quarters and nine months ended September 30, 2021 and 2020 (dollars in millions):
 
    
Quarter
 
    
2021
   
2020
 
    
Amount
   
Ratio
   
Amount
   
Ratio
 
Revenues
  
$
15,276
 
 
 
100.0
 
  $ 13,311       100.0  
Salaries and benefits
  
 
7,094
 
 
 
46.4
 
    6,097       45.8  
Supplies
  
 
2,463
 
 
 
16.1
 
    2,128       16.0  
Other operating expenses
  
 
2,530
 
 
 
16.6
 
    2,251       16.9  
Government stimulus income reversal
  
 
 
 
 
 
    822       6.2  
Equity in earnings of affiliates
  
 
(35
 
 
(0.2
    (40     (0.3
Depreciation and amortization
  
 
716
 
 
 
4.7
 
    694       5.2  
Interest expense
  
 
398
 
 
 
2.6
 
    385       2.9  
Gains on sales of facilities
  
 
(1,047
 
 
(6.9
    (14     (0.1
  
 
 
   
 
 
   
 
 
   
 
 
 
  
 
12,119
 
 
 
79.3
 
    12,323       92.6  
  
 
 
   
 
 
   
 
 
   
 
 
 
Income before income taxes
  
 
3,157
 
 
 
20.7
 
    988       7.4  
Provision for income taxes
  
 
685
 
 
 
4.5
 
    209       1.5  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net income
  
 
2,472
 
 
 
16.2
 
    779       5.9  
Net income attributable to noncontrolling interests
  
 
203
 
 
 
1.3
 
    111       0.9  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net income attributable to HCA Healthcare, Inc.
  
$
2,269
 
 
 
14.9
 
  $ 668       5.0  
  
 
 
   
 
 
   
 
 
   
 
 
 
% changes from prior year:
        
Revenues
  
 
14.8
      4.9  
Income before income taxes
  
 
219.6
 
      0.9    
Net income attributable to HCA Healthcare, Inc.
  
 
239.7
 
      9.0    
Admissions(a)
  
 
5.9
 
      (3.9  
Equivalent admissions(b)
  
 
8.4
 
      (9.1  
Revenue per equivalent admission
  
 
5.9
 
      15.3    
Same facility % changes from prior year(c):
        
Revenues
  
 
15.0
 
      4.5    
Admissions(a)
  
 
6.8
 
      (3.8  
Equivalent admissions(b)
  
 
9.3
 
      (9.0  
Revenue per equivalent admission
  
 
5.2
 
      14.8    
 
24

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Operating Results Summary (continued)
 
    
Nine Months
 
    
2021
   
2020
 
    
Amount
   
Ratio
   
Amount
   
Ratio
 
Revenues
  
$
43,688
 
 
 
100.0
 
  $ 37,240       100.0  
Salaries and benefits
  
 
19,780
 
 
 
45.3
 
    17,545       47.1  
Supplies
  
 
7,067
 
 
 
16.2
 
    5,999       16.1  
Other operating expenses
  
 
7,424
 
 
 
17.0
 
    6,825       18.3  
Equity in earnings of affiliates
  
 
(78
 
 
(0.2
    (48     (0.1
Depreciation and amortization
  
 
2,125
 
 
 
4.8
 
    2,059       5.6  
Interest expense
  
 
1,168
 
 
 
2.7
 
    1,201       3.2  
Losses (gains) on sales of facilities
  
 
(1,057
 
 
(2.4
    6        
Losses on retirement of debt
  
 
12
 
 
 
 
    295       0.8  
  
 
 
   
 
 
   
 
 
   
 
 
 
  
 
36,441
 
 
 
83.4
 
    33,882       91.0  
  
 
 
   
 
 
   
 
 
   
 
 
 
Income before income taxes
  
 
7,247
 
 
 
16.6
 
    3,358       9.0  
Provision for income taxes
  
 
1,531
 
 
 
3.5
 
    665       1.8  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net income
  
 
5,716
 
 
 
13.1
 
    2,693       7.2  
Net income attributable to noncontrolling interests
  
 
574
 
 
 
1.3
 
    365       0.9  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net income attributable to HCA Healthcare, Inc.
  
$
5,142
 
 
 
11.8
 
  $ 2,328       6.3  
  
 
 
   
 
 
   
 
 
   
 
 
 
% changes from prior year:
        
Revenues
  
 
17.3
      (1.5 )%   
Income before income taxes
  
 
115.8
 
      (7.7  
Net income attributable to HCA Healthcare, Inc.
  
 
120.8
 
      (4.4  
Admissions(a)
  
 
5.9
 
      (5.1  
Equivalent admissions(b)
  
 
8.4
 
      (9.8  
Revenue per equivalent admission
  
 
8.2
 
      9.1    
Same facility % changes from prior year(c):
        
Revenues
  
 
17.5
 
      (2.1  
Admissions(a)
  
 
6.2
 
      (5.3  
Equivalent admissions(b)
  
 
8.8
 
      (9.9  
Revenue per equivalent admission
  
 
7.9
 
      8.6    
 
(a)
Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume.
(b)
Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume, resulting in a general measure of combined inpatient and outpatient volume.
(c)
Same facility information excludes the operations of hospitals and their related facilities which were either acquired or divested during the current and prior period.
 
25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
 
Quarters Ended September 30, 2021 and 2020
Revenues increased to $15.276 billion in the third quarter of 2021 from $13.311 billion in the third quarter of 2020. Net income attributable to HCA Healthcare, Inc. totaled $2.269 billion, or $7.00 per diluted share, for the quarter ended September 30, 2021, compared to $668 million, or $1.95 per diluted share, for the quarter ended September 30, 2020. Third quarter results for 2021 and 2020 include gains on sales of facilities of $1.047 billion, or $2.43 per diluted share, and $14 million, or $0.03 per diluted share, respectively. Third quarter results for 2020 include the reversal of $822 million, or $1.72 per diluted share, of government stimulus income recorded in the second quarter of 2020 related to general distribution PRFs established by the CARES Act. During October 2020, we announced we would return, or repay early, our share of the PRFs of approximately $1.6 billion and approximately $4.4 billion in Medicare accelerated payments (repaid during the fourth quarter of 2020). All “per diluted share” disclosures are based upon amounts net of the applicable income taxes. Shares used for diluted earnings per share were 324.029 million shares for the quarter ended September 30, 2021 and 343.346 million shares for the quarter ended September 30, 2020. During the first nine months of 2021, we repurchased 29.343 million shares of our common stock.
Revenues increased 14.8% on a consolidated basis and 15.0% on a same facility basis for the quarter ended September 30, 2021, compared to the quarter ended September 30, 2020. The increase in consolidated revenues can be primarily attributed to the combined impact of a 5.9% increase in revenue per equivalent admission and a 8.4% increase in equivalent admissions. The same facility revenues increase primarily resulted from the combined impact of a 5.2% increase in same facility revenue per equivalent admission and a 9.3% increase in same facility equivalent admissions.
Salaries and benefits, as a percentage of revenues, were 46.4% in the third quarter of 2021 and 45.8% in the third quarter of 2020. Salaries and benefits per equivalent admission increased 7.4% in the third quarter of 2021 compared to the third quarter of 2020. Same facility labor rate increases averaged 8.0% for the third quarter of 2021 compared to the third quarter of 2020 primarily due to certain contract, overtime and other premium rate labor costs being incurred during the third quarter of 2021 to support our clinical staff and address the surge of
COVID-19
patients.
Supplies, as a percentage of revenues, were 16.1% in the third quarter of 2021 and 16.0% in the third quarter of 2020. Supply costs per equivalent admission increased 6.8% in the third quarter of 2021 compared to the third quarter of 2020. Supply costs per equivalent admission increased 24.0% for pharmacy supplies and 9.4% for general medical and surgical items and declined 4.9% for medical devices in the third quarter of 2021 compared to the third quarter of 2020. The increase in pharmacy supplies is primarily related to certain
COVID-19
therapies used in the surge of
COVID-19
cases during the third quarter of 2021, and the increase in general medical and surgical items is primarily related to an increased utilization of personal protective equipment (“PPE”).
Other operating expenses, as a percentage of revenues, were 16.6% in the third quarter of 2021 and 16.9% in the third quarter of 2020. Other operating expenses is primarily comprised of contract services, professional fees, repairs and maintenance, rents and leases, utilities, insurance (including professional liability insurance) and nonincome taxes. Provisions for losses related to professional liability risks were $49 million and $26 million for the third quarters of 2021 and 2020, respectively. During the third quarters of 2021 and 2020, we recorded reductions of $87 million, or $0.21 per diluted share, and $112 million, or $0.25 per diluted share, respectively, to our provision for professional liability risks related to the receipt of updated actuarial information.
During the third quarter of 2020, we recorded the reversal of $822 million of government stimulus income previously recorded in the second quarter of 2020 related to general distribution funds received from the PRFs established by the CARES Act.
 
26

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Quarters Ended September 30, 2021 and 2020 (continued)
 
Equity in earnings of affiliates was $35 million and $40 million in the third quarters of 2021 and 2020, respectively.
Depreciation and amortization increased $22 million, from $694 million in the third quarter of 2020 to $716 million in the third quarter of 2021. The increase in depreciation relates primarily to capital expenditures at our existing facilities.
Interest expense was $398 million in the third quarter of 2021 and $385 million in the third quarter of 2020. Our average debt balance was $32.450 billion for the third quarter of 2021 compared to $30.952 billion for the third quarter of 2020. The average effective interest rate for our long-term debt was 4.9% for both of the quarters ended September 30, 2021 and 2020.
During the third quarters of 2021 and 2020, we recorded gains on sales of facilities of $1.047 billion and $14 million, respectively. The gains on sales of facilities for the third quarter of 2021 include a $655 million gain related to the sale of four hospital facilities in Georgia and gains of $392 million related to the sales of other health care entity investments and minor real estate assets.
The effective tax rates were 23.2% and 23.8% for the third quarters of 2021 and 2020, respectively. The effective tax rate computations exclude net income attributable to noncontrolling interests as it relates to consolidated partnerships.
Net income attributable to noncontrolling interests increased from $111 million for the third quarter of 2020 to $203 million for the third quarter of 2021. The increase in net income attributable to noncontrolling interests related primarily to an increase in partnership operating income as well as the impact of the government stimulus income reversal for certain hospital and surgery center partnerships in the third quarter of 2020.
Nine Months Ended September 30, 2021 and 2020
Revenues increased to $43.688 billion in the first nine months of 2021 from $37.240 billion in the first nine months of 2020. Net income attributable to HCA Healthcare, Inc. totaled $5.142 billion, or $15.43 per diluted share, for the first nine months ended September 30, 2021, compared to $2.328 billion, or $6.79 per diluted share, for the first nine months ended September 30, 2020. Results for the first nine months of 2021 included gains on sales of facilities of $1.057 billion, or $2.39 per diluted share, and losses on retirement of debt of $12 million, or $0.03 per diluted share. Results for the first nine months of 2020 included losses on sales of facilities of $6 million, or $0.03 per diluted share, and losses on retirement of debt of $295 million, or $0.66 per diluted share. Revenues for the first nine months of 2021 and 2020, respectively, include $33 million, or $0.07 per diluted share, and $55 million, or $0.12 per diluted share, related to the settlement of Medicare outlier calculations for prior periods. Results for the first nine months of 2020 also included $60 million, or $0.13 per diluted share, of employee retention payroll tax credits, established by the CARES Act. Our provision for income taxes for the first nine months of 2021 and 2020 included tax benefits of $96 million, or $0.29 per diluted share, and $59 million, or $0.17 per diluted share, respectively, related to employee equity award settlements. All “per diluted share” disclosures are based upon amounts net of the applicable income taxes. Shares used for diluted earnings per share were 333.248 million shares for the nine months ended September 30, 2021 and 343.014 million shares for the nine months ended September 30, 2020. During the first nine months of 2021, we repurchased 29.343 million shares of our common stock.
 
27

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Nine Months Ended September 30, 2021 and 2020 (continued)
 
Revenues increased 17.3% on a consolidated basis and 17.5% on a same facility basis for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020. The increase in consolidated revenues can be primarily attributed to the combined impact of an 8.2% increase in revenue per equivalent admission and an 8.4% increase in equivalent admissions. The increase in same facility revenues can be primarily attributed to the combined impact of a 7.9% increase in revenue per equivalent admission and an 8.8% increase in equivalent admissions.
Salaries and benefits, as a percentage of revenues, were 45.3% in the first nine months of 2021 and 47.1% in the first nine months of 2020. Salaries and benefits per equivalent admission increased 4.0% in the first nine months of 2021 compared to the first nine months of 2020. Same facility labor rate increases averaged 7.3% for the first nine months of 2021 compared to the first nine months of 2020 primarily due to an increased utilization of contract, overtime and other premium rate labor costs during the 2021 period to support our clinical staff and address the surges of COVID-19 cases during the first and third quarters of 2021.
Supplies, as a percentage of revenues, were 16.2% in the first nine months of 2021 and 16.1% in the first nine months of 2020. Supply costs per equivalent admission increased 8.6% in the first nine months of 2021 compared to the first nine months of 2020. Supply costs per equivalent admission increased 3.6% for medical devices, 14.8% for pharmacy supplies and 10.7% for general medical and surgical items in the first nine months of 2021 compared to the first nine months of 2020. The increase in pharmacy supplies is primarily related to certain
COVID-19
therapies used in the surges of
COVID-19
cases during the first and third quarters of 2021, and the increase in general medical and surgical items is primarily related to increased utilization of PPE.
Other operating expenses, as a percentage of revenues, were 17.0% in the first nine months of 2021 and 18.3% in the first nine months of 2020. Other operating expenses is primarily comprised of contract services, professional fees, repairs and maintenance, rents and leases, utilities, insurance (including professional liability insurance) and nonincome taxes. Provisions for losses related to professional liability risks were $318 million and $305 million for the first nine months of 2021 and 2020, respectively. During the first nine months of 2021 and 2020, we recorded reductions of $87 million, or $0.20 per diluted share, and $112 million, or $0.25 per diluted share, respectively, to our provision for professional liability risks related to the receipt of updated actuarial information.
Equity in earnings of affiliates was $78 million and $48 million in the first nine months of 2021 and 2020, respectively.
Depreciation and amortization increased $66 million, from $2.059 billion in the first nine months of 2020 to $2.125 billion in the first nine months of 2021. The increase in depreciation relates primarily to capital expenditures at our existing facilities.
Interest expense was $1.168 billion in the first nine months of 2021 and $1.201 billion in the first nine months of 2020. Our average debt balance was $31.780 billion for the first nine months of 2021 compared to $32.223 billion for the first nine months of 2020. The average effective interest rate for our long-term debt declined to 4.9% for the nine months ended September 30, 2021 from 5.0% for the nine months ended September 30, 2020.
During the first nine months of 2021 and 2020, we recorded net gains of $1.057 billion and net losses on sales of facilities of $6 million, respectively. The gains on sales of facilities for the first nine months of 2021 are primarily related to the sale of four hospital facilities in Georgia and other health care entity investments.
 
28

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Nine Months Ended September 30, 2021 and 2020 (continued)
 
During June 2021, we issued $2.350 billion aggregate principal amount of senior secured notes comprised of $850 million aggregate principal amount of 2 3/8% notes due 2031 and $1.500 billion aggregate principal amount of 3 1/2% notes due 2051 (the “June 2021 Notes”). We also amended and restated our senior secured revolving credit facility and our senior secured asset-based revolving credit facility, including increasing availability under the asset-based revolving credit facility to $4.500 billion, extending the maturity date on both facilities to June 30, 2026 and entering into a new $1.500 billion term loan
A-7
facility and a new $500 million term
loan B-14
facility (the “Credit Agreement Transactions”). We used the net proceeds from the June 2021 Notes and the Credit Agreement Transactions to retire the $1.071 billion term
loan A-6
facility, the $1.455 billion term
loan B-12
facility and the $1.131 billion term
loan B-13
facility. The pretax loss on retirement of debt was $12 million. During February 2020, we issued $2.700 billion aggregate principal amount of 3.50% senior unsecured notes due 2030. During March 2020, we used the net proceeds for the redemption of all $1.000 billion outstanding aggregate principal amount of HCA Healthcare, Inc.’s 6.25% senior notes due 2021 and, together with available funds, for the redemption of all $2.000 billion outstanding aggregate principal amount of HCA Inc.’s 7.50% senior notes due 2022. The pretax loss on retirement of debt was $295 million.
The effective tax rates were 22.9% and 22.2% for the first nine months of 2021 and 2020, respectively. The effective tax rate computations exclude net income attributable to noncontrolling interests as it relates to consolidated partnerships. Our provisions for income taxes for the first nine months of 2021 and 2020 included tax benefits of $96 million and $59 million, respectively, related to employee equity award settlements. Excluding the effect of these adjustments, the effective tax rate for the first nine months of 2021 and 2020 would have been 24.4% and 24.2%, respectively.
Net income attributable to noncontrolling interests increased from $365 million for the first nine months of 2020 to $574 million for the first nine months of 2021. The increase in net income attributable to noncontrolling interests related primarily to the partnership operations of two of our Texas markets and our surgery center partnerships.
Liquidity and Capital Resources
Cash provided by operating activities declined $6.299 billion, from $12.815 billion for the first nine months of 2020 to $6.516 billion for the first nine months of 2021. The $12.815 billion of cash flows from operating activities in the first nine months of 2020 included $6.123 billion of government stimulus refund liability related to unapplied accelerated Medicare payments and PRFs established by the CARES Act (approximately $6 billion was returned or repaid early and reversed out of cash flow from operations in the fourth quarter of 2020). The decline in cash provided by operating activities also included the net impact of negative changes in working capital items of $2.350 billion, primarily related to an increase in accounts receivable, offset by an increase in net income, excluding losses and gains on sales of facilities and losses on retirement of debt, of $2.001 billion. The combination of interest payments and net income tax payments in the first nine months of 2021 and 2020 totaled $2.473 billion and $2.009 billion, respectively. Working capital totaled $3.624 billion at September 30, 2021 and $3.629 billion at December 31, 2020.
Cash used in investing activities was $929 million in the first nine months of 2021 compared to $2.483 billion in the first nine months of 2020. Acquisitions of hospitals and health care entities increased from $380 million in the first nine months of 2020 to $488 million in the first nine months of 2021. Excluding acquisitions, capital expenditures were $2.385 billion in the first nine months of 2021 and $2.087 billion in the first nine months of 2020. Planned capital expenditures are expected to approximate $3.7 billion in 2021. At
 
29

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Liquidity and Capital Resources (continued)
 
September 30, 2021, there were projects under construction which had estimated additional costs to complete and equip over the next five years of approximately $3.6 billion. We expect to finance capital expenditures with internally generated and borrowed funds. Sales of hospitals and health care entities increased $1.912 billion primarily related to the proceeds from our sales of five hospitals in Georgia (the sale of one hospital was effective October 1, 2021) and other health care entity investments.
Cash used in financing activities totaled $6.349 billion in the first nine months of 2021 compared to $4.361 billion in the first nine months of 2020. During the first nine months of 2021, net cash flows used in financing activities included a net increase of $1.050 billion in our indebtedness, payment of dividends of $476 million, repurchase of common stock of $6.143 billion and distributions to noncontrolling interests of $501 million. During the first nine months of 2020, net cash flows used in financing activities included a net decline of $3.183 billion in our indebtedness, payment of dividends of $153 million, repurchase of common stock of $441 million and distributions to noncontrolling interests of $393 million.
We are a highly leveraged company with significant debt service requirements. Our debt totaled $32.299 billion at September 30, 2021. Our interest expense was $1.168 billion for the first nine months of 2021 and $1.201 billion for the first nine months of 2020.
In addition to cash flows from operations, available sources of capital include amounts available under our senior secured credit facilities ($5.920 billion and $5.590 billion available as of September 30, 2021 and October 31, 2021, respectively) and anticipated access to public and private debt markets.
Investments of our insurance subsidiaries, held to maintain statutory equity levels and to provide liquidity to pay claims, totaled $530 million and $504 million at September 30, 2021 and December 31, 2020, respectively. An insurance subsidiary maintained net reserves for professional liability risks of $159 million and $188 million at September 30, 2021 and December 31, 2020, respectively. Our facilities are insured by a 100% owned insurance subsidiary for losses up to $75 million per occurrence; however, this coverage is generally subject, in most cases, to a $15 million per occurrence self-insured retention. Additionally, the insurance subsidiary has entered into reinsurance contracts providing reimbursement for a certain portion of losses in excess of self-insured retentions. Net reserves for the self-insured professional liability risks retained were $1.795 billion and $1.736 billion at September 30, 2021 and December 31, 2020, respectively. Claims payments, net of reinsurance recoveries, during the next 12 months are expected to approximate $476 million. We estimate that approximately $434 million of the expected net claim payments during the next 12 months will relate to claims subject to the self-insured retention.
During June 2021, we issued $2.350 billion aggregate principal amount of senior secured notes comprised of $850 million aggregate principal amount of 2 3/8% notes due 2031 and $1.500 billion aggregate principal amount of 3 1/2% notes due 2051 (the “June 2021 Notes”). We also amended and restated our senior secured revolving credit facility and our senior secured asset-based revolving credit facility, including increasing availability under the asset-based revolving credit facility to $4.500 billion, extending the maturity date on both facilities to June 30, 2026 and entering into a new $1.500 billion term loan
A-7
facility and a new $500 million term loan
B-14
facility (the “Credit Agreement Transactions”). We used the net proceeds from the June 2021 Notes and the Credit Agreement Transactions to retire the $1.071 billion term loan
A-6
facility, the $1.455 billion term loan
B-12
facility and the $1.131 billion term loan
B-13
facility.
Management believes that cash flows from operations, amounts available under our senior secured credit facilities and our anticipated access to public and private debt markets will be sufficient to meet expected liquidity needs during the next 12 months.
 
30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Liquidity and Capital Resources (continued)
 
Summarized Financial Information
HCA Inc., a direct wholly-owned subsidiary of HCA Healthcare, Inc., is the primary obligor under a substantial portion of our indebtedness, including our senior secured credit facilities, senior secured notes and senior unsecured notes. The senior secured notes and senior unsecured notes issued by HCA Inc. are fully and unconditionally guaranteed on an unsecured basis by HCA Healthcare, Inc. The senior secured credit facilities and senior secured notes are fully and unconditionally guaranteed on a senior secured basis by substantially all existing and future, direct and indirect, 100% owned material domestic subsidiaries that are “Unrestricted Subsidiaries” under our Indenture dated December 16, 1993 (except for certain special purpose subsidiaries that only guarantee and pledge their assets under our senior secured asset-based revolving credit facility). For a list of subsidiary guarantors, see Exhibit 22 to this quarterly report on Form
10-Q.
The subsidiary guarantees rank senior in right of payment to all subordinated indebtedness of each subsidiary guarantor, equally in right of payment with all senior indebtedness of the subsidiary guarantors and are structurally subordinated in right of payment to all indebtedness and other liabilities of any nonguarantor subsidiaries of the subsidiary guarantors (other than indebtedness and liabilities owed to one of the subsidiary guarantors). The subsidiary guarantees are secured by first-priority liens on the subsidiary guarantors’ assets, subject to certain exceptions, that secure our senior secured cash flow credit facility on a first-priority basis. The subsidiary guarantees are secured by second-priority liens on the subsidiary guarantors’ assets that secure our senior secured asset-based revolving credit facility on a first-priority basis and our senior secured cash flow credit facility on a second-priority basis.
The subsidiary guarantees may be automatically and unconditionally released and discharged upon certain customary events, including in the event such guarantee is released under our senior secured credit facilities. The indentures governing the senior secured notes include a “savings clause” intended to limit each subsidiary guarantor’s obligations as necessary to prevent the guarantee from constituting a fraudulent conveyance under applicable law, which could reduce a subsidiary guarantor’s liability on its guarantee to zero. For further information regarding the guarantees, refer to the applicable indentures that are filed as exhibits to our annual report on Form
10-K
for the year ended December 31, 2020.
Summarized financial information is presented on a combined basis and transactions between the combining entities have been eliminated. Financial information for nonguarantor entities has been excluded. The summarized operating results information for the nine months ended September 30, 2021 and year ended December 31, 2020 and the summarized balance sheet information at September 30, 2021 and December 31, 2020, for HCA Healthcare, Inc., HCA Inc. and the subsidiary guarantors (the Parent, Subsidiary Issuer and Subsidiary Guarantors) follow (dollars in millions):
Nine Months Ended September 30, 2021 and Year Ended December 31, 2020:
 
    
Nine Months
September 30, 2021
    
Year
December 31, 2020
 
Revenues
  
$
26,140
 
   $ 31,040  
Income before income taxes
  
 
4,578
 
     4,016  
Net income
  
 
3,546
 
     3,172  
Net income attributable to Parent, Subsidiary Issuer and Subsidiary Guarantors
  
 
3,474
 
     3,091  
 
31

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Liquidity and Capital Resources (continued)
Summarized Financial Information (continued)
 
At September 30, 2021 and December 31, 2020:
    
    
September 30, 2021
   
December 31, 2020
 
Current assets
  
$
7,821
 
  $ 7,442  
Property and equipment, net
  
 
15,285
 
    14,939  
Goodwill and other intangible assets
  
 
5,707
 
    5,763  
Total noncurrent assets
  
 
22,277
 
    21,771  
Total assets
  
 
30,098
 
    29,213  
Current liabilities
  
 
5,859
 
    5,316  
Long-term debt, net
  
 
31,597
 
    30,444  
Intercompany balances
  
 
3,229
 
    2,090  
Income taxes and other liabilities
  
 
1,841
 
    1,004  
Total noncurrent liabilities
  
 
37,179
 
    34,035  
Stockholders’ deficit attributable to Parent, Subsidiary Issuer and Subsidiary Guarantors
  
 
(13,155
    (10,247
Noncontrolling interests
  
 
215
 
    109  
The first-priority liens securing the subsidiary guarantees discussed above include liens on (i) substantially all of the capital stock of substantially all wholly owned first-tier subsidiaries of HCA Inc. or of the subsidiary guarantors (but limited to 65% of the stock of any such wholly owned first-tier subsidiary that is a foreign subsidiary), subject to certain limited exceptions, and (ii) substantially all indebtedness owing to HCA Inc. or to the subsidiary guarantors, including any and all intercompany indebtedness owed by HCA Healthcare, Inc. or any subsidiary thereof to HCA Inc., or any subsidiary guarantor. For a list of affiliates whose securities are pledged as collateral for the senior secured notes, see Exhibit 22 to this quarterly report on Form
10-Q.
Under the first lien intercreditor agreement, the administrative agent for the lenders under the cash flow credit facility, subject to the occurrence of certain events, has the exclusive right to direct foreclosures and take other actions with respect to these liens, and the trustee for the senior secured notes has no right to take any such actions. In certain circumstances, including upon certain events of default under the senior secured credit facilities and the senior secured notes, the collateral agent in respect of the cash flow credit facility and the senior secured notes could proceed against the collateral granted to it to secure such indebtedness, including the aforementioned pledged capital stock and pledged indebtedness, and require such collateral to be delivered to the collateral agent to the extent not already in its possession for purposes of perfecting the lien on such assets. For further information regarding the collateral, including events or circumstances that may require delivery of the collateral, refer to the applicable indentures, the first lien intercreditor agreement, the cash flow credit agreement and the pledge agreement that are filed as exhibits to our annual report on Form
10-K
for the year ended December 31, 2020.
There is no trading market for any of HCA Healthcare, Inc.’s affiliates whose securities are pledged as collateral for the senior secured notes.
Rule
13-02
of Regulation
S-X
requires the presentation of summarized financial information of the combined affiliates whose securities are pledged as collateral for the senior secured notes unless such information is not material. The rule provides that such information is not material if the assets, liabilities and results of operations of the combined affiliates whose securities are pledged as collateral are not materially different than the corresponding amounts presented in the consolidated financial statements of the Registrant.
 
32

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Liquidity and Capital Resources (continued)
Summarized Financial Information (continued)
 
Healthtrust, Inc. — The Hospital Company (“Healthtrust”) is the first-tier subsidiary of HCA Inc., and the common stock of Healthtrust is pledged as collateral for the senior secured notes. Due to the corporate structure relationship of HCA Healthcare, Inc. and Healthtrust, all of HCA Healthcare, Inc.’s operating subsidiaries, including all other affiliates whose securities are pledged as collateral for the senior secured notes, are also subsidiaries of Healthtrust. The corporate structure relationship, combined with the application of push-down accounting in Healthtrust’s consolidated financial statements related to HCA Healthcare Inc.’s debt and financial instruments, mean that the assets, liabilities and results of operations of Healthtrust (and, therefore, of the combined affiliates whose securities are pledged as collateral for the senior secured notes) are not materially different than the corresponding amounts presented in the financial statements of HCA Healthcare, Inc. As a result, summarized financial information of affiliates whose securities are pledged as collateral for the senior secured notes is not required to be presented under Rule
13-02.
Market Risk
We are exposed to market risk related to changes in market values of securities. The investment securities held by our insurance subsidiaries were recorded at $530 million at September 30, 2021. These investments are carried at fair value, with changes in unrealized gains and losses that are not credit-related being recorded as adjustments to other comprehensive income. At September 30, 2021, we had a net unrealized gain of $20 million on the insurance subsidiaries’ investments.
We are exposed to market risk related to market illiquidity. Investment securities held by our insurance subsidiaries could be impaired by the inability to access the capital markets. Should the insurance subsidiaries require significant amounts of cash in excess of normal cash requirements to pay claims and other expenses on short notice, we may have difficulty selling these investments in a timely manner or be forced to sell them at a price less than what we might otherwise have been able to in a normal market environment. We may be required to recognize credit-related impairments on our investment securities in future periods should issuers default on interest payments or should the fair market valuations of the securities deteriorate due to ratings downgrades or other issue-specific factors.
We are also exposed to market risk related to changes in interest rates, and we periodically enter into interest rate swap agreements to manage our exposure to these fluctuations. Our interest rate swap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the swap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions. The interest payments under these agreements are settled on a net basis. These derivatives have been recognized in the financial statements at their respective fair values. Changes in the fair value of these derivatives, which are designated as cash flow hedges, are included in other comprehensive income. At September 30, 2021, our variable rate debt was fully covered by our interest rate swap agreements.
Our variable debt is comprised primarily of amounts outstanding under the senior secured credit facilities. Borrowings under the senior secured credit facilities bear interest at a rate equal to an applicable margin plus, at our option, either (a) a base rate determined by reference to the higher of (1) the federal funds rate plus 0.50% or (2) the prime rate of Bank of America or (b) a LIBOR rate for the currency of such borrowing for the relevant interest period. The applicable margin for borrowings under the senior secured credit facilities may fluctuate according to a leverage ratio. The average effective interest rate for our long-term debt was 4.9% and 5.0% for the nine months ended September 30, 2021 and 2020, respectively.
 
33

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Liquidity and Capital Resources (continued)
Market Risk (continued)
 
The estimated fair value of our total long-term debt was $36.567 billion at September 30, 2021. The estimates of fair value are based upon the quoted market prices for the same or similar issues of long-term debt with the same maturities. To mitigate the impact of fluctuations in interest rates, we generally target a portion of our debt portfolio to be maintained at fixed rates.
We are exposed to currency translation risk related to our foreign operations. We currently do not consider the market risk related to foreign currency translation to be material to our consolidated financial statements or our liquidity.
Tax Examinations
The Internal Revenue Service was conducting an examination of the Company’s 2016, 2017 and 2018 federal income tax returns at September 30, 2021. We are also subject to examination by state and foreign taxing authorities. Management believes HCA Healthcare, Inc. and its predecessors, subsidiaries and affiliates properly reported taxable income and paid taxes in accordance with applicable laws and agreements established with IRS, state and foreign taxing authorities and final resolution of any disputes will not have a material, adverse effect on our results of operations or financial position. However, if payments due upon final resolution of any issues exceed our recorded estimates, such resolutions could have a material, adverse effect on our results of operations or financial position.
Operating Data
 
    
2021
    
2020
 
Number of hospitals in operation at:
     
March 31
  
 
186
 
     186  
June 30
  
 
187
 
     186  
September 30
  
 
183
 
     187  
December 31
        185  
Number of freestanding outpatient surgical centers in operation at:
     
March 31
  
 
121
 
     123  
June 30
  
 
122
 
     122  
September 30
  
 
123
 
     121  
December 31
        121  
Licensed hospital beds at(a):
     
March 31
  
 
49,561
 
     49,357  
June 30
  
 
49,693
 
     49,403  
September 30
  
 
48,950
 
     49,473  
December 31
        49,265  
Weighted average beds in service(b):
     
Quarter:
     
First
  
 
42,363
 
     42,177  
Second
  
 
42,464
 
     42,309  
Third
  
 
42,088
 
     42,426  
Fourth
        42,072  
Year
        42,246  
 
34

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Operating Data (continued)
 
    
2021
    
2020
 
Average daily census(c):
     
Quarter:
     
First
  
 
29,678
 
     28,822  
Second
  
 
28,901
 
     24,844  
Third
  
 
31,144
 
     28,186  
Fourth
        29,065  
Year
        27,734  
Admissions(d):
     
Quarter:
     
First
  
 
506,380
 
     528,244  
Second
  
 
532,041
 
     452,992  
Third
  
 
536,848
 
     506,756  
Fourth
        521,917  
Year
        2,009,909  
Equivalent admissions(e):
     
Quarter:
     
First
  
 
832,489
 
     889,035  
Second
  
 
916,212
 
     723,136  
Third
  
 
905,627
 
     835,576  
Fourth
        864,583  
Year
        3,312,330  
Average length of stay (days)(f):
     
Quarter:
     
First
  
 
5.3
 
     5.0  
Second
  
 
4.9
 
     5.0  
Third
  
 
5.3
 
     5.1  
Fourth
        5.1  
Year
        5.1  
Emergency room visits(g):
     
Quarter:
     
First
  
 
1,841,778
 
     2,264,707  
Second
  
 
2,128,428
 
     1,516,116  
Third
  
 
2,338,180
 
     1,813,661  
Fourth
        1,855,823  
Year
        7,450,307  
Outpatient surgeries(h):
     
Quarter:
     
First
  
 
231,228
 
     226,319  
Second
  
 
262,107
 
     170,911  
Third
  
 
249,192
 
     232,493  
Fourth
        252,760  
Year
        882,483  
 
35

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)
Operating Data (continued)
 
    
2021
   
2020
 
Inpatient surgeries(i):
    
Quarter:
    
First
  
 
127,590
 
    135,145  
Second
  
 
136,460
 
    118,591  
Third
  
 
126,436
 
    133,492  
Fourth
       135,157  
Year
       522,385  
Days revenues in accounts receivable(j):
    
Quarter:
    
First
  
 
48
 
    49  
Second
  
 
48
 
    50  
Third
  
 
51
 
    44  
Fourth
       45  
Outpatient revenues as a % of patient revenues(k):
    
Quarter:
    
First
  
 
36
    37
Second
  
 
38
    32
Third
  
 
34
    36
Fourth
       35
Year
       35
 
(a)
Licensed beds are those beds for which a facility has been granted approval to operate from the applicable state licensing agency.
(b)
Represents the average number of beds in service, weighted based on periods owned.
(c)
Represents the average number of patients in our hospital beds each day.
(d)
Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume.
(e)
Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume resulting in a general measure of combined inpatient and outpatient volume.
(f)
Represents the average number of days admitted patients stay in our hospitals.
(g)
Represents the number of patients treated in our emergency rooms.
(h)
Represents the number of surgeries performed on patients who were not admitted to our hospitals. Pain management and endoscopy procedures are not included in outpatient surgeries.
(i)
Represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management and endoscopy procedures are not included in inpatient surgeries.
(j)
Revenues per day is calculated by dividing revenues for the quarter by the days in the quarter. Days revenues in accounts receivable is then calculated as accounts receivable at the end of the quarter divided by revenues per day.
(k)
Represents the percentage of patient revenues related to patients who are not admitted to our hospitals.
 
36

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The information called for by this item is provided under the caption “Market Risk” under Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
ITEM 4.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
HCA’s management, with the participation of HCA’s chief executive officer and chief financial officer, has evaluated the effectiveness of HCA’s disclosure controls and procedures as of September 30, 2021. Based on that evaluation, HCA’s chief executive officer and chief financial officer concluded that HCA’s disclosure controls and procedures were effective as of September 30, 2021.
Changes in Internal Control Over Financial Reporting
During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
The information set forth in Note 9 – Contingencies in the notes to the condensed consolidated financial statements is incorporated herein by reference.
ITEM 1A.    RISK FACTORS
Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on
Form 10-Q
and other risk factors described in our annual report on
Form 10-K
for the year ended December 31, 2020, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on
Form 10-K
for the year ended December 31, 2020.
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During February 2021, our Board of Directors authorized $6 billion for repurchases of our outstanding common stock. During the quarter ended September 30, 2021, we repurchased 9,604,350 shares of our common stock at an average price of $242.53 per share through market purchases pursuant to the February 2021 authorization. At September 30, 2021, we had $2.658 billion of repurchase authorization available under the February 2021 authorization.
 
37

The following table provides certain information with respect to our repurchases of common stock from July 1, 2021 through September 30, 2021 (dollars in millions, except per share amounts).
 
Period
  
Total Number
of Shares
Purchased
    
Average Price
Paid per Share
    
Total Number
of Shares
Purchased as
Part of
Publicly
Announced
Plans or
Programs
    
Approximate
Dollar Value of
Shares That
May Yet Be
Purchased
Under Publicly
Announced
Plans or
Programs
 
July 1, 2021 through July 31, 2021
     3,306,380      $ 225.33        3,306,380      $ 4,242  
August 1, 2021 through August 31, 2021
     3,407,927      $ 247.73        3,407,927      $ 3,398  
September 1, 2021 through September 30, 2021
     2,890,043      $ 256.08        2,890,043      $ 2,658  
  
 
 
       
 
 
    
Total for third quarter 2021
     9,604,350      $ 242.53        9,604,350      $ 2,658  
  
 
 
       
 
 
    
On October 21, 2021, our Board of Directors declared a quarterly dividend of $0.48 per share on our common stock payable on December 29, 2021 to stockholders of record at the close of business on December 14, 2021. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors. Our ability to declare future dividends may also from time to time be limited by the terms of our debt agreements.
 
38

ITEM 6.    
EXHIBITS
(a) List of Exhibits:
 
      22     
      31.1     
      31.2     
      32     
      101     
The following financial information from our quarterly report on
Form 10-Q
for the quarter ended September 30, 2021 filed with the SEC on November 1, 2021, formatted in Inline Extensible Business Reporting Language: (i) the condensed consolidated balance sheets at September 30, 2021 and December 31, 2020, (ii) the condensed consolidated income statements for the quarters and nine months ended September 30, 2021 and 2020, (iii) the condensed consolidated comprehensive income statements for the quarters and nine months ended September 30, 2021 and 2020, (iv) the condensed consolidated statements of stockholders’ equity (deficit) for the quarters and nine months ended September 30, 2021 and 2020, (v) the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 and (vi) the notes to condensed consolidated financial statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
      104     
The cover page from the Company’s Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2021, formatted in Inline XBRL (included in Exhibit 101).
 
39

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
HCA Healthcare, Inc.
By:
 
/
S
/ W
ILLIAM
B. R
UTHERFORD
  William B. Rutherford
 
Executive Vice President and Chief Financial Officer
Date: November 1, 2021
 
40
EX-22 2 d232147dex22.htm EX-22 EX-22

Exhibit 22

List of Subsidiary Guarantors

All of the senior secured notes and senior unsecured notes issued by HCA Inc. are fully and unconditionally guaranteed by HCA Healthcare, Inc. In addition to the guarantee provided by HCA Healthcare, Inc., all of HCA Inc.’s senior secured notes are fully and unconditionally guaranteed by the subsidiary guarantors listed below.

 

American Medicorp Development Co.

Bay Hospital, Inc.

Brigham City Community Hospital, Inc.

Brookwood Medical Center of Gulfport, Inc.

Capital Division, Inc.

CarePartners HHA Holdings, LLLP

CarePartners HHA, LLLP

CarePartners Rehabilitation Hospital, LLLP

Centerpoint Medical Center of Independence, LLC

Central Florida Regional Hospital, Inc.

Central Shared Services, LLC

Central Tennessee Hospital Corporation

CHCA Bayshore, L.P.

CHCA Conroe, L.P.

CHCA Mainland, L.P.

CHCA Pearland, L.P.

CHCA West Houston, L.P.

CHCA Woman’s Hospital, L.P.

Chippenham & Johnston-Willis Hospitals, Inc.

Citrus Memorial Hospital, Inc.

Citrus Memorial Property Management, Inc.

Clinical Education Shared Services, LLC

Colorado Health Systems, Inc.

Columbia ASC Management, L.P.

Columbia Florida Group, Inc.

Columbia Healthcare System of Louisiana, Inc.

Columbia Jacksonville Healthcare System, Inc.

Columbia LaGrange Hospital, LLC

Columbia Medical Center of Arlington Subsidiary, L.P.

Columbia Medical Center of Denton Subsidiary, L.P.

Columbia Medical Center of Las Colinas, Inc.

Columbia Medical Center of Lewisville Subsidiary, L.P.

Columbia Medical Center of McKinney Subsidiary, L.P.

Columbia Medical Center of Plano Subsidiary, L.P.

Columbia North Hills Hospital Subsidiary, L.P.

Columbia Ogden Medical Center, Inc.

Columbia Parkersburg Healthcare System, LLC

Columbia Physician Services - Florida Group, Inc.


Columbia Plaza Medical Center of Fort Worth Subsidiary, L.P.

Columbia Rio Grande Healthcare, L.P.

Columbia Riverside, Inc.

Columbia Valley Healthcare System, L.P.

Columbia/Alleghany Regional Hospital, Incorporated

Columbia/HCA John Randolph, Inc.

Columbine Psychiatric Center, Inc.

Columbus Cardiology, Inc.

Conroe Hospital Corporation

Cy-Fair Medical Center Hospital, LLC

Dallas/Ft. Worth Physician, LLC

Dublin Community Hospital, LLC

East Florida - DMC, Inc.

Eastern Idaho Health Services, Inc.

Edward White Hospital, Inc.

El Paso Surgicenter, Inc.

Encino Hospital Corporation, Inc.

EP Health, LLC

Fairview Park GP, LLC

Fairview Park, Limited Partnership

FMH Health Services, LLC

Frankfort Hospital, Inc.

Galen Property, LLC

GenoSpace, LLC

Good Samaritan Hospital, L.P.

Goppert-Trinity Family Care, LLC

GPCH-GP, Inc.

Grand Strand Regional Medical Center, LLC

Green Oaks Hospital Subsidiary, L.P.

Greenview Hospital, Inc.

H2U Wellness Centers, LLC

HCA - IT&S Field Operations, Inc.

HCA - IT&S Inventory Management, Inc.

HCA American Finance LLC

HCA Central Group, Inc.

HCA Eastern Group, Inc.

HCA Health Services of Florida, Inc.

HCA Health Services of Louisiana, Inc.

HCA Health Services of Tennessee, Inc.

HCA Health Services of Virginia, Inc.

HCA Management Services, L.P.

HCA Pearland GP, Inc.

HCA Realty, Inc.

HCA-HealthONE LLC

 

2


HD&S Corp. Successor, Inc.

Health Midwest Office Facilities Corporation

Health Midwest Ventures Group, Inc.

HealthTrust Workforce Solutions, LLC

Hendersonville Hospital Corporation

hInsight-Mobile Heartbeat Holdings, LLC

Hospital Corporation of Tennessee

Hospital Corporation of Utah

Hospital Development Properties, Inc.

Houston - PPH, LLC

Houston NW Manager, LLC

HPG Enterprises, LLC

HSS Holdco, LLC

HSS Systems, LLC

HSS Virginia, L.P.

HTI Memorial Hospital Corporation

HTI MOB, LLC

Integrated Regional Lab, LLC

Integrated Regional Laboratories, LLP

JFK Medical Center Limited Partnership

JPM AA Housing, LLC

KPH-Consolidation, Inc.

Lakeview Medical Center, LLC

Largo Medical Center, Inc.

Las Encinas Hospital

Las Vegas Surgicare, Inc.

Lawnwood Medical Center, Inc.

Lewis-Gale Hospital, Incorporated

Lewis-Gale Medical Center, LLC

Lewis-Gale Physicians, LLC

Lone Peak Hospital, Inc.

Los Robles Regional Medical Center

Management Services Holdings, Inc.

Marietta Surgical Center, Inc.

Marion Community Hospital, Inc.

MCA Investment Company

Medical Centers of Oklahoma, LLC

Medical Office Buildings of Kansas, LLC

MediCredit, Inc.

Memorial Healthcare Group, Inc.

MH Angel Medical Center, LLLP

MH Blue Ridge Medical Center, LLLP

MH Highlands-Cashiers Medical Center, LLLP

MH Hospital Holdings, Inc.

 

3


MH Hospital Manager, LLC

MH Master Holdings, LLLP

MH Master, LLC

MH Mission Hospital McDowell, LLLP

MH Mission Hospital, LLLP

MH Mission Imaging, LLLP

MH Transylvania Regional Hospital, LLLP

Midwest Division - ACH, LLC

Midwest Division - LSH, LLC

Midwest Division - MCI, LLC

Midwest Division - MMC, LLC

Midwest Division - OPRMC, LLC

Midwest Division - RBH, LLC

Midwest Division - RMC, LLC

Midwest Holdings, Inc.

Mobile Heartbeat, LLC

Montgomery Regional Hospital, Inc.

Mountain Division - CVH, LLC

Mountain View Hospital, Inc.

Nashville Shared Services General Partnership

National Patient Account Services, Inc.

New Iberia Healthcare, LLC

New Port Richey Hospital, Inc.

New Rose Holding Company, Inc.

North Florida Immediate Care Center, Inc.

North Florida Regional Medical Center, Inc.

North Houston - TRMC, LLC

North Texas - MCA, LLC

Northern Utah Healthcare Corporation

Northern Virginia Community Hospital, LLC

Northlake Medical Center, LLC

Notami Hospitals of Louisiana, Inc.

Notami Hospitals, LLC

Okaloosa Hospital, Inc.

Okeechobee Hospital, Inc.

Oklahoma Holding Company, LLC

Outpatient Cardiovascular Center of Central Florida, LLC

Outpatient Services Holdings, Inc.

Oviedo Medical Center, LLC

Palms West Hospital Limited Partnership

Parallon Business Solutions, LLC

Parallon Enterprises, LLC

Parallon Health Information Solutions, LLC

Parallon Holdings, LLC

 

4


Parallon Payroll Solutions, LLC

Parallon Physician Services, LLC

Parallon Revenue Cycle Services, Inc.

Pasadena Bayshore Hospital, Inc.

Pearland Partner, LLC

Plantation General Hospital, L.P.

Poinciana Medical Center, Inc.

Primary Health, Inc.

PTS Solutions, LLC

Pulaski Community Hospital, Inc.

Putnam Community Medical Center of North Florida, LLC

Reston Hospital Center, LLC

Retreat Hospital, LLC

Rio Grande Regional Hospital, Inc.

Riverside Healthcare System, L.P.

Riverside Hospital, Inc.

Samaritan, LLC

San Jose Healthcare System, LP

San Jose Hospital, L.P.

San Jose Medical Center, LLC

San Jose, LLC

Sarah Cannon Research Institute, LLC

Sarasota Doctors Hospital, Inc.

Savannah Health Services, LLC

SCRI Holdings, LLC

Sebring Health Services, LLC

SJMC, LLC

Southeast Georgia Health Services, LLC

Southern Hills Medical Center, LLC

Southpoint, LLC

Spalding Rehabilitation L.L.C.

Spotsylvania Medical Center, Inc.

Spring Branch Medical Center, Inc.

Spring Hill Hospital, Inc.

SSHR Holdco, LLC

Sun City Hospital, Inc.

Sunrise Mountainview Hospital, Inc.

Surgicare of Brandon, Inc.

Surgicare of Florida, Inc.

Surgicare of Houston Women’s, Inc.

Surgicare of Manatee, Inc.

 

5


Surgicare of Newport Richey, Inc.

Surgicare of Palms West, LLC

Surgicare of Riverside, LLC

Tallahassee Medical Center, Inc.

TCMC Madison-Portland, Inc.

Terre Haute Hospital GP, Inc.

Terre Haute Hospital Holdings, Inc.

Terre Haute MOB, L.P.

Terre Haute Regional Hospital, L.P.

The Regional Health System of Acadiana, LLC

Timpanogos Regional Medical Services, Inc.

Trident Medical Center, LLC

U.S. Collections, Inc.

Utah Medco, LLC

VH Holdco, Inc.

VH Holdings, Inc.

Virginia Psychiatric Company, Inc.

Vision Consulting Group LLC

Vision Holdings, LLC

Walterboro Community Hospital, Inc.

WCP Properties, LLC

Weatherford Health Services, LLC

Wesley Medical Center, LLC

West Florida - MHT, LLC

West Florida - PPH, LLC

West Florida Regional Medical Center, Inc.

West Valley Medical Center, Inc.

Western Plains Capital, Inc.

WHMC, Inc.

Woman’s Hospital of Texas, Incorporated

List of Pledged Securities

The subsidiary guarantees discussed above are secured by first-priority liens on substantially all of the capital stock of substantially all wholly owned first-tier subsidiaries of HCA Inc. or of subsidiary guarantors (but limited to 65% of the stock of any such wholly owned first-tier subsidiary that is a foreign subsidiary), subject to certain limited exceptions. Below is a list of all of the entities in which the identified credit party owns stock, partnership interest, limited liability company membership interest or other equity interest that is pledged as collateral for the senior secured notes.

 

6


Credit Party

  

Legal Entity Owned

American Medicorp Development Co.    CVMC Property, LLC
   HCA-HealthONE LLC
   Rapides Healthcare System, L.L.C.
   Surgicare of Evans, Inc.
Brigham City Community Hospital, Inc.    Brigham City Community Hospital Physician Services, LLC
   MountainStar Brigham General Surgery, LLC
Brookwood Medical Center of Gulfport, Inc.    Coastal Imaging Center of Gulfport, Inc.
   EPIC Properties, Inc.
   Garden Park Investments, L.P.
   Garden Park Physician Group - Specialty Care, LLC
   Garden Park Physician Group, Inc.
   GPCH-GP, Inc.
   Gulf Coast Medical Ventures, Inc.
Capital Division, Inc.    Capital Professional Billing, LLC
  

HCA LewisGale Regional Cancer Centers Clinical Co-Management Company, LLC

   Virginia Care Partners ACO LLC
   Virginia Quality Care Partners, LLC
CarePartners HHA Holdings, LLLP    CarePartners HHA, LLLP
CarePartners Rehabilitation Hospital, LLLP    MH Anesthesiology Physicians, LLC
   MH Physician Services, LLC
   Mission Health Community Multispecialty Providers, LLC
Centerpoint Medical Center of Independence, LLC    The Regional Health System of Acadiana, LLC
Central Florida Regional Hospital, Inc.    Central Florida Cardiology Interpretations, LLC
   JPM AA Housing, LLC
Central Shared Services, LLC    Clinical Education Shared Services, LLC
CHCA Bayshore, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at Bayshore Medical Center, LLC
CHCA Conroe, L.P.    CRMC-M, LLC
   HCA-Solis Holdings, Inc.
   Solis Mammography at Conroe Regional Medical Center, LLC
CHCA Pearland, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at Pearland Medical Center, LLC

 

7


CHCA West Houston, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at West Houston Medical Center, LLC
CHCA Woman’s Hospital, L.P.    Fannin MOB Property Management, LLC
   HCA-Solis Holdings, Inc.
   Solis Mammography at Woman’s Hospital of Texas, LLC
Chippenham & Johnston-Willis Hospitals, Inc.    CJW Wound Healing Center, LLC
   Crewe Outpatient Imaging, LLC
   Imaging Services of Richmond, LLC
Colorado Health Systems, Inc.    HealthONE of Denver, Inc.
   New Rose Holding Company, Inc.
Columbia Florida Group, Inc.    Columbia Central Florida Division, Inc.
   Columbia Physician Services - Florida Group, Inc.
   Columbia Tampa Bay Division, Inc.
   East Florida Division, Inc.
   Fort Myers Market, Inc.
   North Florida Division I, Inc.
   West Florida Division, Inc.
Columbia Healthcare System of Louisiana, Inc.    Centerpoint Clinic of Blue Springs, LLC
   Centerpoint Medical Center of Independence, LLC
   Centerpoint Physicians Group, LLC
   Centerpoint Women’s Services, LLC
   Children’s Multi-Specialty Group, LLC
   Columbia/HCA of Baton Rouge, Inc.
   Lafayette OB Hospitalists, LLC
   Lakeview Cardiology Specialists, LLC
   Lakeview Regional Physician Group, LLC
   Research Family Physicians, LLC
   Southwest Medical Center Multi-Specialty Group, LLC
   Southwest Medical Center Surgical Group, LLC
   Tchefuncte Cardiology Associates - Lakeview, LLC
   Women’s & Children’s Pediatric Hematology/Oncology Center, LLC
   Women’s Multi-Specialty Group, LLC
Columbia Jacksonville Healthcare System, Inc.    Memorial Family Practice Associates, LLC
   Memorial Health Primary Care at St. Johns Bluff, LLC
   Memorial Healthcare Group, Inc.
   Memorial Neurosurgery Group, LLC
Columbia LaGrange Hospital, LLC    Kendall Regional Medical Center, LLC

 

8


Columbia Medical Center of Arlington Subsidiary, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at Medical Center Arlington, LLC
Columbia Medical Center of Denton Subsidiary, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at Denton Regional Medical Center, LLC
Columbia Medical Center of Las Colinas, Inc.    HCA-Solis Holdings, Inc.
   Solis Mammography at Las Colinas Medical Center, LLC
   Tuscan Imaging Center at Las Colinas, LLC
Columbia Medical Center of Lewisville Subsidiary, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at Medical Center of Lewisville, LLC
Columbia Medical Center of McKinney Subsidiary, L.P.    HCA-Solis Holdings, Inc.
   Solis Mammography at Medical Center of McKinney, LLC
Columbia Medical Center of Plano Subsidiary, L.P.    HCA-Solis Holdings, Inc.
   Plano Ambulatory Surgery Associates, L.P.
   Plano Heart Management, LLC
   Plano Surgicenter Real Estate Manager, LLC
   Solis Mammography at Medical Center of Plano, LLC
Columbia Ogden Medical Center, Inc.    MountainStar Cardiology Ogden Regional, LLC
   Ogden Regional Medical Center Professional Billing, LLC
   Ogden Senior Center, LLC
Columbia Parkersburg Healthcare System, LLC    Parkersburg SJ Holdings, Inc.
Columbia Physician Services - Florida Group, Inc.    Central Florida Division Practice, Inc.
   North Florida Division Practice, Inc.
   Premier Medical Management, Ltd.
   South Florida Division Practice, Inc.
Columbia Riverside, Inc.    Riverside Healthcare System, L.P.
Columbia/Alleghany Regional Hospital, Incorporated    Alleghany Primary Care, Inc.
   Alleghany Specialists, LLC
Columbia/HCA John Randolph, Inc.    Imaging Services of Appomattox, LLC
Columbine Psychiatric Center, Inc.    HCA-HealthONE LLC

 

9


Conroe Hospital Corporation    CHCA Conroe, L.P.
   Conroe Partner, LLC
Dublin Community Hospital, LLC    Fairview Park GP, LLC
   Fairview Partner, LLC
Eastern Idaho Health Services, Inc.    EIRMC Hospitalist Services, LLC
El Paso Surgicenter, Inc.    El Paso Surgery Centers, L.P.
EP Health, LLC    Brookwood Medical Center of Gulfport, Inc.
   Coastal Healthcare Services, Inc.
   Epic Diagnostic Centers, Inc.
   Epic Healthcare Management Company
   EPIC Surgery Centers, Inc.
   Grace 1011, LLC
   Health Insight Capital, LLC
   MRT&C, Inc.
   Primary Health Asset Holdings, Ltd.
   PSG Delegated Services, LLC
   SSHR Holdco, LLC
Fairview Park GP, LLC    Fairview Park, Limited Partnership
FMH Health Services, LLC    New Hampshire Imaging Services, Inc.
Frankfort Hospital, Inc.    Frankfort Wound Care, LLC
Galen Property, LLC    Henrico Doctors Hospital - Forest Campus Property, LLC
GPCH-GP, Inc.    Garden Park Community Hospital Limited Partnership
Grand Strand Regional Medical Center, LLC    Grand Strand Senior Health Center, LLC
Greenview Hospital, Inc.    Frankfort Hospital, Inc.
   Southern Kentucky Surgicenter, LLC
H2U Wellness Centers, LLC    Health to You, LLC
HCA Central Group, Inc.    Capital Division, Inc.
   HCA Chattanooga Market, Inc.
   MidAmerica Division, Inc.
   TriStar Health System, Inc.
HCA Eastern Group, Inc.    Columbia Florida Group, Inc.
   South Atlantic Division, Inc.
HCA Health Services of Florida, Inc.    Bradenton Cardiology Physician Network, LLC
   Hilltop 408, LLC
   North Physician Services, Inc.
   Oak Hill Acquisition, Inc.
   St. Lucie Medical Center Hyperbarics, LLC
   Surgicare of Bayonet Point, Inc.
   West Florida Physician Network, LLC
   West Florida Trauma Network, LLC
   West Florida Urgent Care Network, LLC

 

10


HCA Health Services of Louisiana, Inc.    Cedar Creek Medical Group, LLC
   Foot & Ankle Specialty Services, LLC
   Goppert-Trinity Family Care, LLC
   Midwest Cardiovascular & Thoracic Surgery, LLC
   Midwest Division - LSH, LLC
   Midwest Division - MCI, LLC
   Midwest Division - RBH, LLC
   Midwest Division - RMC, LLC
   Midwest Trauma Services, LLC
   Midwest Women’s Healthcare Specialists, LLC
   Raymore Medical Group, LLC
   RMC - Pulmonary, LLC
   Senior Health Associates, LLC
   Women’s Center at Brookside, LLC
HCA Health Services of Tennessee, Inc.    2490 Church, LLC
   Centennial CyberKnife Center, LLC
   Centennial Neuroscience, LLC
   Centennial Surgical Clinic, LLC
   Central Tennessee Hospital Corporation
   HCA-Solis Holdings, Inc.
   Hospitalists at Centennial Medical Center, LLC
   Judson Holdings, LLC
   Neuro Affiliates Company
   Old Fort Village, LLC
   Solis Mammography at StoneCrest Medical Center, LLC
   Southpoint, LLC
   Summit General Partner, Inc.
   Summit Walk-In Clinic, LLC
   Surgicare of Brentwood, LLC
   TriStar Cardiovascular Surgery, LLC
   TriStar Medical Group - Centennial Primary Care, LLC
HCA Health Services of Virginia, Inc.    Columbia Arlington Healthcare System, L.L.C.
   Columbia/HCA John Randolph, Inc.
   Preferred Hospitals, Inc.
   Reston Hospital Center, LLC
   Retreat Hospital, LLC
   Spotsylvania Medical Center, Inc.
   West Creek Ambulatory Surgery Center, LLC

 

11


HCA Inc.   

HCA American Finance LLC

HCA Property GP, LLC

Healthtrust, Inc. – The Hospital Company

HSS Holdco, LLC

HCA Management Services, L.P.   

UR Services, LLC

  

HCA Healthcare Marketing and Corporate Affairs, LLC

HCA Pearland GP, Inc.   

CHCA Pearland, L.P.

  

Pearland Partner, LLC

HCA-HealthONE LLC   

Altitude Mid Level Providers, LLC

  

Center for Advanced Diagnostics LLC

  

HCA-Solis Master, LLC

  

HealthONE at Breckenridge, LLC

  

HealthONE Aurora Investment, LLC

  

HealthONE Care Partners, LLC

  

HealthONE CareNow Urgent Care, LLC

  

HealthONE Clear Creek, LLC

  

HealthONE Clinic Services - Bariatric Medicine, LLC

  

HealthONE Clinic Services - Behavioral Health, LLC

  

HealthONE Clinic Services - Cardiovascular, LLC

  

HealthONE Clinic Services - Medical Specialties, LLC

  

HealthONE Clinic Services - Neurosciences, LLC

  

HealthONE Clinic Services - Obstetrics and Gynecology, LLC

  

HealthONE Clinic Services - Occupational Medicine, LLC

  

HealthONE Clinic Services - Oncology Hematology, LLC

  

HealthONE Clinic Services - Orthopedic Specialists, LLC

  

HealthONE Clinic Services - Otolaryngology Specialists, LLC

  

HealthONE Clinic Services - Pediatric Specialties, LLC

  

HealthONE Clinic Services - Primary Care, LLC

  

HealthONE Clinic Services - Surgery Neurological, LLC

  

HealthONE Clinic Services - Surgical Specialties, LLC

  

HealthONE Clinic Services - Youth Rehabilitation LLC

  

HealthONE Clinic Services LLC

  

HealthONE Heart Care LLC

  

HealthONE High Street Primary Care Center, LLC

 

12


   HealthONE IRL Pathology Services, LLC
   HealthONE Lincoln Investment, LLC
   HealthONE Lowry, LLC
   HealthONE Radiation Therapy at Red Rocks, LLC
   HealthONE Radiation Therapy at Thornton, LLC
   HealthONE Surgicare of Ridge View, LLC
   HealthONE Urologic, LLC
   HealthONE Westside Investment, LLC
   Hospital Cooperative Laundry, Inc.
   Hospital Based CRNA Services, Inc.
   HSS Inc.
   Lakewood Surgicare, Inc.
   Medical Care America Colorado, LLC
   Medical Imaging of Colorado LLC
   P/SL Hyperbaric Partnership
   Proaxis Therapy HealthONE LLC
   Rocky Mountain Pediatric Hematology Oncology, LLC
   Rose Health Partners, LLC
   Rose Medical Plaza, Ltd.
   Rose POB, Inc.
   Sky Ridge Spine Manager, LLC
   Solis Mammography at Rose Medical Center, LLC
   Spalding Rehabilitation, L.L.C.
   Surgicare of Denver Mid-Town, Inc.
   Surgicare of Rose, LLC
   Surgicare of Sky Ridge, LLC
   Surgicare of Southeast Denver, Inc.
   Surgicare of Swedish, LLC
   Surgicare of Thornton, LLC
   Swedish Medpro, Inc.
   Swedish MOB Acquisition, Inc.
   Swedish MOB II, Inc.
   Swedish MOB III, Inc.
   Swedish MOB IV, Inc.
HD&S Corp. Successor, Inc.    Plantation General Hospital, L.P.
Health Midwest Ventures Group, Inc.    Clinishare, Inc.
   Eye Care Surgicare, Ltd., a Missouri Limited Partnership
   HCA Midwest Comprehensive Care, Inc.
   Health Midwest Medical Group, Inc.
   Health Midwest Office Facilities Corporation
   HM OMCOS, LLC
   Johnson County Surgicenter, L.L.C.
   Surgicenter of Kansas City, L.L.C.

 

13


HealthTrust Workforce Solutions, LLC    Martin Fletcher Associates Holdings, Inc.
hInsight-Mobile Heartbeat Holdings, LLC    Mobile Heartbeat, LLC
Hospital Development Properties, Inc.    Lafayette Medical Office Building, Ltd. (A partnership in Commendam)
HPG Enterprises, LLC    HCA Management Services, L.P.
   Healthtrust Purchasing Group, L.P.
   Valify, Inc.
HSS Holdco, LLC    HSS Virginia, L.P.
   Nashville Shared Services General Partnership
   Terre Haute MOB, L.P.
HSS Systems, LLC    HSS Virginia, L.P.
   Nashville Shared Services General Partnership
   Parallon Health Information Solutions, LLC
   Parallon Payroll Solutions, LLC
   Parallon Physician Services, LLC
   Texas HSS, LLC
HSS Virginia, L.P.    Nashville Shared Services General Partnership
HTI Memorial Hospital Corporation    DAG Holdings, LLC
   HCA-Solis Holdings, Inc.
   Solis Mammography at Skyline Medical Center, LLC
HTI MOB, LLC    Healthtrust MOB Tennessee, LLC
   Medical Office Buildings of Kansas, LLC
Houston NW Manager, LLC    Houston Northwest Operating Company, L.L.C.
Integrated Regional Lab, LLC    Integrated Regional Laboratories, LLP
Integrated Regional Laboratories, LLP    Integrated Regional Laboratories Pathology Services, LLC
JFK Medical Center Limited Partnership    Palm Beach Hospitalists Program, LLC
   AR Holding 5, LLC
KPH-Consolidation, Inc.    HCA-Solis Holdings, Inc.
   Solis Mammography at Kingwood Medical Center, LLC
Las Encinas Hospital    L E Corporation
Las Vegas Surgicare, Inc.    Las Vegas Surgicare, Ltd., a Nevada Limited Partnership
Lewis-Gale Hospital, Incorporated    Columbia/Alleghany Regional Hospital, Incorporated
   Lewis-Gale Medical Center, LLC
   Lewis-Gale Physicians, LLC
   Roanoke Imaging, LLC
   Roanoke Neurosurgery, LLC
   Salem Hospitalists, LLC
Lewis-Gale Medical Center, LLC    Daleville Imaging Manager, LLC
   Daleville Imaging, L.P.
Los Robles Regional Medical Center    Los Robles Regional Medical Center MOB, LLC
   Los Robles Surgicenter, LLC
   TODIC, L.P.

 

14


Management Services Holdings, Inc.    HPG Enterprises, LLC
   HPG Solutions, LLC
Marietta Surgical Center, Inc.    Marietta Outpatient Surgery, Ltd.
MCA Investment Company    Columbia ASC Management, L.P.
Medical Centers of Oklahoma, LLC    EPIC Properties, Inc.
   Medical Imaging, Inc.
   SWMC, Inc.
Memorial Healthcare Group, Inc.   

Jacksonville Surgery Center, Ltd.

   MHS Partnership Holdings JSC, Inc.
   MHS Partnership Holdings SDS, Inc.
   MSL Acquisition, LLC
MH Hospital Holdings, Inc.    MH Asheville Specialty Hospital, LLC
   MH Hospital Manager, LLC
   MH Master Holdings, LLLP
   Mission Employer Solutions, LLC
   Mission Health Partners, Inc.
MH Hospital Manager, LLC    MH Master Holdings, LLLP
MH Master Holdings, LLLP    Assuring Affordable, Quality Healthcare in North Carolina, LLC
   CarePartners HHA Holdings, LLLP
   CarePartners Rehabilitation Hospital, LLLP
   Imaging Realty LLC
   MH Angel Medical Center, LLLP
   MH Blue Ridge Medical Center, LLLP
   MH Eckerd Living Center, LLLP
   MH Highlands-Cashiers Medical Center, LLLP
   MH Master, LLC
   MH McDowell Imaging, LLLP
   MH Mission Hospital McDowell, LLLP
   MH Mission Hospital, LLLP
   MH Mission Imaging, LLLP
   MH Transylvania Imaging, LLLP
   MH Transylvania Regional Hospital, LLLP
   Provider-Led, Patient-Centered Care, LLC
   Western North Carolina Healthcare Innovators, LLC
MH Master, LLC    CarePartners HHA Holdings, LLLP
   CarePartners HHA, LLLP
   CarePartners Rehabilitation Hospital, LLLP
   MH Angel Medical Center, LLLP
   MH Blue Ridge Medical Center, LLLP
   MH Eckerd Living Center, LLLP
   MH Highlands-Cashiers Medical Center, LLLP

 

15


   MH McDowell Imaging, LLLP
   MH Mission Hospital McDowell, LLLP
   MH Mission Hospital, LLLP
   MH Mission Imaging, LLLP
   MH Transylvania Imaging, LLLP
   MH Transylvania Regional Hospital, LLLP
MH Mission Hospital, LLLP    WNC Stone Center, LLC
Midwest Division - OPRMC, LLC    Forward Pathology Solutions Wichita, LLC
   Heartland Women’s Group at Wesley, LLC
   Neurology Associates of Kansas, LLC
   OPRMC-HBP, LLC
   Wesley Physician Services, LLC
   Wesley Physicians - Medical Specialties LLC
   Wesley Urgent Care, LLC
   Wichita CareNow Urgent Care, LLC
Midwest Division - RBH, LLC    Bone & Joint Specialists Physician Group, LLC
Midwest Division - RMC, LLC    RMC Transplant Physicians, LLC
Midwest Holdings, Inc.    Health Midwest Ventures Group, Inc.
   Medical Center Imaging, Inc.
   Midwest Division - ACH, LLC
   Midwest Division - LRHC, LLC
   Mill Creek Outpatient Services, LLC
Montgomery Regional Hospital, Inc.    Blacksburg Imaging, LLC
   Montgomery Cancer Center, LLC
Mountain View Hospital, Inc.    MVH Professional Services, LLC
   Timpanogos Regional Medical Services, Inc.
National Patient Account Services, Inc.    NPAS Solutions, LLC
   NPAS, Inc.
New Iberia Healthcare, LLC    HTI MOB, LLC
New Rose Holding Company, Inc.    HCA-HealthONE LLC
North Florida Regional Medical Center, Inc.    HCA Imaging Services of North Florida, Inc.
   Medical Partners of North Florida, LLC
North Houston - TRMC, LLC    HCA-Solis Holdings, Inc.
   Solis Mammography at Houston Tomball, LLC
North Texas - MCA, LLC    Solis Mammography at Medical Center Alliance, LLC
Northern Utah Healthcare Corporation    Alta Internal Medicine, LLC
   St. Mark’s Investments, Inc.
Notami Hospitals of Louisiana, Inc.    EPIC Properties, Inc.
   Lakeview Medical Center, LLC
Notami Hospitals, LLC    CFC Investments, Inc.

 

16


   Columbia Good Samaritan Health System Limited Partnership
   EPIC Properties, Inc.
   Good Samaritan Hospital, LLC
   Healdsburg General Hospital, Inc.
   Mission Bay Memorial Hospital, Inc.
   Samaritan, LLC
   San Jose Medical Center, LLC
   SJMC, LLC
   South Valley Hospital, L.P.
   West Lost Angeles Physicians’ Hospital, Inc.
Oklahoma Holding Company, LLC    Edmond General Surgery, LLC
   Edmond Hospitalists, LLC
   Healthcare Oklahoma, Inc.
   Medi Flight of Oklahoma, LLC
   Oklahoma Physicians - Medical Specialties LLC
   Oklahoma Physicians - Obstetrics and Gynecology LLC
   Oklahoma Physicians - Primary Care LLC
   Oklahoma Physicians - Surgical Specialties LLC
Outpatient Services Holdings, Inc.    Eastern Idaho Brachytherapy Equipment Manager, LLC
   HCA Outpatient Imaging Services Group, Inc.
   HCA Research Institute, LLC
   Healthcare Sales National Management Services Group, LLC
   MidAmerica Oncology, LLC
   Midtown Diagnostics, LLC
   National Contact Center Management Group, LLC
   National Transfer Center Management Services, LLC
   North Hills Catheterization Lab, LLC
   Ogden Tomotherapy Manager, LLC
   Red Rock Holdco, LLC
   Riverside CyberKnife Manager, LLC
Parallon Business Solutions, LLC    Central Shared Services, LLC
   HealthTrust Workforce Solutions, LLC
   HSS Systems, LLC
   National Patient Account Services, Inc.
   PTS Solutions, LLC
   U.S. Collections, Inc.
Parallon Holdings, LLC    Parallon Business Solutions, LLC
   Parallon Enterprises, LLC
Parallon Revenue Cycle Services, Inc.    MediCredit, Inc.
Pasadena Bayshore Hospital, Inc.    Bayshore Partner, LLC
   CHCA Bayshore, L.P.
Pearland Partner, LLC    CHCA Pearland, L.P.

 

17


Primary Health, Inc.   

Primary Health Asset Holdings, Ltd.

Regional Health System of Acadiana, LLC, The   

RMCA Professionals Mgmt, LLC

  

Women’s & Children’s Pulmonology Clinic, LLC

  

Women’s and Children’s Professional Management, LLC

Reston Hospital Center, LLC   

Ashburn Imaging, LLC

  

Generations Family Practice, Inc.

  

MRI of Reston Limited Partnership

  

Pavilion 2 Condominium Property, LLC

  

Reston Hospitalists, LLC

Retreat Hospital, LLC   

Surgicare of Hanover, Inc.

Rio Grande Regional Hospital, Inc.   

Columbia Rio Grande Healthcare, L.P.

  

Rio Grande Healthcare MSO, Inc.

  

Rio Grande NP, Inc.

Riverside Healthcare System, L.P.   

Surgicare of Riverside, LLC

Riverside Hospital, Inc.   

Bay Area Healthcare Group, Ltd.

Samaritan, LLC   

Good Samaritan Hospital, L.P.

San Jose Medical Center, LLC   

San Jose Hospital, L.P.

San Jose, LLC   

San Jose Healthcare System, LP

  

San Jose Pathology Outreach, LLC

Sarasota Doctors Hospital, Inc.   

Columbia Midtown Joint Venture

Savannah Health Services, LLC   

4600 Waters Avenue Professional Building Condominium Association, Inc.

  

Georgia Eye Surgicenter, LLC

  

Provident Professional Building Condominium Association, Inc.

  

Savannah Center for Medical Education and Research, LLC

  

Wilmington Island Partners, LLC

SCRI Holdings, LLC   

GenoSpace, LLC

  

Sarah Cannon Development Innovations, LLC

  

Sarah Cannon Research Institute, LLC

  

SCRI Global Services Limited

  

SCRI Scientifics, LLC

  

Summit Research Solutions, LLC

SJMC, LLC   

San Jose Hospital, L.P.

Spotsylvania Medical Center, Inc.   

Spotsylvania Condominium Property, LLC

SSHR Holdco, LLC   

COSCORP, LLC

  

HCA Human Resources, LLC

  

Parallon Holdings, LLC

Surgicare of Brandon, Inc.   

Bay Area Surgicenter, LLC

 

18


Surgicare of Florida, Inc.   

Belleair Surgery Center, Ltd.

Surgicare of Houston Women’s, Inc.   

Outpatient Women’s and Children’s Surgery Center, Ltd.

Surgicare of Manatee, Inc.   

Manatee Surgicare, Ltd.

Surgicare of Newport Richey, Inc.   

New Port Richey Surgery Center, Ltd.

Surgicare of Palms West, LLC   

Palms West Surgery Center, Ltd.

Terre Haute Hospital GP, Inc.   

Terre Haute Regional Hospital, L.P.

Terre Haute Hospital Holdings, Inc.   

Terre Haute Regional Hospital, L.P.

Terre Haute Regional Hospital, L.P.   

Hospitalists of the Wabash Valley, LLC

  

Terre Haute MOB, L.P.

  

Terre Haute Obstetrics and Gynecology, LLC

Timpanogos Regional Medical Services, Inc.   

MountainStar Intensivist Services, LLC

  

Timpanogos Pain Specialists, LLC

Trident Medical Center, LLC   

Trident Behavioral Health Services, LLC

  

Trident Neonatology Services, LLC

U.S. Collections, Inc.   

Parallon Revenue Cycle Services, Inc.

Utah Medco, LLC   

Brigham City Community Hospital, Inc.

  

Brigham City Health Plan, Inc.

  

Columbia Ogden Medical Center, Inc.

  

Healthtrust Utah Management Services, Inc.

  

Hospital Corporation of Utah

  

HTI Physician Services of Utah, Inc.

  

Layton Family Practice, LLC

  

Mountain View Hospital, Inc.

  

MP Management, LLC

  

ODP Manager, LLC

  

Ogden Regional Health Plan, Inc.

  

Park View Insurance Company

  

Utah Holdco, LLC

  

WCP Properties, LLC

  

West Jordan Hospital Corporation

VH Holdco, Inc.   

VH Holdings, Inc.

VH Holdings, Inc.   

Center for Advanced Imaging, LLC

  

EMMC, LLC

  

FHAL, LLC

  

Galen GOK, LLC

  

Galen KY, LLC

  

Galen MCS, LLC

  

Galen MRMC, LLC

  

Galen NMC, LLC

  

Galen NSH, LLC

  

Galen SOM, LLC

  

Galen SSH, LLC

 

19


  

HHNC, LLC

  

HPI Hospital Systems Management, Inc.

  

Notami, LLC

  

POH Holdings, LLC

  

Preferred Works WC, LLC

  

RCH, LLC

  

San Jose, LLC

  

Springview KY, LLC

  

Value Health Holdings, Inc.

  

Value Health Management, Inc.

  

WJHC, LLC

Virginia Psychiatric Company, Inc.   

Columbia Arlington Healthcare System, L.L.C.

Vision Holdings, LLC   

Vision Consulting Group LLC

Walterboro Community Hospital, Inc.   

Colleton Medical Anesthesia, LLC

  

Colleton Medical Hospitalists, LLC

Weatherford Health Services, LLC   

HCA-Solis Holdings, Inc.

  

Weatherford Mammography JV, LLC

Wesley Medical Center, LLC   

Care for Women, LLC

  

Centerpoint Medical Specialists, LLC

  

College Park Ancillary, LLC

  

College Park Radiology, LLC

  

Emergency Physicians at Wesley Medical Center, LLC

  

Family Health Medical Group of Overland Park, LLC

  

Galichia Anesthesia Services, LLC

  

HCA Wesley Rehabilitation Hospital, Inc.

  

Health Partners of Kansas, Inc.

  

Hospitalists as Wesley Medical Center, LLC

  

IRL Pathology Services MidAmerica, LLC

  

Johnson County Neurology, LLC

  

Kansas CareNow Urgent Care, LLC

  

Kansas City Cardiac Arrhythmia Research LLC

  

Kansas City Gastroenterology & Hepatology Physicians Group, LLC

  

Kansas City Vascular & General Surgery Group, LLC

  

Kansas City Women’s Clinic Group, LLC

  

Kansas Pulmonary and Sleep Specialists, LLC

  

Kansas Trauma and Critical Care Specialists, LLC

  

Menorah Medical Group, LLC

  

Menorah Urgent Care, LLC

  

Midwest Cardiovascular and Thoracic Surgeons of Kansas, LLC

  

Midwest Division Spine Care, LLC

 

20


   Midwest Heart & Vascular Specialists, LLC
   Midwest Oncology Associates, LLC
   Overland Park Cardiovascular, Inc.
   Overland Park Medical Specialists, LLC
   Overland Park Orthopedics, LLC
   Overland Park Surgical Specialties, LLC
   Pediatric Specialty Clinic LLC
   Quivira Internal Medicine, Inc.
   Research Neurology Associates, LLC
   Research Neuroscience Institute, LLC
   Statland Medical Group, LLC
   The Medical Group of Kansas City, LLC
   Town Plaza Family Practice, LLC
   Wesley Physicians - Anesthesiologist, LLC
   Wesley Physicians - Cardiovascular, LLC
   Wesley Physicians - Obstetrics and Gynecology LLC
   Wesley Physicians - Primary Care LLC
   Wesley Select Network, LLC
West Florida - PPH, LLC    SSJ St. Petersburg Holdings, Inc.
West Valley Medical Center, Inc.    Saint Alphonsus Caldwell Cancer Treatment Center, L.L.C.
Western Plains Capital, Inc.    C/HCA Capital, Inc.
WHMC, Inc.    CHCA West Houston, L.P.
   West Houston, LLC
Woman’s Hospital of Texas, Incorporated    CHCA Woman’s Hospital, L.P
   Houston Woman’s Hospital Partner, LLC
   Woman’s Hospital Merger, LLC

The subsidiary guarantees discussed above are also secured by first-priority liens on substantially all indebtedness owing to HCA Inc. or to the subsidiary guarantors, including any and all intercompany indebtedness owed by HCA Healthcare, Inc. or any subsidiary thereof to HCA Inc., or any subsidiary guarantor.

Pursuant to the typical and customary cash management system established by HCA Healthcare, Inc., the affiliates of HCA Healthcare, Inc. listed below have entered into revolving promissory notes with Western Plains Capital, Inc., a subsidiary guarantor. The notes are pledged as collateral for the secured notes to the extent described above. Due to the revolving nature of the intercompany debt, the balance due from one party to another fluctuates based on cash activity from daily operations.

* Subsidiary guarantor.

 

21


AC Med, LLC
Acadiana Care Center, Inc.
Acadiana Practice Management, Inc.
Acadiana Regional Pharmacy, Inc.
ACH, Inc.
Advanced Bundle Convener, LLC
All About Staffing, Inc.
Alleghany Primary Care, Inc.
Alliance Surgicare, LLC
Alternaco, LLC
Ambulatory Services Management Corporation of Chesterfield County, Inc.
*American Medicorp Development Co.
AOGN, LLC
AOSC Sports Medicine, Inc.
AR Holding 1, LLC
AR Holding 4, LLC
AR Holding 5, LLC
AR Holding 6, LLC
AR Holding 7, LLC
AR Holding 8, LLC
AR Holding 9, LLC
AR Holding 10, LLC
AR Holding 11, LLC
AR Holding 12, LLC
AR Holding 13, LLC
AR Holding 14, LLC
AR Holding 15, LLC
AR Holding 16, LLC
AR Holding 17, LLC
AR Holding 18, LLC
AR Holding 19, LLC
AR Holding 20, LLC
AR Holding 21, LLC
AR Holding 22, LLC
AR Holding 23, LLC
AR Holding 24, LLC
AR Holding 25, LLC
AR Holding 26, LLC
AR Holding 27, LLC
AR Holding 28, LLC
AR Holding 29, LLC
AR Holding 30, LLC
AR Holding 31, LLC
Arlington Diagnostic South, Inc.
Arlington Surgery Center, L.P.

 

22


Arlington Surgicare, LLC  
ASD Shared Services, LLC  
Ashburn ASC, LLC  
Ashburn Imaging, LLC  
Athens Community Hospital, Inc.  
Atlanta Healthcare Management, L.P.  
Atlanta Market GP, Inc.  
Atlanta Outpatient Surgery Center, Inc.  
Atlantis Surgicare, LLC  
Atrium Surgery Center, L.P.  
Atrium Surgicare, LLC  
Augusta Management Services, LLC  
Austin Medical Center, Inc.  
Aventura Cancer Center Manager, LLC  
Aventura Comprehensive Cancer Research Group of Florida, Inc.  
Bailey Square Outpatient Surgical Center, Inc.  
Basic American Medical, Inc.  
Bay Area Healthcare Group, Ltd.  
Bay Area Surgicare Center, Inc.  
*Bay Hospital, Inc.  
Bayshore Partner, LLC  
Bedford-Northeast Community Hospital, Inc.  
Bellaire Imaging, Inc.  
Big Cypress Medical Center, Inc.  
Bonita Bay Surgery Center, Inc.  
Boynton Beach EFL Imaging Center, LLC  
Bradenton Outpatient Services, LLC  
Brandon Imaging Manager, LLC  
Brandon Regional Cancer Center, LLC  
*Brigham City Community Hospital, Inc.  
Brigham City Health Plan, Inc.  
*Brookwood Medical Center of Gulfport, Inc.  
Broward Healthcare System, Inc.  
Brownsville-Valley Regional Medical Center, Inc.  
C/HCA Capital, Inc.  
C/HCA Development, Inc.  
C/HCA, Inc.  
Calloway Creek Surgicare, LLC  
Cancer Centers of North Florida, LLC  
Cancer Services of Aventura, LLC  
*Capital Division, Inc.  
Capital Network Services, Inc.  
CareOne Home Health Services, Inc.  

 

23


CareOne Home Health Services, Inc.
*CarePartners HHA Holdings, LLLP
*CarePartners HHA, LLLP
*CarePartners Rehabilitation Hospital, LLLP
Carolina Regional Surgery Center, Inc.
CCH-GP, Inc.
Centennial CyberKnife Manager, LLC
Center for Advanced Imaging, LLC
*Centerpoint Medical Center of Independence, LLC
Central Florida Cardiology Interpretations, LLC
Central Florida Imaging Services, LLC
*Central Florida Regional Hospital, Inc.
Central Health Holding Company, Inc.
*Central Shared Services, LLC
*Central Tennessee Hospital Corporation
CFC Investments, Inc.
CH Systems
Chatsworth Hospital Corp.
Chattanooga Healthcare Network Partner, Inc.
CHC Finance Co.
CHC Holdings, Inc.
CHC Payroll Agent, Inc.
CHC Payroll Company
CHC Realty Company
CHC Venture Co.
*CHCA Bayshore, L.P.
CHCA Clear Lake, L.P.
*CHCA Conroe, L.P.
*CHCA Mainland, L.P.
*CHCA Pearland, L.P.
*CHCA West Houston, L.P.
*CHCA Woman’s Hospital, L.P.
CHC-El Paso Corp.
CHCK, Inc.
CHC-Miami Corp.
Chicago Grant Hospital, Inc.
Chino Community Hospital Corporation, Inc.
*Chippenham & Johnston-Willis Hospitals, Inc.
Chippenham Ambulatory Surgery Center, LLC
Chugach PT, Inc.
*Citrus Memorial Hospital, Inc.
*Citrus Memorial Property Management, Inc.

 

24


CLASC Manager, LLC
Clear Lake Cardiac Catheterization Center, L.P.
Clear Lake Cardiac GP, LLC
Clear Lake Merger, LLC
Clear Lake Regional Medical Center, Inc.
Clear Lake Regional Partner, LLC
*Clinical Education Shared Services, LLC
ClinicServ, LLC
Clinishare, Inc.
Coastal Bend Hospital, Inc.
Coastal Carolina Home Care, Inc.
Coastal Healthcare Services, Inc.
Coastal Imaging Center of Gulfport, Inc.
Coliseum Health Group, Inc.
Coliseum Park Hospital, Inc.
College Park Endoscopy Center, LLC
Colleton Ambulatory Care, LLC
Colleton Diagnostic Center, LLC
Collier County Home Health Agency, Inc.
*Colorado Health Systems, Inc.
Columbia Ambulatory Surgery Division, Inc.
*Columbia ASC Management, L.P.
Columbia Bay Area Realty, Ltd.
Columbia Behavioral Healthcare of South Florida, Inc.
Columbia Behavioral Healthcare, Inc.
Columbia Call Center, Inc.
Columbia Central Florida Division, Inc.
Columbia Central Group, Inc.
Columbia Champions Treatment Center, Inc.
Columbia Chicago Division, Inc.
Columbia Coliseum Same Day Surgery Center, Inc.
Columbia Development of Florida, Inc.
Columbia Doctors Hospital of Tulsa, Inc.
*Columbia Florida Group, Inc.
Columbia GP of Mesquite, Inc.
Columbia Greater Houston Division Healthcare Network, Inc.
Columbia Health System of Arkansas, Inc.
*Columbia Healthcare System of Louisiana, Inc.
Columbia Hospital at Medical City Dallas Subsidiary, L.P.
Columbia Hospital Corporation at the Medical Center
Columbia Hospital Corporation of Arlington
Columbia Hospital Corporation of Bay Area
Columbia Hospital Corporation of Central Miami
Columbia Hospital Corporation of Corpus Christi

 

25


Columbia Hospital Corporation of Fort Worth
Columbia Hospital Corporation of Houston
Columbia Hospital Corporation of Kendall
Columbia Hospital Corporation of Massachusetts, Inc.
Columbia Hospital Corporation of Miami
Columbia Hospital Corporation of Miami Beach
Columbia Hospital Corporation of North Miami Beach
Columbia Hospital Corporation of South Broward
Columbia Hospital Corporation of South Dade
Columbia Hospital Corporation of South Florida
Columbia Hospital Corporation of South Miami
Columbia Hospital Corporation of Tamarac
Columbia Hospital Corporation of West Houston
Columbia Hospital Corporation-Delaware
Columbia Hospital Corporation-SMM
Columbia Hospital-El Paso, Ltd.
Columbia Integrated Health Systems, Inc.
*Columbia LaGrange Hospital, LLC
Columbia Lake Worth Surgical Center Limited Partnership
Columbia Medical Arts Hospital Subsidiary, L.P.
Columbia Medical Center at Lancaster Subsidiary, L.P.
Columbia Medical Center Dallas Southwest Subsidiary, L.P.
*Columbia Medical Center of Arlington Subsidiary, L.P.
*Columbia Medical Center of Denton Subsidiary, L.P.
*Columbia Medical Center of Las Colinas, Inc.
*Columbia Medical Center of Lewisville Subsidiary, L.P.
*Columbia Medical Center of McKinney Subsidiary, L.P.
*Columbia Medical Center of Plano Subsidiary, L.P.
*Columbia North Hills Hospital Subsidiary, L.P.
Columbia North Texas Healthcare System, L.P.
Columbia North Texas Subsidiary GP, LLC
Columbia North Texas Surgery Center Subsidiary, L.P.
Columbia Northwest Medical Center, Inc.
*Columbia Ogden Medical Center, Inc.
Columbia Oklahoma Division, Inc.
Columbia Palm Beach GP, LLC
Columbia Park Healthcare System, Inc.
Columbia Park Medical Center, Inc.
*Columbia Parkersburg Healthcare System, LLC
*Columbia Plaza Medical Center of Fort Worth Subsidiary, L.P.
Columbia Psychiatric Management Co.
Columbia Resource Network, Inc.
*Columbia Rio Grande Healthcare, L.P.
*Columbia Riverside, Inc.

 

26


Columbia South Texas Division, Inc.
Columbia Specialty Hospital of Dallas Subsidiary, L.P.
Columbia Specialty Hospitals, Inc.
Columbia Surgery Group, Inc.
Columbia Tampa Bay Division, Inc.
*Columbia Valley Healthcare System, L.P.
Columbia West Bank Hospital, Inc.
*Columbia/Alleghany Regional Hospital, Incorporated
Columbia/HCA Healthcare Corporation of Central Texas
Columbia/HCA Healthcare Corporation of Northern Ohio
Columbia/HCA Healthcare Corporation of South Carolina
Columbia/HCA Heartcare of Corpus Christi, Inc.
Columbia/HCA International Group, Inc.
*Columbia/HCA John Randolph, Inc.
Columbia/HCA of Baton Rouge, Inc.
Columbia/HCA of Houston, Inc.
Columbia/HCA of New Orleans, Inc.
Columbia/HCA of North Texas, Inc.
Columbia/HCA San Clemente, Inc.
Columbia-Georgia PT, Inc.
Columbia-Osceola Imaging Center, Inc.
Columbia-Quantum, Inc.
Columbia-SDH Holdings, Inc.
*Columbine Psychiatric Center, Inc.
Columbus Cath Lab, Inc.
Columbus Cath Lab, LLC
Columbus Doctors Hospital, Inc.
Concept EFL Imaging Center, LLC
Concept West EFL Imaging Center, LLC
*Conroe Hospital Corporation
Conroe Partner, LLC
Continental Division I, Inc.
CoralStone Management, Inc.
Corpus Christi Surgery Center, L.P.
Corpus Surgicare, Inc.
COSCORP, LLC
CPS TN Processor 1, Inc.
Crewe Outpatient Imaging, LLC
CRMC-M, LLC
Cumberland Medical Center, Inc.
CVMC Property, LLC
Daleville Imaging Manager, LLC
Daleville Imaging, L.P.
Davie Medical Center, LLC

 

27


Daytona Medical Center, Inc.
Deep Purple Investments, LLC
Delray EFL Imaging Center, LLC
Denver Surgicenter, LLC
Derry ASC, Inc.
Diagnostic Breast Center, Inc.
Diagnostic Mammography Services, G.P.
Doctors Hospital (Conroe), Inc.
Doctors Hospital Columbus GA-Joint Venture
Doctors Hospital of Augusta, LLC
Doctors Osteopathic Medical Center, Inc.
Doctors Same Day Surgery Center, Inc.
Doctors-I, Inc.
Doctors-II, Inc.
Doctors-III, Inc.
Doctors-IV, Inc.
Doctors-V, Inc.
Doctors-VIII, Inc.
DOMC Property, LLC
*Dublin Community Hospital, LLC
Dura Medical, Inc.
E.P. Physical Therapy Centers, Inc.
East Florida Division, Inc.
East Florida Imaging Holdings, LLC
East Pointe Hospital, Inc.
Eastern Idaho Brachytherapy Equipment Manager, LLC
Eastern Idaho Care Partners ACO, LLC
*Eastern Idaho Health Services, Inc.
Edmond Physician Hospital Organization, Inc.
*Edward White Hospital, Inc.
EHCA, LLC
El Paso Healthcare System, Ltd.
El Paso Nurses Unlimited, Inc.
*El Paso Surgicenter, Inc.
Emergency Providers Group LLC
EMMC, LLC
*Encino Hospital Corporation, Inc.
Endoscopy Surgicare of Plano, LLC
Englewood Community Hospital, Inc.
*EP Health, LLC
EP Holdco, LLC
EPIC Development, Inc.
EPIC Diagnostic Centers, Inc.
EPIC Healthcare Management Company

 

28


EPIC Properties, Inc.
EPIC Surgery Centers, Inc.
*Fairview Park GP, LLC
*Fairview Park, Limited Partnership
Fairview Partner, LLC
Far West Division, Inc.
Fawcett Memorial Hospital, Inc.
FHAL, LLC
Florida Home Health Services-Private Care, Inc.
Flower Mound Surgery Center, Ltd.
*FMH Health Services, LLC
Forest Park Surgery Pavilion, Inc.
Fort Bend Hospital, Inc.
Fort Myers Market, Inc.
Fort Walton Beach Medical Center, Inc.
Fort Worth Investments, Inc.
*Frankfort Hospital, Inc.
Frankfort Wound Care, LLC
Frisco Surgicare, LLC
Frisco Warren Parkway 91, Inc.
Ft. Pierce Surgicare, LLC
Galen (Kansas) Merger, LLC
Galen BH, Inc.
Galen Center for Professional Development, Inc.
Galen Diagnostic Multicenter, Ltd.
Galen Global Finance, Inc.
Galen GOK, LLC
Galen Health Institutes, Inc.
Galen Holdco, LLC
Galen Hospital Alaska, Inc.
Galen Hospital of Baytown, Inc.
Galen Hospital-Pembroke Pines, Inc.
Galen International Holdings, Inc.
Galen KY, LLC
Galen MCS, LLC
Galen Medical Corporation
Galen MRMC, LLC
Galen NMC, LLC
Galen NSH, LLC
Galen of Aurora, Inc.
Galen of Florida, Inc.
Galen of Illinois, Inc.
Galen of Kentucky, Inc.
Galen of Mississippi, Inc.

 

29


Galen of Virginia, Inc.
Galen of West Virginia, Inc.
*Galen Property, LLC
Galen SOM, LLC
Galen SSH, LLC
Galen Virginia Hospital Corporation
Galencare, Inc.
Galendeco, Inc.
Galen-Soch, Inc.
GalTex, LLC
Gardens EFL Imaging Center, LLC
General Hospitals of Galen, Inc.
*GenoSpace, LLC
Georgia Health Holdings, Inc.
Georgia Psychiatric Company, Inc.
Georgia, L.P.
GHC-Galen Health Care, LLC
*Good Samaritan Hospital, L.P.
Good Samaritan Hospital, LLC
Good Samaritan Surgery Center, L.P.
*GPCH-GP, Inc.
*Grand Strand Regional Medical Center, LLC
Greater Houston Preferred Provider Option, Inc.
*Green Oaks Hospital Subsidiary, L.P.
*Greenview Hospital, Inc.
Gulf Coast Division, Inc.
Gulf Coast Medical Ventures, Inc.
Gulf Coast Physician Administrators, Inc.
Gwinnett Community Hospital, Inc.
Hamilton Memorial Hospital, Inc.
HCA - Information Technology & Services, Inc.
*HCA - IT&S Field Operations, Inc.
*HCA - IT&S Inventory Management, Inc.
HCA - IT&S PBS Field Operations, Inc.
HCA - IT&S TN Field Operations, Inc.
HCA - Raleigh Community Hospital, Inc.
*HCA American Finance LLC
HCA ASD Financial Operations, LLC
HCA ASD Sales Services, LLC
*HCA Central Group, Inc.
HCA Chattanooga Market, Inc.
HCA Development Company, Inc.
*HCA Eastern Group, Inc.
HCA Endocrine Investor, LLC

 

30


HCA Health Services of California, Inc.
*HCA Health Services of Florida, Inc.
HCA Health Services of Georgia, Inc.
*HCA Health Services of Louisiana, Inc.
HCA Health Services of Miami, Inc.
HCA Health Services of Midwest, Inc.
HCA Health Services of New Hampshire, Inc.
*HCA Health Services of Tennessee, Inc.
HCA Health Services of Texas, Inc.
*HCA Health Services of Virginia, Inc.
HCA Health Services of West Virginia, Inc.
HCA Healthcare Mission Fund, LLC
HCA Healthcare, Inc.
HCA Holdco, LLC
HCA Human Resources, LLC
HCA Imaging Services of North Florida, Inc.
HCA Inc.
HCA Long Term Health Services of Miami, Inc.
*HCA Management Services, L.P.
HCA Midwest Comprehensive Care, Inc.
HCA North Texas GME PLLC
HCA Outpatient Imaging Services Group, Inc.
*HCA Pearland GP, Inc.
HCA Physician Services, Inc.
HCA Plano Imaging, Inc.
HCA Property GP, LLC
HCA Psychiatric Company
*HCA Realty, Inc.
HCA Squared, LLC
HCA Switzerland Holding GmbH
HCA Western Group, Inc.
*HCA-HealthONE LLC
HCA-Solis Holdings, Inc.
HCA-Solis Master, LLC
HCOL, Inc.
*HD&S Corp. Successor, Inc.
Healdsburg General Hospital, Inc.
Health Care Indemnity, Inc.
Health Insight Capital, LLC
*Health Midwest Office Facilities Corporation
*Health Midwest Ventures Group, Inc.
Health Service Partners, Inc.
Health Services (Delaware), Inc.

 

31


Health Services Merger, Inc.
Health to You, LLC
Healthcare Sales National Management Services Group, LLC
Healthcare Technology Assessment Corporation
Healthco, LLC
Healthnet of Kentucky, LLC
HealthONE Aurora Investment, LLC
HealthONE Clear Creek, LLC
HealthONE High Street Primary Care Center, LLC
HealthOne Lincoln Investment, LLC
HealthONE Lowry, LLC
HealthONE of Denver, Inc.
HealthONE Radiation Therapy at Red Rocks, LLC
HealthONE Radiation Therapy at Thornton, LLC
HealthONE Surgicare of Ridge View, LLC
HealthONE Urologic, LLC
HealthOne Westside Investment, LLC
Healthserv Acquisition, LLC
HealthTrust Locums, Inc.
Healthtrust MOB Tennessee, LLC
Healthtrust Utah Management Services, Inc.
*HealthTrust Workforce Solutions, LLC
Healthtrust, Inc. - The Hospital Company
Healthtrust, Inc. - The Hospital Company
Healthy State, Inc.
Heart of America Surgicenter, LLC
Hearthstone Home Health, Inc.
Heathrow Imaging, LLC
*Hendersonville Hospital Corporation
Henrico Doctors Hospital - Forest Campus Property, LLC
Heritage Hospital, Inc.

HHNC, LLC

hInsight-BMA Holdings, LLC

hInsight-Customer Care Holdings, LLC

hInsight-Digital Reasoning Holdings, LLC

hInsight-Healthbox Holdings, LLC

hInsight-I2 Holdings, LLC

hInsight-InVivoLink Holdings, LLC

hInsight-Loyale Healthcare Holdings, LLC

hInsight-LS Holdings, LLC

*hInsight-Mobile Heartbeat Holdings, LLC

hInsight-NX, LLC

hInsight-OTM Holdings, LLC

hInsight-Procured Holdings, LLC

 

32


hInsight-PWS I Holdings, LLC
hInsight-VAI Holdings, LLC
HM Acquisition, LLC
Homecare North, Inc.
Hometrust Management Services, Inc.
Hospital Corp., LLC
Hospital Corporation of America
Hospital Corporation of Lake Worth
*Hospital Corporation of Tennessee
*Hospital Corporation of Utah
*Hospital Development Properties, Inc.
Hospital Partners Merger, LLC
Hospital Realty Corporation
*Houston - PPH, LLC
Houston Healthcare Holdings, Inc.
Houston Northwest Surgical Partners, Inc.
*Houston NW Manager, LLC
Houston Woman’s Hospital Partner, LLC
*HPG Enterprises, LLC
HPG Solutions, LLC
*HSS Holdco, LLC
*HSS Systems, LLC
*HSS Virginia, L.P.
HTI Gulf Coast, Inc.
HTI Health Services of North Carolina, Inc.
HTI Hospital Holdings, Inc.
*HTI Memorial Hospital Corporation
*HTI MOB, LLC
Illinois Psychiatric Hospital Company, Inc.
Imaging Services of Appomattox, LLC
Imaging Services of Jacksonville, LLC
Imaging Services of Louisiana Manager, LLC
Imaging Services of Louisiana, LLC
Imaging Services of Orlando, LLC
Imaging Services of West Boynton, LLC
IMX Holdings, LLC
Independence Surgicare, Inc.
Indian Path Hospital, Inc.
Indianapolis Hospital Partner, LLC
*Integrated Regional Lab, LLC
*Integrated Regional Laboratories, LLP
InVivoLink, Inc.
Isleworth Partners, Inc.
JDGC Management, LLC

 

33


*JFK Medical Center Limited Partnership
Johnson County Surgicenter, L.L.C.
Jupiter EFL Imaging Center, LLC
KC Surgicare, LLC
Kendall Healthcare Group, Ltd.
Kendall Regional Medical Center, LLC
Kingwood Surgery Center, LLC
*KPH-Consolidation, Inc.
L E Corporation
LAD Imaging, LLC
Lake City Imaging, LLC
*Lakeview Medical Center, LLC
Lakewood Surgicare, Inc.
Laredo Medco, LLC
*Largo Medical Center, Inc.
*Las Encinas Hospital
Las Vegas ASC, LLC
*Las Vegas Surgicare, Inc.
*Lawnwood Medical Center, Inc.
Lebanon Surgicenter, LLC
*Lewis-Gale Hospital, Incorporated
*Lewis-Gale Medical Center, LLC
*Lone Peak Hospital, Inc.
*Los Robles Regional Medical Center
Loudoun Surgery Center, LLC
Louisiana Psychiatric Company, Inc.
Low Country Health Services, Inc. of the Southeast
*Management Services Holdings, Inc.
Marietta Outpatient Medical Building, Inc.
*Marietta Surgical Center, Inc.
*Marion Community Hospital, Inc.
Martin, Fletcher & Associates, L.P.
Maury County Behavioral Health, LLC
Mayhill Cancer Center, LLC
*MCA Investment Company
Meadows DME, LLC
Med Corp., Inc.
Med-Center Hosp./Houston, Inc.
Medi Flight of Oklahoma, LLC
Medical Arts Hospital of Texarkana, Inc.
Medical Care America, LLC
Medical Care Financial Services Corp.
Medical Care Real Estate Finance, Inc.
Medical Care Surgery Center, Inc.

 

34


Medical Center - West, Inc.
Medical Center Imaging, Inc.
Medical Center of Baton Rouge, Inc.
Medical Center of Plano Partner, LLC
Medical Center of Port St. Lucie, Inc.
Medical Center of Santa Rosa, Inc.
*Medical Centers of Oklahoma, LLC
Medical City Dallas Hospital, Inc.
Medical City Dallas Partner, LLC
Medical Corporation of America
Medical Imaging, Inc.
*Medical Office Buildings of Kansas, LLC
Medical Specialties, Inc.
*MediCredit, Inc.
MediPurchase, Inc.
MediStone Healthcare Ventures, Inc.
MediVision of Mecklenburg County, Inc.
MediVision of Tampa, Inc.
MediVision, Inc.
Med-Point of New Hampshire, Inc.
*Memorial Healthcare Group, Inc.
Metroplex Surgicenters, Inc.
MGH Medical, Inc.
*MH Angel Medical Center, LLLP
MH Asheville Specialty Hospital, LLC
*MH Blue Ridge Medical Center, LLLP
MH Eckerd Living Center, LLLP
*MH Highlands-Cashiers Medical Center, LLLP
*MH Hospital Holdings, Inc.
*MH Hospital Manager, LLC
*MH Master Holdings, LLLP
*MH Master, LLC
MH McDowell Imaging, LLLP
*MH Mission Hospital McDowell, LLLP
*MH Mission Hospital, LLLP
*MH Mission Imaging, LLLP
MH Transylvania Imaging, LLLP
*MH Transylvania Regional Hospital, LLLP
MHS Partnership Holdings JSC, Inc.
MHS Partnership Holdings SDS, Inc.
Miami Beach EFL Imaging Center, LLC
Miami Beach Healthcare Group, Ltd.
MidAmerica Division, Inc.
MidAmerica Oncology, LLC

 

35


Mid-America Surgery Center, LLC
Mid-Cities Surgi-Center, Inc.
Mid-Continent Health Services, Inc.
Midtown Diagnostics, LLC
*Midwest Division - ACH, LLC
Midwest Division - LRHC, LLC
*Midwest Division - LSH, LLC
*Midwest Division - MCI, LLC
*Midwest Division - MMC, LLC
*Midwest Division - OPRMC, LLC
*Midwest Division - RBH, LLC
*Midwest Division - RMC, LLC
*Midwest Holdings, Inc.
Millenium Health Care of Oklahoma, Inc.
Mission Bay Memorial Hospital, Inc.
Missouri Healthcare System, L.P.
MMC Sleep Lab Management, LLC
Mobile Corps., Inc.
*Mobile Heartbeat, LLC
Montgomery Cancer Center, LLC
*Montgomery Regional Hospital, Inc.
MOSC Sports Medicine, Inc.
*Mountain Division - CVH, LLC
Mountain Division, Inc.
*Mountain View Hospital, Inc.
Mountain West Surgery Center, LLC
MOVCO, Inc.
MP Management, LLC
MRT&C, Inc.
Nashville Psychiatric Company, Inc.
*Nashville Shared Services General Partnership
Nashville Surgicenter, LLC
Natchez Surgery Center, LLC
National Contact Center Management Group, LLC
*National Patient Account Services, Inc.
Navarro Memorial Hospital, Inc.
Network Management Services, Inc.
Network MS of Florida, Inc.
Nevada Surgery Center of Southern Hills, L.P.
Nevada Surgicare of Southern Hills, LLC
*New Iberia Healthcare, LLC
New Iberia Holdings, Inc.
*New Port Richey Hospital, Inc.
*New Rose Holding Company, Inc.

 

36


Norman Clayman Endocrine Institute, LLC  
North Augusta Imaging Management, LLC  
North Augusta Imaging Services, LLC  
North Augusta Rehab Health Center, LLC  
North Brandon Imaging, LLC  
North Central Florida Health System, Inc.  
North Charleston Diagnostic Imaging Center, LLC  
North Florida Cancer Center Lake City, LLC  
North Florida Cancer Center Live Oak, LLC  
North Florida Cancer Center Tallahassee, LLC  
North Florida Division I, Inc.  
North Florida GI Center GP, Inc.  
North Florida Physician Services, Inc.  
North Florida Regional Investments, Inc.  
*North Florida Regional Medical Center, Inc.  
North Hills Cardiac Catheterization Center, L.P.  
North Hills Catheterization Lab, LLC  
*North Houston - TRMC, LLC  
North Miami Beach Surgical Center, LLC  
North Tampa Imaging, LLC  
*North Texas - MCA, LLC  
North Texas Division, Inc.  
North Texas General, L.P.  
North Texas Medical Center, Inc.  
North Transfer Center, LLC  
Northeast Florida Cancer Services, LLC  
*Northern Utah Healthcare Corporation  
Northern Utah Imaging, LLC  
*Northern Virginia Community Hospital, LLC  
Northern Virginia Hospital Corporation  
Northlake Surgicare, Inc.  
Northwest Florida Healthcare Systems, Inc.  
Northwest Medical Center, Inc.  
Notami (Opelousas), Inc.  
Notami Hospitals of Florida, Inc.  
*Notami Hospitals of Louisiana, Inc.  
Notami Hospitals of Missouri, Inc.  
*Notami Hospitals, LLC  
Notami, LLC  
Notco, LLC  
NPAS Solutions, LLC  
NPAS, Inc.  
NTGP, LLC  

 

37


NTMC Management Company  
NTMC Venture, Inc.  
Nuclear Diagnosis, Inc.  
Ocala Health Imaging Services, LLC  
Ocala Regional Outpatient Services, Inc.  
Ocala Stereotactic Radiosurgery Partner, LLC  
Ocala Stereotactic Radiosurgery, LLC  
Occupational and Family Medicine of South Texas  
ODP Holdings, LLC  
ODP Manager, LLC  
ODP Properties, LLC  
Ogden Imaging, LLC  
Ogden Tomotherapy Manager, LLC  
*Okaloosa Hospital, Inc.  
*Okeechobee Hospital, Inc.  
Oklahoma Surgicare, Inc.  
Oncology Services of Corpus Christi Manager, LLC  
Oncology Services of Corpus Christi, LLC  
OneSourceMed, Inc.  
Orange Park Medical Center, Inc.  
Orlando Outpatient Surgical Center, Inc.  
Orthopaedic Sports Specialty Associates, Inc.  
Osceola Regional Hospital, Inc.  
*Outpatient Cardiovascular Center of Central Florida, LLC  
Outpatient Services - LAD, LLC  
*Outpatient Services Holdings, Inc.  
*Oviedo Medical Center, LLC  
Ozarks Medical Services, Inc.  
Pacific Partners Management Services, Inc.  
Palm Beach EFL Imaging Center, LLC  
Palm Beach Healthcare System, Inc.  
*Palms West Hospital Limited Partnership  
Paragon of Texas Health Properties, Inc.  
Paragon Physicians Hospital Organization of South Texas, Inc.  
Paragon SDS, Inc.  
Paragon Surgery Centers of Texas, Inc.  
Paragon WSC, Inc.  
*Parallon Business Solutions, LLC  
*Parallon Enterprises, LLC  
*Parallon Health Information Solutions, LLC  
*Parallon Holdings, LLC  
*Parallon Payroll Solutions, LLC  

 

38


*Parallon Physician Services, LLC
*Parallon Revenue Cycle Services, Inc.
Park View Insurance Company
Parkersburg SJ Holdings, Inc.
Parkridge Medical Center, Inc.
Parkside Surgery Center, Inc.
Parkway Cardiac Center, Ltd.
Parkway Hospital, Inc.
Parkway Surgery Services, Ltd.
Parthenon Insurance Company, Limited
*Pasadena Bayshore Hospital, Inc.
*Pearland Partner, LLC
Pediatric Surgicare, Inc.
Pinellas Medical, LLC
Pioneer Medical, LLC
Plains Healthcare System, Inc.
Plano Heart Institute, L.P.
Plano Heart Management, LLC
Plano Surgery Center - GP, LLC
*Plantation General Hospital, L.P.
PMM, Inc.
POH Holdings, LLC
*Poinciana Medical Center, Inc.
Preferred Works WC, LLC
Primary Health Asset Holdings, Ltd.
*Primary Health, Inc.
*PTS Solutions, LLC
*Pulaski Community Hospital, Inc.
*Putnam Community Medical Center of North Florida, LLC
Putnam Hospital, Inc.
Putnam Radiation Oncology Manager, LLC
Radiation Oncology Center of Thornton, LLC
Radiation Oncology Manager, LLC
RCH, LLC
Red Rock at Smoke Ranch, LLC
Red Rock Holdco, LLC
*Reston Hospital Center, LLC
*Retreat Hospital, LLC
Richmond Imaging Employer Corp.
Rio Grande Healthcare MSO, Inc.
*Rio Grande Regional Hospital, Inc.

 

39


Riverside CyberKnife Manager, LLC  
*Riverside Healthcare System, L.P.  
Riverside Holdings, Inc.  
*Riverside Hospital, Inc.  
Riverside Imaging, LLC  
Roanoke Imaging, LLC  
Rosewood Medical Center, Inc.  
Round Rock Hospital, Inc.  
Royal Oaks Surgery Center, L.P.  
S.A. Medical Center, Inc.  
Salt Lake City Surgicare, Inc.  
*Samaritan, LLC  
San Antonio Division, Inc.  
San Antonio Regional Hospital, Inc.  
San Bernardino Imaging, LLC  
San Joaquin Surgical Center, Inc.  
*San Jose Healthcare System, LP  
*San Jose Hospital, L.P.  
*San Jose Medical Center, LLC  
San Jose Pathology Outreach, LLC  
*San Jose, LLC  
Sarah Cannon Development Innovations, LLC  
*Sarah Cannon Research Institute, LLC  
*Sarasota Doctors Hospital, Inc.  
*Savannah Health Services, LLC  
*SCRI Holdings, LLC  
SCRI Scientifics, LLC  
*Sebring Health Services, LLC  
Selma Medical Center Hospital, Inc.  
Silicon Valley Health Holdings, LLC  
*SJMC, LLC  
Sky Ridge Spine Manager, LLC  
South Atlantic Division, Inc.  
South Florida Division Practice, Inc.  
South Texas Surgicare, Inc.  
South Transfer Center, LLC  
South Valley Hospital, L.P.  
*Southeast Georgia Health Services, LLC  
*Southern Hills Medical Center, LLC  
*Southpoint, LLC  
Southwest Florida Health System, Inc.  
Southwest Florida Regional Medical Center, Inc.  
*Spalding Rehabilitation L.L.C.  

 

40


*Spotsylvania Medical Center, Inc.  
Spotsylvania Regional Surgery Center, LLC  
*Spring Branch Medical Center, Inc.  
*Spring Hill Hospital, Inc.  
Spring Hill Imaging, LLC  
Springview KY, LLC  
*SSHR Holdco, LLC  
St. Mark’s Investments, Inc.  
Stafford Imaging, LLC  
Stiles Road Imaging LLC  
Stones River Hospital, LLC  
Suburban Medical Center at Hoffman Estates, Inc.  
Sullins Surgical Center, Inc.  
Summit General Partner, Inc.  
Summit Research Solutions, LLC  
Sun Bay Medical Office Building, Inc.  
*Sun City Hospital, Inc.  
Sun City Imaging, LLC  
Sun Towers/Vista Hills Holding Co.  
Sun-Med, LLC  
Sunrise Hospital and Medical Center, LLC  
*Sunrise Mountainview Hospital, Inc.  
Sunrise Outpatient Services, Inc.  
Surgical Center of Irving, Inc.  
Surgical Facility of West Houston, L.P.  
Surgicare America - Winter Park, Inc.  
Surgicare Merger Company of Louisiana  
Surgicare of Alpine, LLC  
Surgicare of Altamonte Springs, Inc.  
Surgicare of Anchorage, LLC  
Surgicare of Arapahoe, LLC  
Surgicare of Arlington, LLC  
Surgicare of Ashburn, LLC  
Surgicare of Augusta, Inc.  
Surgicare of Aurora Endoscopy, LLC  
Surgicare of Aventura, LLC  
Surgicare of Bay Area Endoscopy, LLC  
Surgicare of Bay Area, LLC  
Surgicare of Bayonet Point, Inc.  
Surgicare of Bayside, LLC  
Surgicare of Bountiful, LLC  
*Surgicare of Brandon, Inc.  

 

41


Surgicare of Brentwood, LLC
Surgicare of Brooksville, LLC
Surgicare of Brownsville, LLC
Surgicare of Central Florida, Inc.
Surgicare of Central San Antonio, Inc.
Surgicare of Chattanooga, LLC
Surgicare of Chippenham, LLC
Surgicare of Citrus, LLC
Surgicare of Clarksville, LLC
Surgicare of Corpus Christi, LLC
Surgicare of Countryside, Inc.
Surgicare of Dallas Specialty, LLC
Surgicare of Denton, Inc.
Surgicare of Denver Mid-Town, Inc.
Surgicare of Denver, LLC
Surgicare of Evans, Inc.
Surgicare of Fairfax, Inc.
*Surgicare of Florida, Inc.
Surgicare of Flower Mound, Inc.
Surgicare of Focus Hand, LLC
Surgicare of Fort Worth Co-GP, LLC
Surgicare of Fort Worth, Inc.
Surgicare of Ft. Pierce, Inc.
Surgicare of Good Samaritan, LLC
Surgicare of Gramercy, Inc.
Surgicare of Greenview, Inc.
Surgicare of Hanover, Inc.
*Surgicare of Houston Women’s, Inc.
Surgicare of Houston, LLC
Surgicare of Indianapolis, Inc.
Surgicare of Kansas City, LLC
Surgicare of Kingwood, LLC
Surgicare of Kissimmee, Inc.
Surgicare of Lakeview, Inc.
Surgicare of Las Vegas, Inc.
Surgicare of Laurel Grove, LLC
Surgicare of Lorain County, Inc.
Surgicare of Los Gatos, Inc.
Surgicare of Los Robles, LLC
Surgicare of Madison, Inc.
*Surgicare of Manatee, Inc.
Surgicare of McKinney, Inc.
Surgicare of Medical City Dallas, LLC
Surgicare of Memorial Endoscopy, LLC

 

42


Surgicare of Merritt Island, Inc.  
Surgicare of Miami Lakes, LLC  
Surgicare of Mountain West, LLC  
Surgicare of Mt. Ogden, LLC  
Surgicare of Nashville, LLC  
Surgicare of Natchez, LLC  
*Surgicare of Newport Richey, Inc.  
Surgicare of North San Antonio, Inc.  
Surgicare of Northeast San Antonio, Inc.  
Surgicare of Orange Park, Inc.  
Surgicare of Orlando, Inc.  
Surgicare of Overland Park, LLC  
*Surgicare of Palms West, LLC  
Surgicare of Park Ridge, LLC  
Surgicare of Pasadena, Inc.  
Surgicare of Pavilion, LLC  
Surgicare of Physicians West El Paso, LLC  
Surgicare of Pinellas, Inc.  
Surgicare of Plano, Inc.  
Surgicare of Plantation, Inc.  
Surgicare of Port Charlotte, LLC  
Surgicare of Port St. Lucie, Inc.  
Surgicare of Portsmouth, LLC  
Surgicare of Premier Orthopaedic, LLC  
Surgicare of Reston, Inc.  
Surgicare of Ridgeline, LLC  
Surgicare of Riverwalk, LLC  
Surgicare of Roanoke, LLC  
Surgicare of Rose, LLC  
Surgicare of Round Rock, Inc.  
Surgicare of Royal Oaks, LLC  
Surgicare of Salem, LLC  
Surgicare of Silicon Valley, LLC  
Surgicare of Sky Ridge, LLC  
Surgicare of South Austin, Inc.  
Surgicare of Southeast Denver, Inc.  
Surgicare of Southern Kentucky, LLC  
Surgicare of Spotsylvania, LLC  
Surgicare of St. Andrews, Inc.  
Surgicare of StoneSprings, LLC  
Surgicare of Stuart, Inc.  

 

43


Surgicare of Sugar Land, Inc.
Surgicare of Swedish, LLC
Surgicare of Tallahassee, Inc.
Surgicare of Terre Haute, LLC
Surgicare of Thornton, LLC
Surgicare of Travis Center, Inc.
Surgicare of Tulsa, Inc.
Surgicare of Utah, LLC
Surgicare of Wasatch Front, LLC
Surgicare of West Hills, Inc.
Surgicare of Westlake, Inc.
Surgicare of Wichita, Inc.
Surgicare of Willis, LLC
Surgicare of Wilson County, LLC
Surgicare of Winchester, LLC
Surgicare Outpatient Center of Baton Rouge, Inc.
Surgicare Outpatient Center of Jackson, Inc.
Surgicenter of East Jefferson, Inc.
Surgico, LLC
SWMC, Inc.
Tallahassee Community Network, Inc.
*Tallahassee Medical Center, Inc.
Tampa Bay Health System, Inc.

Tampa Surgi-Centre, Inc.

TBHI Outpatient Services, LLC

*TCMC Madison-Portland, Inc.

Teays Valley Health Services, LLC
Tennessee Valley Outpatient Diagnostic Center, LLC
*Terre Haute Hospital GP, Inc.
*Terre Haute Hospital Holdings, Inc.
*Terre Haute MOB, L.P.
*Terre Haute Regional Hospital, L.P.
Texas HSS, LLC
Texas Psychiatric Company, Inc.
*The Regional Health System of Acadiana, LLC
The West Texas Division of Columbia, Inc.
*Timpanogos Regional Medical Services, Inc.
Total Imaging - Hudson, LLC
Total Imaging - North St. Petersburg, LLC
Total Imaging - Parsons, LLC
Tri Cities Health Services Corp.
Tri-County Community Hospital, Inc.
*Trident Medical Center, LLC
TriStar Health System, Inc.
Ultra Imaging Management Services, LLC

 

44


Ultra Imaging of Tampa, LLC
University Hospital, Ltd.
Utah Imaging GP, LLC
*Utah Medco, LLC
Valify, Inc.
Value Health Holdings, Inc.
Value Health Management, Inc.
Venture Medical Management, LLC
*VH Holdco, Inc.
*VH Holdings, Inc.
Vidalia Health Services, LLC
Village Oaks Medical Center, Inc.
VIP, Inc.
Virginia Care Partners ACO LLC
Virginia Hematology & Oncology Associates, Inc.
*Virginia Psychiatric Company, Inc.
Virginia Quality Care Partners, LLC
*Vision Consulting Group LLC
*Vision Holdings, LLC
W & C Hospital, Inc.
*Walterboro Community Hospital, Inc.
Warren County Ambulance Service, LLC
*WCP Properties, LLC
*Weatherford Health Services, LLC
Wesley Cath Lab, LLC
Wesley Manager, LLC
*Wesley Medical Center, LLC
West Boynton Beach Open Imaging Center, LLC
West Creek Ambulatory Surgery Center, LLC
West Creek Medical Center, Inc.
*West Florida - MHT, LLC
*West Florida - PPH, LLC
West Florida Division, Inc.
West Florida HealthWorks, LLC
West Florida Imaging Services, LLC
West Florida PET Services, LLC
West Florida Professional Billing, LLC
*West Florida Regional Medical Center, Inc.
West Hills Hospital
West Houston ASC, Inc.
West Houston Outpatient Medical Facility, Inc.
West Houston Surgicare, Inc.
West Houston, LLC
West Jacksonville Medical Center, Inc.

 

45


West Jordan Hospital Corporation
West Los Angeles Physicians’ Hospital, Inc.
West McKinney Imaging Services, LLC
West Paces Services, Inc.
West Valley Imaging, LLC
*West Valley Medical Center, Inc.
Westbury Hospital, Inc.
Westminster Community Hospital
WHG Medical, LLC
*WHMC, Inc.
Wildwood Medical Center, Inc.
Wilson County Outpatient Surgery Center, L.P.
WJHC, LLC
Woman’s Hospital Merger, LLC
*Woman’s Hospital of Texas, Incorporated
Women’s & Children’s Pediatric Hematology/Oncology Center, LLC
Women’s & Children’s Pulmonology Clinic, LLC
Women’s Hospital Indianapolis GP, Inc.
Women’s Hospital Indianapolis, L.P.

The affiliates of HCA Healthcare, Inc. listed below have entered into term promissory notes with Western Plains Capital, Inc., a subsidiary guarantor. The notes are owed to Western Plains Capital, Inc. and pledged as collateral for the secured notes.

 

Ambulatory Surgery Center Group, Ltd.
Arapahoe Surgicenter, LLC
Atlanta Surgery Center, Ltd.
Bay Area Surgicenter, LLC
Bayonet Point Surgery Center, Ltd.
Bayside Ambulatory Center, LLC
Belleair Surgery Center, Ltd.
Brownsville Surgicenter, LLC
Carolina Regional Surgery Center, Ltd.
Centennial Surgery Center, L.P.
Central Utah Surgicenter, LLC
Centrum Surgery Center, Ltd.
Chippenham Ambulatory Surgery Center, LLC
Clear Creek Surgery Center, LLC
Clear Lake Surgicare, Ltd.
Columbia Surgicare of Augusta, Ltd.
Comprehensive Digestive Surgicenter, LLC
Coral Springs Surgi-Center, Ltd.

 

46


Countryside Surgery Center, Ltd.
Denton Regional Ambulatory Surgery Center, L.P.
Denver Mid-Town Surgery Center, Ltd.
Denver Surgicenter, LLC
Doctors Hospital Surgery Center, L.P.
Doctors Same Day Surgery Center, Ltd.
El Paso Surgery Centers, L.P.
Fairfax Surgical Center, L.P.
Florida Outpatient Surgery Center, Ltd.
Gramercy Surgery Center, Ltd.
HealthONE Ridge View Endoscopy Center, LLC
Jacksonville Surgery Center, Ltd.
Johnson County Surgery Center, L.P.
KC Pain ASC, LLC
Kingwood Surgery Center, LLC
Las Colinas Surgery Center, Ltd.
Las Vegas Surgicare, Ltd.
Lincoln Surgery Center, LLC
Los Robles Surgicenter, LLC
Manatee Surgicare, Ltd.
Marietta Outpatient Surgery, Ltd.
MEC Endoscopy, LLC
Med City Dallas Outpatient Surgery Center, L.P.
Medical City Surgery Center of Alliance, LLC
Medical City Surgery Center of Frisco, LLC
Medical Plaza Ambulatory Surgery Center Associates, L.P.
Mt. Ogden Utah Surgical Center, LLC
New Port Richey Surgery Center, Ltd.
North Florida Regional Freestanding Surgery Center, L.P.
North Hills Surgicare, L.P.
North Miami Beach Surgery Center Limited Partnership
North Palm Beach County Surgery Center, LLC
North Suburban Spine Center, L.P.
Northlake Surgical Center, L.P.
ODP Manager, LLC
Oklahoma Outpatient Surgery Center Limited Partnership
Orlando Surgicare, Ltd.
Outpatient Surgical Services, Ltd.
Outpatient Women’s and Children’s Surgery Center, Ltd.
Palms West Surgery Center, Ltd.
Park Central Surgical Center, Ltd.
Park Ridge Surgery Center, LLC
Physicians Ambulatory Surgery Center, LLC
Physicians West Surgicenter, LLC
Plano Ambulatory Surgery Associates, L.P.
Port St. Lucie Surgery Center, Ltd.

 

47


Portsmouth Regional Ambulatory Surgery Center, L.L.C.
Premier ASC, LLC
Putnam Radiation Oncology, LLC
Red Rocks Surgery Center, LLC
Reston Surgery Center, L.P.
Riverwalk ASC, LLC
Roanoke Surgery Center, L.P.
Rocky Mountain Surgery Center, LLC
Rose Ambulatory Surgery Center, L.P.
Sahara Outpatient Surgery Center, Ltd.
Sky Ridge Surgery Center, L.P.
Southern Kentucky Surgicenter, LLC
Specialty Surgicare of Las Vegas, LP
St. Mark’s Ambulatory Surgery Associates, L.P.
Sugar Land Surgery Center, Ltd.
Summit Surgery Center, L.P.
Surgery Center of Atlantis, LLC
Surgery Center of Aventura, Ltd.
Surgery Center of Independence, L.P.
Surgery Center of Overland Park, L.P.
Surgery Center of the Rockies, LLC
Surgical Park Center, Ltd.
Surgicare of St. Andrews, Ltd.
Surgicare of Wichita, LLC
Surgicenter of Kansas City, LLC
Tallahassee Orthopaedic Surgery Partners, Ltd.
Tarrant County Surgery Center, L.P.
University Healthcare System, L.C.
Urology Surgery Center of Colorado, LLC
Utah Surgery Center, L.P.
West Hills Surgical Center, Ltd.
West Park Surgery Center, L.P.

 

48

EX-31.1 3 d232147dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Samuel N. Hazen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HCA Healthcare, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By:

 

/S/ SAMUEL N. HAZEN

 

Samuel N. Hazen

 

Chief Executive Officer

Date: November 1, 2021

EX-31.2 4 d232147dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, William B. Rutherford, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HCA Healthcare, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By:

 

/S/ WILLIAM B. RUTHERFORD

 

William B. Rutherford

 

Executive Vice President and Chief Financial Officer

Date: November 1, 2021

EX-32 5 d232147dex32.htm EX-32 EX-32

EXHIBIT 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of HCA Healthcare, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:

 

/S/ SAMUEL N. HAZEN

 

Samuel N. Hazen

 

Chief Executive Officer

November 1, 2021

 

By:

 

/S/ WILLIAM B. RUTHERFORD

 

William B. Rutherford

 

Executive Vice President and Chief Financial Officer

November 1, 2021

EX-101.SCH 6 hca-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Income Statements link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Comprehensive Income Statements link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Acquisitions and Dispositions link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Investments of Insurance Subsidiaries link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Financial Instruments link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Assets and Liabilities Measured at Fair Value link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Long-Term Debt link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Contingencies link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Segment and Geographic Information link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Investments of Insurance Subsidiaries (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Financial Instruments (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Cost of Uncompensated Care (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Investments of Insurance Subsidiaries - Schedule of Investments (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Investments of Insurance Subsidiaries - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Financial Instruments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Assets and Liabilities Measured at Fair Value - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Long-Term Debt - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Segment and Geographic Information - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 hca-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 hca-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 hca-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 hca-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 d232147d10q_htm.xml IDEA: XBRL DOCUMENT 0000860730 2021-01-01 2021-09-30 0000860730 2020-01-01 2020-09-30 0000860730 2020-07-01 2020-09-30 0000860730 2021-07-01 2021-09-30 0000860730 2020-12-31 0000860730 2021-09-30 0000860730 2020-01-01 2020-03-31 0000860730 2020-10-01 2020-12-31 0000860730 2021-01-01 2021-03-31 0000860730 2021-04-01 2021-06-30 0000860730 2020-04-01 2020-06-30 0000860730 2021-01-01 2021-06-30 0000860730 2021-10-25 0000860730 2019-12-31 0000860730 2021-03-31 0000860730 2021-06-30 0000860730 2020-09-30 0000860730 2020-06-30 0000860730 2020-03-31 0000860730 us-gaap:CorporateAndOtherMember 2021-07-01 2021-09-30 0000860730 hca:AmericanGroupMember 2021-07-01 2021-09-30 0000860730 hca:NationalGroupMember 2021-07-01 2021-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000860730 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000860730 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000860730 hca:MedicareMember 2021-07-01 2021-09-30 0000860730 hca:ManagedMedicareMember 2021-07-01 2021-09-30 0000860730 hca:MedicaidMember 2021-07-01 2021-09-30 0000860730 hca:ManagedMedicaidMember 2021-07-01 2021-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2021-07-01 2021-09-30 0000860730 hca:InternationalMember 2021-07-01 2021-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2021-07-01 2021-09-30 0000860730 us-gaap:CorporateAndOtherMember 2020-07-01 2020-09-30 0000860730 hca:AmericanGroupMember 2020-07-01 2020-09-30 0000860730 hca:NationalGroupMember 2020-07-01 2020-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000860730 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000860730 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000860730 hca:MedicareMember 2020-07-01 2020-09-30 0000860730 hca:ManagedMedicareMember 2020-07-01 2020-09-30 0000860730 hca:MedicaidMember 2020-07-01 2020-09-30 0000860730 hca:ManagedMedicaidMember 2020-07-01 2020-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2020-07-01 2020-09-30 0000860730 hca:InternationalMember 2020-07-01 2020-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0000860730 us-gaap:CorporateAndOtherMember 2021-01-01 2021-09-30 0000860730 hca:AmericanGroupMember 2021-01-01 2021-09-30 0000860730 hca:NationalGroupMember 2021-01-01 2021-09-30 0000860730 hca:HospitalMember 2021-01-01 2021-09-30 0000860730 hca:OtherNonhospitalHealthCareEntitiesMember 2021-01-01 2021-09-30 0000860730 hca:SouthernGeorgiaMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2021-01-01 2021-09-30 0000860730 hca:SouthernGeorgiaMember hca:HospitalMember 2021-01-01 2021-09-30 0000860730 country:TN hca:HospitalMember 2021-01-01 2021-09-30 0000860730 us-gaap:InterestRateSwapMember 2021-01-01 2021-09-30 0000860730 hca:RealEstateAndOtherInvestmentsMember 2021-01-01 2021-09-30 0000860730 stpr:GA us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2021-01-01 2021-09-30 0000860730 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000860730 hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyTwoMember us-gaap:FixedIncomeInterestRateMember 2021-01-01 2021-09-30 0000860730 hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMember us-gaap:FixedIncomeInterestRateMember 2021-01-01 2021-09-30 0000860730 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2021-01-01 2021-09-30 0000860730 hca:NorthernGeorgiaMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2021-01-01 2021-09-30 0000860730 hca:MedicareMember 2021-01-01 2021-09-30 0000860730 hca:ManagedMedicareMember 2021-01-01 2021-09-30 0000860730 hca:MedicaidMember 2021-01-01 2021-09-30 0000860730 hca:ManagedMedicaidMember 2021-01-01 2021-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2021-01-01 2021-09-30 0000860730 hca:InternationalMember 2021-01-01 2021-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-09-30 0000860730 srt:MinimumMember 2021-01-01 2021-09-30 0000860730 hca:OutOfNetworkServicesMember 2021-01-01 2021-09-30 0000860730 hca:HomeHealthAndHospiceMember 2021-01-01 2021-09-30 0000860730 us-gaap:CorporateAndOtherMember 2020-01-01 2020-09-30 0000860730 hca:AmericanGroupMember 2020-01-01 2020-09-30 0000860730 hca:NationalGroupMember 2020-01-01 2020-09-30 0000860730 hca:HospitalAndOtherNonhospitalHealthCareEntitiesMember 2020-01-01 2020-09-30 0000860730 hca:RealEstateAndOtherInvestmentsMember 2020-01-01 2020-09-30 0000860730 hca:MedicareMember 2020-01-01 2020-09-30 0000860730 hca:ManagedMedicareMember 2020-01-01 2020-09-30 0000860730 hca:MedicaidMember 2020-01-01 2020-09-30 0000860730 hca:ManagedMedicaidMember 2020-01-01 2020-09-30 0000860730 hca:ManagedCareAndOtherInsurersMember 2020-01-01 2020-09-30 0000860730 hca:InternationalMember 2020-01-01 2020-09-30 0000860730 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0000860730 hca:OutOfNetworkServicesMember 2020-01-01 2020-09-30 0000860730 us-gaap:CorporateAndOtherMember hca:ReorganizationGroupUnitsMember 2021-09-30 0000860730 hca:AmericanGroupMember hca:ReorganizationGroupUnitsMember 2021-09-30 0000860730 hca:NationalGroupMember hca:ReorganizationGroupUnitsMember 2021-09-30 0000860730 hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMember us-gaap:FixedIncomeInterestRateMember 2021-09-30 0000860730 hca:DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyTwoMember us-gaap:FixedIncomeInterestRateMember 2021-09-30 0000860730 hca:MoneyMarketFundsAndOtherMember 2021-09-30 0000860730 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:DebtSecuritiesMember 2021-09-30 0000860730 us-gaap:DebtSecuritiesMember 2021-09-30 0000860730 us-gaap:FairValueInputsLevel2Member us-gaap:DebtSecuritiesMember 2021-09-30 0000860730 hca:MoneyMarketFundsAndOtherMember 2021-09-30 0000860730 us-gaap:FairValueInputsLevel1Member hca:MoneyMarketFundsAndOtherMember 2021-09-30 0000860730 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000860730 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 hca:SeniorSecuredRevolvingCreditFacilityMember 2021-09-30 0000860730 hca:SeniorSecuredAssetBasedRevolvingCreditFacilityMember 2021-09-30 0000860730 hca:SeniorSecuredTermLoanFacilitiesMember 2021-09-30 0000860730 hca:SeniorSecuredNotesMember 2021-09-30 0000860730 hca:OtherSeniorSecuredDebtMember 2021-09-30 0000860730 hca:SeniorUnsecuredNotesMember 2021-09-30 0000860730 srt:BoardOfDirectorsChairmanMember 2021-09-30 0000860730 hca:HomeHealthAndHospiceMember 2021-09-30 0000860730 us-gaap:InterestRateSwapMember 2021-09-30 0000860730 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 hca:OtherNonhospitalHealthCareEntitiesMember 2021-09-30 0000860730 hca:OtherAccruedExpensesMember us-gaap:InterestRateSwapMember 2021-09-30 0000860730 hca:OtherAccruedExpensesMember us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000860730 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:DebtSecuritiesMember 2020-12-31 0000860730 hca:MoneyMarketFundsAndOtherMember 2020-12-31 0000860730 us-gaap:FairValueInputsLevel2Member us-gaap:DebtSecuritiesMember 2020-12-31 0000860730 us-gaap:DebtSecuritiesMember 2020-12-31 0000860730 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000860730 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000860730 us-gaap:FairValueInputsLevel1Member hca:MoneyMarketFundsAndOtherMember 2020-12-31 0000860730 hca:MoneyMarketFundsAndOtherMember 2020-12-31 0000860730 hca:SeniorSecuredRevolvingCreditFacilityMember 2020-12-31 0000860730 hca:SeniorSecuredAssetBasedRevolvingCreditFacilityMember 2020-12-31 0000860730 hca:SeniorSecuredNotesMember 2020-12-31 0000860730 hca:SeniorSecuredTermLoanFacilitiesMember 2020-12-31 0000860730 hca:OtherSeniorSecuredDebtMember 2020-12-31 0000860730 hca:SeniorUnsecuredNotesMember 2020-12-31 0000860730 us-gaap:InterestRateSwapMember 2020-12-31 0000860730 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000860730 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000860730 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000860730 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000860730 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0000860730 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000860730 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000860730 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000860730 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000860730 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000860730 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000860730 hca:SeniorSecuredNotesDue2051Member us-gaap:SeniorNotesMember 2021-06-30 0000860730 hca:SeniorSecuredNotesDue2031Member us-gaap:SeniorNotesMember 2021-06-30 0000860730 us-gaap:SeniorNotesMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanBThirteenFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanBTwelveFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanASixFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanBFourteenFacilityMember 2021-06-30 0000860730 hca:SeniorSecuredTermLoanASevenFacilityMember 2021-06-30 0000860730 hca:AssetBasedRevolvingCreditFacilityMember 2021-06-30 0000860730 srt:BoardOfDirectorsChairmanMember 2019-01-31 0000860730 srt:BoardOfDirectorsChairmanMember 2020-01-31 0000860730 srt:BoardOfDirectorsChairmanMember 2021-02-28 0000860730 us-gaap:CommonStockMember 2021-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000860730 us-gaap:RetainedEarningsMember 2021-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-09-30 0000860730 us-gaap:CommonStockMember 2020-09-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000860730 us-gaap:RetainedEarningsMember 2020-09-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-09-30 0000860730 us-gaap:CommonStockMember 2019-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000860730 us-gaap:RetainedEarningsMember 2019-12-31 0000860730 us-gaap:NoncontrollingInterestMember 2019-12-31 0000860730 us-gaap:CommonStockMember 2020-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000860730 us-gaap:RetainedEarningsMember 2020-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-03-31 0000860730 us-gaap:CommonStockMember 2020-06-30 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000860730 us-gaap:RetainedEarningsMember 2020-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2020-06-30 0000860730 us-gaap:CommonStockMember 2020-12-31 0000860730 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000860730 us-gaap:RetainedEarningsMember 2020-12-31 0000860730 us-gaap:NoncontrollingInterestMember 2020-12-31 0000860730 us-gaap:CommonStockMember 2021-03-31 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000860730 us-gaap:RetainedEarningsMember 2021-03-31 0000860730 us-gaap:NoncontrollingInterestMember 2021-03-31 0000860730 us-gaap:CommonStockMember 2021-06-30 0000860730 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000860730 us-gaap:RetainedEarningsMember 2021-06-30 0000860730 us-gaap:NoncontrollingInterestMember 2021-06-30 iso4217:USD utr:Year shares pure hca:Hospital iso4217:USD shares hca:Surgery_Center hca:Endoscopy_Center hca:State false 0.02375 0.035 1 1 Q3 0000860730 --12-31 10-Q true 2021-09-30 2021 false 1-11239 HCA Healthcare, Inc. DE 27-3865930 One Park Plaza Nashville TN 37203 615 344-9551 Voting common stock, $.01 par value HCA NYSE Yes Yes Large Accelerated Filer false false false 311022800 15276000000 13311000000 43688000000 37240000000 7094000000 6097000000 19780000000 17545000000 2463000000 2128000000 7067000000 5999000000 2530000000 2251000000 7424000000 6825000000 0 -822000000 0 0 35000000 40000000 78000000 48000000 716000000 694000000 2125000000 2059000000 398000000 385000000 1168000000 1201000000 1047000000 14000000 1057000000 -6000000 0 0 -12000000 -295000000 12119000000 12323000000 36441000000 33882000000 3157000000 988000000 7247000000 3358000000 685000000 209000000 1531000000 665000000 2472000000 779000000 5716000000 2693000000 203000000 111000000 574000000 365000000 2269000000 668000000 5142000000 2328000000 7.13 1.97 15.67 6.89 7.00 1.95 15.43 6.79 318072000.000 338168000 328048000.000 338057000.000 324029000.000 343346000 333248000 343014000.000 2472000000 779000000 5716000000 2693000000 -31000000 42000000 -20000000 -39000000 -3000000 1000000 -12000000 13000000 0 0 0 0 -7000000 -4000000 -21000000 -12000000 -7000000 -4000000 -21000000 -12000000 -1000000 0 -1000000 -66000000 -10000000 -9000000 -28000000 -15000000 9000000 9000000 27000000 -51000000 -18000000 56000000 16000000 -65000000 -1000000 9000000 6000000 -10000000 -17000000 47000000 10000000 -55000000 2455000000 826000000 5726000000 2638000000 203000000 111000000 574000000 365000000 2252000000 715000000 5152000000 2273000000 1027000000 1793000000 8433000000 7051000000 2019000000 2025000000 1769000000 1464000000 13248000000 12333000000 50695000000 49317000000 27148000000 26118000000 23547000000 23199000000 418000000 388000000 412000000 422000000 9153000000 8578000000 2099000000 2024000000 685000000 546000000 49562000000 47490000000 3759000000 3535000000 2134000000 1720000000 3481000000 3240000000 250000000 209000000 9624000000 8704000000 253000000 236000000 32049000000 30795000000 1522000000 1486000000 1742000000 1673000000 2800000000 1940000000 0.01 0.01 1800000000 1800000000 313502400 339425600 3000000 3000000 0 294000000 -492000000 -502000000 -206000000 777000000 -695000000 572000000 2520000000 2320000000 1825000000 2892000000 49562000000 47490000000 338446000 3000000 -460000000 -2351000000 2243000000 -565000000 -111000000 581000000 117000000 587000000 3287000 441000000 441000000 2449000 2000000 -35000000 -33000000 0.43 148000000 148000000 154000000 154000000 2000000 -53000000 -51000000 337608000 3000000 -571000000 -2394000000 2259000000 -703000000 9000000 1079000000 137000000 1225000000 352000 93000000 93000000 45000000 45000000 5000000 -3000000 2000000 337960000 3000000 88000000 -562000000 -1315000000 2354000000 568000000 47000000 668000000 111000000 826000000 410000 97000000 97000000 194000000 194000000 -2000000 -2000000 338370000 3000000 185000000 -515000000 -647000000 2273000000 1299000000 13000000 1426000000 268000000 1707000000 1056000.000 108000000 108000000 0.43 2000000 2000000 233000000 233000000 -1000000 -12000000 -13000000 339426000 3000000 294000000 -502000000 777000000 2320000000 2892000000 11000000 1423000000 157000000 1591000000 8477000 225000000 1302000000 1527000000 2765000 -75000000 -75000000 0.48 163000000 163000000 234000000 234000000 -6000000 8000000 2000000 333714000 3000000 -491000000 735000000 2235000000 2482000000 16000000 1450000000 214000000 1680000000 11261000 142000000 2145000000 2287000000 372000 140000000 140000000 0.48 161000000 161000000 123000000 123000000 -2000000 -57000000 -59000000 322825000 3000000 -475000000 -121000000 2383000000 1790000000 -17000000 2269000000 203000000 2455000000 9605000 130000000 2199000000 2329000000 282000 127000000 127000000 0.48 155000000 155000000 144000000 144000000 -3000000 -78000000 -81000000 313502000 3000000 -492000000 -206000000 2520000000 1825000000 5716000000 2693000000 1312000000 -930000000 333000000 36000000 731000000 542000000 0 6123000000 2125000000 2059000000 185000000 -114000000 1057000000 -6000000 -12000000 -295000000 21000000 22000000 341000000 229000000 -87000000 -66000000 6516000000 12815000000 2385000000 2087000000 488000000 380000000 1980000000 68000000 38000000 40000000 -2000000 44000000 -929000000 -2483000000 4337000000 2700000000 500000000 -2480000000 3787000000 3403000000 501000000 393000000 38000000 35000000 476000000 153000000 6143000000 441000000 -241000000 -156000000 -6349000000 -4361000000 -4000000 -4000000 -766000000 5967000000 1793000000 621000000 1027000000 6588000000 1127000000 1230000000 1346000000 779000000 <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES </div></div></div></div> </div> </div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reporting Entity </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HCA Healthcare, Inc. is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At September 30, 2021, these affiliates owned and operated 183 hospitals, 123 freestanding surgery centers, 21 freestanding endoscopy centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA. </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and Article 10 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Regulation S-X.</div> Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $87 million and $117 million for the quarters ended September 30, 2021 and 2020, respectively, and $301 million and $289 million for the nine months ended September 30, 2021 and 2020, respectively. Operating results for the quarter and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K</div> for the year ended December 31, 2020. </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March 11, 2020, the World Health Organization designated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> as a global pandemic. Patient volumes and the related revenues for most of our services were significantly impacted during the latter portion of the first quarter and the first half of the second quarter of 2020 and have continued to be impacted as various policies were implemented by federal, state and local governments in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. During the second quarter of 2021, our patient volumes experienced a strong rebound as the effects of the pandemic moderated and certain pandemic-related restrictions and policies were eased. During the third quarter of 2021, our patient volumes remained strong, with the exception of inpatient surgeries, and included a resurgence of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> admissions. Inpatient surgery volumes were constrained during the quarter as capacity was used to treat the surge of COVID-19 patients. We believe the extent of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate how long or to what extent the pandemic will impact our operations. </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> rates. Our revenues for the nine months ended September 30, 2021 and 2020 included $33 million and $55 million, respectively, related to the settlement of Medicare outlier calculations for prior periods. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,645</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,603</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.6</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,124</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,760</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">692</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.5</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">445</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">813</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">707</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed care and insurers</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,998</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,752</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International (managed care and insurers)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">307</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">680</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.5</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">737</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,276</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,311</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,816</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,618</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">20.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,281</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,074</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,722</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,423</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,369</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,904</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed care and insurers</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,300</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19,028</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">51.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International (managed care and insurers)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">995</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">838</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,205</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,355</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43,688</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">37,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">100.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To quantify the total impact of the trends related to<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,803</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,170</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,396</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,428</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Cost-to-charges</div></div> ratio (patient care costs as percentage of gross patient charges)</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.8</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total uncompensated care</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,782</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,023</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,299</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,625</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Multiply by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-charges</div></div> ratio</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.8</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cost of total uncompensated care</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">916</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,542</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total uncompensated care amounts include<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>charity care of $3.509 billion and $3.160 billion, respectively, and the related estimated costs of charity care were $413 million and $376 million, respectively, for the quarters ended September 30, 2021 and 2020. The total uncompensated care amounts include charity care of $10.135 billion and $9.972 billion, respectively, and the related estimated costs of charity care were $1.155 billion and $1.207 billion, respectively, for the nine months ended September 30, 2021 and 2020. </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain prior year amounts have been reclassified to conform to the current year presentation. </div></div> 183 123 21 20 <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and Article 10 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Regulation S-X.</div> Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $87 million and $117 million for the quarters ended September 30, 2021 and 2020, respectively, and $301 million and $289 million for the nine months ended September 30, 2021 and 2020, respectively. Operating results for the quarter and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K</div> for the year ended December 31, 2020. </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March 11, 2020, the World Health Organization designated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> as a global pandemic. Patient volumes and the related revenues for most of our services were significantly impacted during the latter portion of the first quarter and the first half of the second quarter of 2020 and have continued to be impacted as various policies were implemented by federal, state and local governments in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. During the second quarter of 2021, our patient volumes experienced a strong rebound as the effects of the pandemic moderated and certain pandemic-related restrictions and policies were eased. During the third quarter of 2021, our patient volumes remained strong, with the exception of inpatient surgeries, and included a resurgence of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> admissions. Inpatient surgery volumes were constrained during the quarter as capacity was used to treat the surge of COVID-19 patients. We believe the extent of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate how long or to what extent the pandemic will impact our operations. </div></div> 87000000 117000000 301000000 289000000 <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-for-service</div></div> rates. Our revenues for the nine months ended September 30, 2021 and 2020 included $33 million and $55 million, respectively, related to the settlement of Medicare outlier calculations for prior periods. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,645</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,603</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.6</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,124</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,760</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">692</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.5</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">445</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">813</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">707</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed care and insurers</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,998</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,752</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International (managed care and insurers)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">307</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">680</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.5</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">737</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,276</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,311</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,816</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,618</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">20.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,281</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,074</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,722</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,423</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,369</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,904</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed care and insurers</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,300</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19,028</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">51.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International (managed care and insurers)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">995</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">838</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,205</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,355</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43,688</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">37,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">100.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To quantify the total impact of the trends related to<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,803</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,170</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,396</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,428</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Cost-to-charges</div></div> ratio (patient care costs as percentage of gross patient charges)</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.8</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total uncompensated care</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,782</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,023</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,299</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,625</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Multiply by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-charges</div></div> ratio</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.8</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cost of total uncompensated care</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">916</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,542</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total uncompensated care amounts include<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>charity care of $3.509 billion and $3.160 billion, respectively, and the related estimated costs of charity care were $413 million and $376 million, respectively, for the quarters ended September 30, 2021 and 2020. The total uncompensated care amounts include charity care of $10.135 billion and $9.972 billion, respectively, and the related estimated costs of charity care were $1.155 billion and $1.207 billion, respectively, for the nine months ended September 30, 2021 and 2020. </div></div> Our performance obligations for inpatient services are generally satisfied over periodsthat average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. 33000000 55000000 4 Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions): <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,645</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,603</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.6</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,124</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,760</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.2</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">692</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.5</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">445</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">813</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">707</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed care and insurers</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,998</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">52.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,752</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International (managed care and insurers)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">307</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">680</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.5</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">737</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,276</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,311</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    Ratio    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,816</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,618</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">20.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicare</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,281</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,074</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,722</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.9</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,423</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed Medicaid</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,369</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,904</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managed care and insurers</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,300</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">51.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19,028</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">51.0</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International (managed care and insurers)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">995</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.3</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">838</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,205</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,355</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43,688</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100.0</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">37,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">100.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 2645000000 0.173 2603000000 0.196 2124000000 0.139 1760000000 0.132 692000000 0.045 445000000 0.033 813000000 0.053 707000000 0.053 7998000000 0.524 6752000000 0.507 324000000 0.021 307000000 0.023 680000000 0.045 737000000 0.056 15276000000 1.000 13311000000 1.000 7816000000 0.179 7618000000 0.205 6281000000 0.144 5074000000 0.136 1722000000 0.039 1423000000 0.038 2369000000 0.054 1904000000 0.051 22300000000 0.510 19028000000 0.510 995000000 0.023 838000000 0.023 2205000000 0.051 1355000000 0.037 43688000000 1.000 37240000000 1.000 A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions): <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,803</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,170</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,396</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,428</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Cost-to-charges</div></div> ratio (patient care costs as percentage of gross patient charges)</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.8</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total uncompensated care</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,782</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,023</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,299</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,625</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Multiply by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-charges</div></div> ratio</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.8</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.4</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cost of total uncompensated care</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">916</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,542</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 12803000000 11170000000 36396000000 32428000000 0.118 0.120 0.114 0.121 7782000000 7023000000 22299000000 21625000000 0.118 0.120 0.114 0.121 916000000 843000000 2542000000 2617000000 3509000000 3160000000 413000000 376000000 10135000000 9972000000 1155000000 1207000000 <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain prior year amounts have been reclassified to conform to the current year presentation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2 — ACQUISITIONS AND DISPOSITIONS </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September 30, 2021, we paid $67 million to acquire two hospital facilities, one in southern Georgia and one in Tennessee, and $91 million to acquire other nonhospital health care </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entities (noncontrolling interests of $111 million were recorded).</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> We also paid $330 million and assumed certain liabilities to acquire an 80% interest (noncontrolling interests of $101 million were recorded) in a venture providing post-acute care services (home health and hospice). Purchase price amounts have been allocated to the related assets acquired and liabilities assumed based upon their respective fair values. The purchase price paid in excess of the fair value of identifiable net assets of these acquired entities aggregated $601 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2020, we paid $380 million to acquire a hospital in New Hampshire </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and other nonhospital health care entities. The consolidated financial statements include the accounts and operations of the acquired entities subsequent to the respective acquisition </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dates. The pro forma effects of these acquired entities on our results of operations for periods prior to the respective acquisition dates were not significant. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September 30, 2021, we received proceeds of $860 million and recognized a pretax gain of $655 million related to the sale of four hospital facilities in Georgia (two facilities in northern Georgia and two facilities in southern Georgia). We received proceeds of $647 million on September 30, 2021 related to the <span style="-sec-ix-hidden:hidden27811668">sale</span> of a hospital facility in northern Georgia, which sale was effective October 1, 2021. We also received proceeds of $473 million and recognized a pretax gain of $402 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million related to sales of other health care entity investments and minor real estate assets. During the nine months ended September 30, 2020, we received proceeds of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>68<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million and recognized a net pretax loss of $</div>6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million related to the </div><span style="-sec-ix-hidden:hidden27811669">sale</span><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of a hospital facility in Mississippi and sales of real estate and other investments.</div></div> 67000000 2 1 1 91000000 111000000 330000000 0.80 101000000 601000000 380000000 860000000 655000000 4 2 647000000 473000000 402000000 68000000 6000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3 — INCOME TAXES </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our provisions for income taxes for the quarters ended September 30, 2021 and 2020 were $685 million and $209 million, respectively, and the effective tax rates were 23.2% and 23.8%, respectively. Our provisions for income taxes for the nine months ended September 30, 2021 and 2020 were $1.531 billion and $665 million, respectively, and the effective tax rates were 22.9% and 22.2%, respectively. Our provisions for income taxes included tax benefits related to settlements of employee equity awards of $96 million and $59 million for the nine months ended September 30, 2021 and 2020, respectively. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our liability for unrecognized tax benefits was $626 million, including accrued interest of $95 million, as of September 30, 2021 ($508 million and $73 million, respectively, as of December 31, 2020). Unrecognized tax benefits of $192 million ($157 million as of December 31, 2020) would affect the effective rate, if recognized. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Internal Revenue Service was conducting an examination of the Company’s 2016, 2017 and 2018 federal income tax returns at September 30, 2021. We are also subject to examination by state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change. </div></div> 685000000 209000000 0.232 0.238 1531000000 665000000 0.229 0.222 96000000 59000000 626000000 95000000 508000000 73000000 192000000 157000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4 — EARNINGS PER SHARE </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards, computed using the treasury stock method. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted earnings per share for the quarters and nine months ended September 30, 2021 and 2020 (dollars and shares in millions, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable to HCA Healthcare, Inc.</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,269</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">668</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,142</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,328</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">318.072</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338.168</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">328.048</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338.057</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive incremental shares</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.957</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.200</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.957</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares used for diluted earnings per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324.029</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343.346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">333.248</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343.014</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.13</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.67</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.89</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.00</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.95</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.43</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted earnings per share for the quarters and nine months ended September 30, 2021 and 2020 (dollars and shares in millions, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable to HCA Healthcare, Inc.</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,269</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">668</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,142</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,328</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">318.072</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338.168</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">328.048</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338.057</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive incremental shares</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.957</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.200</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.957</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares used for diluted earnings per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">324.029</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343.346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">333.248</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343.014</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.13</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.67</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.89</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted earnings</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.00</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.95</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.43</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 2269000000 668000000 5142000000 2328000000 318072000.000 338168000 328048000.000 338057000.000 5957000 5178000 5200000 4957000 324029000.000 343346000 333248000 343014000.000 7.13 1.97 15.67 6.89 7.00 1.95 15.43 6.79 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of our insurance subsidiaries’ investments at September 30, 2021 and December 31, 2020 follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Amounts</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">391</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">510</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">530</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(112</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment carrying value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">418</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Amounts</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">384</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">472</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">504</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment carrying value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At September 30, 2021 and December 31, 2020, the investments in debt securities of our insurance subsidiaries were classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“available-for-sale.”</div></div> Changes in unrealized gains and losses that are not credit-related are recorded as adjustments to other comprehensive income (loss). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scheduled maturities of investments in debt securities at September 30, 2021 were as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due in one year or less</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after one year through five years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">134</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after five years through ten years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after ten years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">391</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">411</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The average expected maturity of the investments in debt securities at September 30, 2021 was 5.5 years, compared to the average scheduled maturity of 9.3 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of our insurance subsidiaries’ investments at September 30, 2021 and December 31, 2020 follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Amounts</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">391</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">510</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">530</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(112</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment carrying value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">418</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Amounts</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">384</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">472</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">504</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment carrying value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 391000000 21000000 1000000 411000000 119000000 119000000 510000000 21000000 1000000 530000000 112000000 418000000 384000000 32000000 416000000 88000000 88000000 472000000 32000000 504000000 116000000 388000000 <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scheduled maturities of investments in debt securities at September 30, 2021 were as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due in one year or less</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after one year through five years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">134</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after five years through ten years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after ten years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">391</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">411</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 0 0 134000000 141000000 177000000 187000000 80000000 83000000 391000000 411000000 P5Y6M P9Y3M18D <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6 — FINANCIAL INSTRUMENTS </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Rate Swap Agreements </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between us and our counterparties based on common notional principal amounts and maturity dates. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pay-fixed</div> interest rate swaps effectively convert variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at September 30, 2021 (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity Date</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pay-fixed</div> interest rate swaps</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 2021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pay-fixed</div> interest rate swaps</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 2022</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the next 12 months, we estimate $17 million will be reclassified from other comprehensive income (“OCI”) and will be included in interest expense. </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives — Results of Operations </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the effect of our interest rate swaps on our results of operations for the nine months ended September 30, 2021 (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 50%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives in Cash Flow Hedging Relationships</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Loss<br/> Recognized in OCI on<br/> Derivatives, Net of Tax</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Location of Loss<br/> Reclassified from<br/> Accumulated OCI<br/> into Operations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Loss<br/> Reclassified from<br/> Accumulated OCI<br/> into Operations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Interest expense</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit-risk-related Contingent Features </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have agreements with each of our derivative counterparties that contain a provision where we could be declared in default on our derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to our default on the indebtedness. As of September 30, 2021, we have not been required to post any collateral related to these agreements. If we had breached these provisions at September 30, 2021, we would have been required to settle our obligations under the agreements at their aggregate, estimated termination value of $19 million. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at September 30, 2021 (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity Date</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pay-fixed</div> interest rate swaps</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 2021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pay-fixed</div> interest rate swaps</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">December 2022</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> 2000000000 2021-12 -7000000 500000000 2022-12 -12000000 17000000 <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the effect of our interest rate swaps on our results of operations for the nine months ended September 30, 2021 (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 50%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives in Cash Flow Hedging Relationships</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Loss<br/> Recognized in OCI on<br/> Derivatives, Net of Tax</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Location of Loss<br/> Reclassified from<br/> Accumulated OCI<br/> into Operations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Loss<br/> Reclassified from<br/> Accumulated OCI<br/> into Operations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Interest expense</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> -1000000 -28000000 19000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7 — ASSETS AND LIABILITIES MEASURED<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>AT FAIR<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>VALUE </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Accounting Standards Codification 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures </div></div>(“ASC 820”), emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment. </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment Securities </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The investments of our insurance subsidiaries are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices in<br/> Active Markets for<br/> Identical Assets<br/> and Liabilities<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Other<br/> Observable Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">530</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Less amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(112</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(105</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">418</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">404</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps (Other accrued expenses)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps (Income taxes and other liabilities)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices in<br/> Active Markets for<br/> Identical Assets<br/> and Liabilities<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Other<br/> Observable Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">504</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Less amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps (Income taxes and other liabilities)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of our long-term debt was $36.567 billion and $35.814 billion at September 30, 2021 and December 31, 2020, respectively, compared to carrying amounts, excluding debt issuance costs and discounts, aggregating $32.552 billion and $31.240 billion, respectively. The estimates of fair value are generally based upon the quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices in<br/> Active Markets for<br/> Identical Assets<br/> and Liabilities<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Other<br/> Observable Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">530</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">119</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">411</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Less amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(112</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(105</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">418</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">404</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps (Other accrued expenses)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps (Income taxes and other liabilities)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices in<br/> Active Markets for<br/> Identical Assets<br/> and Liabilities<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Other<br/> Observable Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt securities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments of insurance subsidiaries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">504</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Less amounts classified as current assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swaps (Income taxes and other liabilities)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 411000000 411000000 119000000 119000000 530000000 119000000 411000000 112000000 105000000 7000000 418000000 14000000 404000000 17000000 17000000 2000000 2000000 416000000 416000000 88000000 88000000 504000000 88000000 416000000 116000000 87000000 29000000 388000000 1000000 387000000 46000000 46000000 36567000000 35814000000 32552000000 31240000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8 — LONG-TERM DEBT </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of long-term debt at September 30, 2021 and December 31, 2020, including related interest rates at September 30, 2021, follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">500</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured revolving credit facility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured term loan facilities (effective interest rate of 3.1%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,980</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,671</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured notes (effective interest rate of 4.8%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,200</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other senior secured debt (effective interest rate of 4.2%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">920</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">767</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured debt</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,600</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,288</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior unsecured notes (effective interest rate of 5.5%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,952</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,952</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issuance costs and discounts</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(253</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(236</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt (average life of 9.5 years, rates averaging 4.9%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,299</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,004</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less amounts due within one year</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,049</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,795</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During June 2021, we issued $2.350 billion aggregate principal amount of senior secured notes comprised of $850 million aggregate principal amount of <span style="-sec-ix-hidden:hidden27811634">2 3/8</span>% notes due 2031 and $1.500 billion aggregate principal amount of <span style="-sec-ix-hidden:hidden27811635">3 1/2</span>% notes due 2051 (the “June 2021 Notes”). We also amended and restated our senior secured revolving credit facility and our senior secured asset-based revolving credit facility, including increasing availability under the asset-based revolving credit facility to $4.500 billion, extending the maturity date on both facilities to June 30, 2026 and entering into a new $1.500 billion term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">loan A-7</div> facility and a new $500 million term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">loan B-14</div> facility (the “Credit Agreement Transactions”). We used the net proceeds from the June 2021 Notes and the Credit Agreement Transactions to retire the $1.071 billion term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">loan A-6</div> facility, the $1.455 billion term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">loan B-12</div> facility and the $1.131 billion term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">loan B-13</div> facility. The pretax loss on retirement of debt was $12 million. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of long-term debt at September 30, 2021 and December 31, 2020, including related interest rates at September 30, 2021, follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">500</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured revolving credit facility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured term loan facilities (effective interest rate of 3.1%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,980</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,671</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured notes (effective interest rate of 4.8%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,200</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,850</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other senior secured debt (effective interest rate of 4.2%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">920</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">767</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior secured debt</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,600</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,288</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior unsecured notes (effective interest rate of 5.5%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,952</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,952</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issuance costs and discounts</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(253</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(236</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt (average life of 9.5 years, rates averaging 4.9%)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,299</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,004</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less amounts due within one year</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">32,049</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,795</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 0.027 500000000 0 0 0 0.031 1980000000 3671000000 0.048 16200000000 13850000000 0.042 920000000 767000000 19600000000 18288000000 0.055 12952000000 12952000000 253000000 236000000 P9Y6M 0.049 32299000000 31004000000 250000000 209000000 32049000000 30795000000 2350000000 850000000 1500000000 4500000000 1500000000 500000000 1071000000.000 1455000000 1131000000 -12000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9 — CONTINGENCIES </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Health care companies are routinely subject to investigations by various governmental agencies. Under the federal False Claims Act (“FCA”), private parties have the right to bring <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">qui tam</div></div>, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity. </div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Texas operates a state Medicaid program pursuant to a waiver from the Centers for Medicare &amp; Medicaid Services under Section 1115 of the Social Security Act (“Program”). The Program includes uncompensated-care pools; payments from these pools are intended to defray the uncompensated costs of services provided by our and other hospitals to Medicaid eligible or uninsured individuals. Separately, we and other hospitals provide charity care services in several communities in the state. In 2018, the Civil Division of the U.S. Department of Justice and the U.S. Attorney’s Office for the Southern District of Texas requested information about whether the Program, as operated in Harris County, complied with the laws and regulations applicable to provider related donations, and the Company cooperated with that request. On May 21, 2019, a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">qui tam</div></div> lawsuit asserting violations of the FCA and the Texas Medicaid Fraud Prevention Act related to the Program, as operated in Harris County, was unsealed by the U.S. District Court for the Southern District of Texas. Both the federal and state governments declined to intervene in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">qui tam</div></div> lawsuit. The Company believes that our participation is and has been consistent with the requirements of the Program and is vigorously defending against the lawsuit being pursued by the relator. We cannot predict what effect, if any, the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">qui tam</div></div> lawsuit could have on the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10 — SHARE REPURCHASE TRANSACTIONS AND OTHER COMPREHENSIVE LOSS </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During January 2020 and 2019, our Board of Directors authorized share repurchase programs for up to $4 billion ($2 billion for each authorization) of our outstanding common stock. During February 2021, our Board of Directors authorized an additional $6 billion for repurchases of our outstanding common stock. During the nine months ended September 30, 2021, we repurchased 29.343 million shares of our common stock at an average price of $209.35 per share through market purchases pursuant to the January 2019 authorization (which was completed during the first quarter of 2021), the January 2020 authorization (which was completed during the second quarter of 2021) and the February 2021 authorization. At September 30, 2021, we had $2.658 billion of repurchase authorization available under the February 2021 authorization. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of accumulated other comprehensive loss are as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains on<br/> Available-<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-Sale</div><br/> Securities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> Currency<br/> Translation<br/> Adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Defined<br/> Benefit<br/> Plans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change<br/> in Fair<br/> Value of<br/> Derivative<br/> Instruments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances at December 31, 2020</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(271</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(220</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(502</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities, net of $3 income tax benefit</div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments, net of $2 income tax benefit</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative instruments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expense reclassified into operations from other comprehensive income, net of $5 and $6 income tax benefits, respectively</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances at September 30, 2021</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(289</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(492</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 4000000000 2000000000 6000000000 29343000 209.35 2658000000 <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of accumulated other comprehensive loss are as follows (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains on<br/> Available-<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-Sale</div><br/> Securities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> Currency<br/> Translation<br/> Adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Defined<br/> Benefit<br/> Plans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change<br/> in Fair<br/> Value of<br/> Derivative<br/> Instruments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances at December 31, 2020</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(271</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(220</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(502</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities, net of $3 income tax benefit</div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustments, net of $2 income tax benefit</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative instruments</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expense reclassified into operations from other comprehensive income, net of $5 and $6 income tax benefits, respectively</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances at September 30, 2021</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(289</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(204</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(492</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 25000000 -271000000 -220000000 -36000000 -502000000 3000000 -9000000 -9000000 2000000 -18000000 -18000000 -1000000 -1000000 5000000 6000000 16000000 -22000000 38000000 16000000 -289000000 -204000000 -15000000 -492000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate in <div style="letter-spacing: 0px; top: 0px;;display:inline;">one</div> line of business, which is operating hospitals and related health care entities. We operate in two geographically organized groups: the National and American Groups. The National Group includes 96 hospitals located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, North Carolina, South Carolina, Utah and Virginia, and the American Group includes 80 hospitals located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Missouri, Tennessee and </div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Texas. We also operate seven hospitals in England, and these facilities are included in the Corporate and other group. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, losses and gains on sales of facilities, losses on retirement of debt, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,787</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,633</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,143</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,653</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,767</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,073</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,562</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,920</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">722</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,983</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,276</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,311</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43,688</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of affiliates:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(38</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(78</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted segment EBITDA:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,780</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,128</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,330</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,828</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,604</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,130</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,698</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,653</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(160</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(205</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(533</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(562</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,224</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,053</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,495</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,919</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">343</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,005</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">295</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">884</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">868</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">78</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">716</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,125</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,059</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted segment EBITDA</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,224</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,053</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,495</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,919</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">716</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,125</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,059</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">398</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,168</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,201</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses (gains) on sales of facilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,047</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,057</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses on retirement of debt</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income before income taxes</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,157</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">988</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,247</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,358</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> 2 96 80 7 The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions): <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarter</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,787</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,633</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,143</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,653</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,767</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,073</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,562</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,920</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">722</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,983</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,276</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,311</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">43,688</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,240</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of affiliates:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(30</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(14</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(38</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(35</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(78</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted segment EBITDA:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,780</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,128</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,330</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,828</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,604</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,130</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,698</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,653</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(160</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(205</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(533</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(562</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,224</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,053</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,495</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,919</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">343</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,005</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Group</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">295</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">884</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">868</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">78</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">236</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">716</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,125</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,059</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"><div style="line-height: 6pt; font-size: 6pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="vertical-align: bottom; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 6pt; font-size: 6pt;"> <div style="font-size: 6pt; line-height: 6pt;"><div style="font-size:6pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted segment EBITDA</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,224</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,053</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,495</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,919</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">716</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,125</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,059</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">398</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,168</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,201</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses (gains) on sales of facilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,047</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,057</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Losses on retirement of debt</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income before income taxes</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,157</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">988</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,247</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,358</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 7787000000 6633000000 22143000000 18653000000 6767000000 6073000000 19562000000 16920000000 722000000 605000000 1983000000 1667000000 15276000000 13311000000 43688000000 37240000000 14000000 23000000 30000000 26000000 14000000 15000000 38000000 26000000 7000000 2000000 10000000 -4000000 35000000 40000000 78000000 48000000 1780000000 1128000000 5330000000 3828000000 1604000000 1130000000 4698000000 3653000000 -160000000 -205000000 -533000000 -562000000 3224000000 2053000000 9495000000 6919000000 343000000 312000000 1005000000 930000000 295000000 286000000 884000000 868000000 78000000 96000000 236000000 261000000 716000000 694000000 2125000000 2059000000 3224000000 2053000000 9495000000 6919000000 716000000 694000000 2125000000 2059000000 398000000 385000000 1168000000 1201000000 1047000000 14000000 1057000000 -6000000 0 0 -12000000 -295000000 3157000000 988000000 7247000000 3358000000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
9 Months Ended
Sep. 30, 2021
Oct. 25, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Trading Symbol HCA  
Entity Registrant Name HCA Healthcare, Inc.  
Entity Central Index Key 0000860730  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Shell Company false  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   311,022,800
Entity Interactive Data Current Yes  
Entity File Number 1-11239  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 27-3865930  
Entity Address, Address Line One One Park Plaza  
Entity Address, City or Town Nashville  
Entity Address, State or Province TN  
Entity Address, Postal Zip Code 37203  
City Area Code 615  
Local Phone Number 344-9551  
Document Quarterly Report true  
Document Transition Report false  
Title of 12(b) Security Voting common stock, $.01 par value  
Security Exchange Name NYSE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Income Statements - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenues $ 15,276 $ 13,311 $ 43,688 $ 37,240
Salaries and benefits 7,094 6,097 19,780 17,545
Supplies 2,463 2,128 7,067 5,999
Other operating expenses 2,530 2,251 7,424 6,825
Government stimulus income reversal 0 822 0 0
Equity in earnings of affiliates (35) (40) (78) (48)
Depreciation and amortization 716 694 2,125 2,059
Interest expense 398 385 1,168 1,201
Losses (gains) on sales of facilities (1,047) (14) (1,057) 6
Losses on retirement of debt 0 0 12 295
Total expenses including equity in earnings of affiliates 12,119 12,323 36,441 33,882
Income before income taxes 3,157 988 7,247 3,358
Provision for income taxes 685 209 1,531 665
Net income 2,472 779 5,716 2,693
Net income attributable to noncontrolling interests 203 111 574 365
Net income attributable to HCA Healthcare, Inc. $ 2,269 $ 668 $ 5,142 $ 2,328
Per share data:        
Basic earnings $ 7.13 $ 1.97 $ 15.67 $ 6.89
Diluted earnings $ 7.00 $ 1.95 $ 15.43 $ 6.79
Shares used in earnings per share calculations (in millions):        
Basic 318,072 338,168 328,048 338,057
Diluted 324,029 343,346 333,248 343,014
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Comprehensive Income Statements - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net income $ 2,472 $ 779 $ 5,716 $ 2,693
Other comprehensive income (loss) before taxes:        
Foreign currency translation (31) 42 (20) (39)
Unrealized gains (losses) on available-for-sale securities (3) 1 (12) 13
Defined benefit plans 0 0 0 0
Pension costs included in salaries and benefits 7 4 21 12
Total defined benefit plans 7 4 21 12
Change in fair value of derivative financial instruments (1) 0 (1) (66)
Interest costs included in interest expense 10 9 28 15
Total change in fair value of derivative financial instruments 9 9 27 (51)
Other comprehensive income (loss) before taxes (18) 56 16 (65)
Income taxes (benefits) related to other comprehensive income items (1) 9 6 (10)
Other comprehensive income (loss) (17) 47 10 (55)
Comprehensive income 2,455 826 5,726 2,638
Comprehensive income attributable to noncontrolling interests 203 111 574 365
Comprehensive income attributable to HCA Healthcare, Inc. $ 2,252 $ 715 $ 5,152 $ 2,273
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 1,027 $ 1,793
Accounts receivable 8,433 7,051
Inventories 2,019 2,025
Other 1,769 1,464
Total current assets 13,248 12,333
Property and equipment, at cost 50,695 49,317
Accumulated depreciation (27,148) (26,118)
Property and equipment, net 23,547 23,199
Investments of insurance subsidiaries 418 388
Investments in and advances to affiliates 412 422
Goodwill and other intangible assets 9,153 8,578
Right-of-use operating lease assets 2,099 2,024
Other 685 546
Total assets 49,562 47,490
Current liabilities:    
Accounts payable 3,759 3,535
Accrued salaries 2,134 1,720
Other accrued expenses 3,481 3,240
Long-term debt due within one year 250 209
Total current liabilities 9,624 8,704
Long-term debt, less debt issuance costs and discounts of $253 and $236 32,049 30,795
Professional liability risks 1,522 1,486
Right-of-use operating lease obligations 1,742 1,673
Income taxes and other liabilities 2,800 1,940
Stockholders' equity:    
Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 313,502,400 shares — 2021 and 339,425,600 shares — 2020 3 3
Capital in excess of par value 0 294
Accumulated other comprehensive loss (492) (502)
Retained (deficit) earnings (206) 777
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc. (695) 572
Noncontrolling interests 2,520 2,320
Total stockholders' equity 1,825 2,892
Total liabilities and stockholders' equity $ 49,562 $ 47,490
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Debt issuance costs $ 253 $ 236
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 1,800,000,000 1,800,000,000
Common stock, shares outstanding 313,502,400 339,425,600
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Millions
Total
Common Stock [Member]
Capital in Excess of Par Value [Member]
Accumulated Other Comprehensive Loss [Member]
Retained Earnings (Deficit) [Member]
Equity Attributable to Noncontrolling Interests [Member]
Balances at Dec. 31, 2019 $ (565) $ 3   $ (460) $ (2,351) $ 2,243
Balance, shares at Dec. 31, 2019   338,446,000        
Comprehensive income (loss) 587     (111) 581 117
Repurchase of common stock (441)       (441)  
Repurchase of common stock, shares   (3,287,000)        
Share-based benefit plans (33)   $ 2   (35)  
Share-based benefit plans, shares   2,449,000        
Cash dividends declared (148)       (148)  
Distributions (154)         (154)
Other 51   (2)     53
Balance at Mar. 31, 2020 (703) $ 3   (571) (2,394) 2,259
Balance, shares at Mar. 31, 2020   337,608,000        
Balances at Dec. 31, 2019 (565) $ 3   (460) (2,351) 2,243
Balance, shares at Dec. 31, 2019   338,446,000        
Comprehensive income (loss) 2,638          
Balance at Sep. 30, 2020 1,299 $ 3 185 (515) (647) 2,273
Balance, shares at Sep. 30, 2020   338,370,000        
Balances at Mar. 31, 2020 (703) $ 3   (571) (2,394) 2,259
Balance, shares at Mar. 31, 2020   337,608,000        
Comprehensive income (loss) 1,225     9 1,079 137
Share-based benefit plans 93   93      
Share-based benefit plans, shares   352,000        
Distributions (45)         (45)
Other (2)   (5)     3
Balance at Jun. 30, 2020 568 $ 3 88 (562) (1,315) 2,354
Balance, shares at Jun. 30, 2020   337,960,000        
Comprehensive income (loss) 826     47 668 111
Share-based benefit plans 97   97      
Share-based benefit plans, shares   410,000        
Distributions (194)         (194)
Other 2         2
Balance at Sep. 30, 2020 1,299 $ 3 185 (515) (647) 2,273
Balance, shares at Sep. 30, 2020   338,370,000        
Comprehensive income (loss) 1,707     13 1,426 268
Share-based benefit plans 108   108      
Share-based benefit plans, shares   1,056,000.000        
Cash dividends declared (2)       (2)  
Distributions (233)         (233)
Other 13   1     12
Balance at Dec. 31, 2020 2,892 $ 3 294 (502) 777 2,320
Balance, shares at Dec. 31, 2020   339,426,000        
Comprehensive income (loss) 1,591     11 1,423 157
Repurchase of common stock (1,527)   (225)   (1,302)  
Repurchase of common stock, shares   (8,477,000)        
Share-based benefit plans (75)   (75)      
Share-based benefit plans, shares   2,765,000        
Cash dividends declared (163)       (163)  
Distributions (234)         (234)
Other (2)   6     (8)
Balance at Mar. 31, 2021 2,482 $ 3   (491) 735 2,235
Balance, shares at Mar. 31, 2021   333,714,000        
Balances at Dec. 31, 2020 2,892 $ 3 294 (502) 777 2,320
Balance, shares at Dec. 31, 2020   339,426,000        
Comprehensive income (loss) $ 5,726          
Repurchase of common stock, shares (29,343,000)          
Balance at Sep. 30, 2021 $ 1,825 $ 3   (492) (206) 2,520
Balance, shares at Sep. 30, 2021   313,502,000        
Balances at Mar. 31, 2021 2,482 $ 3   (491) 735 2,235
Balance, shares at Mar. 31, 2021   333,714,000        
Comprehensive income (loss) 1,680     16 1,450 214
Repurchase of common stock (2,287)   (142)   (2,145)  
Repurchase of common stock, shares   (11,261,000)        
Share-based benefit plans 140   140      
Share-based benefit plans, shares   372,000        
Cash dividends declared (161)       (161)  
Distributions (123)         (123)
Other 59   2     57
Balance at Jun. 30, 2021 1,790 $ 3   (475) (121) 2,383
Balance, shares at Jun. 30, 2021   322,825,000        
Comprehensive income (loss) 2,455     (17) 2,269 203
Repurchase of common stock (2,329)   (130)   (2,199)  
Repurchase of common stock, shares   (9,605,000)        
Share-based benefit plans 127   127      
Share-based benefit plans, shares   282,000        
Cash dividends declared (155)       (155)  
Distributions (144)         (144)
Other 81   $ 3     78
Balance at Sep. 30, 2021 $ 1,825 $ 3   $ (492) $ (206) $ 2,520
Balance, shares at Sep. 30, 2021   313,502,000        
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - $ / shares
3 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]          
Cash dividends declared, per share $ 0.48 $ 0.48 $ 0.48 $ 0.43 $ 0.43
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net income $ 5,716 $ 2,693
Increase (decrease) in cash from operating assets and liabilities:    
Accounts receivable (1,312) 930
Inventories and other assets (333) (36)
Accounts payable and accrued expenses 731 542
Contract liabilities-deferred revenues 0 6,123
Depreciation and amortization 2,125 2,059
Income taxes 185 (114)
Losses (gains) on sales of facilities (1,057) 6
Losses on retirement of debt 12 295
Amortization of debt issuance costs and discounts 21 22
Share-based compensation 341 229
Other 87 66
Net cash provided by operating activities 6,516 12,815
Cash flows from investing activities:    
Purchase of property and equipment (2,385) (2,087)
Acquisition of hospitals and health care entities (488) (380)
Sales of hospitals and health care entities 1,980 68
Change in investments (38) (40)
Other 2 (44)
Net cash used in investing activities (929) (2,483)
Cash flows from financing activities:    
Issuances of long-term debt 4,337 2,700
Net change in revolving credit facilities 500 (2,480)
Repayment of long-term debt (3,787) (3,403)
Distributions to noncontrolling interests (501) (393)
Payment of debt issuance costs (38) (35)
Payment of dividends (476) (153)
Repurchase of common stock (6,143) (441)
Other (241) (156)
Net cash used in financing activities (6,349) (4,361)
Effect of exchange rate changes on cash and cash equivalents (4) (4)
Change in cash and cash equivalents (766) 5,967
Cash and cash equivalents at beginning of period 1,793 621
Cash and cash equivalents at end of period 1,027 6,588
Interest payments 1,127 1,230
Income tax payments, net $ 1,346 $ 779
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies
NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
Reporting Entity
HCA Healthcare, Inc. is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At September 30, 2021, these affiliates owned and operated 183 hospitals, 123 freestanding surgery centers, 21 freestanding endoscopy centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA.
Basis of Presentation
The accompanying unaudited condensed consolidated financial
 
statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to
Form 10-Q
and Article 10 of
Regulation S-X.
Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.
The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $87 million and $117 million for the quarters ended September 30, 2021 and 2020, respectively, and $301 million and $289 million for the nine months ended September 30, 2021 and 2020, respectively. Operating results for the quarter and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on
Form 10-K
for the year ended December 31, 2020.
COVID-19
Pandemic
On March 11, 2020, the World Health Organization designated
COVID-19
as a global pandemic. Patient volumes and the related revenues for most of our services were significantly impacted during the latter portion of the first quarter and the first half of the second quarter of 2020 and have continued to be impacted as various policies were implemented by federal, state and local governments in response to the
COVID-19
pandemic. During the second quarter of 2021, our patient volumes experienced a strong rebound as the effects of the pandemic moderated and certain pandemic-related restrictions and policies were eased. During the third quarter of 2021, our patient volumes remained strong, with the exception of inpatient surgeries, and included a resurgence of
COVID-19
admissions. Inpatient surgery volumes were constrained during the quarter as capacity was used to treat the surge of COVID-19 patients. We believe the extent of the
COVID-19
pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate how long or to what extent the pandemic will impact our operations.
Revenues
Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods
 
that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted
fee-for-service
rates. Our revenues for the nine months ended September 30, 2021 and 2020 included $33 million and $55 million, respectively, related to the settlement of Medicare outlier calculations for prior periods. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for
non-elective
care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
 
    
Quarter
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
2,645
 
  
 
17.3
  $ 2,603        19.6
Managed Medicare
  
 
2,124
 
  
 
13.9
 
    1,760        13.2  
Medicaid
  
 
692
 
  
 
4.5
 
    445        3.3  
Managed Medicaid
  
 
813
 
  
 
5.3
 
    707        5.3  
Managed care and insurers
  
 
7,998
 
  
 
52.4
 
    6,752        50.7  
International (managed care and insurers)
  
 
324
 
  
 
2.1
 
    307        2.3  
Other
  
 
680
 
  
 
4.5
 
    737        5.6  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
15,276
 
  
 
100.0
  $ 13,311        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
 
 
    
Nine Months
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
7,816
 
  
 
17.9
  $ 7,618        20.5
Managed Medicare
  
 
6,281
 
  
 
14.4
 
    5,074        13.6  
Medicaid
  
 
1,722
 
  
 
3.9
 
    1,423        3.8  
Managed Medicaid
  
 
2,369
 
  
 
5.4
 
    1,904        5.1  
Managed care and insurers
  
 
22,300
 
  
 
51.0
 
    19,028        51.0  
International (managed care and insurers)
  
 
995
 
  
 
2.3
 
    838        2.3  
Other
  
 
2,205
 
  
 
5.1
 
    1,355        3.7  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
43,688
 
  
 
100.0
  $ 37,240        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
To quantify the total impact of the trends related to
 
uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions):
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)
  
$
12,803
 
  $ 11,170    
$
36,396
 
  $ 32,428  
Cost-to-charges
ratio (patient care costs as percentage of gross patient charges)
  
 
11.8
    12.0  
 
11.4
    12.1
Total uncompensated care
  
$
7,782
 
  $ 7,023    
$
22,299
 
  $ 21,625  
Multiply by the
cost-to-charges
ratio
  
 
11.8
    12.0  
 
11.4
    12.1
    
 
 
   
 
 
   
 
 
   
 
 
 
Estimated cost of total uncompensated care
  
$
916
 
  $ 843    
$
2,542
 
  $ 2,617  
    
 
 
   
 
 
   
 
 
   
 
 
 
The total uncompensated care amounts include
 
charity care of $3.509 billion and $3.160 billion, respectively, and the related estimated costs of charity care were $413 million and $376 million, respectively, for the quarters ended September 30, 2021 and 2020. The total uncompensated care amounts include charity care of $10.135 billion and $9.972 billion, respectively, and the related estimated costs of charity care were $1.155 billion and $1.207 billion, respectively, for the nine months ended September 30, 2021 and 2020.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Dispositions
9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Acquisitions and Dispositions
NOTE 2 — ACQUISITIONS AND DISPOSITIONS
During the nine months ended September 30, 2021, we paid $67 million to acquire two hospital facilities, one in southern Georgia and one in Tennessee, and $91 million to acquire other nonhospital health care
entities (noncontrolling interests of $111 million were recorded).
 We also paid $330 million and assumed certain liabilities to acquire an 80% interest (noncontrolling interests of $101 million were recorded) in a venture providing post-acute care services (home health and hospice). Purchase price amounts have been allocated to the related assets acquired and liabilities assumed based upon their respective fair values. The purchase price paid in excess of the fair value of identifiable net assets of these acquired entities aggregated $601 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2020, we paid $380 million to acquire a hospital in New Hampshire
and other nonhospital health care entities. The consolidated financial statements include the accounts and operations of the acquired entities subsequent to the respective acquisition
dates. The pro forma effects of these acquired entities on our results of operations for periods prior to the respective acquisition dates were not significant.
During the nine months ended September 30, 2021, we received proceeds of $860 million and recognized a pretax gain of $655 million related to the sale of four hospital facilities in Georgia (two facilities in northern Georgia and two facilities in southern Georgia). We received proceeds of $647 million on September 30, 2021 related to the sale of a hospital facility in northern Georgia, which sale was effective October 1, 2021. We also received proceeds of $473 million and recognized a pretax gain of $402 
million related to sales of other health care entity investments and minor real estate assets. During the nine months ended September 30, 2020, we received proceeds of
 
$
68
 million and recognized a net pretax loss of $
6
 million related to the
sale
of a hospital facility in Mississippi and sales of real estate and other investments.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
NOTE 3 — INCOME TAXES
Our provisions for income taxes for the quarters ended September 30, 2021 and 2020 were $685 million and $209 million, respectively, and the effective tax rates were 23.2% and 23.8%, respectively. Our provisions for income taxes for the nine months ended September 30, 2021 and 2020 were $1.531 billion and $665 million, respectively, and the effective tax rates were 22.9% and 22.2%, respectively. Our provisions for income taxes included tax benefits related to settlements of employee equity awards of $96 million and $59 million for the nine months ended September 30, 2021 and 2020, respectively.
Our liability for unrecognized tax benefits was $626 million, including accrued interest of $95 million, as of September 30, 2021 ($508 million and $73 million, respectively, as of December 31, 2020). Unrecognized tax benefits of $192 million ($157 million as of December 31, 2020) would affect the effective rate, if recognized.
The Internal Revenue Service was conducting an examination of the Company’s 2016, 2017 and 2018 federal income tax returns at September 30, 2021. We are also subject to examination by state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Earnings Per Share
NOTE 4 — EARNINGS PER SHARE
We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards, computed using the treasury stock method.
 
The following table sets forth the computation of basic and diluted earnings per share for the quarters and nine months ended September 30, 2021 and 2020 (dollars and shares in millions, except per share amounts):
 
    
Quarter
    
Nine Months
 
    
2021
    
2020
    
2021
    
2020
 
Net income attributable to HCA Healthcare, Inc.
  
$
2,269
 
   $ 668     
$
5,142
 
   $ 2,328  
         
Weighted average common shares outstanding
  
 
318.072
 
     338.168     
 
328.048
 
     338.057  
Effect of dilutive incremental shares
  
 
5.957
 
     5.178     
 
5.200
 
     4.957  
    
 
 
    
 
 
    
 
 
    
 
 
 
Shares used for diluted earnings per share
  
 
324.029
 
     343.346     
 
333.248
 
     343.014  
    
 
 
    
 
 
    
 
 
    
 
 
 
Earnings per share:
                                   
Basic earnings
  
$
7.13
 
   $ 1.97     
$
15.67
 
   $ 6.89  
Diluted earnings
  
$
7.00
 
   $ 1.95     
$
15.43
 
   $ 6.79  
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Investments of Insurance Subsidiaries
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments of Insurance Subsidiaries
NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES
A summary of our insurance subsidiaries’ investments at September 30, 2021 and December 31, 2020 follows (dollars in millions):
 
    
September 30, 2021
 
    
Amortized
Cost
    
Unrealized
Amounts
    
Fair
Value
 
    
Gains
    
Losses
 
Debt securities
  
$
391
 
  
$
21
 
  
$
(1
  
$
411
 
Money market funds and other
  
 
119
 
  
 
 
  
 
 
  
 
119
 
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
510
 
  
$
21
 
  
$
(1
  
 
530
 
    
 
 
    
 
 
    
 
 
          
Amounts classified as current assets
                             
 
(112
                               
 
 
 
Investment carrying value
                             
$
418
 
                               
 
 
 
 
    
December 31, 2020
 
    
Amortized
Cost
    
Unrealized
Amounts
    
Fair
Value
 
    
Gains
    
Losses
 
Debt securities
   $ 384      $ 32      $      $ 416  
Money market funds and other
     88                      88  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ 472      $ 32      $        504  
    
 
 
    
 
 
    
 
 
          
Amounts classified as current assets
                                (116
                               
 
 
 
Investment carrying value
                              $ 388  
                               
 
 
 
At September 30, 2021 and December 31, 2020, the investments in debt securities of our insurance subsidiaries were classified as
“available-for-sale.”
Changes in unrealized gains and losses that are not credit-related are recorded as adjustments to other comprehensive income (loss).
 
Scheduled maturities of investments in debt securities at September 30, 2021 were as follows (dollars in millions):
 
    
Amortized
Cost
    
Fair
Value
 
Due in one year or less
   $      $  
Due after one year through five years
     134        141  
Due after five years through ten years
     177        187  
Due after ten years
     80        83  
    
 
 
    
 
 
 
     $ 391      $ 411  
    
 
 
    
 
 
 
The average expected maturity of the investments in debt securities at September 30, 2021 was 5.5 years, compared to the average scheduled maturity of 9.3 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments
9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
NOTE 6 — FINANCIAL INSTRUMENTS
Interest Rate Swap Agreements
We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. These swap agreements involve the exchange of fixed and variable rate interest payments between us and our counterparties based on common notional principal amounts and maturity dates.
Pay-fixed
interest rate swaps effectively convert variable rate obligations to fixed interest rate obligations. The interest payments under these agreements are settled on a net basis. The net interest payments, based on the notional amounts in these agreements, generally match the timing of the related liabilities for the interest rate swap agreements which have been designated as cash flow hedges. The notional amounts of the swap agreements represent amounts used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions.
The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at September 30, 2021 (dollars in millions):
 
    
Notional
Amount
    
Maturity Date
    
Fair
Value
 
Pay-fixed
interest rate swaps
   $ 2,000        December 2021      $ (7
Pay-fixed
interest rate swaps
     500        December 2022        (12
During the next 12 months, we estimate $17 million will be reclassified from other comprehensive income (“OCI”) and will be included in interest expense.
Derivatives — Results of Operations
The following table presents the effect of our interest rate swaps on our results of operations for the nine months ended September 30, 2021 (dollars in millions):
 
Derivatives in Cash Flow Hedging Relationships
  
Amount of Loss
Recognized in OCI on
Derivatives, Net of Tax
    
Location of Loss
Reclassified from
Accumulated OCI
into Operations
    
Amount of Loss
Reclassified from
Accumulated OCI
into Operations
 
Interest rate swaps
   $ 1        Interest expense      $ 28  
Credit-risk-related Contingent Features
We have agreements with each of our derivative counterparties that contain a provision where we could be declared in default on our derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to our default on the indebtedness. As of September 30, 2021, we have not been required to post any collateral related to these agreements. If we had breached these provisions at September 30, 2021, we would have been required to settle our obligations under the agreements at their aggregate, estimated termination value of $19 million.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Assets and Liabilities Measured at Fair Value
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Assets and Liabilities Measured at Fair Value
NOTE 7 — ASSETS AND LIABILITIES MEASURED
 
AT FAIR
 
VALUE
Accounting Standards Codification 820,
Fair Value Measurements and Disclosures
(“ASC 820”), emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).
Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment.
Investment Securities
The investments of our insurance subsidiaries are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.
Derivative Financial Instruments
We have entered into interest rate swap agreements to manage our exposure to fluctuations in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. We incorporate credit valuation adjustments to reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements of these instruments.
 
The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):
 
    
September 30, 2021
 
          
Fair Value Measurements Using
 
    
Fair Value
   
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Assets:
                                
Investments of insurance subsidiaries:
                                
Debt securities
  
$
411
 
 
$
 
 
$
411
 
 
$
 
Money market funds and other
  
 
119
 
 
 
119
 
 
 
 
 
 
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Investments of insurance subsidiaries
  
 
530
 
 
 
119
 
 
 
411
 
 
 
 
Less amounts classified as current assets
  
 
(112
 
 
(105
 
 
(7
 
 
 
    
 
 
   
 
 
   
 
 
   
 
 
 
    
$
418
 
 
$
14
 
 
$
404
 
 
$
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                
Interest rate swaps (Other accrued expenses)
  
$
17
 
 
$
 
 
$
17
 
 
$
 
Interest rate swaps (Income taxes and other liabilities)
  
 
2
 
 
 
 
 
 
2
 
 
 
 
 
    
December 31, 2020
 
          
Fair Value Measurements Using
 
    
Fair Value
   
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Assets:
                                
Investments of insurance subsidiaries:
                                
Debt securities
   $ 416     $     $ 416     $  
Money market funds and other
     88       88              
    
 
 
   
 
 
   
 
 
   
 
 
 
Investments of insurance subsidiaries
     504       88       416        
Less amounts classified as current assets
     (116     (87     (29      
    
 
 
   
 
 
   
 
 
   
 
 
 
     $ 388     $ 1     $ 387     $  
    
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                
Interest rate swaps (Income taxes and other liabilities)
   $ 46     $     $ 46     $  
The estimated fair value of our long-term debt was $36.567 billion and $35.814 billion at September 30, 2021 and December 31, 2020, respectively, compared to carrying amounts, excluding debt issuance costs and discounts, aggregating $32.552 billion and $31.240 billion, respectively. The estimates of fair value are generally based upon the quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Long-Term Debt
NOTE 8 — LONG-TERM DEBT
A summary of long-term debt at September 30, 2021 and December 31, 2020, including related interest rates at September 30, 2021, follows (dollars in millions):
 
    
September 30,
2021
   
December 31,
2020
 
Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)
  
$
500
 
  $  
Senior secured revolving credit facility
  
 
 
     
Senior secured term loan facilities (effective interest rate of 3.1%)
  
 
1,980
 
    3,671  
Senior secured notes (effective interest rate of 4.8%)
  
 
16,200
 
    13,850  
Other senior secured debt (effective interest rate of 4.2%)
  
 
920
 
    767  
    
 
 
   
 
 
 
Senior secured debt
  
 
19,600
 
    18,288  
Senior unsecured notes (effective interest rate of 5.5%)
  
 
12,952
 
    12,952  
Debt issuance costs and discounts
  
 
(253
    (236
    
 
 
   
 
 
 
Total debt (average life of 9.5 years, rates averaging 4.9%)
  
 
32,299
 
    31,004  
Less amounts due within one year
  
 
250
 
    209  
    
 
 
   
 
 
 
    
$
32,049
 
  $ 30,795  
    
 
 
   
 
 
 
During June 2021, we issued $2.350 billion aggregate principal amount of senior secured notes comprised of $850 million aggregate principal amount of 2 3/8% notes due 2031 and $1.500 billion aggregate principal amount of 3 1/2% notes due 2051 (the “June 2021 Notes”). We also amended and restated our senior secured revolving credit facility and our senior secured asset-based revolving credit facility, including increasing availability under the asset-based revolving credit facility to $4.500 billion, extending the maturity date on both facilities to June 30, 2026 and entering into a new $1.500 billion term
loan A-7
facility and a new $500 million term
loan B-14
facility (the “Credit Agreement Transactions”). We used the net proceeds from the June 2021 Notes and the Credit Agreement Transactions to retire the $1.071 billion term
loan A-6
facility, the $1.455 billion term
loan B-12
facility and the $1.131 billion term
loan B-13
facility. The pretax loss on retirement of debt was $12 million.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Contingencies
NOTE 9 — CONTINGENCIES
We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity.
Health care companies are routinely subject to investigations by various governmental agencies. Under the federal False Claims Act (“FCA”), private parties have the right to bring
qui tam
, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity.
Texas operates a state Medicaid program pursuant to a waiver from the Centers for Medicare & Medicaid Services under Section 1115 of the Social Security Act (“Program”). The Program includes uncompensated-care pools; payments from these pools are intended to defray the uncompensated costs of services provided by our and other hospitals to Medicaid eligible or uninsured individuals. Separately, we and other hospitals provide charity care services in several communities in the state. In 2018, the Civil Division of the U.S. Department of Justice and the U.S. Attorney’s Office for the Southern District of Texas requested information about whether the Program, as operated in Harris County, complied with the laws and regulations applicable to provider related donations, and the Company cooperated with that request. On May 21, 2019, a
qui tam
lawsuit asserting violations of the FCA and the Texas Medicaid Fraud Prevention Act related to the Program, as operated in Harris County, was unsealed by the U.S. District Court for the Southern District of Texas. Both the federal and state governments declined to intervene in the
qui tam
lawsuit. The Company believes that our participation is and has been consistent with the requirements of the Program and is vigorously defending against the lawsuit being pursued by the relator. We cannot predict what effect, if any, the
qui tam
lawsuit could have on the Company.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Share Repurchase Transactions and Other Comprehensive Loss
9 Months Ended
Sep. 30, 2021
Federal Home Loan Banks [Abstract]  
Share Repurchases Transactions and Other Comprehensive Loss
NOTE 10 — SHARE REPURCHASE TRANSACTIONS AND OTHER COMPREHENSIVE LOSS
During January 2020 and 2019, our Board of Directors authorized share repurchase programs for up to $4 billion ($2 billion for each authorization) of our outstanding common stock. During February 2021, our Board of Directors authorized an additional $6 billion for repurchases of our outstanding common stock. During the nine months ended September 30, 2021, we repurchased 29.343 million shares of our common stock at an average price of $209.35 per share through market purchases pursuant to the January 2019 authorization (which was completed during the first quarter of 2021), the January 2020 authorization (which was completed during the second quarter of 2021) and the February 2021 authorization. At September 30, 2021, we had $2.658 billion of repurchase authorization available under the February 2021 authorization.
The components of accumulated other comprehensive loss are as follows (dollars in millions):
 
   
Unrealized
Gains on
Available-
for-Sale

Securities
   
Foreign
Currency
Translation
Adjustments
   
Defined
Benefit
Plans
   
Change
in Fair
Value of
Derivative
Instruments
   
Total
 
Balances at December 31, 2020
  $ 25     $ (271   $ (220   $ (36   $ (502
Unrealized losses on
available-for-sale
securities, net of $3 income tax benefit
    (9                             (9
Foreign currency translation adjustments, net of $2 income tax benefit
            (18                     (18
Change in fair value of derivative instruments
                            (1     (1
Expense reclassified into operations from other comprehensive income, net of $5 and $6 income tax benefits, respectively
                    16       22       38  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances at September 30, 2021
  $ 16     $ (289   $ (204   $ (15   $ (492
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Geographic Information
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment and Geographic Information
NOTE 11 — SEGMENT AND GEOGRAPHIC INFORMATION
We operate in
one
line of business, which is operating hospitals and related health care entities. We operate in two geographically organized groups: the National and American Groups. The National Group includes 96 hospitals located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, North Carolina, South Carolina, Utah and Virginia, and the American Group includes 80 hospitals located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Missouri, Tennessee and
Texas. We also operate seven hospitals in England, and these facilities are included in the Corporate and other group.
Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, losses and gains on sales of facilities, losses on retirement of debt, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
 
    
Quarter
    
Nine Months
 
    
2021
    
2020
    
2021
    
2020
 
Revenues:
                                   
National Group
  
$
7,787
 
   $ 6,633     
$
22,143
 
   $ 18,653  
American Group
  
 
6,767
 
     6,073     
 
19,562
 
     16,920  
Corporate and other
  
 
722
 
     605     
 
1,983
 
     1,667  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
15,276
 
   $ 13,311     
$
43,688
 
   $ 37,240  
    
 
 
    
 
 
    
 
 
    
 
 
 
Equity in earnings of affiliates:
                                   
National Group
  
$
(14
   $ (23   
$
(30
   $ (26
American Group
  
 
(14
     (15   
 
(38
     (26
Corporate and other
  
 
(7
     (2   
 
(10
     4  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
(35
   $ (40   
$
(78
   $ (48
    
 
 
    
 
 
    
 
 
    
 
 
 
Adjusted segment EBITDA:
                                   
National Group
  
$
1,780
 
   $ 1,128     
$
5,330
 
   $ 3,828  
American Group
  
 
1,604
 
     1,130     
 
4,698
 
     3,653  
Corporate and other
  
 
(160
     (205   
 
(533
     (562
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
3,224
 
   $ 2,053     
$
9,495
 
   $ 6,919  
    
 
 
    
 
 
    
 
 
    
 
 
 
Depreciation and amortization:
                                   
National Group
  
$
343
 
   $ 312     
$
1,005
 
   $ 930  
American Group
  
 
295
 
     286     
 
884
 
     868  
Corporate and other
  
 
78
 
     96     
 
236
 
     261  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
716
 
   $ 694     
$
2,125
 
   $ 2,059  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted segment EBITDA
  
$
3,224
 
   $ 2,053     
$
9,495
 
   $ 6,919  
Depreciation and amortization
  
 
716
 
     694     
 
2,125
 
     2,059  
Interest expense
  
 
398
 
     385     
 
1,168
 
     1,201  
Losses (gains) on sales of facilities
  
 
(1,047
     (14   
 
(1,057
     6  
Losses on retirement of debt
  
 
 
         
 
12
 
     295  
    
 
 
    
 
 
    
 
 
    
 
 
 
Income before income taxes
  
$
3,157
 
   $ 988     
$
7,247
 
   $ 3,358  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial
 
statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to
Form 10-Q
and Article 10 of
Regulation S-X.
Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.
The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $87 million and $117 million for the quarters ended September 30, 2021 and 2020, respectively, and $301 million and $289 million for the nine months ended September 30, 2021 and 2020, respectively. Operating results for the quarter and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on
Form 10-K
for the year ended December 31, 2020.
COVID-19
Pandemic
On March 11, 2020, the World Health Organization designated
COVID-19
as a global pandemic. Patient volumes and the related revenues for most of our services were significantly impacted during the latter portion of the first quarter and the first half of the second quarter of 2020 and have continued to be impacted as various policies were implemented by federal, state and local governments in response to the
COVID-19
pandemic. During the second quarter of 2021, our patient volumes experienced a strong rebound as the effects of the pandemic moderated and certain pandemic-related restrictions and policies were eased. During the third quarter of 2021, our patient volumes remained strong, with the exception of inpatient surgeries, and included a resurgence of
COVID-19
admissions. Inpatient surgery volumes were constrained during the quarter as capacity was used to treat the surge of COVID-19 patients. We believe the extent of the
COVID-19
pandemic’s impact on our operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate how long or to what extent the pandemic will impact our operations.
Revenues
Revenues
Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods
that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted
fee-for-service
rates. Our revenues for the nine months ended September 30, 2021 and 2020 included $33 million and $55 million, respectively, related to the settlement of Medicare outlier calculations for prior periods. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for
non-elective
care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
 
    
Quarter
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
2,645
 
  
 
17.3
  $ 2,603        19.6
Managed Medicare
  
 
2,124
 
  
 
13.9
 
    1,760        13.2  
Medicaid
  
 
692
 
  
 
4.5
 
    445        3.3  
Managed Medicaid
  
 
813
 
  
 
5.3
 
    707        5.3  
Managed care and insurers
  
 
7,998
 
  
 
52.4
 
    6,752        50.7  
International (managed care and insurers)
  
 
324
 
  
 
2.1
 
    307        2.3  
Other
  
 
680
 
  
 
4.5
 
    737        5.6  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
15,276
 
  
 
100.0
  $ 13,311        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
 
    
Nine Months
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
7,816
 
  
 
17.9
  $ 7,618        20.5
Managed Medicare
  
 
6,281
 
  
 
14.4
 
    5,074        13.6  
Medicaid
  
 
1,722
 
  
 
3.9
 
    1,423        3.8  
Managed Medicaid
  
 
2,369
 
  
 
5.4
 
    1,904        5.1  
Managed care and insurers
  
 
22,300
 
  
 
51.0
 
    19,028        51.0  
International (managed care and insurers)
  
 
995
 
  
 
2.3
 
    838        2.3  
Other
  
 
2,205
 
  
 
5.1
 
    1,355        3.7  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
43,688
 
  
 
100.0
  $ 37,240        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
To quantify the total impact of the trends related to
 
uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions):
 
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)
  
$
12,803
 
  $ 11,170    
$
36,396
 
  $ 32,428  
Cost-to-charges
ratio (patient care costs as percentage of gross patient charges)
  
 
11.8
    12.0  
 
11.4
    12.1
Total uncompensated care
  
$
7,782
 
  $ 7,023    
$
22,299
 
  $ 21,625  
Multiply by the
cost-to-charges
ratio
  
 
11.8
    12.0  
 
11.4
    12.1
    
 
 
   
 
 
   
 
 
   
 
 
 
Estimated cost of total uncompensated care
  
$
916
 
  $ 843    
$
2,542
 
  $ 2,617  
    
 
 
   
 
 
   
 
 
   
 
 
 
The total uncompensated care amounts include
 
charity care of $3.509 billion and $3.160 billion, respectively, and the related estimated costs of charity care were $413 million and $376 million, respectively, for the quarters ended September 30, 2021 and 2020. The total uncompensated care amounts include charity care of $10.135 billion and $9.972 billion, respectively, and the related estimated costs of charity care were $1.155 billion and $1.207 billion, respectively, for the nine months ended September 30, 2021 and 2020.
Reclassifications
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of Revenues from Third Party Payers, Uninsured and Other Payers Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
    
Quarter
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
2,645
 
  
 
17.3
  $ 2,603        19.6
Managed Medicare
  
 
2,124
 
  
 
13.9
 
    1,760        13.2  
Medicaid
  
 
692
 
  
 
4.5
 
    445        3.3  
Managed Medicaid
  
 
813
 
  
 
5.3
 
    707        5.3  
Managed care and insurers
  
 
7,998
 
  
 
52.4
 
    6,752        50.7  
International (managed care and insurers)
  
 
324
 
  
 
2.1
 
    307        2.3  
Other
  
 
680
 
  
 
4.5
 
    737        5.6  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
15,276
 
  
 
100.0
  $ 13,311        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
 
    
Nine Months
 
    
2021
    
    Ratio    
   
2020
    
    Ratio    
 
Medicare
  
$
7,816
 
  
 
17.9
  $ 7,618        20.5
Managed Medicare
  
 
6,281
 
  
 
14.4
 
    5,074        13.6  
Medicaid
  
 
1,722
 
  
 
3.9
 
    1,423        3.8  
Managed Medicaid
  
 
2,369
 
  
 
5.4
 
    1,904        5.1  
Managed care and insurers
  
 
22,300
 
  
 
51.0
 
    19,028        51.0  
International (managed care and insurers)
  
 
995
 
  
 
2.3
 
    838        2.3  
Other
  
 
2,205
 
  
 
5.1
 
    1,355        3.7  
    
 
 
    
 
 
   
 
 
    
 
 
 
Revenues
  
$
43,688
 
  
 
100.0
  $ 37,240        100.0
    
 
 
    
 
 
   
 
 
    
 
 
 
Schedule of Estimated Cost of Uncompensated Care A summary of the estimated cost of total uncompensated care for the quarters and nine months ended September 30, 2021 and 2020 follows (dollars in millions):
    
Quarter
   
Nine Months
 
    
2021
   
2020
   
2021
   
2020
 
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)
  
$
12,803
 
  $ 11,170    
$
36,396
 
  $ 32,428  
Cost-to-charges
ratio (patient care costs as percentage of gross patient charges)
  
 
11.8
    12.0  
 
11.4
    12.1
Total uncompensated care
  
$
7,782
 
  $ 7,023    
$
22,299
 
  $ 21,625  
Multiply by the
cost-to-charges
ratio
  
 
11.8
    12.0  
 
11.4
    12.1
    
 
 
   
 
 
   
 
 
   
 
 
 
Estimated cost of total uncompensated care
  
$
916
 
  $ 843    
$
2,542
 
  $ 2,617  
    
 
 
   
 
 
   
 
 
   
 
 
 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Computations of Basic and Diluted Earnings Per Share
The following table sets forth the computation of basic and diluted earnings per share for the quarters and nine months ended September 30, 2021 and 2020 (dollars and shares in millions, except per share amounts):
 
    
Quarter
    
Nine Months
 
    
2021
    
2020
    
2021
    
2020
 
Net income attributable to HCA Healthcare, Inc.
  
$
2,269
 
   $ 668     
$
5,142
 
   $ 2,328  
         
Weighted average common shares outstanding
  
 
318.072
 
     338.168     
 
328.048
 
     338.057  
Effect of dilutive incremental shares
  
 
5.957
 
     5.178     
 
5.200
 
     4.957  
    
 
 
    
 
 
    
 
 
    
 
 
 
Shares used for diluted earnings per share
  
 
324.029
 
     343.346     
 
333.248
 
     343.014  
    
 
 
    
 
 
    
 
 
    
 
 
 
Earnings per share:
                                   
Basic earnings
  
$
7.13
 
   $ 1.97     
$
15.67
 
   $ 6.89  
Diluted earnings
  
$
7.00
 
   $ 1.95     
$
15.43
 
   $ 6.79  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Investments of Insurance Subsidiaries (Tables)
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investments
A summary of our insurance subsidiaries’ investments at September 30, 2021 and December 31, 2020 follows (dollars in millions):
 
    
September 30, 2021
 
    
Amortized
Cost
    
Unrealized
Amounts
    
Fair
Value
 
    
Gains
    
Losses
 
Debt securities
  
$
391
 
  
$
21
 
  
$
(1
  
$
411
 
Money market funds and other
  
 
119
 
  
 
 
  
 
 
  
 
119
 
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
510
 
  
$
21
 
  
$
(1
  
 
530
 
    
 
 
    
 
 
    
 
 
          
Amounts classified as current assets
                             
 
(112
                               
 
 
 
Investment carrying value
                             
$
418
 
                               
 
 
 
 
    
December 31, 2020
 
    
Amortized
Cost
    
Unrealized
Amounts
    
Fair
Value
 
    
Gains
    
Losses
 
Debt securities
   $ 384      $ 32      $      $ 416  
Money market funds and other
     88                      88  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ 472      $ 32      $        504  
    
 
 
    
 
 
    
 
 
          
Amounts classified as current assets
                                (116
                               
 
 
 
Investment carrying value
                              $ 388  
                               
 
 
 
Schedule of Maturities of Investments
Scheduled maturities of investments in debt securities at September 30, 2021 were as follows (dollars in millions):
 
    
Amortized
Cost
    
Fair
Value
 
Due in one year or less
   $      $  
Due after one year through five years
     134        141  
Due after five years through ten years
     177        187  
Due after ten years
     80        83  
    
 
 
    
 
 
 
     $ 391      $ 411  
    
 
 
    
 
 
 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges
The following table sets forth our interest rate swap agreements, which have been designated as cash flow hedges, at September 30, 2021 (dollars in millions):
 
    
Notional
Amount
    
Maturity Date
    
Fair
Value
 
Pay-fixed
interest rate swaps
   $ 2,000        December 2021      $ (7
Pay-fixed
interest rate swaps
     500        December 2022        (12
Effect of Interest Rate on Results of Operations
The following table presents the effect of our interest rate swaps on our results of operations for the nine months ended September 30, 2021 (dollars in millions):
 
Derivatives in Cash Flow Hedging Relationships
  
Amount of Loss
Recognized in OCI on
Derivatives, Net of Tax
    
Location of Loss
Reclassified from
Accumulated OCI
into Operations
    
Amount of Loss
Reclassified from
Accumulated OCI
into Operations
 
Interest rate swaps
   $ 1        Interest expense      $ 28  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Assets and Liabilities Measured at Fair Value (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Assets Measured at Fair Value on Recurring Basis
The following tables summarize our assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):
 
    
September 30, 2021
 
          
Fair Value Measurements Using
 
    
Fair Value
   
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Assets:
                                
Investments of insurance subsidiaries:
                                
Debt securities
  
$
411
 
 
$
 
 
$
411
 
 
$
 
Money market funds and other
  
 
119
 
 
 
119
 
 
 
 
 
 
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Investments of insurance subsidiaries
  
 
530
 
 
 
119
 
 
 
411
 
 
 
 
Less amounts classified as current assets
  
 
(112
 
 
(105
 
 
(7
 
 
 
    
 
 
   
 
 
   
 
 
   
 
 
 
    
$
418
 
 
$
14
 
 
$
404
 
 
$
 
    
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                
Interest rate swaps (Other accrued expenses)
  
$
17
 
 
$
 
 
$
17
 
 
$
 
Interest rate swaps (Income taxes and other liabilities)
  
 
2
 
 
 
 
 
 
2
 
 
 
 
 
    
December 31, 2020
 
          
Fair Value Measurements Using
 
    
Fair Value
   
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Assets:
                                
Investments of insurance subsidiaries:
                                
Debt securities
   $ 416     $     $ 416     $  
Money market funds and other
     88       88              
    
 
 
   
 
 
   
 
 
   
 
 
 
Investments of insurance subsidiaries
     504       88       416        
Less amounts classified as current assets
     (116     (87     (29      
    
 
 
   
 
 
   
 
 
   
 
 
 
     $ 388     $ 1     $ 387     $  
    
 
 
   
 
 
   
 
 
   
 
 
 
Liabilities:
                                
Interest rate swaps (Income taxes and other liabilities)
   $ 46     $     $ 46     $  
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
A summary of long-term debt at September 30, 2021 and December 31, 2020, including related interest rates at September 30, 2021, follows (dollars in millions):
 
    
September 30,
2021
   
December 31,
2020
 
Senior secured asset-based revolving credit facility (effective interest rate of 2.7%)
  
$
500
 
  $  
Senior secured revolving credit facility
  
 
 
     
Senior secured term loan facilities (effective interest rate of 3.1%)
  
 
1,980
 
    3,671  
Senior secured notes (effective interest rate of 4.8%)
  
 
16,200
 
    13,850  
Other senior secured debt (effective interest rate of 4.2%)
  
 
920
 
    767  
    
 
 
   
 
 
 
Senior secured debt
  
 
19,600
 
    18,288  
Senior unsecured notes (effective interest rate of 5.5%)
  
 
12,952
 
    12,952  
Debt issuance costs and discounts
  
 
(253
    (236
    
 
 
   
 
 
 
Total debt (average life of 9.5 years, rates averaging 4.9%)
  
 
32,299
 
    31,004  
Less amounts due within one year
  
 
250
 
    209  
    
 
 
   
 
 
 
    
$
32,049
 
  $ 30,795  
    
 
 
   
 
 
 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Share Repurchase Transactions and Other Comprehensive Loss (Tables)
9 Months Ended
Sep. 30, 2021
Federal Home Loan Banks [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss are as follows (dollars in millions):
 
   
Unrealized
Gains on
Available-
for-Sale

Securities
   
Foreign
Currency
Translation
Adjustments
   
Defined
Benefit
Plans
   
Change
in Fair
Value of
Derivative
Instruments
   
Total
 
Balances at December 31, 2020
  $ 25     $ (271   $ (220   $ (36   $ (502
Unrealized losses on
available-for-sale
securities, net of $3 income tax benefit
    (9                             (9
Foreign currency translation adjustments, net of $2 income tax benefit
            (18                     (18
Change in fair value of derivative instruments
                            (1     (1
Expense reclassified into operations from other comprehensive income, net of $5 and $6 income tax benefits, respectively
                    16       22       38  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balances at September 30, 2021
  $ 16     $ (289   $ (204   $ (15   $ (492
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Geographic Information (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization, Assets and Goodwill and other intangible assets. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters and nine months ended September 30, 2021 and 2020 are summarized in the following table (dollars in millions):
    
Quarter
    
Nine Months
 
    
2021
    
2020
    
2021
    
2020
 
Revenues:
                                   
National Group
  
$
7,787
 
   $ 6,633     
$
22,143
 
   $ 18,653  
American Group
  
 
6,767
 
     6,073     
 
19,562
 
     16,920  
Corporate and other
  
 
722
 
     605     
 
1,983
 
     1,667  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
15,276
 
   $ 13,311     
$
43,688
 
   $ 37,240  
    
 
 
    
 
 
    
 
 
    
 
 
 
Equity in earnings of affiliates:
                                   
National Group
  
$
(14
   $ (23   
$
(30
   $ (26
American Group
  
 
(14
     (15   
 
(38
     (26
Corporate and other
  
 
(7
     (2   
 
(10
     4  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
(35
   $ (40   
$
(78
   $ (48
    
 
 
    
 
 
    
 
 
    
 
 
 
Adjusted segment EBITDA:
                                   
National Group
  
$
1,780
 
   $ 1,128     
$
5,330
 
   $ 3,828  
American Group
  
 
1,604
 
     1,130     
 
4,698
 
     3,653  
Corporate and other
  
 
(160
     (205   
 
(533
     (562
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
3,224
 
   $ 2,053     
$
9,495
 
   $ 6,919  
    
 
 
    
 
 
    
 
 
    
 
 
 
Depreciation and amortization:
                                   
National Group
  
$
343
 
   $ 312     
$
1,005
 
   $ 930  
American Group
  
 
295
 
     286     
 
884
 
     868  
Corporate and other
  
 
78
 
     96     
 
236
 
     261  
    
 
 
    
 
 
    
 
 
    
 
 
 
    
$
716
 
   $ 694     
$
2,125
 
   $ 2,059  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted segment EBITDA
  
$
3,224
 
   $ 2,053     
$
9,495
 
   $ 6,919  
Depreciation and amortization
  
 
716
 
     694     
 
2,125
 
     2,059  
Interest expense
  
 
398
 
     385     
 
1,168
 
     1,201  
Losses (gains) on sales of facilities
  
 
(1,047
     (14   
 
(1,057
     6  
Losses on retirement of debt
  
 
 
         
 
12
 
     295  
    
 
 
    
 
 
    
 
 
    
 
 
 
Income before income taxes
  
$
3,157
 
   $ 988     
$
7,247
 
   $ 3,358  
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Endoscopy_Center
Surgery_Center
State
Hospital
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Endoscopy_Center
Surgery_Center
State
Hospital
Sep. 30, 2020
USD ($)
Summary Of Significant Accounting Policies [Line Items]        
Number of owned and operated hospitals | Hospital 183   183  
Number of freestanding surgery centers | Surgery_Center 123   123  
Number of freestanding endoscopy centers | Endoscopy_Center 21   21  
Number of facilities locations | State 20   20  
General and administrative expense $ 87 $ 117 $ 301 $ 289
Performance obligations for inpatient/ outpatient services satisfied period     Our performance obligations for inpatient services are generally satisfied over periodsthat average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day.  
Charity care amount 3,509 3,160 $ 10,135 9,972
Estimated costs of charity care $ 413 $ 376 1,155 1,207
Out of Network Services [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Revenues     $ 33 $ 55
Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Percentage of income of federal poverty level eligible for charity care     400.00%  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 15,276 $ 13,311 $ 43,688 $ 37,240
Revenues ratio from third party payers 100.00% 100.00% 100.00% 100.00%
Medicare [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 2,645 $ 2,603 $ 7,816 $ 7,618
Revenues from third party payers, Ratio 17.30% 19.60% 17.90% 20.50%
Managed Medicare [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 2,124 $ 1,760 $ 6,281 $ 5,074
Revenues from third party payers, Ratio 13.90% 13.20% 14.40% 13.60%
Medicaid [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 692 $ 445 $ 1,722 $ 1,423
Revenues from third party payers, Ratio 4.50% 3.30% 3.90% 3.80%
Managed Medicaid [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 813 $ 707 $ 2,369 $ 1,904
Revenues from third party payers, Ratio 5.30% 5.30% 5.40% 5.10%
Managed Care and Insurers [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 7,998 $ 6,752 $ 22,300 $ 19,028
Revenues from third party payers, Ratio 52.40% 50.70% 51.00% 51.00%
International (managed care and insurers) [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 324 $ 307 $ 995 $ 838
Revenues from third party payers, Ratio 2.10% 2.30% 2.30% 2.30%
Other [Member]        
Revenues From Third Party Payers [Line Items]        
Revenues from third party payers $ 680 $ 737 $ 2,205 $ 1,355
Other, Ratio 4.50% 5.60% 5.10% 3.70%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Cost of Uncompensated Care (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Accounting Policies [Abstract]        
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization) $ 12,803 $ 11,170 $ 36,396 $ 32,428
Cost-to-charges ratio (patient care costs as percentage of gross patient charges) 11.80% 12.00% 11.40% 12.10%
Total uncompensated care $ 7,782 $ 7,023 $ 22,299 $ 21,625
Multiply by the cost-to-charges ratio 11.80% 12.00% 11.40% 12.10%
Estimated cost of total uncompensated care $ 916 $ 843 $ 2,542 $ 2,617
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Dispositions - Additional Information (Detail)
$ in Millions
9 Months Ended
Sep. 30, 2021
USD ($)
Hospital
Sep. 30, 2020
USD ($)
Business Acquisitions And Dispositions [Line Items]    
Proceeds from sale of business $ 1,980 $ 68
Real Estate and Other Investments [Member]    
Business Acquisitions And Dispositions [Line Items]    
Pretax gain (loss) before tax 402 6
Proceeds from sale of business $ 473 68
Number of hospitals sold | Hospital 1  
Discontinued Operations, Disposed of by Sale [Member]    
Business Acquisitions And Dispositions [Line Items]    
Proceeds from sale of business $ 647  
Discontinued Operations, Disposed of by Sale [Member] | Southern Georgia [Member]    
Business Acquisitions And Dispositions [Line Items]    
Number of hospitals purchased | Hospital 2  
Discontinued Operations, Disposed of by Sale [Member] | Georgia [Member]    
Business Acquisitions And Dispositions [Line Items]    
Pretax gain (loss) before tax $ 655  
Proceeds from sale of business $ 860  
Number of hospitals sold | Hospital 4  
Discontinued Operations, Disposed of by Sale [Member] | Northern Georgia [Member]    
Business Acquisitions And Dispositions [Line Items]    
Number of hospitals sold | Hospital 1  
Hospitals [Member]    
Business Acquisitions And Dispositions [Line Items]    
Aggregate purchase price $ 67  
Number of hospitals purchased | Hospital 2  
Hospitals [Member] | Southern Georgia [Member]    
Business Acquisitions And Dispositions [Line Items]    
Number of hospitals purchased | Hospital 1  
Hospitals [Member] | Tennessee [Member]    
Business Acquisitions And Dispositions [Line Items]    
Number of hospitals purchased | Hospital 1  
Other Nonhospital Health Care Entities [Member]    
Business Acquisitions And Dispositions [Line Items]    
Aggregate purchase price $ 91  
Fair value of the noncontrolling interest in the acquiree at the acquisition date 111  
Home Health and Hospice [Member]    
Business Acquisitions And Dispositions [Line Items]    
Goodwill 601  
Payment to acquire venture providing post acute care services $ 330  
Business acquisition percentage of voting interests acquired 80.00%  
Fair value of the noncontrolling interest in the acquiree at the acquisition date $ 101  
Hospital and other nonhospital health care entities [Member]    
Business Acquisitions And Dispositions [Line Items]    
Aggregate purchase price   $ 380
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Income Tax Contingency [Line Items]          
Effective tax rate 23.20% 23.80% 22.90% 22.20%  
Provision for tax benefits related to settlement of employee awards     $ 96 $ 59  
Provision for income taxes $ 685 $ 209 1,531 $ 665  
Liability for unrecognized tax benefits 626   626   $ 508
Unrecognized tax benefits, accrued interest 95   95   73
Unrecognized tax benefits that would impact effective tax rate $ 192   $ 192   $ 157
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Earnings Per Share [Abstract]        
Net income attributable to HCA Healthcare, Inc. $ 2,269 $ 668 $ 5,142 $ 2,328
Weighted average common shares outstanding 318,072 338,168 328,048 338,057
Effect of dilutive incremental shares 5,957 5,178 5,200 4,957
Shares used for diluted earnings per share 324,029 343,346 333,248 343,014
Basic earnings per share $ 7.13 $ 1.97 $ 15.67 $ 6.89
Diluted earnings per share $ 7.00 $ 1.95 $ 15.43 $ 6.79
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Investments of Insurance Subsidiaries - Schedule of Investments (Detail) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amounts classified as current assets $ (112) $ (116)
Investment carrying value 418 388
Amortized Cost 510 472
Unrealized Amounts, Gains 21 32
Unrealized Amounts, Losses (1)  
Fair Value 530 504
Money Market Funds and Other [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 119 88
Fair Value 119 88
Debt Securities [Member] | States and Municipalities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 391 384
Unrealized Amounts, Gains 21 32
Unrealized Amounts, Losses (1)  
Fair Value $ 411 $ 416
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail)
$ in Millions
Sep. 30, 2021
USD ($)
Investments, Debt and Equity Securities [Abstract]  
Due in one year or less, Amortized Cost $ 0
Due after one year through five years, Amortized Cost 134
Due after five years through ten years, Amortized Cost 177
Due after ten years, Amortized Cost 80
Amortized Cost, Total 391
Due in one year or less, Fair Value 0
Due after one year through five years, Fair Value 141
Due after five years through ten years, Fair Value 187
Due after ten years, Fair Value 83
Fair Value, Total $ 411
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Investments of Insurance Subsidiaries - Additional Information (Detail)
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Available for sale securities expected maturity of debt securities 5 years 6 months
Available for sale securities average scheduled maturity 9 years 3 months 18 days
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail) - Pay-Fixed Interest Rate Swaps [Member]
$ in Millions
9 Months Ended
Sep. 30, 2021
USD ($)
Maturity Date, 2021 [Member]  
Derivative Instruments, Gain (Loss) [Line Items]  
Notional Amount $ 2,000
Fair Value $ (7)
Maturity Date 2021-12
Maturity Date, 2022 [Member]  
Derivative Instruments, Gain (Loss) [Line Items]  
Notional Amount $ 500
Fair Value $ (12)
Maturity Date 2022-12
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments - Additional Information (Detail)
$ in Millions
9 Months Ended
Sep. 30, 2021
USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Estimated amount reclassified from other comprehensive income and reduce interest expense $ 17
Estimated termination value $ 19
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail)
$ in Millions
9 Months Ended
Sep. 30, 2021
USD ($)
Derivative Instruments, Gain (Loss) [Line Items]  
Amount of Loss Recognized in OCI on Derivatives, Net of Tax $ 1
Interest Rate Swaps [Member]  
Derivative Instruments, Gain (Loss) [Line Items]  
Amount of Loss Recognized in OCI on Derivatives, Net of Tax 1
Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income into Operations [Member]  
Derivative Instruments, Gain (Loss) [Line Items]  
Interest rate swaps $ 28
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Assets and Liabilities Measured at Fair Value - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Assets, Fair Value Disclosure $ 530 $ 504
Less amounts classified as current assets (112) (116)
Investments of insurance subsidiaries, noncurrent 418 388
Interest Rate Swaps [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Derivative Liability 2 46
Interest Rate Swaps [Member] | Other Accrued Expenses [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Derivative Liability, Current 17  
Money Market Funds and Other [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Assets, Fair Value Disclosure 119 88
Debt Securities [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Debt Securities, Available-for-sale Securities 411 416
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Assets, Fair Value Disclosure 119 88
Less amounts classified as current assets (105) (87)
Investments of insurance subsidiaries, noncurrent 14 1
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member] | Money Market Funds and Other [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Assets, Fair Value Disclosure 119 88
Significant Other Observable Inputs (Level 2) [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Assets, Fair Value Disclosure 411 416
Less amounts classified as current assets (7) (29)
Investments of insurance subsidiaries, noncurrent 404 387
Significant Other Observable Inputs (Level 2) [Member] | Interest Rate Swaps [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Derivative Liability 2 46
Significant Other Observable Inputs (Level 2) [Member] | Interest Rate Swaps [Member] | Other Accrued Expenses [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Derivative Liability, Current 17  
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Debt Securities, Available-for-sale Securities $ 411 $ 416
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Assets and Liabilities Measured at Fair Value - Additional Information (Detail) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Estimated fair value of long-term debt $ 36,567 $ 35,814
Carrying amounts of long-term debt $ 32,552 $ 31,240
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt - Schedule of Long-Term Debt (Detail) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Senior secured debt $ 19,600 $ 18,288
Net debt issuance costs (253) (236)
Total debt (average life of 9.5 years, rates averaging 4.9%) 32,299 31,004
Less amounts due within one year 250 209
Long-term debt 32,049 30,795
Senior Secured Asset-Based Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Long-term line of credit 500 0
Senior Secured Term Loan Facilities [Member]    
Debt Instrument [Line Items]    
Senior secured debt 1,980 3,671
Senior Secured Notes [Member]    
Debt Instrument [Line Items]    
Senior secured debt 16,200 13,850
Other Senior Secured Debt [Member]    
Debt Instrument [Line Items]    
Other senior secured debt 920 767
Senior Unsecured Notes [Member]    
Debt Instrument [Line Items]    
Senior unsecured notes 12,952 12,952
Senior Secured Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Long-term line of credit $ 0 $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail)
9 Months Ended
Sep. 30, 2021
Debt Instrument [Line Items]  
Total debt average term 9 years 6 months
Total debt average rate 4.90%
Senior Secured Asset-Based Revolving Credit Facility [Member]  
Debt Instrument [Line Items]  
Effective interest rate 2.70%
Senior Secured Term Loan Facilities [Member]  
Debt Instrument [Line Items]  
Effective interest rate 3.10%
Senior Secured Notes [Member]  
Debt Instrument [Line Items]  
Effective interest rate 4.80%
Other Senior Secured Debt [Member]  
Debt Instrument [Line Items]  
Effective interest rate 4.20%
Senior Unsecured Notes [Member]  
Debt Instrument [Line Items]  
Effective interest rate 5.50%
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Debt Instrument [Line Items]          
Gain (loss) on extinguishment of debt $ 0 $ 0 $ (12) $ (12) $ (295)
Asset Based Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     4,500    
Senior Secured Term Loan A-6 Facility [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     1,071    
Senior Secured Term Loan A-7 Facility [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     1,500    
Senior Secured Term Loan B-12 Facility [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     1,455    
Senior Secured Term Loan B-13 Facility [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     1,131    
Senior Secured Term Loan B-14 Facility [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     500    
Senior Notes [Member]          
Debt Instrument [Line Items]          
Debt instrument, principal amount     2,350    
Senior Notes [Member] | Senior Secured Notes Due 2031 [Member]          
Debt Instrument [Line Items]          
Debt instrument, principal amount     $ 850    
Debt instrument, stated interest     2.375%    
Senior Notes [Member] | Senior Secured Notes Due 2051 [Member]          
Debt Instrument [Line Items]          
Debt instrument, principal amount     $ 1,500    
Debt instrument, stated interest     3.50%    
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail)
$ in Millions
9 Months Ended
Sep. 30, 2021
USD ($)
Equity [Abstract]  
Unrealized gains on available-for-sale securities, beginning balances $ 25
Unrealized gains (losses) on available-for-sale securities (9)
Unrealized gains on available-for-sale securities, ending balances 16
Foreign currency translation adjustments, beginning balances (271)
Foreign currency translation adjustments (18)
Foreign currency translation adjustments, ending balances (289)
Defined benefit plans, beginning balances (220)
Defined benefit plans, (income) expense reclassified into operations from other comprehensive income 16
Defined benefit plans, ending balances (204)
Change in fair value of derivative instruments, beginning balances (36)
Change in fair value of derivative instruments (1)
Change in fair value of derivatives instruments, (income) expense reclassified into operations from other comprehensive income 22
Change in fair value of derivative instruments, ending balances (15)
Accumulated other comprehensive income (loss), net of tax, beginning balances (502)
Unrealized gains (losses) on available-for-sale securities, net of income taxes (9)
Foreign currency translation adjustments (18)
Change in fair value of derivative instruments (1)
Expense (income) reclassified into operations from other comprehensive income, Total 38
Accumulated other comprehensive income (loss), net of tax, ending balances $ (492)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail)
$ in Millions
9 Months Ended
Sep. 30, 2021
USD ($)
Equity [Abstract]  
Unrealized gains (losses) on available-for-sale securities, tax benefit $ 3
Foreign currency translation adjustments, income tax benefit 2
Defined benefit plans, Expense reclassified into operations from other comprehensive income, Income tax benefits 5
Change in fair value of derivative instruments, Expense reclassified into operations from other comprehensive income, Income tax benefits $ 6
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Share Repurchase Transactions and Other Comprehensive Loss - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended
Sep. 30, 2021
Feb. 28, 2021
Jan. 31, 2020
Jan. 31, 2019
Repurchase of common stock, shares 29,343,000      
Repurchase price of common stock, per share $ 209.35      
Board of Directors Chairman [Member]        
Share repurchase program authorized amount $ 2,658 $ 6,000 $ 4,000 $ 2,000
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Geographic Information - Additional Information (Detail)
9 Months Ended
Sep. 30, 2021
Hospital
Segment Reporting Information [Line Items]  
Number of geographically organized groups 2
Number of owned and operated hospitals 183
Reorganization Group [Member] | National Group [Member]  
Segment Reporting Information [Line Items]  
Number of owned and operated hospitals 96
Reorganization Group [Member] | American Group [Member]  
Segment Reporting Information [Line Items]  
Number of owned and operated hospitals 80
Reorganization Group [Member] | Corporate and Other [Member]  
Segment Reporting Information [Line Items]  
Number of owned and operated hospitals 7
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]          
Revenues $ 15,276 $ 13,311   $ 43,688 $ 37,240
Equity in earnings of affiliates (35) (40)   (78) (48)
Adjusted segment EBITDA 3,224 2,053   9,495 6,919
Depreciation and amortization 716 694   2,125 2,059
Interest expense 398 385   1,168 1,201
Losses (gains) on sales of facilities (1,047) (14)   (1,057) 6
Losses on retirement of debt 0 0 $ 12 12 295
Income before income taxes 3,157 988   7,247 3,358
National Group [Member]          
Segment Reporting Information [Line Items]          
Revenues 7,787 6,633   22,143 18,653
Equity in earnings of affiliates (14) (23)   (30) (26)
Adjusted segment EBITDA 1,780 1,128   5,330 3,828
Depreciation and amortization 343 312   1,005 930
American Group [Member]          
Segment Reporting Information [Line Items]          
Revenues 6,767 6,073   19,562 16,920
Equity in earnings of affiliates (14) (15)   (38) (26)
Adjusted segment EBITDA 1,604 1,130   4,698 3,653
Depreciation and amortization 295 286   884 868
Corporate and Other [Member]          
Segment Reporting Information [Line Items]          
Revenues 722 605   1,983 1,667
Equity in earnings of affiliates (7) (2)   (10) 4
Adjusted segment EBITDA (160) (205)   (533) (562)
Depreciation and amortization $ 78 $ 96   $ 236 $ 261
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

QR$L(I?9(P'%$1X8[J7MW3.U4T=:Z=I=*4I#0, M+\!Y&'WHOT0;O8-Q&#P"&\>!M:RQ_F>":0,:5VO%[# Q,-.K/2T9-(_0^_T\2N$2V=#U;'^7'7T_2)YVE*CB>3Z&>T M<9"\V??S5WR/T_1(%XS[+AB_N0MNF>EB\7I/O TVIZ -08?%3_6;_Y2"Y_MA MBPIMC%[I@$/:7:ZO*4K$0)F#'3(%4@$]G_I1;O<[Q\L*0TI[=E,JV:Q+*&A@ M.8J&,$X@3,(!]^"RXS=8=^R3"83I9,!^N$L#2.-1UVG47<^ETA^,E K5V@U. M*A5;/^UTZ:G];%ZT(^G W@[V6Z;6MO0%%B0:G$TH?:H=ENW!R(T;4"MI:-RY M;4G_%Z@L ]T74IKN8!7T?RSS_P!02P,$% @ R8-A4]AKCK1! P K0< M !D !X;"]W;W)K&ULE95?3]LP$,#?^12GB >0 M&$E3& RUE0H%#6ELJ+#M8=J#FUP:"\?.? Z%;[^STX:RE6I[:6/?O]_Y[NS! MPM@'*A$=/%5*TS JG:O/XIBR$BM!AZ9&S9+"V$HX7MIY3+5%D0>C2L5IDKR/ M*R%U-!J$O5L[&IC&*:GQU@(U527L\SDJLQA&O6BU,97STOF->#2HQ1SOT'VM M;RVOXLY++BO4)(T&B\4P&O?.SH^]?E#X)G%!:]_@,YD9\^ 7U_DP2CP0*LR< M]R#X[Q$O4"GOB#%^+7U&74AON/Z]\GX5(C+O,)@)E1%'YAT>J>]"/(&G*F6AHS025U^R^>EN>P9G":O&&0+@W2P-T& M"I03X<1H8,T"K-=F;_XCI!JL&4YJ7Y0[9UDJVP M=R]F"FE_$#N.X37C;.GOO/67ON'O ]P8[4J"2YUC_MH^9K8.,%T!GJ=;'=YA M?0C]Y #2).UM\=?O$NX'?_TW_$W0RD?A6^%5QD+G\!'SN=1S&/M.D4XBP412 MI@PU%N''>,;JW$4_MU <=11'@>+HK:QXN/)&(9B",1Q:) =3X1#N%J*&\=PB MMF 3)#G7+,E!$%P(*N&*)RG (FTJT-;(?LC/J!89#B.>8D+[B-'HOD0HC&*_ M/G_GBP^$')VGWI5@&@MR16D])7E*T5$>P**460FEX&.=(6H>C'7LS&,7'KL, MV <@''!E'58SM%UY82]G"&&)HW&S*\5S2_MG.Y^-GV#NT1OA&BO=,TP\Q)60 M=N=6/+\KY!/'V87T($D2/K&L=1M<[L+>">ROJ1W_H9+"7B^%?=A2U>.NJL=; MJWI9%'S9_%U3OGVF2'Q/D)=]J9'/T*>VJ7I;(_Q[]8+4]X]C(79QQYZB:L.5DGG&E6ET(/YDB/@G M"\)NX[5\YWI#2KO0>RD#/O$K1NA[Y'1CI>.U*[1".P\/!3>N#]/>IMUN]Q:- MVROX1;U]R&Z$Y8P(%!9LFAR><$EM^SBT"V?J<"'/C./K/7R6_)ZB]0HL+XQQ MJX4/T+W0H]]02P,$% @ R8-A4];H#*G0 P Y0D !D !X;"]W;W)K M&ULS5;;;N,V$'WW5Q!J421 $5WL.(YK&X@W76R M#9HFN]N'H@^4-+*(4*1+4G;2K^\,=5DE&P?I/A5(+ [).7-F>'A9[+6YMR6 M8P^55'89E,YMYV%HLQ(J;D_T%A2.%-I4W*%I-J'=&N"Y=ZIDF$31-*RX4,%J MX?MNS&JA:R>%@AO#;%U5W#RN0>K],HB#KN-6;$I''>%JL>4;N /W>7MCT I[ ME%Q4H*S0BADHEL%%/%]/:+Z?\$7 W@[:C#))M;XGXRI?!A$1 @F9(P2.GQV\ M RD)"&G\W6(&?4AR'+8[]/<^=\PEY1;>:?F'R%VY#&8!RZ'@M72W>O\!VGQ. M"2_3TOI?MF_F3C%B5ENGJ]89[4JHYLL?VCH,'&;1 8>D=4@\[R:09WG)'5\M MC-XS0[,1C1H^5>^-Y(2B1;ES!D<%^KG5A;7@+.,J9Q\%3X443H!EU\!M;2!G MW+'W7!CVAL+?R!0J->;R&KC1%JP];<"OM2R5^-1MMY M;K<\@V6 ^]6"V4&P^E0"*[3$O4C(SB]GNR/%/QBW-HQ_E80<2*(:,"V(Z:YC MRG%W=EQ3XHH0E"(ND8,J!=.ODP>]A*SMC7TOCO'-QL"&.T1/'YE#CA)V()E0 MWAB$*P48;K+R$?>)*W%\7XJLQ%G:0D<1SPSD7W IV5&.N7)C":D24N)!8(_G MHV^9C0;%OQ["?+:8UG#T]UH3SQLC,O"X=V*C1"$RKAS[#>F:8<^H6>?YZ$KM MP+H&$VLC%(;@*@,L?FI%+K#^@-,N(77,4CF;JO_()G&,OS_],$OBY)?G]@AW M%3SB@6#N\0 O:I4W"Z<]CS@^]_^=<^?T)B[L=!QY;PK8>7X$BP$J79-K)E$J MF"=I BU4 ")V\CF*XX0=XR[Y%V*;"/,M,C7'A 6\GBR<2P9T]J=/0?!GJ2F6Z MP$#S"LVD#TQRSI M$?O6Z!L!_Y_%,WTFGNE;Q3.;T=]W2@<7%9TIVG#JKO, MNN9F@_7$HZ] U^CD[#1@IGE4-(;36W^1I]KAL\ W2WR'@:$).%YH%%=K4(#^ M9;?Z%U!+ P04 " #)@V%3*MO+)UL# "@!P &0 'AL+W=OQ-M MG-M>)XDM-]AP.]);5'12:]-P1TNS3NS6(*\"J)$)2]-ITG"AHN4B[#V8Y4*W M3@J%#P9LVS3ZSWOV"?3RYYRNU MM.$+N\Z6S2(H6^MTTX-)02-4-_)O_3T< >;I&0#K 2SH[AP%E??<\>7"Z!T8 M;TUL?A)"#6@2)Y3_*8_.T*D@G%M^U&K]_@E- _>X MYKK=5X@GDY[,>;+*Z^<.Z%X<-BLTA\L!KBKR5?:[X[!+9T*5LJV$6E/U2.ZP MHAVB0NO T-*^S19#K275JH6KBB;<6()1ZDE)562'UX-3R+%?.E)"4\EC23=< M ;<6W7M?-!5)>-;RV8LIZ4@XJ'DII' O<(5UC:$X3_7Y\-EH]OT0WD&>IO3] MX;LY&[,?7[LY3]T#S@'#O4K-U1XAZ%(NRXX0J_._+3(R8"I;";#I[+22@QT4\]5[F,9O/ M]Q:M^O]B\U'NQ;*XR%D_#$(="6M;KDJ$4EMG0P)65%JZ5;2Z8GD&0QJR*0P' M3]IQV4?#G]%0JP)^1P<#_RLFH(-<9BUE1^-Q*T\G@(UHR M:3HO58O4*]V&DE,K##3 \I1RN!B\\\!T4E#.4([.BORM$D^.NF:#9AW>!@LA MB*Z!'G8/S\]MUW7_->_>KD_&PO=V]R:W-H965T[25UC"+2H'<:4 M.4!=PN^^)@MW1G'1ZU"-+<%OQCFX>,2U)'P/M*)5F4 M\,VH$"QJ6*)^*P)BE<\>,1C(D_QBD>&TH8W@0XJ([EIN=(E"V@=",UO4,KP-BYO MSGYJ'@-2_,=(/!T^KE 2<*MP(VCX3!6[4L)=C7K#K\IXE&=+E*@+8GS/"@6I M-=,/![%L&9Q#/N;E(O\T@,LH\&44AI-N'VS)%QA, M(,]A.'U5!6XA[Q[.,VN&[$^O^S)DHTX8C+M]=,UE>*L!TJ,YI,ANXK1U M'$*K?3>2#K>'@7[;S;%?ZMW?X ?:#2<0)%5LFEU]&B=@NPG;';QIXE1;&\\S M,HHU_Y3(!@7^7AGC]X= &PO=V]R:W-H965T,.0 M $(LW>DU2P(X3=8%6(LNZ;8/PSZ<+=J^5=*Y=^9)=-W/3 ?L@W1OY MD _)DWBQ-?:=6R%Z>&R;SEV.5]ZOSR<3-U]AJ]R966-')PMC6^5I:9<3M[:H MZJ#4-A,1Q_FD5;H;7UV$O3?VZL)L?*,[?&/!;=I6V8_7V)CMY3@9[S;N]7+E M>6-R=;%62WQ _]OZC:759(]2ZQ8[ITT'%A>7XVER?IVR?!#X7>/6'<>+N_IR'+-#V.#<,X*BX0.^P*9A('+C_8 YWIMDQ,-VD(W',-\X;]I!F3QH==>/ZG&( MPW]1$(.""'[WAH*7-\JKJPMKMF!9FM!X$J@&;7).=YR4!V_I5).>OWK )878 M@^IJ>(EF:=5ZI>=PU_7YYL"=O%6S!MWIQ<2305:;S ?PZQYF\RL' MMUV-]9?Z$W)T[ZW8>7LMG@5\P/49R#@"$8OD&3RY9R\#GOP&^WM<&^MUMX0_ MIS/G+=7*7\_ IWOX-,"G7X.G*U1O&@2S. SNC283>K;AZ#H^N\J6FO(,*@B>'Z9XP%0=,%4[INX+IL'K^BE9=4 6J':!:,'[C;(>;<^:;""T M?3TBUR-%<.VQG1']74D%09K$H"P.'RK]B43)309C[ZM;<+K]ED?P5& 3Y [V>C7=[/1Z^#XZJ!E]9LUO ]%%%1%C3F M42XEC4)$2%Q MDJ1PRJ.0_2CC89W#Z5,6O?!)DO%;EOP.8L3/ YN MQX%B)F48*%NG(X87(N5<1W'&J:ZBM,I"#51)-?K7_3XL^2,D9"@7F8A )(X9 MJ9+Q4_<%F1!E#F690IF7Q^NEA"H'(>G)$W*T2+A,\JIW-A'9X'3UM1C#_R(7 M[+&UWE9OZ:ZC&X;. SY2@^(0)$>^Y*).\I+>(DY&OQCZF#DX65)WXDZ!H)RB M7QE7[4+-J6J]YF,*3QK*::@_,L#+?*?[?_Q^=]\A3?O&X+-XWUZ]4G9)08 &%Z0:GQ79&&S?LO0+;]:A39@9 M3TU'F*ZHRT/+ G2^,,;O%FQ@WS=>_0-02P,$% @ R8-A4]^\=.KS! M11$ !D !X;"]W;W)K&ULO5AM;]LV$/XKA-$! M+=!9HN37P#&0V-D:H&F#&-T^%,/ 2&>;*"5J)&TGPW[\CI0LVY*L!!L0((@E M^EZ>Y^YX/'JRD^J'7@,8\I2(5%]VUL9D%YZGHS4D3'=E!BE^LY0J809?U('O#[R$\;0SG;BU>S6=R(T1/(5[1?0F29AZO@8A=Y<=VMDO//#5 MVM@%;SK)V H68+YE]PK?O-)*S!-(-9^B^./))Y9!IF M4OS.8[.^[(PZ)(8EVPCS('>?H"#4M_8B*;3[3W:%K-\AT48;F13*B"#A:?[) MGHI '"D,>F<4@D(AJ"@$](Q"6"B$%86SD'J%0N^U'OJ%@J/NY=Q=X.;,L.E$ MR1U15AJMV0<7?:>-\>*I+92%4?@M1STSO6:::R*7Y%Z!AM2P/'UI3!9\E?(E MCUAJR%44R4UJ>+HB]U+PB(,F/Y.K..96G ERF^8U:Y7?S\$P+CZ0=X2GY(X+ M@:MZXAF$:YUZ40'M.H<6G($6DCN9FK4F-VD,<8/^O%U_W*+O89C*6 7[6%T' MK087D'5)Z'\D@1_0;XLY>?_N ]J6.I+9\Y\SC!ZHQ4:M0)5O&$_X)'7,- M#&:O=^@7#IOB\-:P;_XO[)/PAV6IALYL>,YLWLO(U^6+M?G],^J26P.)_J/% M>V<\?]DDCZ#L+I&[%&*W/;!5*XQ23-9%G#3YA[3$[#IWT7 M3NDHG'C;XT2VRYQ@[Y?8^Z_$OE0 VB!V&RJ=)YQ$+N$6^VD)-#'HU]$%50;M M,B<,!B6#P7]A /L2/N)0+>LF%H,:PH!62+2*G' 8EAR&K^7 (BZP;6*5"AFY MCNFB;[=<$]QA'8M?@=LJ<@)W5,(=M<+]%5*L;N$*G<5X['!ML-KQ2"?PA#.* M;H2:VQP38#+ I<-EX5K4[_[I15O=E M >G3 %9Y7D2ST<0Y!94@4.;-3.$X0+.?(1EF9)/'$]I0(6E36;,GO5'EV4% M6T@WA5D%D<0&^S=:LT,8VDQ)M&;8'S0BB39*X1JW@Z+(CWPC\0_[GJN.R';% M0KQ+7F+6%,]6:JP@9S>3 *T)DDP1H6/3;>GVU#_,1'YK-F8(GAML+!8(2^SQ MTCB^^+6-%_;]<:7DFZ3HH+J'"ZF3G>'3L%^I^P9CX_$P:*Y\>C0$TE;"-]JX MNL"\26WJT?F;0?HUY@U3@#\\P#P[,@QJ"'P86^]>1"#Z,+;9]='HJ-W3@_]^KI":MQ MK\L84U&$FH>U#R1V>*,DF>564#V,"';QUE _'.VT_W_'PL%.(;;-83=@C M9>*>EA"[@S2SK0MWD\!L8)?$%L@?!;@&^,)&F[_@N>?[7=__J8F%=W0M3 #; ML;V/:^+"D8_=Y6IYY[]R-]W*^C6]F-&&];G]C;O2U&*9$L4Y7@3O]BZS)G1C.9H9LC1-F4_LA6E'/R,HR2[&JPX7U\:1C9? MT=C/ANF:)N+.(F6QS\4I6QK9FE$_D* X,C"$MA'[83(8C^2U>S8>I1L>A0F] M9R#;Q+'/7F]HE&ZO!FCP=N$A7*YX?L$8C];^DCY2_K2^9^+,J+0$84R3+$P3 MP.CB:G"-+F>$Y I\7=(M]G.,4[3'_G);7 U@/D3T8C.>:["%W\O=$*C M*-((X3(I__V<9B!V T*,&X!* FP"S T!* M #G4@ED"S$,M6"5 NFX4OLO 37WNCT(5)GBB/G(F[ MH<#Q\8V?A1E(%^">T8PFW"]>7Q* QW"9A(MP[B<<7,_GZ2;A8;($]VD4SD.: M@=_!H\C:8!/1'/Y 7VBR$9<7+(W!7ZN0!>#>9_Q5_+Y2EEV IR1,L@VC@=3^ M)U]15MX#9U/*_3 Z%SJ?'J?@[,LY^ +"!-R%420>)QL97+B:/[ Q+]VZ*=S" M'6X1<)!F^($%=QQF]QOL%:A8]T/00$7@ ,,5(\S^1P M.%2Y\VO69T=;WPL&J9*.2'VD0U^5+%_5R0*^?Q,(<,MIG/VKL6=6]DQIS^RS M)Y.32WMK:6\M[:GRJ]!H2XWYU_9EC"SLV"/C9?>M*:0(06A?:MJ6,HGMNOM2 ML[84<; )*ZD]UZW*=>LPUUG.[/<$0*\703B$\#=5)A\+G!X+G!T!W NF7073 MUFJZHX'X'C(*OM_1^)DR76XZE4[G)%QP*WONAW/!;64FMDVK0065$"0-)K2% M'!G#>TU33HM>>I6:#' M83BTM"1 L&X9H)X&?B)ZR "\APYHIR%!)R$$PK5%_.&4*%7NI3O"9H,3"BGD MV+!!"H64C=U&$9DII"SHF&I:H+H4(_)9Q.C1C$A'ID[Z@5A-C3Z@.335W.BW MV"+C?CSK5@/I>XV"%&%P$"GJ*HZLTY"B+G5(7^N.(H7=3F0/-SG1%C*;Q62J M$$(.QDU***1,3#HH45=DY'P:)?2:S?8WN R*'D! M].W&?JTXD!9U44?>26B!Z]J'];7O&%J4*G?3U$6-SFBB$'*@TZ"%0@@3VVO0 M0B&%/-A1*7!=F#'Z+%KT:+:Z6J@C<=->7$>9Z,4A+2UPW7)@?]/D_ ]\,[IH@=G=:U$]>+4!)OUX$B[(!4!,W;VL6+*EG(# M,0-R[ZG87:BN5IN4UW)KKG']!EU.D.+Z%%W.BBW(6GVQ(WKGLZ4H)B"B"V%* ME$Q1XEBQR5B<\'0M=]&>4\[36!ZNJ!]0E@N(^XLTY6\GN8%JJW?\/U!+ P04 M " #)@V%3'-^=L*P# #N"P &0 'AL+W=O5CM@TD,6./8&=N4 M=G[]'#LAA1!"=^<%XI/SG&AM"SD>BIUFE).%1&J795B^ M30@3^Y'C.P?#5[K9:F-PQ\,<;\B2Z.=\(6'E5E%2FA&NJ.!(DO7(>?0?YK'Q MMPY_4[)71\_(=+(2XKM9?$E'CF<*(HPDVD3 \/="IH0Q$PC*^%'&=*J4!GC\ M?(C^A^T=>EEA1::"?:.IWHZ,=TU_%_D]2]M,U\1+!E/U%^]+7 M+7$SK/%X*,4>2>,-TJO0G*K="^UN$^V6&Z #$..0#?Y.<-8(> N M,8?%QN[]C10*; ?/(D C5^TE^'XG]CXW;9HKN*#C->)F5_-%C;CYU7Q^'7?" M>:_BO-<:Z"^A,4.[DX/2$-U$7>_LH_?[<5!368.3%]2D.#MW"H)@,*B)K,'+ M[P7=9I'UJX;[K0T_P?5-<_:&5F\(=J$5U)GHFKIO#WM9.%=P%X5S-=\%X5S- MURZ.ZD(Z]PFZ44V2\P:GGM^O MR<@]&F R E(PDZ-"]O8HKIO*6@VGCW8FJ]DG_L/4;[#/8)@M9L_W\,4D_ 3* MHUPA1M:0RNOT8>_+8KHL%EKD=GQ:"0W#F'W@4 #H; 9 >&PO=V]R:W-H965TOEE$8S/ ]OB3LYUJ7".SE#LAOIB;#\G9(# >L93%VIB@ M\&_+%BQ-C27PXVME=%#/:08VK_?6W]G%PV+NJ&(+D?[%$[T^&TP&*&%+6J3Z MD]A=L6I!(V,O%JFR?]&NZAL,4%PH+;)J,'B0\;S\3[]50C0&X&G/ %P-P \' MA#T#2#6 V(66GMEE75)-YS,I=DB:WF#-7%AM[&A8#<]-&&^UA*<?RU MX(H;216B>8(NN=J(?<.OZ#Q)[#5-T8>\S!JC_LM+IBE/7Z$7B.?HFJ>IZ3\; M:G#)&![&U?07Y?2X9_HINA:Y7BOT-D]88$D> U MP@$./]]>HI&:IAWN+0ZW%E36/$Z26G1BS9(>LQ>%@A:ET#WUSQ^J M__=OT M]T"Q3_WAFC>I9(SMKU#/KC10Q8XE"2RDRI&C*D%BBN\J7KMB5]L;6 MGN'!=AY.)\%LN&TJV.XTGM1=[CDZJAT=>1W]Q"#;WBI--;,I^;M>,PGIMV5* M T$T*'/-LCLF?:J,Z\G&1XS%:3WKZ0]B ?7S#:V L^AE*I1ZA>X8E!=#T-P5 MBM+WGU.OGQ\)D M@_%M796Z0DJD"?H7>6K_8MIR).SV(PP<30.O)Y S,0"-YP6#O-TP:7&I7E?) M!(U&P._HUFAY0!:'#8Z'1\SC$+MY\3/G2&7P'C&BTQ[E'5)#\OS*0X+%!6'W# Z9E0<04,_0KLJ8E/(>$V-$OZRJ$PWZP+W1,=!-AS_ ME.@\)BB.O>'I,8/B:!K^"*>/A'[8QNEX-.J)A8-EZ*?E$RIVVO)C,@ZZ_<". ME=C/RB=2N[)Z[U78XXJ#)PY_2GI^%/+1\, .K1@?,4^Q0RGVH_2I@2&'OD^Q MXR?V[UFO:@<.4=;A$8^.J:S#(/9C\'RUDFQE]K5[&*.-Y#'KE'/<+OZ>MR1V MZ,/^?>?_>2_@]OZRY[V '1*Q'XGM^#[QE8P=_O#TB+$G#G?D\;@[5'K29EY/ M:1''/.)G7J?T?[#<:,,.VIP21S)R3)*1QN_LQY/L8,T/QAEQ."-^G)6_9#^* M?.\.NH+?NGJ-%A1V 6_A#:0Y.XAUQ+&.')-UQ+&./!_K2)MUTSZQ'>N(GW7O M*)=H2]/"[F] >92+W+SFI4BA[PKQ7#/)E#:?L,QC:@22D/M4N_M2'Y3 0CH] M;T,Q#/M<=U@D/\)BQO:I8;Z V#R-#RM*!T)R3!!&#H21'X3OA4AV/.TLNJ@- MNG'0(V?D4!?Y47=#OYOO1DB+?8S1%NX+:5)2;'EBL@%6K.%Q 0D;FVI43&Y! M\^X/8V$K7PGIV1!'CI*1_Z=T'9!FXL%F- 9?ZM@.T]:9L'S.&WQ>ET5H,X(]@L^1 MXW-T3#Y'CL_1L_%Y$;7Y3"8/\WW8.(7(F%S9PQF%8E'DNOR 7[?6!T#G]MCC M0?M%^&91'N,X,^6ITC6%_2"(D;(EF Q.3D%:61[4E#=:;.Q9QYW06F3V$B*8 M,&DZP/.E$'I_8R:HC\OF_P%02P,$% @ R8-A4S5J.Q!V P K@L !D M !X;"]W;W)K&ULI5;;;MLX$/T50FB!%FBMFR5; M@6T@L6QL@ 8(FJ9]6.P#+8UMHA3I)>DXV:]?DE)47QC9NWVQ1?*<.3PSE#BC M'1<_Y1I H>>*,CGVUDIMKGQ?%FNHL.SQ#3"]LN2BPDH/QS3.#MX#O!'9R[QD9)PO.?YK!;3GV K,A MH% H$P'KOR>8 J4FD-[&WTU,KY4TQ/WGU^ASZUU[66 )4TY_D%*MQ][00R4L M\9:JKWSW!S1^$A.OX%3:7[2KL0.M6&REXE5#UN.*L/H?/S=YV"/H.&Y"U!"B M8T+_#4+<$.)+%?H-H7^I0M(0DDL):4-(;>[K9-E,YUCAR4CP'1(&K:.9!ULN MR]8))LP%"?VH M$8\/.?KP[B-ZAPA#=X12O2Y'OM)[,1']HM&]J76C-W1C=,>96DLT8R64#G[> MS<\Z^+[.09N(Z#41-U%GP ?8]% )"UIDY9T M!KH7_(G86T&_W39Q"V"P)$KJ:X+J')9(<21!*0KZ_E"(+Q%4&\I? !#>85&Z M7O:\%DVMJ+G+GB99.O*?]@V>0I*LA1QX25LOZ7_P0NI#I\R7S'40TA/]=)@< M[G%ZBHF"[!"3UYAD#Q,F<7ADUB&6)FZW@];MH-/M%X(7A!+U8MUNF8""KQCY MQU1LKXPNZX.3+:?147GR"S#SP6D)@Z';U;!U->QT]?B6CT^ZZ2C$5L\2ID" M5"YGPY-=9T00>RVE;6VLO]G"ZDU5KK;VE)MK-KHQ@K!1=^Q["3W M818=6;T ,W=@DL&167^OGZA K&SG)U'!MTS5MT [VS:7U[:G.IJ_":^FH6,^ M#Z]F=>_X*WS=R=YAL2),(@I++17T!KHJHNX.ZX'B&]O-++C2O9%]7.N&&H0! MZ/4EY^IU8 3:%GWR+U!+ P04 " #)@V%3]%=61;@# #["P &0 'AL M+W=OAN1,#XQ_$P4A M$GVOREK,K$+*YLYQQ+8@%18V:T@-;W:,5UC"D.\=T7"">^+S*6ME26ORQ)%HJPKS'PM2LL/,\JSCQ">Z+Z2:<.;3!N_)FLCGYHG# MR!E8N\M2A=> ?RDYB)-GI)1L&/NF!A_RF>6J!9&2;*5B MP/#W0I:D+!41+.._GM,:4JK T^H#M'2GTZZ-6V&)YU/.#H@K-+"I!^V^C@:_:*WJ9"TY MO*40)^<9YC6M]P(]$8[6!>8$_8764(UY6Q+$=FC)JJ:56'U5H<8++.@6X3I' M*UJVDN3(0/%N122FY7O@>EZOT+N;]^@&.4BHEP+1&CW75(K;DXE_"M8*8(7) M&S5^I&6I4DX="2K56IUMKVC1*?+?4!2@1U;+0J"LSDENB%]=CD\OQ#O@[F"Q M?[1XX5\D7)/&1H%[BWS7]PSK65X?[IKD_+_LV1]G?V5&,-1;H/F"Z^OMR_U& M2 XGQM<+_.' 'VK^\ W^CW"TTGK+*H*PE)QNH'8W4,F2H8?E/7H@N)3%%M+> MH@_UUC:55Y<@U@G4,?LR]_TXG3HOI]_L'!3'D]>8U3DF\D+_-2@S9 O\7TRO M3(@&$Z*+)GS6QR-L3?Q".)SV"/RHX%3NMQM<%T+"7H/O8-+?<49/W' $RXQL;I28C8@'(^*+1F2['5Q(ZMC*U6$%5Y(J#D[@ MHI.X[/TP>1"?+2=*3Q;3.6 >]U&"CC#VEIV M%\TP.W2J][I!&\TOO+NE9YA?06?;-:*_Z+NV^!'S/84^IR0[2.7:"=0B[UK- M;B!9HWNI#9/0F>G' KISPA4 WN\8D\>!2C#T^_.?4$L#!!0 ( ,F#85,8 ME?U\C@, T- 9 >&PO=V]R:W-H965TFF/L#7S9!IF4OS+8[.9.*%#8EBQ3)A/*(O&:/8BKTW. MQMGPU+9Q810^Y<@ST[MT!]I@7XPFSYMH,^ZZ3<0(9WF=.^4[F)MR@+Y98'\/%[0&F]IR *B3'&#I;@@ MUSN<+UL*Z.$FZFF&-?GR$4GDSD"B_^M(&90I@SQEOR7E=2(S6]M(,*WYBD-, M&(XRI;#D>*G!--;U$'681[7;=S?M4>J/W=UQ]1I!PQ)T(KA?"NYW"JX6!(F8 M4D\\79,=$QDTJ3R$&AP)Z-/P3&0=$X1AL\9!J7'PLZ(JP[]C+6=2FR9A@UK2 M ?7.A-4Q_9'?+&Q8"AMV"GM(T7Y%KJQH_ 7Y"_VWL<7#6GZ[1TXDUB%!B\)1 MJ7#TRPH_2ER&C1)'M?P]VIP_+/.'G?EO&5?D<]MZ"NMM"\[;UH#Q^LVBKDI1 M5YVBYC*%)S)GZA'?M;=9&FO"TIC\8S:@R)Y*7V"O#9@V?Z65P=+?Z;#TY19+*X^EKS'9@CP\>6O72M,$.C]:N$=G5?NA M@ ZZQG80 2MD>9AO/+#7ZO@+( ?+Z2TCP/[(FX M_ *:_@]02P,$% @ R8-A4VL_NYW< @ )PD !D !X;"]W;W)K&ULK99+3^,P$,>_BA5Q (DEC[Y16PGHHN6 A,C"'E9[ M<)M)8^'8Q9ZTP*=?VTW3LFU*67%)_)KY_V8RL=U?2/6D,P D+SD7>N!EB+-S MW]>3#'*JS^0,A)E)I,.^&[M3P[XLD#,! M=XKH(L^I>KT$+A<#+_16 _=LFJ$=\(?]&9U"#/@PNU.FYU=>$I:#T$P*HB = M>!?A^64860.WXI'!0F^TB0UE+.63[=PD R^P1,!A@M8%-:\Y7 'GUI/A>"Z= M>I6F-=QLK[Q?N^!-,&.JX4KR7RS!;.!U/9) 2@N.]W+Q \J 6M;?1'+MGF11 MK@T\,BDTRKPT-@0Y$\LW?2D3L6$0A34&46G@$N$OA1SEB"(=]I5<$&57&V^V MX4)UU@:."?M58E1FEAD['-Z(.6@T:49-9$INA"X4%1,@<3'6+&%4,=#D&XE- M.20%![OHEF*A&-H)9[+V<#P"I(R?D"/"!+EEG)O,Z[Z/AM3J^9.2ZG))%=50 MQ3 [(XW@E$1!%#[$(W)\=/+>BV_BK(*-JF CY[;Q<;"G9 1C)%0DY/MSP?"5 MQ#!91?7[8JQ1F8+YLT>T48DVG&BS1G14@$V&%$!>@2HB%>&@#\V'0]^<[6)H52_-#%IHBJ#4.9DH6TXRDYN=P(P>1+65: M&V1AH[F;K56QM0YD6Z-4= CB<+C6-ERGLQNN7<&U#X3[%$E[BZ1;\P4[%4AG M+\A[S5/R4R+ENZ0[6]*-7KA;NUMI=_^ODJ\I4^21\@)VD72W2&IRT*LX>E]1 MQ?NI>MM%TJS)3QBL-]/@2VIX/UHI\HZM6U/ X<9&'WZ^A#\ ";?KMU'#L=Z# MPV@OQUIR3_66/C:WOF;X[^?Q-XX]>X6XI6K*A#9%F1JKX*QCP-7R5%YV4,[< M23B6:,Y5U\S,30:476#F4REQU;&':W4W&OX%4$L#!!0 ( ,F#85,O[69N M7P( )$% 9 >&PO=V]R:W-H965TKK-/5%B97PI[9&PR5D*99#:)>X]N-K$-:67PT8%OJDJXW0*UW4Z38;+?>%+KDL)&.IO4 M8HU+I._UHV,K[;-(5:'QRAIPN)HF\^'U8AS\H\,/A5M_L(:@)+?V.1CW'@X!L_$% U@5D MD7<+%%G>"A*SB;-;<,&;LX5%E!JCF9PRX5*6Y/A4<1S-[LT&/7&5R8-=P;WQ MC1.F0%@VN5=2":?0PQ>82ZE"&85FG_8MA*)^ND422G^>I,1D0LJTZ( 7+7#V M ? 5/%A#I8<[(U'^'9^RB%Y)ME>RR(XF7&)]"J/!"62#;'@DWZBOS"CF&_V[ M,B=PBSF!,!+N7AI%.UABT3@N"-?FUSSWY/AU_3X">M:#GD70LP] YQNNIL@U M M<8O."%?X/"UYH?,TI^ !3V=N'*9*#VYO3>31S'',,.A?-P#E6\D2,RQKV, M\7_($!MTW/ 0)HQL](&>]\@?1[KJR(\Z\C"\!"EV[XI(#]JD0K>.P\!#81M# M;#JL'X=;*>-"XXM#!Z06S=.T : VR=6RZW!*W<%R6/#/1 M!0<^7UE+>R, ]%-X]@=02P,$% @ R8-A4WRH6+CA @ ?@@ !D !X M;"]W;W)K&ULO59;3^) %/XK)XT/FHB](* &2$"6 MU40V1*+[8/9AH(=VXG2F.S,%_?<[TY9:(W3=F.Q+.[?O^\ZM<]K?"OFL8D0- M+PGC:N#$6J=7KJM6,29$G8D4N=E9"YD0;:8RW \9W=PCV-8FT7W&$_)1$N4#^DY\\:9)5%X+=A/&NIXX%PX$.*:9$S?B^T-E@YU M+-]*,)4_85N>]1Q894J+I 0;"Q+*BS=Y*0-1 P3^ 4!0 O) N(50;N6$:#+L M2[$%:4\;-CO(7C1*7AGFB$Q9:D,(HD8G%V@HI&W.R$0!1<$Q7#U.0:;C",4,'Q!#6A M[,1PSLEK:TI?S,&/C J>9I@L4?Z"(Z <9I0QDS75=[7QTMKJKDJ/QH5'P0&/ M+F$FN(X5?.,AAN_QKHE.%:)@%Z)QT$BXP/0,VMXI!%[@/RPF<'QTTD#;KB+? MSFG/#]#.B,XDU:]@\H8%>16#!OKSBOX\IV\?H)^@I!MB2[Z>V5/X;KY4.+X3 M2IW TYT!P:W&1#5)=BK)3J-'/X3]T$PIC1*1<;TO=05!-R>P%\9F:*X/K^]N M]LAV*]ENH^R44 F/A&6X3['[0;'5VZ_7J_1ZGT_TLZA&O)K]Z#_A2HJP>_*R.9PKV;P MIAE\K9+^@K<9/U!*;JTE)"BCO/$I6-F@%MVA6JV:ZZAH*6_'B\X\(S*B7 '# MM8%Z9SWS$&ULC51+3]M $/XK(XL#2"UV' (%.982 H(#$B*B/50];.QQO&(?[NXZ MH?^^LVO'#2U!O=@[LS/??//:;*O-BZT1';Q*H>PTJIUKKN+8%C5*9D]U@XIN M*FTD59T#V:/-.M$USAHP';2LG,KSD*O9U& MHVBG>.+KVGE%G&<-6^,2W7/S:$B*!Y222U26:P4&JVDT&UW-)]X^&'SEN+5[ M9_"9K+1^\<)].8T23P@%%LXC,/IM\!J%\$!$XV>/&0TAO>/^>8=^&W*G7%;, MXK46WWCIZFGT)8(2*]8*]Z2W=]CG$P@66MCPA6UOFT10M-9IV3L3 \E5]V>O M?1WV'-+1 8>T=T@#[RY08+E@CN69T5LPWIK0_"&D&KR)'%>^*4MGZ):3G\MO MN6*JX$S O;+.M%1O9^$SS,J2^[*%BZ[WOHC'"W2,BQ,X J[@@0M!6IO%CJAX MP+CHP\Z[L.F!L)?PH)6K+=RH$LNW_C&E,.21[O*8IQ\"+K$YA7'R"=(D'3TO M%W!\=/(!['@HSSC C@_ +M#P#?.#\Z8^3)5PA^6:JS7,_%Q1K=#"@MM":-L: MA.^S%9G3S/WX@,79P.(LL#@[P.+&.DX-P!*8U*URM V%8-;RBI.N,EJ"=C4: M*+2DU:S]SA!CKDC&0-9@V19>X]"@=8"OM-46WVM<1^4\4/$KO8?^ M9* _^4_Z%)UFN!NE#1/MNP0F_Q*X_(M O#?P$LTZK+6E]*DXW>P/VN'EF'4+ M\\>\>W8>F*$V6A!8D6MR>D'A3;?*G>!T$]9GI1TM8SC6]/JA\09T7VGM=H(/ M,+RG^6]02P,$% @ R8-A4SAKN(S6 @ XP< !D !X;"]W;W)K&ULO55-;QHQ$/TKHU4.B91FER40$@$2'TF+%)H(FO80 M]6!V9UDK_MC:!M*J/[ZV%S:T!1KUD O8WIDW;][8,^V55$\Z1S3PS)G0G2 W MIK@*0YWDR(D^DP4*^R63BA-CMVH>ZD(A2;T39V$<1@%YT1][R.3JTY0"S8'$SK/C3L(N^V"S'&*YJ&X5W875B@IY2@TE0(4 M9IV@5[OJUR+GX"T^4USIK36X5&92/KG-*.T$D6.$#!/C((C]6^( &7-(EL>W M-6A0Q72.V^L-^HU/WB8S(QH'DGVAJ.\2>=QG(LQP20[IM)5>@G+5% MVY*AP59D:9;]2ZV>Z-U00D5#"8"2T40LKN-'P#JZSS.H&,K/G!A5J M Q-B$*8K4FBPQMO4[A??V/<#QK=3Z!!YOK1.,#'+]]4#(\RKD MN0]YOB=DC\N%\)5Q\+8.B9P+^@-3I_C=8.2*\T++=Y5AS)8TP=S M3WC9K;7#Y0Y^C8I?XR"_7??E<8Q\ANI0^LT*OOE6BE]4(2_>4O$R6./?BKM/7<]U\N;2(XV M1R.WG_@K:GE9$;]\JUK6HI>&%[U.+>74TDZMG?TI^NMAQ*T_ZA1N]5V.:NZG MBX;$79>R!5>GU03KE7W[Q;PO<74$L#!!0 ( ,F#85.XZZ:S* 4 +H< M 9 >&PO=V]R:W-H965T/BJY-<9VD/?B22-;, MZ..\/@YUODG5DUX"&/(<1XF^:"V-67WH='2XA%CH]^D*$GRR2%4L#-ZJQXY> M*1#S0BF..BP(^IU8R*0U/B]^NU?C\S0SD4S@7A&=Q;%0WZX@2C<7+=KZ_L.# M?%R:_(?.^'PE'F$*YO/J7N%=I[8RES$D6J8)4;"X:%W2#]=\E"L4$E\D;/36 M-% M;PIM7(U,\C!.C<*G$O7,^%)K,)J(9$YNI9C)2!H)FMR!T)F".1&&?!12D2\B MRH"?0(CJM% / M?E3OH"-K;[+:FZRPQQOLV>6WR1]8@Q-0,XH93N@G4)]-^I>C;KG17V3K$$;;'\( M&BM')NA5D82 [7.FY5P*A577)@D&N%R$"WUO#UB7#G? [\OPX="-O5]C[_\/ M=@,*T9,'88!,-V*ER=<[B&>@?(DWJ,T/CJUFAC7TH="LIMS M^Q+=AHP;U=A&KXX:^9=\,DM0Y#(,58;>_.T9MP4:#HHK#2RU!,<66;K%B_3% ML6V3Z^;JK.QMQY .W#&DED\H\Z*X2Q/X1NZ$>D)W?4G59?0."99M_Y0? M7; L)U _*;R8O.A^DZ=TM%.4#J&F7DHM$5 _$TQ@9L@T]UFYTSHDB+93T_[1 M!='R !V\Q#-MJ+J&&9DLM$U _%?R9 MI09=>:]DB$'%/>UE,9]4I:L)KH#4OUCVZ"K6,QOR,]O(* MW1]2'!6Z+]18H98?F7^4F!.'<$M^W$]^KRLM[+*O/%[@EMWX\1W*;9W*^=GMT".&RHSO MC,$ATG3(P"US.+C$LE7$_E;WX?**R=\CY!+>LQOTS MVZO#_XHQF%NZXL.C"ZSE+^[GK[>/P=4+^E[R=0KMMH/.UH>E_*L>[H4?D9E( M! O4"MX/,)M4^:&LO#'IJOC6-$N-2>/B<@EB#BH7P.>+%#?KU4W^^:K^7#G^ M#U!+ P04 " #)@V%3 4!0 &0 'AL+W=OE;FTALU0TFE&."PFJJ2HB MW^^1B=W8"[W]PA-=;[1=\+.T)FMB[$76$'(,->6@9AABU-DS!(9&7\[3J\O:8&'\SW[ M@^O=]+(B"J>"_:*%WHR]6P\*+$G#])/8_<"NGZ'ERP53[@N[+C?P(&^4%E4' M-@HJRMN1O'4^' #"Y 0@Z@#15P%Q!XA=HZTRU]:,:)*E4NQ VFS#9B?.&XIO#QT[DC6\#9,^ZX/HI!>=G!4])5*^4[X&4HF& MFZ/T)<')_U*BX3#Z)/A(5A@EP2?!_L'IMR_/G,@UY0H8E@87#&Z&'LCV-K>! M%K6[$"NAS?5RTXUY %':!+-?"J'W@;UC_9.:_0-02P,$% @ R8-A4W%> M,6T!! [0\ !D !X;"]W;W)K&ULM5?1;N(X M%/T5"\U*K30EL4,"&0'2E&JTE=K9JDQW'T;[8,(%K$EBUG9@^O=C)VD"Q&13 M[?("27SO]3DGU\?Q>,_%#[D!4.AG$J=RTMLHM?WD.#+:0$)EGV\AU2,K+A*J M]*U8.W(K@"[SI"1VB.L&3D)9VIN.\V=/8CKFF8I9"D\"R2Q)J'B]A9CO)SW< M>WOPS-8;91XXT_&6KF$.ZF7[)/2=4U59L@12R7B*!*PFO<_XTXSX)B&/^)/! M7AY<(T-EP?D/&6"EQ,MD.6T[JBBT['@>R1,M*YF+G)M M\FS-AJ7F-*LOA: M1[W,[]#5AVOT ;$4/;(XUJ]$CAVE$9FZ3E3.?EO,3L[,/H=M'WGN1T1<@BWI ML_;T.XAT.L[3W>-T1^M0B4$J,4A>SSM;3[.\3Z42F>Y4A;X_Z !TKR"1?[>4 M]ZKR7EY^<)9MRKA>0A!E I:ZV1;*)EE1),B+F%6XF^(P<#6_W:$REJ@1&8VJ MJ".$@PKAH!7A5^T;!A9B4F8TC0!%7"KKBRT*^0?SWQ#?.P%I"_(".T:_PNBW M8OS&%8T+E%=T!T*;#8K9*F_8L.^C5Z!"?D2"*I"H"&#I&@WZX6_7-B)^ Z-' M2!B>,+%$8=<=V*D$%96@E^VN@%Q777&1HVN$$#"/%/ M>\,2XX9VJ,,*ZK =JK$"9:S@7-L.+3JZ@U,=+5'N,/3MX$85N%&7A34O%]9G M*4'=W&IS7Z)GV/%X9QI@IH>80E]HQ&*F7M'W1T@6(-H6=EC-'U["-[!;F[3; M47TS8CH]RME8'==M2.PWW,,2Y-K? 3[82?![WD*^;SQPFKY)SO1Z[" ZKMT: M7\2N<>W7^'\Q[+**?^38HX;DS2@O&.(SJM>.C=LM^T3UKUQUE+GV6^Q?1.;: M!7&[#7:5N6EK."#-UK:$>2/_7'O7!HC;'? /M0&C\Y'V-JDMB^!+B$T./BA) M%Q)912(U)&Q*EX6.VI:$/CG1^E_#CH'65DF!-?=<*?_@)02P,$% @ R8-A4SL^ M838A P ^@L !D !X;"]W;W)K&ULM5;;;MLX M$/V5@8 %6F CB?(M+FP#<=)B R1M$+?;AZ(/M#2VB5*DEQS'S=^7HAS)7<1L M#,0OEGB9,V<.J>,9;;7Y85>(!#]+J>PX6A&MWR6)S5=8^*!2)EF:]I.2"Q5-1G[NSDQ&>D-2*+PS8#=ERCB,6/4W< MB^6*JHED,EKS)SS@)4I9(3D>_^U HR9G%;C__H3^P1?OBIES MBY=:?A4%K<;1>00%+OA&TKW>_H.[@GH57JZE];^PK??VAQ'D&TNZW 4[!J50 M]9/_W FQ%\ &!P*R74#F>=>)/,LK3GPR,GH+IMKMT*H77ZJ/=N2$JDYE1L:M M"A='DQNMEF>?T91PA7.",YBY7"%Q(=^. M$G),*KPDWV6=UEFS UF'<*L=D(7WJL#B]_C$5="4D3V5,'2+0F"#SP74M C?+O% MQ['7DOB/R!U8A;4F&4MI^P8E3]J>J&LK86Q MDW@8:TV,AIOXGHE7J)M:TFL?Q)M6\]A M@U?3-HS4C;.PMJU1L;#![%3]HNS1E[;U'C8\A;!9:S99^EK"_@&I%_>>%S;9 M:\=*-$O?=%K(]491W9DULTUC>U&W<^WVNBN^Y68IE 6)"Q>:Q@-W^TW=:-8# MTFO?W,TUN5;1OZY<&PO=V]R:W-H965TFJ755E9_=BM!>&&+ FB5G;@5;:'[_.1^.T M)"ZPY:;DP^<]QT].WSCN;[GX*5>4*O T$7@]8UO)I@G 9D M(_YD="LKQR"=RHSSG^G)73!HN6E%-*1SE4H0_;.A-S0,4R5=QS^%:*O,F096 MCU_5)]GD]61F1-(;'O[% K4:M+HM$- %24+UQ+??:#$A+]6;\U!F?\$V']O! M+3!/I.)1$:PKB%B<_Y+G D0E0.O4!Z B +T/:#<$X"( [YNA702T]PWPB@!O MWY+\(L#/V.>P,M)CHLBP+_@6B'2T5DL/LL>516O +$X[:ZJ$OLMTG!K>\WAY M\0<5$1C3F0(7X#H(6/K,20CNXKQSTPXX&U-%6'BN1WR?CL'9EW/P!; 8/+ P MU/=EWU&ZFE33F1>91WEFU) 9@P<>JY4$MW% @YKXL3W>_RC^UA[?L\0[FF*) M$KVB'"&KX)2N+P%VOP+D(EA3S\W^X6X=#GOX;TELS7[[_XJ?'%W\&Y:X;$N< MZ>$&O:P9[V*I1*)M3($?]WH N%,TDG];Y-NE?#N3;S?(_ZHM%YR%7,ISH)N; M/BL6+Q,F5UDROM#>-%-U+9W+^IEL:MJ;H9[MIOJ0/QPQWAUQ =';,;=[C)G4 MC$$]KQST!HQ7@O&L8*ZEU&^SD;;J #S1#0\W&@RX$52; IB0.0N9>@$_'F@T MH\+V)/PRH7^*!]TIY3O6^3R09Q8E$9AQH2/3NJ+=LH*NM8(IC1D78$KGB:8(,JN]YR0&UQ?^041[9<+>*8A"U[PQW$]D6HA5 MH4*W ^NAPLIK"QZ+M7,05HA,2G02L,;S(/Y,L'@7;&.W0N.,T&Z-C6!'VH$. M(VM,!WHG(6M,!OJ?2=;?)=OV&IP5&BN"=B^RD<6'D37F [LG(6O,!O8^DVQO MERS$#6: C",ANR/9R+8/(HN, 2%X"K+(V U"GTBV$*N2;30#9!P)V1VI /L[ M5U3NA<_8#&J?!)_Q%&1?R60)6)G@*U@+%L_96G_7D(@G<=WR;EQH5BDB[#5A M-/:#[/93BQ'\"][U;7Y_G%"]BL9P+][&?%#G)+R-TR#[.NS4#-MZ%3^)= MV'@7MGO74*1]GABI* BG2 OK_@NN.*DS1!N;DY_ ]02P,$% @ MR8-A4\GLC@,L! PA !D !X;"]W;W)K&UL MM9C;;N,V$(9?A3#V(@;B2*+/"\= 3D4+-&B0;-J+HA>T-+;8I4@O2=E)G[Y# M29'L6E*<0V]BB1*'W_SD\!PKCLS&=9VYV>SU1J!9=PIXE)DX3IYTL0 M:GO>"3HO#?=\%5O7X,UG:[:"!["/ZSN-=UX9)>()2,.5)!J6YYV+X.LEI:Y# M]L;O'+9FYYJX5!9*?7O M7Z+_E"6/R2R8@2LE_N"1C<\[DPZ)8,E28>_5]F*$2)OM+ML6[?H>$ MJ;$J*3HC0<)E_LN>"B%V.M"@H0,M.F1">/E &>4ULVP^TVI+M'L;H[F++-6L M-\)QZ6;EP6I\RK&?G3_$3 .YAW6JPQBS(]\TDX9EDAG"9$1^LS%H_,CY?:9_'FQ,%:CK'^UQ!R4,0=9S$%#S$>)]2?X M/ZCS"NL.Q4*E[!@,H1:R?-A M1]FPKIPW9L:U&&).GP;ZHG 50"F^RIS'5\^UG"'KS>MYQN5?*//EA)D M])J.HP/.8%3/.2XYQZV<5(R3CZ%L8YGZ_?BG@- M2VR)<,XD7EFR1H"CI["(O<]$_0:F'3\(WL-TPF6H$N@2>,(/ O0)#:%@QO E MQY>YM(K@EX)FN6\LM4J(RCP@W/. /$IM.L'111/0*AGZGF2.F/ B\+ZZ_J ! MJ'*#H-\*=!4SN7(RD"7CFFR82,%Y9P2:;YC-)4*G2-]4S<6@>[#])O$JEPG: M;>9MK+5<@YJR;L"J'"5HMY37LNE&/6]*$O M]8(&@P\J9PK:K6GWLZ]9M]SXNZ=$XDD#T[#LZ>C576-60[])X,JM@G:[>O^G M29E$D1KFTD!>8VM-IE'96O YOE8+5.-C33Y+*QNC[3;V\8V"UGA9PT9!*R>C M[4YV4Y1[6?\?J?M3\DU9)FKA#YVKWZ1IY5RTW;D^4%5'[ 3%X+M?^KW!]+\E MY>T<*Q/0J^SP;! DE38_89:MY0'](C^65J_GI_M;IE>NQ@0LL:M_-D:U='Y@ MSF^L6F>'U(6R>.3-+F-@N(+<"_A\J91]N7$#E/^VF/\+4$L#!!0 ( ,F# M85/F[#P9!0, $H' 9 >&PO=V]R:W-H965T*=HS1<2="8CH))YVHZX"O'M=E9@U.R M4.K);>Z24=!VA%!@;!T"H[\57J,0#HAH/->801/2.>ZNM^@?O';2LF &KY7X MQA.;C8)W 228LE+8![7^B+6>GL.+E3#^%]:U;3N N#16Y;4S, 0U0Z1YUT%\BQOF&7CH59KT,Z:T-S"2_7>1(Y+]U'F5M,M)S\[GF=, M(SQ@4>HX(W7P13-IF$^9 283^&PSU'"M._"%;1 M>CL$H_T$^PW!_E&"-Q1)4B;KF% (XM>"VPV-06H/C;%@QO"4DPV75@'-1\VJ M=DFURD'YTH]?E7ZEI05W;S3M+?7^&U&]_:(&C:C!45'7&9-+1P-2QC6LF"C1 MM6R"FJ^8K2A2099U[O^KVL&;&NO_I3;_TRH\<.M3.@^U0IN]VX M ,WS.?X-4$L#!!0 ( ,F#85/^*(/2Y@( *T' 9 >&PO=V]R:W-H M965TQE$T# 7C,IB,_-F]GHS4UN9< MXKT&LQ6"Z5]3S-5^''2#EX,'OLFL.P@GHX)M<(GVL;C7M MKEI0+E(8K"1K7 MX^"F>WT[=/;>X"O'O6FLP46R4NK);3ZDXR!R@C#'Q#H&1J\=SC#/'1')^%EQ M!K5+!VRN7]CO?.P4RXH9G*G\&T]M-@XN TAQS;:Y?5#[]UC%,W!\BA5@-ZQ@'X%Z!\+&%0 M'WI8QNX3-V>6349:[4$[:V)S"Y]]CZ9\<>GZ9&DU?>6$LY-EQC3" Q9;G624 M4ACH7\4LNIO%!PB46'>A%YQ!'<;=%S^PP_ Y7'8@O MWX3/#\,_,DG>NQX>M;K)+\HBDK MNNKT!NVB!K6HP4%14\5TZI3,N::YI[2!6<8X_082OB]0K%#_.%")8>UF>-!- M^8OJ9@;41C,!;&LSI?EO3($)M96V+?22>]@,?3BXK ,O&_NUT;!9LK)]7QOU M7QG=MKA[7?RP,:\$ZHV_* P5E&(H1U=]6M]%-WX$AW_-RXMLP?2&TZ3*<4W0 MJ'-!)=/EY5!NK"K\]%LI2[/4+S.Z3U$[ _J^5LJ^;)R#^H:>_ %02P,$% M @ R8-A4_1L:GG6 @ APD !D !X;"]W;W)K&ULO59=3]LP%/TK5IXV:2,?_49MI18V0!H,M=KV@'APF]O$PK$SVR4P[_K>0H9U4S+I>%,P+4B>IEE5#V.@:F#"DM38 7_8SVD"4S#?\FN%/;]&B5D&0C,IB(+%P!N%Q^.P:0/!F>X7^V26/ MRLT0NL/7(IA4DU^21BB+?C? #B8(H M/)!'1P7[!3%)E%SF>I?A)73+0=M/\7X8]?W['6I:M9K6 M*]7(0B"U/2%8#!0UV$DKBW=*:3V3$G8;N\6T:S'MO6(F4'E0&G]F;2 WEV E MWI+?Y(I6YW-[9L^F=&KFSN%/0+%,%@7I>#PIH<;-3 \D.T5\*;OW6"W[V&TEA.]R?D3J= 6%.>$?C4I:G^- M_>NB%_Z'JA>NRU[XVKKWS_8_KWJ=)^[[&W;>NEY=/E$NJ$B8TX;# T."H@[RJO/7+CI&YNVEGTN"][9HIOI1 V04XOY#2 MK#J6H'Y[#?\ 4$L#!!0 ( ,F#85,@:A;# P8 %P< 9 >&PO=V]R M:W-H965T63.REM29 MN,W83?N0Z0,E0A(;DE!(R';Z]047=T.N%'$84)^YRB[!C'?OKC@D7\[GR$1P\/KL/=7N0/QM/)P=^Q M&R:^'#ZG\FY<9PG"F"59R!.4LNWY:(;/5L3+ PK$'R&[RUK7**>RYOQ;?G,9 MG(^,O$$ K;UCY&XYG>_L(J0G>?;\"@K_J*["FN,T.:8"1Y7P;('<9B4__W[ M:B!: 3(/'$"J *(&6#T!9A5@/K4%JPJPGAI@5P'V4[M$JP!:C'TY6,5(+WSA M3R7OKMDM2XXL>X^6WX^A^('" M!"W]- F37?%^MMV&4>B+'#$+_I;L6( >>K"\N/Q],7N/%DQND4U8MIUW:Q;S M5(3_M!YD&1,9>KM@P@^C=[*#7VX6Z.V;=^A-WN)5&$5YCR9C(05(-Q M40X&Z1D,$UWQ1.PSM$P"%@#QB^%X^EC\&X@?RXFM9Y<\S.X%&4QXPPZG MR#3>(V(0#/1G_O1P QJ.X?"/QV2P]>5_Z_SJQ9WOC*59[Q2SR&<^LE.NV2%? MC\FNLTF^?I)P="E8G/TUT)A5-V85C5D]C3WL)&@-EY&TB,P+Q^T4V\2AD_%M M>V8!E&EBW$4M=91E4M?MHE8ZRG2(9=2H#D6[IF@/4FPD@K4DPJ\E J)>9K1; M'3DQ;84X@&EUM:0-8!R5-)3'A2G3FC(=I%QK7M;1/(@IU5HW";$4JCJ(&+:I M<-5!GN4I@[;20=3#'LS6J=DZ@VPU(?=;0@YQ=K1..%A=UCJ&>LJP+'4,P41E M#( ,NX>Q6S-V!QE?)H*E+!.(W4OGES&(I*M/K*9'[%B\V[]C=R\(H0WKZ=O*&Q8CL(= M0JD3#&:RE4PK'45AYMAHS)+Q%.Z%J19ARHI-+(D';"U NV%H?5"D:/XX9%%! M.EI.E"$!TJB8%8 A+27HCDG+0.)'%OV&QPRMF2R&3,IY<2?\>W@15,DZ:QNK M4S<'4)Y:E98 2%8E=15 #9IVCY!CTK F@ZQ_+53,C]"'E!\/Z.L5B]VREJ79F,W M\.O[#0R8 %6-YA"(:.0AZV*HU*%,?:+5F [\:JX#ZSX .ZXF60 *$VU[ZBC; MU"D#1L \LP>1XT;_X&'#<@L M9FFX\9-GJ%)3]K'W_ZL2:4HM&2ZU0ZI$]$)&':JJ$H0R''5C BCLV52MG1", M>J1GQDA3/+2>,OR+"_F/-4*H9I4]1)M)4=F+_!&5JZBD9KJ>#RJ27,X<0 M=<* KVVU0"P!$/9SU D_=#5I"_/W:[\=!M+R**N\$?Q0 M'+VLN1 \+B[WS ]8F@/D^RWGXN$F;Z ^4)S^"U!+ P04 " #)@V%3O;X) M2O\" ")#P #0 'AL+W-T>6QEUW%19/Z:ZWK#T'0K-:T(LV9K*DP2"%51;29JC)H:D5)WH!3Q8/I M9!('%6'"7\Q%6UU6NO%6LA4Z]:>CR;.WSWGJA_$[W[-TFOO[12GWQ MRK/WD[>.,'3M+S)Y">37!>@_74P9##8EY(L4LE\JW!Q"85 M]>X(3_V,<+94#+P*4C&^L>8I&%:22^5I4T,C)@1+^SN' M_F:"+*7*J1K#A/[6M)AS6H P]9C&!C:%>7\ M&GKO>W' W15[NSJ!/17CT @:AI;&3H!_G\UR[]'.GD7KU>Q.ZD^MR4;T<^@5 M>J5HP;I^WA5C?(P]Q-E)7?/-1\Y*45&;^Y,#+N9DZ^>MI6+W)AITRLH8J/*] M.ZHT6^U;?BI2W]!.;[NI*W#-TW]0\Y^M5&,!^+N1' L#B8 LS'>F%Q_J=\ M9F@^%L.TS9S(#/69H3[6RX5D_0>+X_9)S.7.-$FB*(ZQBF:94T&&U2V.X>MF MP[2!!Q8'(OU>K?'=QCOD\3[ ]O2Q#L$RQ3L1RQ2O-2#NNH%'DKAW&XL#'M@N M8+T#\=UQH*?=/=H'"/5B>'CWA_L*8FB)'$C@+D5 M1!&&P-.((Y@"T( A4=2?@T?G4; ]IX+=C^_%+U!+ P04 " #)@V%3EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M ,F#85,+$=@:^P, +(A / >&PO=V]R:V)O;VLN>&ULQ9I!<],X%(#_ MBL:GY=!-;"L!.@TSI04V,]W=#.EP913[.=9@2UE);H%?O\]*0R4H;[@(GQ++ MBOSYR7J?I/CB7IM/.ZT_L<]]I^PJ:YT[G,]FMFJA%_9/?0"%9QIM>N'PT.QG M]F! U+8%<'TW*^;SY:P74F6O+DYM;UPL*QX(.$>_MX?CQD=]+* MG>RD^[+*_/<.,M9+)7OY%>I5-L^8;?7]7]K(KUHYT6TKH[MNE>7'$Q_ .%G] M4+P=(6_%SOH2)W;O!8*LLN4<&VRDL<[7\.T+9+P#K'P\&IQ^*SL'YEHX>&?T M<)!J/S:#=S$+;L/'X?1Y#.*Y^94PZJ:1%5SK:NA!N6,<#70CH+*M/-B,*='# M*KO2=V#81NQAO"F\RKH^WJ!#LB!]M6V$B\5%2R1-;9:WNP+JQDG_ZULH.QJ?J[;"SL@XQ*:WD MB;WR5BJDDJ(;"9WQU:/>I722)_;)I;4X8?(#XD8*/^F38-G?(#"8$,60$DJ> MV"@W6NW/;L'T[!IV+J2B#)*G5XC#H0'8N_%XI8R1)U:&'Z+L/1P&4[7"8C;! M06%%]9#Y0DS*&7EB:6QA/];P3]X[T'LC#JVL<(@<6PLQ*6ODB;5!NBV:)124 M.(K$XJ QPWE"0;FD^.TN87_@&J\#^RQ$)%3LDOQ6^WR9!0IS12)-4-F]#B*E'B*U.*A,GJ,28FGF'*U\I&'F)1XBDG% MLPBW3"CQE).*9QEB4N(I$XN'7/VQLQ"3DD^97#Z/ZS]VQB[KVA/Z+(\-AICD M1EEB^3RA\3.VQ8;KH0.F0TS*/F5B^] J#R=%)66?,K%]:,PP(964A.&4A MGMA"]#PS'.FV$+T(B,:0I2%^*1KH6@(41;B4V["1;+DE(7XE)MP M<:=3%N*)+41CAIV^H"RT\!::G=X1J*&1"NI_\!(6RRO151O#QH_C/QM\,>X\ M-D/776'9O^I&B_KTRL'I=8E7_P-02P,$% @ R8-A4SB#;R;$ 0 #1X M !H !X;"]?;7/NGT-(JVW<-^FAZ^/A?&7=#?LFGY?#)O3-ZJ/9Q*#C\20, MOV=4B]GOF:.W4Q__,[%;KW>K^-*M/O?QD/\8'+ZZX2-M8\S5Z*T9-C'/JW!L MKZ=3N!SDX3RY&BW?Y]6P?) M*9_:F*X]/VM\_CVISN=[X_7QE^7/27Q?U!>< _S]77P#4$L#!!0 ( ,F# M85. A/B=P $ > 3 6T-O;G1E;G1?5'EP97-=+GAM;,W9R6[",!0% MT%]!V5;$>( . C9MMRV+_H";/" BB2W;4/C[.F&06M&HB$J]FT2)[7=?;.EL M,G[;6?*];576?I(L0[ /C/EL297VJ;%4QY&Y<94.\=$MF-792B^(B<%@Q#)3 M!ZI#/S0UDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$)FN2:&O+(M,ACK--G7]+ MZ1\2TKBRG>.7A?4W<4+"SB8T(S\''-:];LBY(J?>3+OPHJLXBVU+YL.N))]V MESC3HYG/BXQRDZVKN"3UUI'._9(H5&6Z+WK3G1SB#M/^RJ_.;\MT!<:9,V>L MCR?FZ/*XXY$TJ_LV%B(7BNY//"7&TE=_'S6GG5/^R^RXO1_&K=KS\*R]7;_' M7\_X5/_"/@1('Q*D#P72QQ"DCQ%('[<@?=R!]'$/T@&UL M4$L! A0#% @ R8-A4S]BL"@U!0 5Q4 !@ ("!# @ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A M4[P^<@N.!@ R1D !@ ("!,1D 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ R8-A4_EJ@'F+ @ #@< !@ M ("!+BT 'AL+W=O\O !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ R8-A4W).K,6O! & P !D ("!-4( M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MR8-A4[8,\0I&! ? H !D ("!F4\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A4ZWT20!)!@ P X !D M ("!Z&\ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ R8-A4VU[KI1: P ' < !D ("!\(0 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A M4];H#*G0 P Y0D !D ("!I8\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A4X,&_+Z*! 0PH M !D ("!Q9H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A4QS?G;"L P [@L !D M ("!4*H 'AL+W=O&PO=V]R:W-H965T M2S !X;"]W;W)K&UL4$L! A0# M% @ R8-A4_175D6X P ^PL !D ("!D;< 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A4R_M M9FY? @ D04 !D ("!6,( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R8-A4SAKN(S6 @ XP< !D M ("!LLH 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ R8-A4W%>,6T!! [0\ !D ("! ML-4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ R8-A4\GLC@,L! PA !D ("!U^$ 'AL+W=O&UL4$L! A0#% @ R8-A4_1L:GG6 M @ APD !D ("!D^P 'AL+W=O&PO=V]R:W-H965T : " 17^ !X;"]? 3 M " 1$ 0!;0V]N=&5N=%]4>7!E&UL4$L%!@ Z #H S0\ ' (" 0 $! end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 202 319 1 false 57 0 false 9 false false R1.htm 1001 - Document - Cover Page Sheet http://www.hcahealthcare.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Income Statements Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements Condensed Consolidated Income Statements Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Comprehensive Income Statements Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements Condensed Consolidated Comprehensive Income Statements Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 1008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 1009 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Acquisitions and Dispositions Sheet http://www.hcahealthcare.com/role/AcquisitionsAndDispositions Acquisitions and Dispositions Notes 10 false false R11.htm 1011 - Disclosure - Income Taxes Sheet http://www.hcahealthcare.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 1012 - Disclosure - Earnings Per Share Sheet http://www.hcahealthcare.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 1013 - Disclosure - Investments of Insurance Subsidiaries Sheet http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiaries Investments of Insurance Subsidiaries Notes 13 false false R14.htm 1014 - Disclosure - Financial Instruments Sheet http://www.hcahealthcare.com/role/FinancialInstruments Financial Instruments Notes 14 false false R15.htm 1015 - Disclosure - Assets and Liabilities Measured at Fair Value Sheet http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValue Assets and Liabilities Measured at Fair Value Notes 15 false false R16.htm 1016 - Disclosure - Long-Term Debt Sheet http://www.hcahealthcare.com/role/LongTermDebt Long-Term Debt Notes 16 false false R17.htm 1017 - Disclosure - Contingencies Sheet http://www.hcahealthcare.com/role/Contingencies Contingencies Notes 17 false false R18.htm 1018 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss Sheet http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLoss Share Repurchase Transactions and Other Comprehensive Loss Notes 18 false false R19.htm 1019 - Disclosure - Segment and Geographic Information Sheet http://www.hcahealthcare.com/role/SegmentAndGeographicInformation Segment and Geographic Information Notes 19 false false R20.htm 1020 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPolicies 20 false false R21.htm 1021 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPolicies 21 false false R22.htm 1022 - Disclosure - Earnings Per Share (Tables) Sheet http://www.hcahealthcare.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.hcahealthcare.com/role/EarningsPerShare 22 false false R23.htm 1023 - Disclosure - Investments of Insurance Subsidiaries (Tables) Sheet http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesTables Investments of Insurance Subsidiaries (Tables) Tables http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiaries 23 false false R24.htm 1024 - Disclosure - Financial Instruments (Tables) Sheet http://www.hcahealthcare.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.hcahealthcare.com/role/FinancialInstruments 24 false false R25.htm 1025 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables) Sheet http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables Assets and Liabilities Measured at Fair Value (Tables) Tables http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValue 25 false false R26.htm 1026 - Disclosure - Long-Term Debt (Tables) Sheet http://www.hcahealthcare.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.hcahealthcare.com/role/LongTermDebt 26 false false R27.htm 1027 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss (Tables) Sheet http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossTables Share Repurchase Transactions and Other Comprehensive Loss (Tables) Tables http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLoss 27 false false R28.htm 1028 - Disclosure - Segment and Geographic Information (Tables) Sheet http://www.hcahealthcare.com/role/SegmentAndGeographicInformationTables Segment and Geographic Information (Tables) Tables http://www.hcahealthcare.com/role/SegmentAndGeographicInformation 28 false false R29.htm 1029 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 29 false false R30.htm 1030 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail) Sheet http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail) Details 30 false false R31.htm 1031 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Cost of Uncompensated Care (Detail) Sheet http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfEstimatedCostOfUncompensatedCareDetail Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Cost of Uncompensated Care (Detail) Details 31 false false R32.htm 1032 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail Acquisitions and Dispositions - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 33 false false R34.htm 1034 - Disclosure - Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail) Sheet http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail) Details 34 false false R35.htm 1035 - Disclosure - Investments of Insurance Subsidiaries - Schedule of Investments (Detail) Sheet http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail Investments of Insurance Subsidiaries - Schedule of Investments (Detail) Details 35 false false R36.htm 1036 - Disclosure - Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail) Sheet http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail) Details 36 false false R37.htm 1037 - Disclosure - Investments of Insurance Subsidiaries - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesAdditionalInformationDetail Investments of Insurance Subsidiaries - Additional Information (Detail) Details 37 false false R38.htm 1038 - Disclosure - Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail) Sheet http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail) Details 38 false false R39.htm 1039 - Disclosure - Financial Instruments - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/FinancialInstrumentsAdditionalInformationDetail Financial Instruments - Additional Information (Detail) Details 39 false false R40.htm 1040 - Disclosure - Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail) Sheet http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail) Details 40 false false R41.htm 1041 - Disclosure - Assets and Liabilities Measured at Fair Value - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail Assets and Liabilities Measured at Fair Value - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) Details 41 false false R42.htm 1042 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail Assets and Liabilities Measured at Fair Value - Additional Information (Detail) Details 42 false false R43.htm 1043 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Detail) Sheet http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail Long-Term Debt - Schedule of Long-Term Debt (Detail) Details 43 false false R44.htm 1044 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail) Sheet http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail) Details 44 false false R45.htm 1045 - Disclosure - Long-Term Debt - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail Long-Term Debt - Additional Information (Detail) Details 45 false false R46.htm 1046 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) Sheet http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) Details 46 false false R47.htm 1047 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) Sheet http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossParentheticalDetail Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) Details 47 false false R48.htm 1048 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail Share Repurchase Transactions and Other Comprehensive Loss - Additional Information (Detail) Details 48 false false R49.htm 1049 - Disclosure - Segment and Geographic Information - Additional Information (Detail) Sheet http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail Segment and Geographic Information - Additional Information (Detail) Details 49 false false R50.htm 1050 - Disclosure - Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail) Sheet http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail) Details 50 false false All Reports Book All Reports d232147d10q.htm d232147dex22.htm d232147dex311.htm d232147dex312.htm d232147dex32.htm hca-20210930.xsd hca-20210930_cal.xml hca-20210930_def.xml hca-20210930_lab.xml hca-20210930_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/stpr/2021 http://xbrl.sec.gov/country/2021 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d232147d10q.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 202, "dts": { "calculationLink": { "local": [ "hca-20210930_cal.xml" ] }, "definitionLink": { "local": [ "hca-20210930_def.xml" ] }, "inline": { "local": [ "d232147d10q.htm" ] }, "labelLink": { "local": [ "hca-20210930_lab.xml" ] }, "presentationLink": { "local": [ "hca-20210930_pre.xml" ] }, "schema": { "local": [ "hca-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 420, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://www.hcahealthcare.com/20210930": 2, "http://xbrl.sec.gov/dei/2021": 4, "total": 8 }, "keyCustom": 31, "keyStandard": 288, "memberCustom": 35, "memberStandard": 20, "nsprefix": "hca", "nsuri": "http://www.hcahealthcare.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.hcahealthcare.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Acquisitions and Dispositions", "role": "http://www.hcahealthcare.com/role/AcquisitionsAndDispositions", "shortName": "Acquisitions and Dispositions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Income Taxes", "role": "http://www.hcahealthcare.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Earnings Per Share", "role": "http://www.hcahealthcare.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Investments of Insurance Subsidiaries", "role": "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiaries", "shortName": "Investments of Insurance Subsidiaries", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Financial Instruments", "role": "http://www.hcahealthcare.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Assets and Liabilities Measured at Fair Value", "role": "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValue", "shortName": "Assets and Liabilities Measured at Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Long-Term Debt", "role": "http://www.hcahealthcare.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Contingencies", "role": "http://www.hcahealthcare.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss", "role": "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLoss", "shortName": "Share Repurchase Transactions and Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Segment and Geographic Information", "role": "http://www.hcahealthcare.com/role/SegmentAndGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Income Statements", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "shortName": "Condensed Consolidated Income Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "lang": null, "name": "us-gaap:LaborAndRelatedExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "hca:ScheduleOfRevenuesFromThirdPartyPayersAndUninsuredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)", "role": "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "hca:ScheduleOfRevenuesFromThirdPartyPayersAndUninsuredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.hcahealthcare.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Investments of Insurance Subsidiaries (Tables)", "role": "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesTables", "shortName": "Investments of Insurance Subsidiaries (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Financial Instruments (Tables)", "role": "http://www.hcahealthcare.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)", "role": "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables", "shortName": "Assets and Liabilities Measured at Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Long-Term Debt (Tables)", "role": "http://www.hcahealthcare.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss (Tables)", "role": "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossTables", "shortName": "Share Repurchase Transactions and Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Segment and Geographic Information (Tables)", "role": "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "0", "first": true, "lang": null, "name": "hca:NumberOfOwnedAndOperatedHospitals", "reportCount": 1, "unitRef": "Unit_Hospital", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Comprehensive Income Statements", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements", "shortName": "Condensed Consolidated Comprehensive Income Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail)", "role": "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail", "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Revenues from Third Party Payers, Uninsured and Other Payers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "INF", "lang": null, "name": "hca:RevenueRatio", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "hca:PatientCareCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Cost of Uncompensated Care (Detail)", "role": "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfEstimatedCostOfUncompensatedCareDetail", "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Cost of Uncompensated Care (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "hca:PatientCareCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail", "shortName": "Acquisitions and Dispositions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021_RealEstateAndOtherInvestmentsMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "decimals": "-6", "lang": null, "name": "us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail)", "role": "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail", "shortName": "Earnings Per Share - Schedule of Computations of Basic and Diluted Earnings Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Investments of Insurance Subsidiaries - Schedule of Investments (Detail)", "role": "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail", "shortName": "Investments of Insurance Subsidiaries - Schedule of Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail)", "role": "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail", "shortName": "Investments of Insurance Subsidiaries - Schedule of Maturities of Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "hca:AvailableForSaleSecuritiesExpectedMaturityPeriodOfDebtSecurities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Investments of Insurance Subsidiaries - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesAdditionalInformationDetail", "shortName": "Investments of Insurance Subsidiaries - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "hca:AvailableForSaleSecuritiesExpectedMaturityPeriodOfDebtSecurities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021_DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FixedIncomeInterestRateMemberusgaapTradingActivityByTypeAxis", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail)", "role": "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail", "shortName": "Financial Instruments - Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021_DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FixedIncomeInterestRateMemberusgaapTradingActivityByTypeAxis", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Financial Instruments - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/FinancialInstrumentsAdditionalInformationDetail", "shortName": "Financial Instruments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail)", "role": "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail", "shortName": "Financial Instruments - Effect of Interest Rate Swaps on Results of Operations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Assets and Liabilities Measured at Fair Value - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail)", "role": "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Assets and Liabilities Measured at Fair Value - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail", "shortName": "Assets and Liabilities Measured at Fair Value - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Detail)", "role": "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "hca:LongTermDebtAverageTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail)", "role": "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail", "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "hca:LongTermDebtAverageTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Long-Term Debt - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail", "shortName": "Long-Term Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn06_30_2021_AssetBasedRevolvingCreditFacilityMemberusgaapCreditFacilityAxis", "decimals": "-6", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail)", "role": "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail", "shortName": "Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "hca:OtherComprehensiveIncomeUnrealizedHoldingLossOnSecuritiesArisingDuringPeriodTaxBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail)", "role": "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossParentheticalDetail", "shortName": "Share Repurchase Transactions and Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "hca:OtherComprehensiveIncomeUnrealizedHoldingLossOnSecuritiesArisingDuringPeriodTaxBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Share Repurchase Transactions and Other Comprehensive Loss - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail", "shortName": "Share Repurchase Transactions and Other Comprehensive Loss - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "2", "lang": null, "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Hospital", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Segment and Geographic Information - Additional Information (Detail)", "role": "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "shortName": "Segment and Geographic Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Hospital", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNoncurrentNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNoncurrentNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail)", "role": "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail", "shortName": "Segment and Geographic Information - Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization and Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "-6", "lang": null, "name": "hca:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-6", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P07_01_2021To09_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": "-6", "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Basis of Presentation and Significant Accounting Policies", "role": "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d232147d10q.htm", "contextRef": "P01_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 57, "tag": { "country_TN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TUNISIA", "terseLabel": "Tennessee [Member]" } } }, "localname": "TN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hca_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesDepreciationAndAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income before depreciation and amortization, interest expense, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs, income taxes and net income attributable to non controlling interests.", "label": "Adjusted Income Loss From Continuing Operations Before Income Taxes Depreciation And Amortization", "terseLabel": "Adjusted segment EBITDA" } } }, "localname": "AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesDepreciationAndAmortization", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hca_AmericanGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American group.", "label": "American Group [Member]", "terseLabel": "American Group [Member]" } } }, "localname": "AmericanGroupMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "domainItemType" }, "hca_AssetBasedRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset based revolving credit facility.", "label": "Asset Based Revolving Credit Facility [Member]", "terseLabel": "Asset Based Revolving Credit Facility [Member]" } } }, "localname": "AssetBasedRevolvingCreditFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_AvailableForSaleSecuritiesAverageScheduledMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available-for-sale securities average scheduled maturity period.", "label": "Available For Sale Securities Average Scheduled Maturity Period", "terseLabel": "Available for sale securities average scheduled maturity" } } }, "localname": "AvailableForSaleSecuritiesAverageScheduledMaturityPeriod", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hca_AvailableForSaleSecuritiesExpectedMaturityPeriodOfDebtSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities expected maturity of debt securities (in years).", "label": "Available For Sale Securities Expected Maturity Period Of Debt Securities", "terseLabel": "Available for sale securities expected maturity of debt securities" } } }, "localname": "AvailableForSaleSecuritiesExpectedMaturityPeriodOfDebtSecurities", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hca_BusinessAcquisitionsAndDispositionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisitions and dispositions.", "label": "Business Acquisitions And Dispositions [Line Items]" } } }, "localname": "BusinessAcquisitionsAndDispositionsLineItems", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hca_CharityCare": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charity care.", "label": "Charity Care", "terseLabel": "Charity care amount" } } }, "localname": "CharityCare", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hca_CostToChargesRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost-to-charges ratio.", "label": "Cost To Charges Ratio", "terseLabel": "Cost-to-charges ratio (patient care costs as percentage of gross patient charges)", "verboseLabel": "Multiply by the cost-to-charges ratio" } } }, "localname": "CostToChargesRatio", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfEstimatedCostOfUncompensatedCareDetail" ], "xbrltype": "percentItemType" }, "hca_DerivativeCreditRiskRelatedContingentFeaturesEstimatedTerminationValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative, credit risk related contingent features estimated termination value.", "label": "Derivative Credit Risk Related Contingent Features Estimated Termination Value", "terseLabel": "Estimated termination value" } } }, "localname": "DerivativeCreditRiskRelatedContingentFeaturesEstimatedTerminationValue", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hca_DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument maturity date December 2021.", "label": "Derivative Instrument Maturity Date December Two Thousand And Twenty One [Member]", "terseLabel": "Maturity Date, 2021 [Member]" } } }, "localname": "DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyOneMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "domainItemType" }, "hca_DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument maturity date December 2022.", "label": "Derivative Instrument Maturity Date December Two Thousand And Twenty Two [Member]", "terseLabel": "Maturity Date, 2022 [Member]" } } }, "localname": "DerivativeInstrumentMaturityDateDecemberTwoThousandAndTwentyTwoMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "domainItemType" }, "hca_DerivativeMaturityMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative \u200bmaturity \u200bmonth\u200b and \u200byear.", "label": "Derivative Maturity Month And Year", "verboseLabel": "Maturity Date" } } }, "localname": "DerivativeMaturityMonthAndYear", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "gYearMonthItemType" }, "hca_EstimatedCostOfCharityCare": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated cost of charity care.", "label": "Estimated Cost Of Charity Care", "terseLabel": "Estimated costs of charity care" } } }, "localname": "EstimatedCostOfCharityCare", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hca_EstimatedCostOfUncompensatedCare": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated cost of uncompensated care.", "label": "Estimated Cost Of Uncompensated Care", "terseLabel": "Estimated cost of total uncompensated care" } } }, "localname": "EstimatedCostOfUncompensatedCare", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfEstimatedCostOfUncompensatedCareDetail" ], "xbrltype": "monetaryItemType" }, "hca_GovernmentReliefFundAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Relief Fund [Axis]" } } }, "localname": "GovernmentReliefFundAxis", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hca_GovernmentReliefFundDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Relief Fund [Domain]" } } }, "localname": "GovernmentReliefFundDomain", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_GovernmentStimulusIncomeReversal": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 8.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Government stimulus income reversal.", "label": "Government Stimulus Income Reversal", "negatedLabel": "Government stimulus income reversal" } } }, "localname": "GovernmentStimulusIncomeReversal", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "hca_HomeHealthAndHospiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Home health and hospice.", "label": "Home Health and Hospice [Member]" } } }, "localname": "HomeHealthAndHospiceMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_HospitalAndOtherNonhospitalHealthCareEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hospital and other nonhospital health care entities.", "label": "Hospital and other nonhospital health care entities [Member]" } } }, "localname": "HospitalAndOtherNonhospitalHealthCareEntitiesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_HospitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hospital [Member]", "label": "Hospital [Member]", "terseLabel": "Hospitals [Member]" } } }, "localname": "HospitalMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_IncomeTaxesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income taxes and other liabilities.", "label": "Income Taxes And Other Liabilities", "terseLabel": "Income taxes and other liabilities" } } }, "localname": "IncomeTaxesAndOtherLiabilities", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hca_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International.", "label": "International [Member]", "terseLabel": "International (managed care and insurers) [Member]" } } }, "localname": "InternationalMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "hca_LongTermDebtAverageTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt average term.", "label": "Long Term Debt Average Term", "terseLabel": "Total debt average term" } } }, "localname": "LongTermDebtAverageTerm", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "durationItemType" }, "hca_ManagedCareAndOtherInsurersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed care and other insurers.", "label": "Managed Care And Other Insurers [Member]", "terseLabel": "Managed Care and Insurers [Member]" } } }, "localname": "ManagedCareAndOtherInsurersMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "hca_ManagedMedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed Medicaid.", "label": "Managed Medicaid [Member]", "terseLabel": "Managed Medicaid [Member]" } } }, "localname": "ManagedMedicaidMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "hca_ManagedMedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed Medicare.", "label": "Managed Medicare [Member]", "terseLabel": "Managed Medicare [Member]" } } }, "localname": "ManagedMedicareMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "hca_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid.", "label": "Medicaid [Member]", "terseLabel": "Medicaid [Member]" } } }, "localname": "MedicaidMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "hca_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare.", "label": "Medicare [Member]", "terseLabel": "Medicare [Member]" } } }, "localname": "MedicareMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "hca_MoneyMarketFundsAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Money market funds and other.", "label": "Money Market Funds And Other [Member]", "terseLabel": "Money Market Funds and Other [Member]" } } }, "localname": "MoneyMarketFundsAndOtherMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "hca_NationalGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "National group.", "label": "National Group [Member]", "terseLabel": "National Group [Member]" } } }, "localname": "NationalGroupMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "domainItemType" }, "hca_NorthernGeorgiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northern Georgia.", "label": "Northern Georgia [Member]" } } }, "localname": "NorthernGeorgiaMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_NumberOfFacilitiesLocations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of facilities locations.", "label": "Number Of Facilities Locations", "terseLabel": "Number of facilities locations" } } }, "localname": "NumberOfFacilitiesLocations", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "hca_NumberOfFreestandingEndoscopyCenters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of freestanding endoscopy centers", "label": "Number Of Freestanding Endoscopy Centers", "terseLabel": "Number of freestanding endoscopy centers" } } }, "localname": "NumberOfFreestandingEndoscopyCenters", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "hca_NumberOfFreestandingSurgeryCenters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of freestanding surgery centers.", "label": "Number Of Freestanding Surgery Centers", "terseLabel": "Number of freestanding surgery centers" } } }, "localname": "NumberOfFreestandingSurgeryCenters", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "hca_NumberOfHospitalsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of hospitals acquired.", "label": "Number Of Hospitals Acquired", "terseLabel": "Number of hospitals purchased" } } }, "localname": "NumberOfHospitalsAcquired", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hca_NumberOfHospitalsSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of hospitals sold.", "label": "Number Of Hospitals Sold", "terseLabel": "Number of hospitals sold" } } }, "localname": "NumberOfHospitalsSold", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hca_NumberOfOwnedAndOperatedHospitals": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of owned and operated hospitals.", "label": "Number Of Owned And Operated Hospitals", "terseLabel": "Number of owned and operated hospitals" } } }, "localname": "NumberOfOwnedAndOperatedHospitals", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "hca_OtherAccruedExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other accrued expenses.", "label": "Other Accrued Expenses [Member]" } } }, "localname": "OtherAccruedExpensesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "hca_OtherComprehensiveIncomeUnrealizedHoldingLossOnSecuritiesArisingDuringPeriodTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other comprehensive income unrealized holding loss on securities arising during period tax benefit.", "label": "Other Comprehensive Income Unrealized Holding Loss On Securities Arising During Period Tax Benefit", "verboseLabel": "Unrealized gains (losses) on available-for-sale securities, tax benefit" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingLossOnSecuritiesArisingDuringPeriodTaxBenefit", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "hca_OtherComprehensiveLossForeignCurrencyTranslationAdjustmentTaxExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other comprehensive loss foreign currency translation adjustment tax expense.", "label": "Other Comprehensive Loss Foreign Currency Translation Adjustment Tax Expense", "verboseLabel": "Foreign currency translation adjustments, income tax benefit" } } }, "localname": "OtherComprehensiveLossForeignCurrencyTranslationAdjustmentTaxExpense", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "hca_OtherNonhospitalHealthCareEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other nonhospital health care entities.", "label": "Other Nonhospital Health Care Entities [Member]" } } }, "localname": "OtherNonhospitalHealthCareEntitiesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_OtherRevenuesRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other revenues ratio.", "label": "Other Revenues Ratio", "terseLabel": "Other, Ratio" } } }, "localname": "OtherRevenuesRatio", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "percentItemType" }, "hca_OtherSeniorSecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other senior secured debt.", "label": "Other Senior Secured Debt [Member]", "terseLabel": "Other Senior Secured Debt [Member]" } } }, "localname": "OtherSeniorSecuredDebtMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "domainItemType" }, "hca_OutOfNetworkServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Out of network services.", "label": "Out Of Network Services [Member]", "terseLabel": "Out of Network Services [Member]" } } }, "localname": "OutOfNetworkServicesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_PatientCareCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Patient care costs.", "label": "Patient Care Costs", "terseLabel": "Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)" } } }, "localname": "PatientCareCosts", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfEstimatedCostOfUncompensatedCareDetail" ], "xbrltype": "monetaryItemType" }, "hca_PatientsTreatedAtHospitalsForNonelectiveCareIncomeLessThanOrEqualToSpecifiedPercentageOfFederalPovertyLevelEligibleForCharityCare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patients treated at hospitals for nonelective care income less than or equal to specified percentage of the federal poverty level eligible for charity care.", "label": "Patients Treated At Hospitals For Nonelective Care Income Less Than Or Equal To Specified Percentage Of Federal Poverty Level Eligible For Charity Care", "terseLabel": "Percentage of income of federal poverty level eligible for charity care" } } }, "localname": "PatientsTreatedAtHospitalsForNonelectiveCareIncomeLessThanOrEqualToSpecifiedPercentageOfFederalPovertyLevelEligibleForCharityCare", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hca_ProfessionalLiabilityRisks": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Professional liability risks.", "label": "Professional Liability Risks", "terseLabel": "Professional liability risks" } } }, "localname": "ProfessionalLiabilityRisks", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hca_RealEstateAndOtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate And Other Investments [Member]", "label": "Real Estate And Other Investments [Member]", "terseLabel": "Real Estate and Other Investments [Member]" } } }, "localname": "RealEstateAndOtherInvestmentsMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_RegulatoryAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory assets.", "label": "Regulatory Assets [Abstract]" } } }, "localname": "RegulatoryAssetsAbstract", "nsuri": "http://www.hcahealthcare.com/20210930", "xbrltype": "stringItemType" }, "hca_ReorganizationGroupUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reorganization group units.", "label": "Reorganization Group Units [Member]", "terseLabel": "Reorganization Group [Member]" } } }, "localname": "ReorganizationGroupUnitsMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_RevenueRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue ratio.", "label": "Revenue Ratio", "verboseLabel": "Revenues ratio from third party payers" } } }, "localname": "RevenueRatio", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "percentItemType" }, "hca_RevenuesFromThirdPartyPayers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenues from third party payers.", "label": "Revenues From Third Party Payers", "terseLabel": "Revenues from third party payers" } } }, "localname": "RevenuesFromThirdPartyPayers", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "monetaryItemType" }, "hca_RevenuesFromThirdPartyPayersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues From Third Party Payers [Line Items]", "label": "Revenues From Third Party Payers [Line Items]", "terseLabel": "Revenues From Third Party Payers [Line Items]" } } }, "localname": "RevenuesFromThirdPartyPayersLineItems", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "stringItemType" }, "hca_RevenuesFromThirdPartyPayersRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues from third party payers ratio.", "label": "Revenues From Third Party Payers Ratio", "terseLabel": "Revenues from third party payers, Ratio" } } }, "localname": "RevenuesFromThirdPartyPayersRatio", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "percentItemType" }, "hca_RevenuesFromThirdPartyPayersTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues from third party payers [Table]", "label": "Revenues From Third Party Payers [Table]", "terseLabel": "Revenues From Third Party Payers [Table]" } } }, "localname": "RevenuesFromThirdPartyPayersTable", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "stringItemType" }, "hca_ScheduleOfEstimatedCostsOfUncompensatedCareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of estimated costs of uncompensated care.", "label": "Schedule Of Estimated Costs Of Uncompensated Care [Table Text Block]", "terseLabel": "Schedule of Estimated Cost of Uncompensated Care" } } }, "localname": "ScheduleOfEstimatedCostsOfUncompensatedCareTableTextBlock", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hca_ScheduleOfRevenuesFromThirdPartyPayersAndUninsuredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of revenues from third party payers and uninsured.", "label": "Schedule Of Revenues From Third Party Payers And Uninsured [Table Text Block]", "terseLabel": "Schedule of Revenues from Third Party Payers, Uninsured and Other Payers" } } }, "localname": "ScheduleOfRevenuesFromThirdPartyPayersAndUninsuredTableTextBlock", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hca_SeniorSecuredAssetBasedRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured asset-based revolving credit facility.", "label": "Senior Secured Asset Based Revolving Credit Facility [Member]", "terseLabel": "Senior Secured Asset-Based Revolving Credit Facility [Member]" } } }, "localname": "SeniorSecuredAssetBasedRevolvingCreditFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured notes due 2031.", "label": "Senior Secured Notes Due 2031 [Member]", "terseLabel": "Senior Secured Notes Due 2031 [Member]" } } }, "localname": "SeniorSecuredNotesDue2031Member", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredNotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured notes due 2051.", "label": "Senior Secured Notes Due 2051 [Member]", "terseLabel": "Senior Secured Notes Due 2051 [Member]" } } }, "localname": "SeniorSecuredNotesDue2051Member", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured notes.", "label": "Senior Secured Notes [Member]", "terseLabel": "Senior Secured Notes [Member]" } } }, "localname": "SeniorSecuredNotesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Secured Revolving Credit Facility [Member]", "terseLabel": "Senior Secured Revolving Credit Facility [Member]" } } }, "localname": "SeniorSecuredRevolvingCreditFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredTermLoanASevenFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loan a seven facility.", "label": "Senior Secured Term Loan A Seven Facility [Member]", "terseLabel": "Senior Secured Term Loan A-7 Facility [Member]" } } }, "localname": "SeniorSecuredTermLoanASevenFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredTermLoanASixFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loan a six facility.", "label": "Senior Secured Term Loan A Six Facility [Member]", "terseLabel": "Senior Secured Term Loan A-6 Facility [Member]" } } }, "localname": "SeniorSecuredTermLoanASixFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredTermLoanBFourteenFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loan b fourteen facility.", "label": "Senior Secured Term Loan B Fourteen Facility [Member]", "terseLabel": "Senior Secured Term Loan B-14 Facility [Member]" } } }, "localname": "SeniorSecuredTermLoanBFourteenFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredTermLoanBThirteenFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loan b thirteen facility.", "label": "Senior Secured Term Loan B Thirteen Facility [Member]", "terseLabel": "Senior Secured Term Loan B-13 Facility [Member]" } } }, "localname": "SeniorSecuredTermLoanBThirteenFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredTermLoanBTwelveFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loan b twelve facility.", "label": "Senior Secured Term Loan B Twelve Facility [Member]", "terseLabel": "Senior Secured Term Loan B-12 Facility [Member]" } } }, "localname": "SeniorSecuredTermLoanBTwelveFacilityMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorSecuredTermLoanFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loan facilities.", "label": "Senior Secured Term Loan Facilities [Member]", "terseLabel": "Senior Secured Term Loan Facilities [Member]" } } }, "localname": "SeniorSecuredTermLoanFacilitiesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "domainItemType" }, "hca_SeniorUnsecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior unsecured notes.", "label": "Senior Unsecured Notes [Member]", "terseLabel": "Senior Unsecured Notes [Member]" } } }, "localname": "SeniorUnsecuredNotesMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "domainItemType" }, "hca_SouthernGeorgiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Southern Georgia.", "label": "Southern Georgia [Member]" } } }, "localname": "SouthernGeorgiaMember", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hca_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hca_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hca_UncompensatedCare": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Uncompensated care.", "label": "Uncompensated Care", "terseLabel": "Total uncompensated care" } } }, "localname": "UncompensatedCare", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfEstimatedCostOfUncompensatedCareDetail" ], "xbrltype": "monetaryItemType" }, "hca_UnrecognizedTaxBenefitsIncludingInterestAccruedNetOfDeferredTaxAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits including interest accrued net of deferred tax assets.", "label": "Unrecognized Tax Benefits Including Interest Accrued Net of Deferred Tax Assets", "terseLabel": "Liability for unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsIncludingInterestAccruedNetOfDeferredTaxAssets", "nsuri": "http://www.hcahealthcare.com/20210930", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r276", "r303", "r350", "r352", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r571", "r574", "r615", "r616" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r190", "r334", "r335", "r517", "r570", "r572" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r190", "r334", "r335", "r517", "r570", "r572" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r276", "r303", "r338", "r350", "r352", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r571", "r574", "r615", "r616" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r276", "r303", "r338", "r350", "r352", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r571", "r574", "r615", "r616" ], "lang": { "en-us": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r191", "r192", "r334", "r336", "r573", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r191", "r192", "r334", "r336", "r573", "r604", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r196", "r481" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GEORGIA", "terseLabel": "Georgia [Member]" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41", "r484" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r15", "r29", "r197", "r198" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r18", "r19", "r44" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued salaries" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r248" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax", "periodEndLabel": "Unrealized gains on available-for-sale securities, ending balances", "periodStartLabel": "Unrealized gains on available-for-sale securities, beginning balances" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax": { "auth_ref": [ "r57", "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax", "periodEndLabel": "Change in fair value of derivative instruments, ending balances", "periodStartLabel": "Change in fair value of derivative instruments, beginning balances" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r60", "r65", "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "periodEndLabel": "Defined benefit plans, ending balances", "periodStartLabel": "Defined benefit plans, beginning balances" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56", "r62", "r64", "r65", "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "periodEndLabel": "Foreign currency translation adjustments, ending balances", "periodStartLabel": "Foreign currency translation adjustments, beginning balances" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r62", "r64", "r65", "r556", "r582", "r586" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax, ending balances", "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax, beginning balances", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r61", "r65", "r74", "r75", "r76", "r124", "r125", "r126", "r406", "r577", "r578", "r635" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r30" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r124", "r125", "r126", "r359", "r360", "r361", "r442" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r127", "r128", "r129", "r130", "r139", "r200", "r201", "r227", "r228", "r229", "r230", "r231", "r232", "r261", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r376", "r377", "r378", "r379", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r480", "r518", "r519", "r520", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r631", "r632", "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r88", "r110", "r289", "r475" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "presentationGuidance": "Amortization of debt issuance costs and discounts" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r119", "r172", "r179", "r186", "r226", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r401", "r407", "r454", "r482", "r484", "r524", "r554" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r16", "r17", "r52", "r119", "r226", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r401", "r407", "r454", "r482", "r484" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r203", "r238" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost, Total" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r205" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Amounts, Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Amounts, Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available-for-sale Securities, Current", "negatedLabel": "Amounts classified as current assets", "negatedTerseLabel": "Less amounts classified as current assets" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r210" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost", "terseLabel": "Due after five years through ten years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r206", "r210", "r546" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 7.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Due after five years through ten years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r209" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "terseLabel": "Due after one year through five years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r206", "r209", "r545" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 6.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Due after one year through five years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r211" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost", "terseLabel": "Due after ten years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r206", "r211", "r547" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 8.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value", "terseLabel": "Due after ten years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r208" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "terseLabel": "Due in one year or less, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r206", "r208", "r544" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Due in one year or less, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r212", "r548" ], "calculation": { "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value", "totalLabel": "Fair Value, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfMaturitiesOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r202", "r204", "r238", "r529" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.", "label": "Available-for-sale Securities, Noncurrent", "positiveLabel": "Investments of insurance subsidiaries, noncurrent", "terseLabel": "Investment carrying value", "verboseLabel": "Investments of insurance subsidiaries" } } }, "localname": "AvailableForSaleSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r417", "r420" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r349", "r351", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "terseLabel": "Fair value of the noncontrolling interest in the acquiree at the acquisition date" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r13", "r36", "r112" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r106", "r112", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r106", "r463" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r116", "r119", "r142", "r143", "r144", "r146", "r148", "r156", "r157", "r158", "r226", "r262", "r266", "r267", "r268", "r271", "r272", "r301", "r302", "r305", "r309", "r454", "r622" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r254", "r255", "r256", "r257", "r605" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared, per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r124", "r125", "r442" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r28", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r28" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "verboseLabel": "Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 313,502,400 shares \u2014 2021 and 339,425,600 shares \u2014 2020" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r86", "r536", "r566" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to HCA Healthcare, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r72", "r85", "r399", "r400", "r411", "r535", "r565" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 14.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r72", "r84", "r398", "r411", "r534", "r564" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income (loss)", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]", "terseLabel": "Corporate and Other [Member]" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r90" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses including equity in earnings of affiliates" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r23", "r24", "r25", "r118", "r122", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r294", "r295", "r296", "r297", "r476", "r525", "r526", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r25", "r291", "r526", "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Carrying amounts of long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r273", "r294", "r295", "r474", "r476", "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r46", "r293", "r474", "r476" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46", "r274" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated interest" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47", "r118", "r122", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r294", "r295", "r296", "r297", "r476" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r47", "r118", "r122", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r317", "r318", "r319", "r320", "r473", "r474", "r476", "r477", "r552" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r40", "r280", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Net debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r40", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r111" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r110", "r167" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 9.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail", "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r55", "r418", "r419", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail", "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r433", "r445" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r415", "r418", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r415", "r418", "r423", "r425", "r426", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail", "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail", "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Estimated amount reclassified from other comprehensive income and reduce interest expense" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r53", "r54", "r55", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r7", "r8", "r9" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "terseLabel": "Pretax gain (loss) before tax" } } }, "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale [Member]" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Per share data:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r87", "r131", "r132", "r133", "r134", "r135", "r140", "r142", "r146", "r147", "r148", "r152", "r153", "r443", "r444", "r537", "r567" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share", "verboseLabel": "Basic earnings" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r87", "r131", "r132", "r133", "r134", "r135", "r142", "r146", "r147", "r148", "r152", "r153", "r443", "r444", "r537", "r567" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share", "verboseLabel": "Diluted earnings" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r463" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r120", "r365", "r382" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "terseLabel": "Provision for tax benefits related to settlement of employee awards" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r74", "r75", "r76", "r124", "r125", "r126", "r128", "r136", "r138", "r155", "r230", "r316", "r321", "r359", "r360", "r361", "r378", "r379", "r442", "r464", "r465", "r466", "r467", "r468", "r470", "r577", "r578", "r579", "r635" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r37", "r173", "r224" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Investments in and advances to affiliates" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r446", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r282", "r294", "r295", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r348", "r447", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Assets and Liabilities Measured at Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r282", "r339", "r340", "r345", "r348", "r447", "r489" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r282", "r294", "r295", "r339", "r340", "r345", "r348", "r447", "r490" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r282", "r294", "r295", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r348", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r448", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FederalHomeLoanBanksAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal Home Loan Banks [Abstract]" } } }, "localname": "FederalHomeLoanBanksAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r213", "r214", "r221", "r222", "r223", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r290", "r314", "r433", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r622", "r623", "r624", "r625", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FixedIncomeInterestRateMember": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Trading in a derivative or nonderivative instrument that provides a return in the form of fixed periodic payments of interest and eventual return of principal at maturity.", "label": "Fixed Income Interest Rate [Member]", "terseLabel": "Pay-Fixed Interest Rate Swaps [Member]" } } }, "localname": "FixedIncomeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r110", "r246", "r250" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 12.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 }, "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Losses (gains) on sales of facilities", "negatedTerseLabel": "Losses (gains) on sales of facilities" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r110", "r298", "r299" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 13.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 }, "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Losses on retirement of debt", "terseLabel": "Gain (loss) on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r243", "r244", "r484", "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r80", "r172", "r178", "r182", "r185", "r188", "r521", "r531", "r541", "r568" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes", "verboseLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r81", "r110", "r169", "r224", "r530", "r561" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 10.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Equity in earnings of affiliates", "negatedTerseLabel": "Equity in earnings of affiliates" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r369", "r371", "r373", "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r120", "r366", "r372", "r374", "r380", "r383", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r137", "r138", "r170", "r364", "r381", "r385", "r569" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r109" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r109" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Contract liabilities-deferred revenues" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets": { "auth_ref": [ "r109" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in inventory, and assets classified as other.", "label": "Increase (Decrease) in Inventories and Other Operating Assets", "negatedLabel": "Inventories and other assets" } } }, "localname": "IncreaseDecreaseInInventoriesAndOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Increase (decrease) in cash from operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill and other intangible assets" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r78", "r166", "r472", "r475", "r540" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 11.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedLabel": "Interest rate swaps" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r104", "r107", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest payments" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeDerivativeAtFairValueNet": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all interest rate derivatives designated as cash flow hedging instruments.", "label": "Interest Rate Cash Flow Hedge Derivative at Fair Value, Net", "terseLabel": "Fair Value" } } }, "localname": "InterestRateCashFlowHedgeDerivativeAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swaps [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r14", "r50", "r484" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of Maturities of Investments" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r220", "r522", "r549", "r603", "r629" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments of Insurance Subsidiaries" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiaries" ], "xbrltype": "textBlockItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Labor and Related Expense", "terseLabel": "Salaries and benefits" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r119", "r226", "r454", "r484", "r528", "r559" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r119", "r226", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r402", "r407", "r408", "r454", "r482", "r483", "r484" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r42", "r118" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r42", "r118" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r25", "r281", "r292", "r294", "r295", "r526", "r555" ], "calculation": { "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt (average life of 9.5 years, rates averaging 4.9%)" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less amounts due within one year", "verboseLabel": "Long-term debt due within one year" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Estimated fair value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Long-term debt, less debt issuance costs and discounts of $253 and $236", "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r47", "r258", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "verboseLabel": "Long-term line of credit" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r47", "r260" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail", "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Total debt average rate" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtParentheticalDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r12", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions and Dispositions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositions" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r49", "r119", "r226", "r262", "r266", "r267", "r268", "r271", "r272", "r454", "r527", "r558" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r106", "r108", "r111" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r11", "r68", "r71", "r76", "r82", "r111", "r119", "r127", "r131", "r132", "r133", "r134", "r137", "r138", "r145", "r172", "r178", "r182", "r185", "r188", "r226", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r444", "r454", "r532", "r562" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to HCA Healthcare, Inc.", "verboseLabel": "Net income attributable to HCA Healthcare, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r71", "r76", "r137", "r138", "r404", "r410" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 15.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r124", "r125", "r126", "r321", "r396" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Equity Attributable to Noncontrolling Interests [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of geographically organized groups" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r479" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Right-of-use operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r478" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 29.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18", "r19", "r20", "r44" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r51", "r484" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r74", "r75", "r83", "r225", "r464", "r469", "r470", "r533", "r563" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Tax", "totalLabel": "Other comprehensive income (loss) before taxes" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive income (loss) before taxes:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r57" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "totalLabel": "Total change in fair value of derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r56", "r62" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 11.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r69", "r72", "r74", "r75", "r77", "r83", "r316", "r464", "r469", "r470", "r533", "r563" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r60", "r62", "r346", "r348" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 8.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "negatedTotalLabel": "Total defined benefit plans" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r59", "r62", "r346" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 9.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Defined benefit plans" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax": { "auth_ref": [ "r62", "r66", "r67", "r422" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 7.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax", "negatedLabel": "Interest costs included in interest expense" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r62", "r66", "r67", "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedLabel": "Change in fair value of derivatives instruments, (income) expense reclassified into operations from other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax", "terseLabel": "Change in fair value of derivative instruments, Expense reclassified into operations from other comprehensive income, Income tax benefits" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r62", "r66", "r67", "r346" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 10.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "negatedLabel": "Pension costs included in salaries and benefits" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r62", "r66", "r67", "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "verboseLabel": "Defined benefit plans, (income) expense reclassified into operations from other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r63", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax", "terseLabel": "Defined benefit plans, Expense reclassified into operations from other comprehensive income, Income tax benefits" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r63", "r74", "r83", "r364", "r384", "r386", "r464", "r467", "r470", "r533", "r563" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "verboseLabel": "Income taxes (benefits) related to other comprehensive income items" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r57", "r62", "r431" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Change in fair value of derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r57", "r62", "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Change in fair value of derivative instruments", "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "negatedLabel": "Amount of Loss Recognized in OCI on Derivatives, Net of Tax", "verboseLabel": "Change in fair value of derivative instruments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail", "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r58", "r62", "r219" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 12.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax", "terseLabel": "Unrealized gains (losses) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r58", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized gains (losses) on available-for-sale securities", "verboseLabel": "Unrealized gains (losses) on available-for-sale securities, net of income taxes" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r91" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r111" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedLabel": "Change in investments" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r94", "r97" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r100" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r102" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r100" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Payment of dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "terseLabel": "Payment to acquire venture providing post acute care services" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r95", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Aggregate purchase price" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r95" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "negatedLabel": "Acquisition of hospitals and health care entities" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r96" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r103" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedLabel": "Distributions to noncontrolling interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r93" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Sales of hospitals and health care entities", "verboseLabel": "Proceeds from sale of business" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r98" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "verboseLabel": "Issuances of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r99", "r103" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net change in revolving credit facilities" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r11", "r68", "r71", "r76", "r105", "r119", "r127", "r137", "r138", "r172", "r178", "r182", "r185", "r188", "r226", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r398", "r403", "r405", "r410", "r411", "r444", "r454", "r541" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements": { "order": 13.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedComprehensiveIncomeStatements", "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r247" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r21", "r22", "r249", "r484", "r550", "r560" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r21", "r247" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r65", "r74", "r75", "r77", "r464", "r468", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "verboseLabel": "Expense (income) reclassified into operations from other comprehensive income, Total" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossComponentsOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income into Operations [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsEffectOfInterestRateSwapsOnResultsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r101" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r321", "r362", "r484", "r557", "r581", "r586" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained (deficit) earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r124", "r125", "r126", "r128", "r136", "r138", "r230", "r359", "r360", "r361", "r378", "r379", "r442", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Deficit) [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r163", "r164", "r177", "r183", "r184", "r190", "r191", "r194", "r333", "r334", "r517" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 14.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Revenues from third party payers" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfRevenuesFromThirdPartyPayersUninsuredAndOtherPayersDetail", "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r115", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation", "terseLabel": "Performance obligations for inpatient/ outpatient services satisfied period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r79", "r119", "r163", "r164", "r177", "r183", "r184", "r190", "r191", "r194", "r226", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r454", "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r65", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Components of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r207", "r212", "r215", "r216", "r217", "r218", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Effect of Interest Rate on Results of Operations" } } }, "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computations of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of Interest Rate Swap Agreements Designated as Cash Flow Hedges" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r172", "r175", "r181", "r245" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r172", "r175", "r181", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Geographic Distributions of Revenues, Equity in Earnings of Affiliates, Adjusted Segment EBITDA, Depreciation and Amortization, Assets and Goodwill and other intangible assets." } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r25", "r526", "r555" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "terseLabel": "Senior secured debt" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtOther": { "auth_ref": [ "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of collateralized debt obligations classified as other.", "label": "Secured Debt, Other", "terseLabel": "Other senior secured debt" } } }, "localname": "SecuredDebtOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r159", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r188", "r194", "r252", "r253", "r570" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r159", "r161", "r162", "r172", "r176", "r182", "r186", "r187", "r188", "r189", "r190", "r193", "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r109" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r10", "r159", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r188", "r194", "r245", "r251", "r252", "r253", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail", "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationScheduleOfGeographicDistributionsOfRevenuesEquityInEarningsOfAffiliatesAdjustedSegmentEbitdaDepreciationAndAmortizationAndAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r26", "r27", "r28", "r116", "r119", "r142", "r143", "r144", "r146", "r148", "r156", "r157", "r158", "r226", "r262", "r266", "r267", "r268", "r271", "r272", "r301", "r302", "r305", "r309", "r316", "r454", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r48", "r74", "r75", "r76", "r124", "r125", "r126", "r128", "r136", "r138", "r155", "r230", "r316", "r321", "r359", "r360", "r361", "r378", "r379", "r442", "r464", "r465", "r466", "r467", "r468", "r470", "r577", "r578", "r579", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/SegmentAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r124", "r125", "r126", "r155", "r517" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r353", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Granted, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based benefit plans" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r27", "r28", "r316", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based benefit plans, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Share repurchase program authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r27", "r28", "r316", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of common stock, shares", "verboseLabel": "Repurchase of common stock, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r27", "r28", "r316", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r28", "r33", "r34", "r119", "r199", "r226", "r454", "r484" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Stockholders' (deficit) equity attributable to HCA Healthcare, Inc." } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r75", "r119", "r124", "r125", "r126", "r128", "r136", "r226", "r230", "r321", "r359", "r360", "r361", "r378", "r379", "r396", "r397", "r409", "r442", "r454", "r464", "r465", "r470", "r578", "r579", "r635" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balances", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r117", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r315", "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Share Repurchases Transactions and Other Comprehensive Loss" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r471", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r471", "r485" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SuppliesExpense": { "auth_ref": [ "r539" ], "calculation": { "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense associated with supplies that were used during the current accounting period.", "label": "Supplies Expense", "terseLabel": "Supplies" } } }, "localname": "SuppliesExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradingActivityByTypeAxis": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by type of trading activity.", "label": "Trading Activity [Axis]", "terseLabel": "Trading Activity [Axis]" } } }, "localname": "TradingActivityByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeDomain": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).", "label": "Trading Activity, by Type [Domain]", "terseLabel": "Trading Activity, by Type [Domain]" } } }, "localname": "TradingActivityByTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/FinancialInstrumentsScheduleOfInterestRateSwapAgreementsDesignatedAsCashFlowHedgesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r213", "r214", "r221", "r222", "r223", "r290", "r314", "r433", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r622", "r623", "r624", "r625", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/AssetsAndLiabilitiesMeasuredAtFairValueScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail", "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "verboseLabel": "Repurchase price of common stock, per share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/ShareRepurchaseTransactionsAndOtherComprehensiveLossAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r127", "r128", "r129", "r130", "r139", "r200", "r201", "r227", "r228", "r229", "r230", "r231", "r232", "r261", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r376", "r377", "r378", "r379", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r480", "r518", "r519", "r520", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r631", "r632", "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r339", "r587" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]", "terseLabel": "States and Municipalities [Member]" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/InvestmentsOfInsuranceSubsidiariesScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense accrued for an underpayment of income taxes.", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "terseLabel": "Unrecognized tax benefits, accrued interest" } } }, "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r25", "r526", "r555" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Senior unsecured notes" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtScheduleOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r148" ], "calculation": { "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive incremental shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r141", "r148" ], "calculation": { "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Shares used for diluted earnings per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in earnings per share calculations (in millions):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r140", "r148" ], "calculation": { "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.hcahealthcare.com/role/CondensedConsolidatedIncomeStatements", "http://www.hcahealthcare.com/role/EarningsPerShareScheduleOfComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r445": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r522": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r549": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r603": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r617": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r618": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r619": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r620": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r621": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r622": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r623": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r624": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r625": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r626": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r627": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r628": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r629": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r630": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 69 0001193125-21-315476-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-315476-xbrl.zip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�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end